

January 2009

Volume 16 Number 0

**Editors**

Julie Lagan & Scott Brydon  
 email: [schedule@pharmac.govt.nz](mailto:schedule@pharmac.govt.nz)  
 Telephone +64 4 460 4990  
 Facsimile +64 4 460 4995  
 Level 14, Cigna House  
 40 Mercer Street  
 PO Box 10 254  
 Wellington

**Freephone Information Line**

0800 66 00 50 (9am – 5pm weekdays)

**Circulation**

Published each April, August and December. Changes to the contents are published in monthly updates. Annual subscription includes three Pharmaceutical Schedule books, 12 updates and occasional information on rule changes and news items. The Schedule is distributed free of charge to over 9,000 professionals, and is also available on an annual subscription.

**Prices**

\$22.22 One Schedule book

\$4.44 One Update

\$120.00 Annual subscription

All prices include postage and exclude GST.

**Production**

Typeset automatically from XML and  $\text{\TeX}$ . Source XML suitable for database import available on request.

**Programmers**

Peter Ericson & John Geering  
 email: [texschedule@pharmac.govt.nz](mailto:texschedule@pharmac.govt.nz)

<http://www.pharmac.govt.nz>

ISSN 1172 - 9376

Copyright © 1994 Pharmaceutical Management Agency. No part may be reproduced in any form or by any process without written permission, nor be used in any form of advertising, sales, promotion or publicity. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising therefrom.

**Section A** General Rules 13**Section B** Alimentary Tract & Metabolism 26

Blood & Blood Forming Organs 40

Cardiovascular System 53

Dermatologicals 63

Genito Urinary System 73

Hormone Preparations – Systemic 79

Infections – Agents For Systemic Use 88

Musculo-Skeletal System 104

Nervous System 110

Oncology Agents & Immunosuppressants 134

Respiratory System & Allergies 150

Sensory Organs 157

Various 162

**Section C** Extemporaneous Compounds (ECPs) 163**Section D** Special Foods 169**Section E** Supply Orders (PSO & WSO) 189

Rural Areas 193

**Section F** Dispensing Period Exemptions 194**Section G** Safety Cap Medicines 196

Index 199

## Introducing PHARMAC

PHARMAC, the Pharmaceutical Management Agency, is a Crown entity established pursuant to the New Zealand Public Health and Disability Act 2000 (The Act). The primary objective of PHARMAC is to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided.

The PHARMAC Board consists of up to six members appointed by the Minister of Health. All decisions relating to PHARMAC's operation are made by or under the authority of the Board. In particular, Board members decide on the strategic direction of PHARMAC and may decide which community pharmaceuticals should be subsidised and at what levels, and determine national prices for some pharmaceuticals to be purchased by and used in DHB Hospitals, and whether or not special conditions are to be applied to such purchases.

### Members of the PHARMAC Board

Richard Waddell  
David Kerr

Gregor Coster  
David Moore

Kura Denness  
Adrienne von Tunzelmann

Decisions taken by the PHARMAC Board members, or made under the authority of the Board, incorporate a balanced view of the needs of prescribers and patients. The aim is to achieve long-term gains and efficient ways of making pharmaceuticals available to the community and for DHB Hospitals to purchase them.

Murray Georger, CE MidCentral DHB, attends PHARMAC's Board meetings as an observer.

The functions of PHARMAC are to perform the following, within the amount of funding provided to it in the Pharmaceutical Budget or to DHBs from their own budgets for the use of pharmaceuticals in their hospitals, as applicable, and in accordance with its annual plan and any directions given by the Minister (Section 103 of the Crown Entities Act):

- a) to maintain and manage a pharmaceutical schedule that applies consistently throughout New Zealand, including determining eligibility and criteria for the provision of subsidies;
- b) to manage incidental matters arising out of (a), including in exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the pharmaceutical schedule;
- c) to engage as it sees fit, but within its operational budget, in research to meet its objectives as set out in Section 47(a) of the Act;
- d) to promote the responsible use of pharmaceuticals;
- e) to manage the purchasing of any or all pharmaceuticals, whether used either in a hospital or outside it, on behalf of DHBs;
- f) any other functions given to PHARMAC by or under any enactment or authorised by the Minister.

The policies and criteria set out in the Pharmaceutical Schedule and PHARMAC's Operating Policies and Procedures arise out of, and are designed to help PHARMAC achieve and perform, PHARMAC's objective and functions under the Act.

However PHARMAC may, having regard to its public law obligations, depart from the strict application of those policies and criteria in certain exceptional cases where it considers this necessary or appropriate in the proper exercise of its statutory discretion and to give effect to its objective and functions, particularly with respect to:

- Determining eligibility and criteria for the provision of subsidies; and
- In exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the Pharmaceutical Schedule.

### Decision Criteria

PHARMAC updates the Pharmaceutical Schedule at regular intervals to notify prescribers, pharmacists, hospital managers and patients of changes to Community Pharmaceutical subsidies and the prices for Hospital Pharmaceuticals. In making decisions about amendments to the Pharmaceutical Schedule, PHARMAC is guided by its Operating Policies and Procedures, as amended or supplemented from time to time. PHARMAC takes into account the following criteria when making decisions about Community Pharmaceuticals:

- the health needs of all eligible people within New Zealand (eligible defined by the Government's then current rules of eligibility);
- the particular health needs of Māori and Pacific peoples;
- the availability and suitability of existing medicines, therapeutic medical devices and related products and related things;
- the clinical benefits and risks of pharmaceuticals;
- the cost-effectiveness of meeting health needs by funding pharmaceuticals rather than using other publicly funded health and disability support services;
- the budgetary impact (in terms of the pharmaceutical budget and the Government's overall health budget) of any changes to the Pharmaceutical Schedule;
- the direct cost to health service users;
- the Government's priorities for health funding, as set out in any objectives notified by the Crown to PHARMAC, or in PHARMAC's Funding Agreement, or elsewhere; and
- such other criteria as PHARMAC thinks fit. PHARMAC will carry out appropriate consultation when it intends to take any such "other criteria" into account.

The Operating Policies and Procedures, including any supplements, also describe the way in which PHARMAC determines the level of subsidy or purchase price payable for each Community Pharmaceutical or Hospital Pharmaceutical, respectively.

The decision criteria for Hospital Pharmaceuticals are set out in the hospital supplement to the Operating Policies and Procedures and in the introductory part of Section H of the Pharmaceutical Schedule.

Copies of PHARMAC's Operating Policies and Procedures and of any applicable supplements are available on the PHARMAC website ([www.pharmac.govt.nz](http://www.pharmac.govt.nz)), or on request.

## **PHARMAC and the Pharmaceutical Schedule:**

PHARMAC manages the national Pharmaceutical Schedule, which lists:

- Pharmaceuticals available in the community and subsidised by the Government with funding from the Pharmaceutical Budget; and
- some Pharmaceuticals purchased by DHBs for use in their hospitals, and includes those Hospital Pharmaceuticals for which national prices have been negotiated by PHARMAC.

In the community approximately 1848 Pharmaceuticals are subsidised by the Government. Most are available to all eligible people within New Zealand on prescription by a medical doctor. Some are listed with guidelines or conditions such as 'only if prescribed for a dialysis patient' or 'Special Authority - Retail Pharmacy', to ensure that Pharmaceuticals are used by those people who are most likely to benefit from them. Pharmaceuticals provided to patients for use while in DHB hospitals are not covered by Sections A to G of the Pharmaceutical Schedule.

Section H of the Pharmaceutical Schedule is not a comprehensive list of Pharmaceuticals that are used within the DHB Hospitals.

Section H of the Pharmaceutical Schedule includes Pharmaceuticals that can be purchased at a national price by DHBs for use in their hospitals. These are referred to as National Contract Pharmaceuticals.

Section H of the Pharmaceutical Schedule also identifies new Pharmaceuticals used in hospitals, which have been or are being assessed by PHARMAC, the results of that analysis being available to DHB Hospitals via PHARMAC's website.

A list of Discretionary Community Supply Pharmaceuticals, in Section H of the Pharmaceutical Schedule, identifies those products that currently are not subsidised from the Pharmaceutical Budget as Community Pharmaceuticals in Sections A to G of the Pharmaceutical Schedule but which DHBs can at their discretion fund for use in the community from their own budgets without specific Hospital Exceptional Circumstances approval.

### **PHARMAC's clinical advisors**

#### **Pharmacology and Therapeutics Advisory Committee (PTAC)**

PHARMAC works closely with the Pharmacology and Therapeutics Advisory Committee (PTAC), an expert medical committee which provides independent advice to PHARMAC on health needs and the clinical benefits of particular pharmaceuticals for use in the community and/or in DHB Hospitals.

The committee members are all senior, practising clinicians. The chair of PTAC sits with the PHARMAC Board in an advisory capacity.

PTAC helps decide which community pharmaceuticals are to be subsidised from public monies by making recommendations to PHARMAC. Part of the role of PTAC is to review whether Community Pharmaceuticals already listed on the Schedule should continue to receive Government funds. The resources freed up can be used to subsidise other community pharmaceuticals with a greater therapeutic worth.

PHARMAC may obtain clinical advice from PTAC in relation to national purchasing strategies for Hospital Pharmaceuticals. There may be additional specialist hospital representatives on PTAC subcommittees, or additional PTAC subcommittees, where PHARMAC considers this necessary.

#### **PTAC members are:**

Carl Burgess MBChB, MD, MRCP (UK), FRACP, FRCP, physician/clinical pharmacologist, Chair  
Ian Hosford MBChB, FRANZCP, psychiatrist  
Sisira Jayathissa MBBS, MD, MRCP, FAFPHM, FRCP, FRACP, physician  
Peter Jones BMedSci, MBChB, PhD, FRCP, FRACP, physician  
George Laking PhD, MBChB, DCH, FRNZCGP, oncologist  
Jim Lello BHB, MBChB, DCH, FRNZCGP, general practitioner  
Graham Mills MBChB, MTropHlth, MD, FRACP, infectious disease specialist  
Peter Pillans MBChB, MD, FCP, FRACP, clinical pharmacologist  
Paul Tomlinson MBChB, MD, MRCP, FRACP, BSc, paediatrician, Deputy Chair  
Mark Weatherall MBChB, BA, MB, BS, Dip Obst, FRNZCGP, physician  
Howard Wilson BSc, PhD, MAppStats, FRNZCGP, FRACGP, general practitioner  
Contact PTAC C/- PTAC Secretary  
Pharmaceutical Management Agency  
PO Box 10 254, WELLINGTON  
PTAC@pharmac.govt.nz

## The PHARMAC Team

The PHARMAC team has a wide range of expertise in health, medicine, economics, commerce, critical analysis, and policy development and implementation.

Matthew Brougham	Chief Executive	Rachel Mackay	Manager, Schedule and Contracts
Jason Arnold	Senior Analyst		
Paul Alexander	Health Economist	Trish Mahoney	Contract Manager
Peter Alsop	Manager, Corporate and External Relations	Adam McRae	Team Leader, Access & Optimal Use
Karen Barris	Senior Receptionist	Scott Metcalfe	Chief Advisor Population Medicine / Public Health Physician
Mike Bignall	Therapeutic Group Manager		
Stephen Boxall	Creative Director		
Scott Brydon	Schedule Analyst	Peter Moodie	Medical Director
Diane Buysman-Bakkam	Executive Assistant to Chief Executive / Office Manager	Deborah Nisbet	Receptionist
		Jessica Nisbet	Funding and Procurement Assistant
Hayley Bythell	PA to Medical Director		
Davina Carpenter	Records Manager	Jan Quin	Team Leader, Medical Team
Christine Chapman	Contract Manager	Marama Parore	Manager, Access & Optimal Use & Māori Health
Yvonne Chen	Tender Analyst		
Mary Chesterfield	High Cost Medicines Co-ordinator	Chris Peck	Analyst
		Melanie Pemberton Fisher	Communications Advisor
Steffan Crausaz	Manager, Funding and Procurement	Sharon Ponniah	Access and Optimal Use Manager
Andrew Davies	Procurement Initiatives Manager	Matthew Poynton	Analyst/Health Economist
Sean Dougherty	Therapeutic Group Manager	Rachel Pratt	Hospital Exceptional Circumstances Panel Co-ordinator
Kim Ellis	Access & Optimal Use Co-ordinator		
Simon England	Communications Manager	Dilky Rasiah	Deputy Medical Director
Andy Erceg	IT Support	Kyle Reid	High Cost Medicines Panel Co-ordinator / Growth Hormone
Jackie Evans	Therapeutic Group Manager		
John Geering	Systems Architect	Brian Roulston	Analyst
Rachel Grocott	Health Economist / Team Leader Assessment	Fiona Rutherford	Senior Policy Analyst
		Rico Schoeler	Manager, Analysis and Assessment
Susan Haniel	Advisory Committee Manager		
David Harland	Health Economist	Liz Skelley	Finance Manager
Karen Jacobs	Access & Optimal Use Manager	Moana Tane	Māori Health Manager
Cherie Jacobson	Corporate Assistant	Jayne Watkins	Community Exceptional Circumstances Panel Co-ordinator
Elsbeth Kay	Access & Optimal Use Manager		
Geoff Lawn	Applications Developer		
Julie Lagan	Schedule Analyst	Greg Williams	Therapeutic Group Manager
Geraldine MacGibbon	Therapeutic Group Manager	Lisa Williams	Legal Counsel
Janet Mackay	Access & Optimal Use Manager	Mary-Ann Wilson	Māori Health Analyst
		Stephen Woodruffe	Therapeutic Group Manager

## Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price (if it differs from the Subsidy) and any access conditions that may apply; and
- some Hospital Pharmaceuticals that are purchased and used by DHB Hospitals, including those for which national prices have been negotiated by PHARMAC.

The purpose of the Schedule is not to show the final cost to Government of subsidising each Community Pharmaceutical or to DHBs in purchasing each Hospital Pharmaceutical since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for some Hospital Pharmaceuticals, on any logistics arrangements put in place by individual DHB Hospitals.

## Finding Information in the Pharmaceutical Schedule

### Community Pharmaceuticals

For Community Pharmaceuticals, the Schedule is organised in a way to help the reader find Community Pharmaceuticals, which may be used to treat similar conditions. To do this, Community Pharmaceuticals are first classified anatomically, originally based on the Anatomical Therapeutic Chemical (ATC) system, and then further classified under section headings structured for the New Zealand medical system.

- Section **A** lists the General Rules in relation to Community Pharmaceuticals and related products.
- Section **B** lists Community Pharmaceuticals and related products by anatomical classification, which are further divided into one or more therapeutic headings. Community Pharmaceuticals used to treat similar conditions are grouped together.
- Section **C** lists the rules in relation to Extemporaneously Compounded Products (ECPs) and Community Pharmaceuticals that will be subsidised when extemporaneously compounded.
- Section **D** lists the rules in relation to Special Foods and the Special Foods that are subsidised.
- Section **E Part I** lists the Community Pharmaceuticals that are subsidised on a Practitioner's Supply Order (PSO) and Wholesale Supply Order (WSO).
- Section **E Part II** lists rural areas for the purpose of PSOs.
- Section **F** lists the Community Pharmaceuticals dispensing period exemptions.
- Section **G** lists the Community Pharmaceuticals eligible for reimbursement of safety cap and related rules.

The listings are displayed alphabetically (where practical) within each level of the classification system. Each anatomical section contains a series of therapeutic headings, some of which may contain a further classification level. Where a Community Pharmaceutical is used in more than one therapeutic area, they may be cross-referenced.

The therapeutic headings in the Pharmaceutical Schedule do not necessarily correspond to the therapeutic groups and therapeutic subgroups, which PHARMAC establishes for the separate purpose of determining the level of subsidy to be paid for each Community Pharmaceutical.

The index located at the back of the book in which Sections A-G of the Pharmaceutical Schedule are published can be used to find page numbers for generic chemical entities, or product brand names.

## Hospital Pharmaceuticals

Section **H** lists Pharmaceuticals that DHBs fund from their own budgets. The Hospital Pharmaceuticals are grouped into the following Parts in Section H:

- Part I lists the rules in relation to Hospital Pharmaceuticals.
- Part II lists Hospital Pharmaceuticals for which national contracts exist (National Contract Pharmaceuticals). These are listed alphabetically by generic chemical entity name and line item, the relevant Price negotiated by PHARMAC and, if applicable, an indication of whether it has Hospital Supply Status (HSS) and any associated Discretionary Variance (DV) Pharmaceuticals and DV Limit.
- Part III lists Assessed Pharmaceuticals, which have been or are being assessed by PHARMAC and, where such assessment is available, PHARMAC's opinion regarding the use of the Assessed Pharmaceuticals in hospitals. DHB Hospitals are not obliged to implement those recommendations.
- Part IV lists Discretionary Community Supply Pharmaceuticals, which are not Community Pharmaceuticals, but which a DHB Hospital can, in its discretion, fund for use in the community from its own budget.

The index located at the back of the Section H supplement can be used to find page numbers for generic chemical entities, or product brand names, for Hospital Pharmaceuticals.



# Glossary

## Units of Measure

gram .....	g	microgram.....	µg	millimole.....	mmol
kilogram.....	kg	milligram.....	mg	unit.....	u
international unit.....	iu	millilitre.....	ml		

## Abbreviations

Ampoule .....	Amp	Granules.....	Gran	Suppository .....	Supp
Capsule .....	Cap	Infusion .....	Inf	Tablet .....	Tab
Cream.....	Crn	Injection .....	Inj	Tincture.....	Tinc
Device.....	Dev	Linctus .....	Linc	Trans Dermal Delivery	
Dispersible.....	Disp	Liquid.....	Liq	System.....	TDDS
Effervescent.....	Eff	Long Acting.....	LA		
Emulsion.....	Emul	Ointment.....	Oint		
Enteric Coated.....	EC	Sachet .....	Sach		
Gelatinous .....	Gel	Solution.....	Soln		

BSO Bulk Supply Order.

CBS Cost Brand Source. There is no set manufacturer's price, and the Government subsidises the product at the price it is obtained by the pharmacy.

CE Compounded Extemporaneously.

CPD Cost Per Dose. The Funder (as defined in Part I of the General Rules) cost of a standard dose, without mark-ups or fees and excluding GST.

ECP Extemporaneously Compounded Preparation.

HSS Hospital Supply Status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

OP Original Pack – subsidy is rounded up to a multiple at whole packs.

PSO Practitioner's Supply Order.

### Sole Subsidised

Supplier Only brand of this medicine subsidised.

WSO Wholesale Supply Order.

XPharm Pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements.

▲ Three months supply may be dispensed at one time if the exempted medicine is endorsed 'certified exemption' by the practitioner.

\* Three months dispensed all-at-once or, in the case of oral contraceptives, six months dispensed all-at-once, unless medicine is endorsed "close control" or "cc" and the endorsement is initialled by the prescriber.

‡ Safety cap required and subsidised for oral liquid formulations, including extemporaneously compounded preparations.

✓ Fully subsidised brand of a given medicine. Brands without the tick are not fully subsidised and may cost the patient a manufacturer's surcharge.

§29 This medicine is an unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should:

- be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984;
- be aware of and comply with their obligations under the Health and disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- exercise their own skill, judgement, expertise and discretions, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.

Note: Where medicines supplied under Section 29 that are used for emergency situations, patient details required under Section 29 of the Medicines Act may be retrospectively provided to the supplier.

Definitions		
Abbrev.	Pharmacy Services Agreement	All other Pharmacy Agreements
[HP1]	Subsidised when dispensed from pharmacies that have the Complex Medicines Variation of the Pharmacy Services Agreement	Available from selected pharmacies that have an exclusive contract to dispense 'Hospital Pharmacy' [HP1] pharmaceuticals.
[HP3]	Subsidised when dispensed from pharmacies that have the Pharmacy Services Agreement. A Special Food with [HP3] annotation is subsidised when dispensed by a pharmacy that has a Special Foods Service appended to their Pharmacy Services Agreement by their DHB.	Available from selected pharmacies that have an exclusive contract to dispense 'Hospital Pharmacy' [HP3] pharmaceuticals.
[HP4]	Subsidised when dispensed from pharmacies that have the Monitored Therapy Variation (for Clozapine Services)	Available from selected pharmacies that have an exclusive contract to dispense 'Hospital Pharmacy' [HP4] pharmaceuticals.

## Patient costs

### Community Pharmaceutical costs met by the Government

Most of the cost of a subsidised prescription Community Pharmaceutical is met by the Government through the Pharmaceutical Budget. The Government pays a subsidy for the Community Pharmaceutical to Contractors, and a fee covering distribution and pharmacy dispensing services. The subsidy paid to Contractors does not necessarily represent the final cost to Government of subsidising a particular Community Pharmaceutical. The final cost will depend on the nature of PHARMAC's contractual arrangements with the supplier. Fully subsidised medicines are identified with a ✓ in the product's Schedule listing.

SALBUTAMOL Aerosol inhaler 100 µg per dose.....	3.80 (6.00)	✓Fully subsidised brand Higher priced brand
--	----------------	--

### Community Pharmaceutical costs met by the patient

Some Community Pharmaceutical costs are met by the patient. Generally a patient pays a prescription charge. In addition a patient will sometimes pay a manufacturer's surcharge, after hours service fee and any special packaging fee.

#### PRESCRIPTION CHARGE

The prescription charge for a three month course of a fully subsidised Community Pharmaceutical ranges up to \$15.00 and represents the patient's contribution to the cost of the Community Pharmaceutical, and a pharmacy dispensing fee. Where the cost of the Community Pharmaceutical and dispensing fee exceed the prescription charge the Government pays the rest of the cost.

Maximum prescription charges vary by patient status as set out below. More information about prescription charges is contained in the pamphlet, Community Services Card, available from Work and Income.

Patient's subsidy entitlements	Maximum prescription charge	
<b>Not a PHO enrollee or No Card</b>	Adult	\$15
	Child 6 - 17	\$10
	Child under 6	\$0
	Contraceptives	\$3
<b>PHO enrollee or Care plus patient</b>	No other card	\$3
<b>Community Services Card (CSC)</b>	No other card	\$3
<b>High Use Health Card (HUHC)</b>	No other card	\$3
<b>Eligible person and eligible provider/prescriber</b>	No other card	\$3
<b>Prescription Subsidy Card</b> for families after first 20 prescriptions since previous February*	No other card	\$2
	With HUHC only	\$2
	With CSC	\$0
	* Except prescriptions with \$0 charge	Low-cost PHO

#### MANUFACTURER'S SURCHARGE

Not all Community Pharmaceuticals are fully subsidised. Although PHARMAC endeavours to fully subsidise at least one Community Pharmaceutical in each therapeutic group, and has contracts with some suppliers to maintain the price of a particular product, manufacturers are able to set their own price to pharmacies. When these prices exceed the subsidy, the pharmacist may recoup the difference from the patient.

To estimate the amount a patient will pay on top of the prescription charge, take the difference between the manufacturer's price and the subsidy, and multiply this by 1.86. The 1.86 factor represents the pharmacy mark-up on the surcharge plus other costs such as GST. Pharmacies charge different mark-ups so this may vary.

$$\text{Manufacturer's surcharge to patient} = (\text{price} - \text{subsidy}) \times 1.86$$

For example, a Community Pharmaceutical with a supplier (ex-manufacturer) cost of \$11.00 per pack with a \$10.00 subsidy will cost the patient a surcharge of \$1.86 on top of the prescription charge. The most a patient should pay is therefore \$16.86 - being \$15.00 maximum prescription charge, plus \$1.86.

### **Hospital Pharmaceutical and Pharmaceutical Cancer Treatment Costs**

The cost of purchasing Hospital Pharmaceuticals and Pharmaceutical Cancer Treatments (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) is met by the Funder (in particular, the relevant DHB) from its own budget. As required by section 23(7) of the Act, in performing any of their functions in relation to the supply of Pharmaceuticals including Pharmaceutical Cancer Treatments, DHBs must not act inconsistently with the Pharmaceutical Schedule.

### **PHARMAC web site**

PHARMAC has set up an interactive Schedule on the Internet. It can be used to calculate the cost of a prescribed Community Pharmaceutical. This site at <http://www.pharmac.govt.nz> takes into account the quantity of Community Pharmaceutical prescribed as well as the patient's age, whether the patient has a community services card, high use health card or prescription subsidy card, the fee for pharmacy services and prescription charges.

Other information about PHARMAC is also available on our website. This includes copies of the Annual Review, Annual Report and Annual Plan, as well as information such as the Pharmaceutical Schedule, Pharmaceutical Schedule Updates, National Hospital Pharmaceutical Strategy, other publications and recent press releases.

## **Special Authority Applications**

Special Authority is an application process in which a prescriber requests government subsidy on a Community Pharmaceutical for a particular person. Applications must be submitted to the Ministry of Health by the prescriber for the request to be processed.

### **Subsidy**

Once approved, the prescriber and the patient are provided a Special Authority number which must appear on the prescription. Specialists who make an application must communicate the valid authority number to the prescriber who will be writing the prescriptions.

The authority number can provide access to subsidy, increased subsidy, or waive certain restrictions otherwise present on the Community Pharmaceutical.

Some approvals are dependent on the availability of funding from the Pharmaceutical Budget.

### **Criteria**

The criteria for approval of Special Authority applications are included below each Community Pharmaceutical listing, and on the application forms available on PHARMAC's website.

For some Special Authority Community Pharmaceuticals, not all indications that have been approved by Medsafe are subsidised. Criteria for each Special Authority Community Pharmaceutical are updated regularly, based on the decision criteria of PHARMAC. The appropriateness of the listing of a Community Pharmaceutical in the Special Authority category will also be regularly reviewed. Applications for inclusion of further Community Pharmaceuticals in the Special Authority category will generally be made by a pharmaceutical supplier.

### **Special Authority Applications**

Application forms can be found at [www.pharmac.govt.nz](http://www.pharmac.govt.nz). Requests for fax copies should be made to PHARMAC, phone 04 460 4990. Applications are processed by Ministry of Health Sector Services and DHB Support (MOH SS & DHB Support), and should be sent to:

MOH SS & DHB Support, Private Bag 3015, Fax: (06) 349 1983 of free fax 0800 100 131  
WANGANUI

For enquiries, phone the Call Centre, free phone 0800 CHEM NO (0800 243 666)

*Note:* MOH SS & DHB Support can only provide information on Special Authority applications to prescribers and pharmacists.

### *Each application must:*

- Include the patient's name, date of birth and NHI number (codes for AIDS patients' applications)
- Include the practitioner's name, address and Medical Council registration number
- Clearly indicate that the relevant criteria, have been met.
- Be signed by the practitioner.

## Exceptional Circumstances policies

The purpose of the Exceptional Circumstances policies are to provide:

- funding from the Community Exceptional Circumstances budget for medication, to be used in the community, in circumstances where the provision of a funded community medication is appropriate, but funding from the Pharmaceutical Budget is not able to be provided through the Pharmaceutical Schedule (“Community Exceptional Circumstances”); or
- an assessment process for the DHB Hospitals to determine whether they can fund medication, to be used in the community, in circumstances where the medication is neither a Community Pharmaceutical nor a Discretionary Community Supply Pharmaceutical and where the patient does not meet the criteria for Community Exceptional Circumstances (“Hospital Exceptional Circumstances”); or
- an assessment process for DHB Hospitals to determine whether they can fund pharmaceuticals for the treatment of cancer in their DHB Hospital, or in association with Outpatient services provided in their DHB hospital, in circumstances where the pharmaceutical is not identified as a Pharmaceutical Cancer Treatment (“Cancer Exceptional Circumstances”) in Sections A-H of the Pharmaceutical Schedule.

Upon receipt of an application for approval for Community Exceptional Circumstances or Hospital Exceptional Circumstances, the Exceptional Circumstances Panel first decides whether an application will be assessed initially under the Community Exceptional Circumstances criteria or the Hospital Exceptional Circumstances criteria. Cancer Exceptional Circumstances is a separate process.

### Hospital Exceptional Circumstances

If the application is first assessed but not approved under the Community Exceptional Circumstances criteria, the Exceptional Circumstances Panel may recommend the funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances.

If the application is first assessed under the Hospital Exceptional Circumstances criteria, the Exceptional Circumstances Panel may:

- a) recommend against the funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget, in which case a DHB Hospital must not fund the pharmaceutical from its own budget;
- b) recommend the funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances, in which case a DHB Hospital may, but is not obliged to, fund the pharmaceutical from its own budget;
- c) defer its decision until further assessment under the Community Exceptional Circumstances criteria can be undertaken; or
- d) recommend interim funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances until further assessment under the Community Exceptional Circumstances criteria can be undertaken.

Permission to fund a pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances will only be granted by PHARMAC where it has been demonstrated that such funding is cost-effective for the relevant DHB in the region in which the patient resides.

If the patient being treated with a pharmaceutical under Hospital Exceptional Circumstances usually resides in a district other than that within the jurisdiction of the DHB initiating the treatment, then the DHB initiating the treatment must either agree to fund any on-going treatment required once the patient has returned to his/her usual DHB, or obtain written consent from the DHB or DHBs in which the patient will reside following the commencement of treatment.

Applications for Hospital Exceptional Circumstances should be made on the standard application form available from the PHARMAC website [www.pharmac.govt.nz](http://www.pharmac.govt.nz) or the address below:

The Coordinator, Hospital Exceptional Circumstances Panel  
PHARMAC, PO Box 10 254  
Wellington

Phone: (04) 916 7521  
or fax (09) 523 6870  
Email: [ecpanel@pharmac.govt.nz](mailto:ecpanel@pharmac.govt.nz)

## Cancer Exceptional Circumstances

Permission to fund a pharmaceutical for the treatment of cancer from the Hospital's own budget under Cancer Exceptional Circumstances will only be granted by PHARMAC where it has been demonstrated that the proposed use meets the criteria.

If the patient being treated with a pharmaceutical under Cancer Exceptional Circumstances usually resides in a district other than that within the jurisdiction of the DHB initiating the treatment, then the DHB initiating the treatment must either agree to fund any on-going treatment required once the patient has returned to his/her usual DHB, or obtain written consent from the DHB or DHBs in which the patient will reside following the commencement of treatment.

## Community Exceptional Circumstances

In order to qualify for Community Exceptional Circumstances approval one of the following criteria must be met:

- a) the condition must be rare; *or*
- b) the reaction to alternative funded treatment must be unusual; *or*
- c) an unusual combination of circumstances applies.

Rare and unusual are considered to be in the order of less than 10 people nationally.

Where one of the above Community Exceptional Circumstances entry criteria is met, the application may then be further examined under supplementary criteria, assessing suitability of the pharmaceutical, clinical benefit, the cost effectiveness of the treatment, and the patient's ability to pay for the treatment. Where these documented criteria are met, a subsidy sufficient to fully fund the pharmaceutical will be made available to the specific patient on whose behalf the application was made.

Community Exceptional Circumstances funding is only available where the criteria are met and is not available for financial reasons alone.

Applications for Community Exceptional Circumstances, Hospital Exceptional Circumstances and Cancer Exceptional Circumstances should be made on the standard application form available from the PHARMAC website [www.pharmac.govt.nz](http://www.pharmac.govt.nz) or the address below:

The Coordinator, Community Exceptional Circumstances Panel	Phone (04) 916 7553
PO Box 10 254	or fax (09) 523 6870
Wellington	Email: <a href="mailto:ecpanel@pharmac.govt.nz">ecpanel@pharmac.govt.nz</a>

## INTRODUCTION

Section A contains the restrictions and other general rules that apply to Subsidies on Community Pharmaceuticals. The amounts payable by the Funder to Contractors are currently determined by:

- the quantities, forms, and strengths, of subsidised Community Pharmaceuticals dispensed under valid prescription by each Contractor;
- the amount of the Subsidy on the Manufacturer's Price payable for each unit of the Community Pharmaceuticals dispensed by each Contractor and;
- the contractual arrangements between the Contractor and the Funder for the payment of the Contractor's dispensing services.

The Pharmaceutical Schedule shows the level of subsidy payable in respect of each Community Pharmaceutical so that the amount payable by the Government to Contractors, for each Community Pharmaceutical, can be calculated. The Pharmaceutical Schedule also shows the standard price (exclusive of GST) at which a Community Pharmaceutical is supplied ex-manufacturer to wholesalers if it differs from the subsidy. The manufacturer's surcharge to patients can be estimated using the subsidy and the standard manufacturer's price as set out in this Schedule.

The cost to Government of subsidising each Community Pharmaceutical and the manufacturer's prices may vary, in that suppliers may provide rebates to other stakeholders in the primary health care sector, including dispensers, wholesalers, and the Government. Rebates are not specified in the Pharmaceutical Schedule.

This Schedule is dated 1 January 2009 and is to be referred to as the Pharmaceutical Schedule Volume 16 Number 0, 2009. Distribution will be from 20 January 2009. This Schedule comes into force on 1 January 2009.

## PART I INTERPRETATIONS AND DEFINITIONS

1.1 In this Schedule, unless the context otherwise requires:

**"90 Day Lot"** means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 90 consecutive days' treatment;

**"180 Day Lot"** means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 180 consecutive days' treatment;

**"Access Exemption Criteria"** means the criteria under which patients may receive greater than one Month's supply of a Community Pharmaceutical covered by Section F Part II (b) subsidised in one Lot. The specifics of these criteria are conveyed in the Ministry of Health guidelines, which are issued from time to time. The criteria the patient must meet are that they:

- a) have limited physical mobility;
- b) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- c) are relocating to another area;
- d) are travelling extensively and will be out of town when the repeat prescriptions are due.

**"Act"** means the New Zealand Public Health and Disability Act 2000.

**"Advisory Committee"** means the Pharmaceutical Services Advisory Committee convened by the Ministry of Health under the terms of the Advice Notice issued to Contractors pursuant to Section 88 of the Act.

**"Alternate Subsidy"** means a higher level of subsidy that the Government will pay contractors for a particular community Pharmaceutical dispensed to a person who has either been granted a Special Authority for that pharmaceutical, or where the prescription is endorsed in accordance with the requirements of this Pharmaceutical Schedule.

**"Assessed Pharmaceuticals"** means the list of Pharmaceuticals set out in Section H Part III of the Schedule, that have been or are being assessed by PHARMAC.

**"Authority to Substitute"** means an authority for the dispensing pharmacist to change a prescribed medicine in accordance with regulation 42(4) of the Medicines Regulations 1984. An authority to substitute letter, which may be used by Practitioners, is available on the final page of the Schedule.

**"Bulk Supply Order"** means a written order, on a form supplied by the Ministry of Health, or approved by HealthPAC, made by the licensee or manager of an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 for the supply of such Community Pharmaceuticals as are expected to be required for the treatment of persons who are under the medical or dental supervision of such a Private Hospital or institution.

**"Cancer Exceptional Circumstances"** means the policies and criteria administered by PHARMAC relating to the ability to fund, from a DHB hospital's own budget, pharmaceuticals for the treatment of cancer that are not identified as Pharmaceutical

## SECTION A: GENERAL RULES

Cancer Treatments in Sections A-H of the Pharmaceutical Schedule.

**“Class B Controlled Drug”** means a Class B controlled drug within the meaning of the Misuse of Drugs Act 1975.

**“Close Control”** means the dispensing of a Community Pharmaceutical, in accordance with a Prescription, in quantities less than one 90 Day Lot (or for oral contraceptives, less than one 180 Day Lot) for a Community Pharmaceutical referred to in Section F Part I, or in quantities less than a Monthly Lot for any other Community Pharmaceutical, where any of a), b) or c) apply.

- a) All of the following conditions are met:
  - i) the Community Pharmaceutical has been prescribed for a patient who:
    - 1) is not a resident in a Penal Institution, Rest Home or Residential Disability Care Institution; and
    - 2) either of the following:
      - i) in the opinion of the prescribing Practitioner is:
        - a) frail; or
        - b) infirm; or
        - c) unable to manage their medication without additional support; or
        - d) intellectually impaired; or
        - e) requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient's first changed Prescription only); and
        - f) requires that Community Pharmaceutical to be dispensed in a smaller quantity than that for which it is currently funded, or
      - ii) the Community Pharmaceutical is any of the following:
        - a) a tri-cyclic antidepressant; or
        - b) an antipsychotic; or
        - c) a benzodiazepine; or
        - d) a Class B Controlled Drug; and
    - ii) the prescribing Practitioner has:
      - A) endorsed each Community Pharmaceutical on the Prescription clearly with the words “Close Control” or “CC”; and
      - B) initialled the endorsement in their own handwriting; and
      - C) specified the maximum quantity or period of supply to be dispensed at any one time.
  - b) All of the following conditions are met:
    - i) The Community Pharmaceutical is prescribed for a patient who is a resident in a Rest Home or Residential Disability Care Institution; and
      - A) the quantity or period of supply to be dispensed at any one time is not less than 28 days' supply; and
      - B) the prescriber or pharmacist has written the name of the Rest Home or Residential Disability Care Institution on the prescription; and
      - C) the prescriber or pharmacist has:
        - 1) written on the Prescription the words “Close Control” or “CC” (this applies to all medicines prescribed on the prescription), and
        - 2) initialled the endorsement/annotation in their own handwriting; and
        - 3) specified the maximum quantity or period of supply to be dispensed at any one time.
    - c) All of the following conditions are met:
      - i) where PHARMAC has approved and notified pharmacists to annotate prescriptions for a specified Community Pharmaceutical(s) “Close Control” without prescriber endorsement for a specified time; and
      - ii) the dispensing pharmacist has:
        - A) clearly annotated each of the approved Community Pharmaceuticals that appear on the prescription with the words “Close Control” or “CC”; and
        - B) initialled the annotation in their own handwriting; and
        - C) specified the maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification.

**“Community Exceptional Circumstances”** means the policies and criteria administered by the Exceptional Circumstances Panel relating to funding from the Community Exceptional Circumstances budget for medication, to be used in the community, in circumstances where the provision of a funded community medication is appropriate, but funding from the Pharmaceutical

Budget is not able to be provided through the Pharmaceutical Schedule.

“**Community Pharmaceutical**” means a Pharmaceutical listed in Sections A to G of the Pharmaceutical Schedule that is subsidised by the Funder from the Pharmaceutical Budget for use in the community.

“**Contractor**” means a person who is entitled to receive a payment from the Crown or a DHB under a notice issued by the Crown or a DHB under Section 88 of the Act or under a contract with the Ministry of Health or a DHB for the supply of Community Pharmaceuticals.

“**Controlled Drug**” means a controlled drug within the meaning of the Misuse of Drugs Act 1975 (other than a controlled drug specified in Part VI of the Third Schedule to that Act).

“**Cost, Brand, Source of Supply**” means that the Community Pharmaceutical is eligible for Subsidy on the basis of the Contractor’s annotated purchase price, brand, and source of supply.

“**Dentist**” means a person registered with the Dental Council, and who holds a current annual practising certificate, under the HPCA Act 2003.

“**DHB**” means an organisation established as a District Health Board by or under Section 19 of the Act.

“**DHB Hospital**” means a DHB, including its hospital or associated provider unit that the DHB purchases Hospital Pharmaceuticals for.

“**Discretionary Community Supply Pharmaceutical**” means the list of Pharmaceuticals set out in Section H Part IV of the Schedule, which may be funded by a DHB Hospital from its own budget for use in the community.

“**Doctor**” means a medical Practitioner registered with the Medical Council of New Zealand and, who holds a current annual practising certificate under the HPCA Act 2003.

“**DV Limit**” means, for a particular Hospital Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

“**DV Pharmaceutical**” means a discretionary variance Pharmaceutical, that does not have HSS and which:

- a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or
- b) is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical.

“**Endorsements**” - unless otherwise specified, endorsements should be either handwritten or computer generated by the practitioner prescribing the medication. The endorsement can be written as “certified condition”, or state the condition of the patient, where that condition is specified for the Community Pharmaceutical in Section B of the Pharmaceutical Schedule. Where the practitioner writes “certified condition” as the endorsement, he/she is making a declaration that the patient meets the criteria as set out in Section B of the Pharmaceutical Schedule.

“**Exceptional Circumstances Panel**” means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for administering policies in relation to Community Exceptional Circumstances and Hospital Exceptional Circumstances.

“**Funder**” means the body or bodies responsible, pursuant to the Act, for the funding of pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

“**GST**” means goods and services tax under the Goods and Services Tax Act 1985.

“**Hospital Care Operator**” means a person for the time being in charge of providing hospital care, in accordance with the Health and Disability Services (Safety) Act 2001.

“**Hospital Exceptional Circumstances**” means the policies and criteria administered by the Exceptional Circumstances Panel relating to the ability to fund, from a DHB Hospital’s own budget, pharmaceuticals for use in the community by a specific patient where a subsidy is not available from the Pharmaceutical Budget or under Community Exceptional Circumstances.

“**Hospital Pharmaceuticals**” means National Contract Pharmaceuticals, DV Pharmaceuticals, Discretionary Community Supply Pharmaceuticals and Assessed Pharmaceuticals.

“**Hospital Pharmacy**” means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an person on the Prescription of a Practitioner.

“**Hospital Pharmacy-Specialist**” means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy:

- a) to an Outpatient; and
- b) on a Prescription signed by a Specialist; or  
if the treatment of an Outpatient with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a Practitioner endorsed with the words “recommended by [name of specialist and year of authorisation]” and signed by the Practitioner.

“As recommended by a Specialist” to be interpreted as:

- a) follows a substantive consultation with an appropriate Specialist;
- b) the consultation to relate to the Patient for whom the Prescription is written;

## SECTION A: GENERAL RULES

- c) consultation to mean communication by referral, telephone, letter, facsimile or email;
- d) except in emergencies consultation to precede annotation of the Prescription; and
- e) both the specialist and the General Practitioner must keep a written record of the consultation.

For the purposes of the definition it makes no difference whether or not the Specialist is employed by a hospital.

“**Hospital Pharmacy-Specialist Prescription**” means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy:

- a) to an Outpatient; and
- b) on a Prescription signed by a Specialist.

For the purposes of this definition, a “specialist” means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

“**HSS**” means hospital supply status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

“**In Combination**” means that the Community Pharmaceutical is only subsidised when prescribed in combination with another subsidised pharmaceutical as specified in Section B or C of the Pharmaceutical Schedule.

“**Individual DV Limit**” means, for a particular Hospital Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital’s Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

“**Licensed Hospital**” means a place or institution that is certified to provide hospital care within the meaning of the Health and Disability Services (Safety) Act 2001.

“**Lot**” means a quantity of a Community Pharmaceutical supplied in one dispensing.

“**Manufacturer’s Price**” means the standard price at which a Community Pharmaceutical is supplied to wholesalers (excluding GST), as notified to PHARMAC by the supplier.

“**Maternity hospital**” means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied pursuant to a Bulk Supply Order to a maternity hospital certified under the Health and Disability Services (Safety) Act 2001.

“**Midwife**” means a person registered as a midwife with the Midwifery Council, and who holds a current annual practising certificate under the HPCA Act 2003.

“**Month**” means a period of 30 consecutive days.

“**Month restriction**” means that no Subsidy is available:

- a) unless the Community Pharmaceutical is dispensed on the Prescription of a Practitioner; and
- b) for any quantity of that Community Pharmaceutical dispensed on the Prescription (whether or not dispensed as a repeat) in excess of a Monthly Lot.

“**Monthly Lot**” means the quantity of a Community Pharmaceutical required for the number of days’ treatment covered by the Prescription, being up to 30 consecutive days’ treatment;

“**National Contract Pharmaceutical**” means a Hospital Pharmaceutical for which PHARMAC has negotiated a national contract and the Price.

“**National DV Limit**” means, for a particular Hospital Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

“**Not In Combination**” means that no Subsidy is available for any Prescription containing the Community Pharmaceutical in combination with other ingredients unless the particular combination of ingredients is separately specified in Section B or C of the Schedule, and then only to the extent specified.

“**Nurse Prescriber**” means a nurse registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003 and who is approved by the Nursing Council, to prescribe specified prescription medicines relating to his/her scope of practice.

“**Optometrist**” means a person registered as an optometrist with the Optometrists and Dispensing Opticians Board, who holds a current annual practising certificate under the HPCA Act 2003, and who is authorised by regulations under the Medicines Act 1981 and approved by the Optometrists and Dispensing Opticians Board to prescribe specified medicines.

“**Outpatient**”, in relation to a Community Pharmaceutical, means a person who, as part of treatment at a hospital or other institution under the control of a DHB, is prescribed the Community Pharmaceutical for consumption or use in the person’s home.

“**PCT**” means Pharmaceutical Cancer Treatment in respect of which DHB hospital pharmacies and other Contractors can claim Subsidies.

“**PCT only**” means Pharmaceutical Cancer Treatment in respect of which only DHB hospital pharmacies can claim Subsi-

dies.

**“Penal Institution”** means a penal institution, as that term is defined in The Penal Institutions Act 1954;

**“PHARMAC”** means the Pharmaceutical Management Agency established by Section 46 of the Act (PHARMAC).

**“Pharmaceutical”** means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to H of the Schedule.

**“Pharmaceutical Benefits”** means the right of:

- a) a person; and
- b) any member under 16 years of age of that person’s family, to have made by the Government on his or her behalf, subject to any conditions for the time being specified in the Schedule, such payment in respect of any Community Pharmaceutical supplied to that person or family member under the order of a Practitioner in the course of his or her practice.

**“Pharmaceutical Budget”** means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals.

**“Pharmaceutical Cancer Treatment”** means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a “PCT” or “PCT only” Pharmaceutical that DHBs must fund, from their own budgets, for use in their hospitals, and/or in association with Outpatient services provided in their DHB Hospitals, in relation to the treatment of cancers.

**“Practitioner”** means a Doctor, a Dentist, a Midwife, a Nurse Prescriber or an Optometrist as those terms are defined in the Pharmaceutical Schedule.

**“Practitioner’s Supply Order”** means a written order made by a Practitioner on a form supplied by the Ministry of Health, or approved by HealthPAC, for the supply of Community Pharmaceuticals to the Practitioner, which the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.

**“Prescription”** means a quantity of a Community Pharmaceutical prescribed for a named person on a document signed by a Practitioner.

**“Private Hospital”** means a hospital certified under the Health and Disability Services (Safety) Act 2001 that is not owned or operated by a DHB.

**“Residential Disability Care Institution”** means premises used to provide residential disability care in accordance with the Health and Disability Services (Safety) Act 2001.

**“Rest Home”** means premises used to provide rest home care in accordance with the Health and Disability Services (Safety) Act 2001.

**“Retail Pharmacy-Specialist”** means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription or Practitioner’s Supply Order signed by a Specialist, or, in the case of treatment recommended by a Specialist, a Prescription or Practitioner’s Supply Order and endorsed with the words “recommended by [name of Specialist and year of authorisation]” and signed by the Practitioner.

“As recommended by a Specialist” to be interpreted as:

- a) follows a substantive consultation with an appropriate Specialist;
- b) the consultation to relate to the Patient for whom the Prescription is written;
- c) consultation to mean communication by referral, telephone, letter, facsimile or email;
- d) except in emergencies consultation to precede annotation of the Prescription; and
- e) both the Specialist and the General Practitioner must keep a written record of consultation.

**“Retail Pharmacy-Specialist Prescription”** means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription, or Practitioner’s Supply Order, signed by a Specialist. For the purposes of this definition, a “specialist” means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

**“Schedule”** means this Pharmaceutical Schedule and all its sections and appendices.

**“Section B”** of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for Subsidies included in the Schedule.

**“Section C”** of this Pharmaceutical Schedule means the list of community extemporaneously compounded preparations and galenicals eligible for Subsidies included in the Schedule.

**“Section D”** of this Pharmaceutical Schedule means the list of community special foods eligible for Subsidies included in the Schedule.

**“Section E Part I”** of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for Subsidies and available on a Practitioner’s Supply Order or a Wholesale Supply Order included in the Schedule.

## SECTION A: GENERAL RULES

“**Section E Part II**” of this Pharmaceutical Schedule means the list of rural areas for the purpose of community Practitioner’s Supply Orders included in the Schedule.

“**Section F Part I**” of this Pharmaceutical Schedule means the part of Section F relating to the exemption from dispensing in Monthly Lots, and requirement to dispense in 90 Day Lots or 180 Day Lots, as applicable, in respect of the Community Pharmaceuticals referred to in this part of Section F;

“**Section F Part II**” of this Pharmaceutical Schedule means the part of Section F relating to the exemption from dispensing in Monthly Lots in respect of the Community Pharmaceuticals referred to in this part of Section F;

“**Section G**” of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for reimbursement of safety caps.

“**Section H**” of this Pharmaceutical Schedule means the general rules for Hospital Pharmaceuticals and the lists of National Contract Pharmaceuticals and any associated DV Pharmaceuticals, of Discretionary Community Supply Pharmaceuticals and Assessed Pharmaceuticals included in Section H of the Schedule.

“**Section H Part I**” of this Pharmaceutical Schedule means the general rules for Hospital Pharmaceuticals.

“**Section H Part II**” of this Pharmaceutical Schedule means the list of National Contract Pharmaceuticals, the relevant Price, an indication of whether the Pharmaceutical has HSS and any associated DV Pharmaceuticals and DV Limit.

“**Section H Part III**” of this Pharmaceutical Schedule means the list of Assessed Pharmaceuticals.

“**Section H Part IV**” of this Pharmaceutical Schedule means the list of Discretionary Community Supply Pharmaceuticals.

“**Special Authority**” means that the Community Pharmaceutical or Pharmaceutical Cancer Treatment is only eligible for Subsidy or additional Subsidy for a particular person if an application meeting the criteria specified in the Schedule has been approved, and the valid Special Authority number is present on the prescription.

“**Specialist**”, in relation to a Prescription, a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) or (d) below:

- a)
  - i) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the Prescription in the course of practising in that area of medicine; and
  - ii) the doctor’s vocational scope of practice is one of those listed below: — anaesthetics, cardiothoracic surgery, dermatology, diagnostic radiology, emergency medicine, general surgery, internal medicine, neurosurgery, obstetrics and gynaecology, occupational medicine, ophthalmology, oral and maxillofacial surgery, otolaryngology head and neck surgery, orthopaedic surgery, paediatric surgery, paediatrics, pathology, plastic and reconstructive surgery, psychological medicine or psychiatry, public health medicine, radiation oncology, rehabilitation medicine, urology and venereology;
- b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that Prescription in the course of practising in that area of medicine;
- c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of medicine;
- d) the doctor writes the Prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so.

“**Subsidy**” means the maximum amount that the Government will pay Contractors for a Community Pharmaceutical dispensed to a person eligible for Pharmaceutical Benefits and is different from the cost to Government of subsidising that Community Pharmaceutical. For the purposes of a DHB hospital pharmacy claiming for Pharmaceutical Cancer Treatments, Subsidy refers to any payment made to the DHB hospital pharmacy or service provider to which that pharmacy serves, and does not relate to a specific payment that might be made on submission of a claim.

“**Supply Order**” means a Bulk Supply Order, a Practitioner’s Supply Order or a Wholesale Supply Order.

“**Unapproved Indication**” means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981.

“**Wholesale Supply Order**” means a written order by a Practitioner, on a form supplied by the Ministry of Health for the supply of certain Community Pharmaceuticals as listed in Section B and Section E Part I of the Schedule.

1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:

- a) the singular includes the plural; and
- b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regu-

lation, Order in Council, and other instrument from time to time issued or made under that legislation, where that legislation, regulation, Order in Council or other instrument has an effect on the prescribing, dispensing or subsidising of Community Pharmaceuticals.

## PART II

### COMMUNITY PHARMACEUTICALS SUBSIDY

- 2.1 Community Pharmaceuticals eligible for Subsidy include every medicine, therapeutic medical device or related product, or related thing listed in Sections B to G of the Schedule, and every preparation (having an inert base) of any of them, is hereby declared to be a Community Pharmaceutical for the purposes of the Schedule, subject to:
- 2.1.1 clauses 2.2 and 2.3 of the Schedule; and
  - 2.1.2 clauses 3.1 to 4.4 of the Schedule; and
  - 2.1.3 the conditions (if any) specified in Sections B to G of the Schedule;
- 2.2 The following medicines, therapeutic medical devices, or related products or related things are not eligible for Subsidy:
- 2.2.1 substances, or combinations of substances, ordered for any purpose other than:
    - a) treatment of a patient's medical or dental condition; or
    - b) pregnancy tests; or
    - c) the prevention of sexually transmitted disease; or
    - d) contraception.
  - 2.2.2 substances and combinations of substances packed under pressure in aerosol cans or other similar devices, unless it is specified in Sections B to G of the Schedule that they may be so packed;
  - 2.2.3 electrode jellies;
  - 2.2.4 eye drops packed in single-dose units, unless it is specified in Sections B to G of the Schedule that they may be so packed;
  - 2.2.5 insect repellents and similar preparations;
  - 2.2.6 oral preparations in long-acting form, unless it is specified in Sections B to G of the Schedule that they may be in such a form;
  - 2.2.7 substances or combinations of substances in lozenge or similar form, unless it is specified in Sections B to G of the Schedule that they may be in such a form;
  - 2.2.8 machine-spread plasters;
  - 2.2.9 preparations prescribed as foods, unless they are specified in Section D of the Schedule;
  - 2.2.10 substances, combinations of substances, or articles, in the form of proprietary medicines or proprietary articles, unless they are deemed or declared to be Pharmaceuticals elsewhere in the Schedule;
  - 2.2.11 shampoos, other than extemporaneously prepared medicated shampoos, or shampoos specified in Sections B to G of the Schedule intended for the treatment of a patient's medical condition;
  - 2.2.12 toilet preparations;
  - 2.2.13 tooth pastes and powders;
  - 2.2.14 lubricating jellies and catheter lubricants;
  - 2.2.15 sterile diluents for nebulising solutions;
  - 2.2.16 substances in a form intended to enable delivery by transdermal diffusion or osmosis or by the insertion of any solid object or substance into the eye cavity, unless it is specified in Sections B to G of the Schedule that they may be in such a form;
  - 2.2.17 substances in a form intended for intravenous delivery (other than by injection), unless it is specified in Sections B to G of the Schedule that they may be in such a form;
  - 2.2.18 substances packed in pre-loaded syringes known as Min-I-Jets, unless it is specified in Sections B to G of the Schedule that they may be so packed;
  - 2.2.19 Community Pharmaceuticals prescribed as cough mixtures, unless they are specified in Sections B to G of the Schedule otherwise than in combination with other ingredients;
  - 2.2.20 vitamin preparations in capsule form, unless they are specified in Sections B to G of the Schedule;
  - 2.2.21 substances prescribed for use as irrigating solutions, unless it is specified in Sections B to G of the Schedule that they may be prescribed for such use.
- 2.3 No claim by a Contractor for payment in respect of the supply of Community Pharmaceuticals will be allowed unless the Community Pharmaceuticals so supplied:
- 2.3.1 comply with the appropriate standards prescribed by regulations for the time being in force under the Medicines

## SECTION A: GENERAL RULES

Act 1981; or

- 2.3.2 in the absence of any such standards, comply with the appropriate standards for the time being prescribed by the British Pharmacopoeia; or
- 2.3.3 in the absence of the standards prescribed in clauses 2.3.1 and 2.3.2, comply with the appropriate standards for the time being prescribed by the British Pharmaceutical Codex; or
- 2.3.4 in the absence of the standards prescribed in clauses 2.3.1, 2.3.2 and 2.3.3, are of a grade and quality not lower than those usually applicable to Community Pharmaceuticals intended to be used for medical purposes.

### PART III

#### PERIOD AND QUANTITY OF SUPPLY

##### 3.1 Doctors', Midwives', Nurse Prescribers' and Optometrists' Prescriptions (other than oral contraceptives)

The following provisions apply to all Prescriptions, other than those for an oral contraceptive, written by a Doctor, Midwife, Nurse Prescriber or Optometrist:

- 3.1.1 For a Community Pharmaceutical other than a Class B Controlled Drug, only a quantity sufficient to provide treatment for a period not exceeding three Months will be subsidised.
- 3.1.2 For methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity sufficient to provide treatment for a period not exceeding one Month will be subsidised.
- 3.1.3 For a Class B Controlled Drug other than methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity:
  - a) sufficient to provide treatment for a period not exceeding 10 days; and
  - b) which has been dispensed pursuant to a Prescription sufficient to provide treatment for a period not exceeding one Month, will be subsidised.
- 3.1.4 Subject to clauses 3.1.3 and 3.1.7, for a Doctor, Midwife or Nurse Prescriber and 3.1.7 for an Optometrist, where a practitioner has prescribed a quantity of a Community Pharmaceutical sufficient to provide treatment for:
  - a) one Month or less than one Month, but dispensed by the Contractor in quantities smaller than the quantity prescribed, the Community Pharmaceutical will only be subsidised as if that Community Pharmaceutical had been dispensed in a Monthly Lot;
  - b) more than one Month, the Community Pharmaceutical will be subsidised only if it is dispensed:
    - i) in a 90 Day Lot, where the Community Pharmaceutical is a Pharmaceutical covered by Section F Part I of the Pharmaceutical Schedule; or
    - ii) if the Community Pharmaceutical is not a Pharmaceutical referred to in Section F Part I of the Pharmaceutical Schedule, in Monthly Lots, unless:
      - A) the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect; or
      - B) both:
        - 1) the Practitioner endorses the Community Pharmaceutical on the Prescription with the words "certified exemption" written in the Practitioner's own handwriting, or signed or initialled by the Practitioner; and
        - 2) every Community Pharmaceutical endorsed as "certified exemption" is covered by Section F Part II of the Pharmaceutical Schedule.
- 3.1.5 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor:
  - a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or
  - b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written.
- 3.1.6 No subsidy will be paid for any Prescription, or part thereof, that is not fulfilled within:
  - a) in the case of a Prescription for a total supply of from one to three Months, three Months from the date the Community Pharmaceutical was first dispensed; or
  - b) in any other case, one Month from the date the Community Pharmaceutical was first dispensed. Only that part of any Prescription that is dispensed within the time frames specified above is eligible for Subsidy.

## 3.1.7 If a Community Pharmaceutical:

- a) is stable for a limited period only, and the Doctor, Midwife, Nurse Prescriber or Optometrist has endorsed the Prescription with the words “unstable medicine” and has specified the maximum quantity that may be dispensed at any one time; or
- b) is stable for a limited period only, and the Contractor has endorsed the Prescription with the words “unstable medicine” and has specified the maximum quantity that should be dispensed at any one time in all the circumstances of the particular case; or
- c) is Close Control,

The actual quantity dispensed will be subsidised in accordance with any such specification.

**3.2 Oral Contraceptives**

The following provisions apply to all Prescriptions written by a Doctor, Midwife or Nurse Prescriber for an oral contraceptive:

## 3.2.1 The prescribing Doctor, Midwife or Nurse Prescriber must specify on the Prescription the period of treatment for which the Community Pharmaceutical is to be supplied. This period must not exceed:

- a) three Months if prescribed by a Midwife; or
- b) six Months if prescribed by a Doctor or Nurse Practitioner.

## 3.2.2 Where the period of treatment specified in the Prescription does not exceed six Months, the Community Pharmaceutical is to be dispensed:

- a) in Lots as specified in the Prescription if the Community Pharmaceutical is Close Control; or
- b) where no Lots are specified, in one Lot sufficient to provide treatment for the period prescribed.

## 3.2.3 An oral contraceptive is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor within three Months of the date on which it was written.

## 3.2.4 An oral contraceptive prescribed by a Midwife is only eligible for Subsidy if the Prescription under which it has been dispensed has been written within the period of post natal care of the eligible person.

## 3.2.5 Where a Community Pharmaceutical in a Prescription is Close Control and a repeat on the Prescription remains unfulfilled after six Months from the date the Community Pharmaceutical was first dispensed only the actual quantity supplied by the Contractor within this time limit will be eligible for Subsidy.

**3.3 Dentists' Prescriptions**

The following provisions apply to every Prescription written by a Dentist:

## 3.3.1 The maximum quantity of a Community Pharmaceutical that will be subsidised is as follows:

- a) where the Community Pharmaceutical is a Controlled Drug, only such quantity as is necessary to provide treatment for a period not exceeding five days; and
- b) in any other case, only such quantity as is necessary to provide treatment for a period not exceeding five days and, where the Prescription specifies a repeat, one further period not exceeding five days.

## 3.3.2 Notwithstanding clause 3.3.1, if, in the opinion of the Dentist, an eligible person needs extended treatment with sodium fluoride for up to three Months, the Community Pharmaceutical will be subsidised for that extended period. A Prescription for any such extended supply of sodium fluoride will be subsidised only if it is dispensed in Monthly Lots, unless the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect.

## 3.3.3 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed has been presented to the Contractor:

- a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or
- b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written.

## 3.3.4 No Subsidy will be paid for any Prescription, or part thereof, that is not fulfilled within:

- a) one Month from the date the Community Pharmaceutical was first dispensed; or
- b) in the case of sodium fluoride, three Months from the date the Community Pharmaceutical was first dispensed.

Only that part of any Prescription that is dispensed within the time frames specified above is eligible for Subsidy.

**3.4 Original Packs, and Certain Antibiotics**

## 3.4.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community Pharmaceutical that is identified as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an

## SECTION A: GENERAL RULES

amount or quantity eligible for Subsidy, is deemed to be a reference:

- a) where an amount by weight or volume of the Community Pharmaceutical is specified in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufficient to provide that amount; and
  - b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand.
- 3.4.2 If a Community Pharmaceutical is the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will only be made for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, unless the Contractor satisfies the Funder that he or she has not been able to dispense the balance of the pack or packs from which the Community Pharmaceutical has been dispensed. In such cases all of that pack or those packs is eligible for Subsidy.

## PART IV MISCELLANEOUS PROVISIONS

### 4.1 Bulk Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals under Bulk Supply Orders:

- 4.1.1 No Community Pharmaceutical supplied under a Bulk Supply Order will be subsidised unless all the requirements in Section B, C or D of the Schedule applicable to that pharmaceutical are met.
- 4.1.2 The person who placed the Bulk Supply Order may be called upon by the Ministry of Health to justify the amount ordered.
- 4.1.3 Class B Controlled Drugs will be subsidised only if supplied under Bulk Supply Orders placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001.
- 4.1.4 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Bulk Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 4.1.5 Community Pharmaceuticals listed in Part I of the First Schedule to the Medicines Regulations 1984 will be subsidised only if supplied under a Bulk Supply Order placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 and:
  - a) that institution employs a registered general nurse, registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003; and
  - b) the Bulk Supply Order is supported by a written requisition signed by a Hospital Care Operator.
- 4.1.6 No Subsidy will be paid for any quantity of a Community Pharmaceutical supplied under a Bulk Supply Order in excess of what is a reasonable monthly allocation for the particular institution, after taking into account stock on hand.
- 4.1.7 The Ministry of Health may, at any time, by public notification, declare that any approved institution within its particular region, is not entitled to obtain supplies of Community Pharmaceuticals under Bulk Supply Orders with effect from the date specified in that declaration. Any such notice may in like manner be revoked by the Ministry of Health at any time.

### 4.2 Practitioner's Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under a Practitioner's Supply Order:

- 4.2.1 Subject to clause 4.2.3, a Practitioner may only order under a Practitioner's Supply Order those Community Pharmaceuticals listed in Section E Part I and only in such quantities as set out in Section E Part I that the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.
- 4.2.2 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Practitioner's Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 4.2.3 A Practitioner may order such Community Pharmaceuticals as he or she expects to be required for personal administration to patients under the Practitioner's care if:
  - a) the Practitioner's normal practice is in the specified areas listed in Section E Part II of the Schedule, or if the Practitioner is a locum for a Practitioner whose normal practice is in such an area.
  - b) the quantities ordered are reasonable for up to one Month's supply under the conditions normally exist-

ing in the practice. (The Practitioner may be called on by the Ministry of Health to justify the amounts of Community Pharmaceuticals ordered.)

- 4.2.4 No Community Pharmaceutical ordered under a Practitioner's Supply order will be eligible for Subsidy unless:
- a) the Practitioner's Supply Order is made on a form supplied for that purpose by the Ministry of Health, or approved by HealthPAC's and which:
    - i) is personally signed and dated by the Practitioner; and
    - ii) sets out the Practitioner's address; and
    - iii) sets out the Community Pharmaceuticals and quantities, and;
  - b) all the requirements of Sections B and C of the Schedule applicable to that pharmaceutical are met.
- 4.2.5 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notification, declare that a Practitioner specified in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Practitioner's Supply Orders until such time as the Ministry of Health notifies otherwise.

#### 4.3 Wholesale Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under Wholesale Supply Orders:

- 4.3.1 Notwithstanding anything contained in the Schedule, but subject nevertheless to subclause 4.3.3 of this clause, a Practitioner may obtain from a wholesaler or distributor, pursuant to a Wholesale Supply Order made on a form supplied by the Ministry of Health, any Community Pharmaceutical specified in Section B and Section E Part I of the Schedule as being available on a Wholesale Supply Order.
- 4.3.2 Subject to clause 4.3.3, Community Pharmaceuticals supplied to Practitioners under Wholesale Supply Orders will be subsidised at a rate not exceeding the Manufacturer's Price for each such Community Pharmaceutical as set out in Section B and Section E Part I of the Schedule.
- 4.3.3 No subsidy will be paid for any quantity of a Community Pharmaceutical supplied to a Practitioner under a Wholesale Supply Order in excess of what is a reasonable monthly allocation for that particular Practitioner, after taking into account stock on hand.
- 4.3.4 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notification, declare that a Practitioner specified in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Wholesale Supply Orders until such time as the Ministry of Health notifies otherwise.

#### 4.4 Retail Pharmacy and Hospital Pharmacy-Specialist Restriction

The following provisions apply to Prescriptions for Community Pharmacy-Specialist eligible to be subsidised as "Retail Pharmacy-Specialist" and "Hospital Pharmacy-Specialist":

##### 4.4.1 Record Keeping

It is expected that a record will be kept by both the General Practitioner and the Specialist of the fact of consultation and enough of the clinical details to justify the recommendation. This means referral by telephone will need to be followed up by written consultation.

##### 4.4.2 Expiry

The recommendation expires at the end of two years and can be renewed by a further consultation.

- 4.4.3 The circulation by Specialists of the circumstances under which they are prepared to recommend a particular Community Pharmaceutical is acceptable as a guide. It must however be followed up by the procedure in subclauses 4.4.1 and 4.4.2, for the individual Patient.

- 4.4.4 The use of preprinted forms and named lists of Specialists (as circulated by some pharmaceutical companies) is regarded as inappropriate.

- 4.4.5 The Rules for Retail Pharmacy-Specialist and Hospital Pharmacy-Specialist will be audited as part of HealthPAC's routine auditing procedures.

#### 4.5 Pharmaceutical Cancer Treatments

- 4.5.1 DHBs must provide access to Pharmaceutical Cancer Treatments by funding their use in the treatment of cancers in their DHB hospitals, and/or in association with Outpatient services provided in their DHB hospitals.
- 4.5.2 DHBs must only provide access to Pharmaceuticals for the treatment of cancer that are listed as Pharmaceutical Cancer Treatments in Sections A to G of the Schedule, provided that DHBs may provide access to an unlisted pharmaceutical for the treatment of cancer where that unlisted pharmaceutical:
- a) has Cancer Exceptional Circumstances approval;
  - b) has Community Exceptional Circumstances or Hospital Exceptional Circumstances approval;

- c) is being used as part of a bona fide clinical trial which has Ethics Committee approval;
- d) is being used and funded as part of a paediatric oncology service; or
- e) was being used to treat the patient in question prior to 1 July 2005.

4.5.3 A DHB hospital pharmacy that holds a claiming agreement for Pharmaceutical Cancer Treatments with the Funder may claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" or "PCT only" in Sections A to G of this Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with:

- a) Part 1;
- b) clauses 2.1 to 2.3;
- c) clauses 3.1 to 3.4; and
- d) clause 4.5,

of Section A of the Schedule

4.5.4 A Contractor (other than a DHB hospital pharmacy) may only claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" in Sections A to G of the Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with the rules applying to Sections A to G of the Schedule.

4.5.5 Some indications for Pharmaceutical Cancer Treatments listed in the Schedule are Unapproved Indications. Some of these formed part of the October 2001 direction from the Minister of Health as to pharmaceuticals and indications for which DHBs must provide funding. As far as reasonably practicable, these Unapproved Indications are marked in the Schedule. However, PHARMAC makes no representation and gives no guarantee as to the accuracy of this information. Practitioners prescribing Pharmaceutical Cancer Treatments for such Unapproved Indications should:

- a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under the Medicines Act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- c) exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical Cancer Treatment or a Pharmaceutical Cancer Treatment for an Unapproved Indication.

#### 4.6 Practitioners prescribing unapproved Pharmaceuticals

Practitioners should, where possible, prescribe Pharmaceuticals that are approved under the Medicines Act 1981. However, the access criteria under which a Pharmaceutical is listed on the Pharmaceutical Schedule may:

- a) in some case, explicitly permit Government funded access to a Pharmaceutical that is not approved under the Medicines Act 1981 or for an Unapproved Indication; or
- b) not explicitly preclude Government funded access to a Pharmaceutical when it is used for an Unapproved Indication;

Accordingly, if Practitioners are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, Practitioners should:

- a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Practitioners should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

#### 4.7 Substitution

Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer's Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical available, a Contractor may dispense the fully subsidised Community Pharmaceutical, subject to:

- a) the Contractor having received a general Authority to Substitute from the Practitioner in relation to the particular medicine or medicines in general; or
  - b) the Practitioner having indicated their Authority to Substitute on the prescription; or
  - c) the Practitioner having given their Authority to Substitute in relation to the particular prescription.
- Such an Authority to Substitute is valid whether or not there is a financial implication for the Pharmaceutical Budget. When dispensing a subsidised alternative brand, the Contractor must annotate and initial the prescription.

#### **4.8 Alteration to Presentation of Pharmaceutical Dispensed**

A Contractor, when dispensing a Community Pharmaceutical, may alter the presentation of a Pharmaceutical dispensed but may not alter the total daily dose. If the change will result in additional cost to the DHBs, then:

- a) the Practitioner must authorise and initial the alteration; or
  - b) in cases where PHARMAC has approved and notified in writing such a change in dispensing of a named Pharmaceutical due to an out of stock event or short supply, the Contractor must annotate and initial the alteration.
- #### **4.9 Amendment of Schedule**
- PHARMAC may amend the terms of the Schedule from time to time by notice in writing given in such manner as PHARMAC thinks fit, and in accordance with such protocols as agreed with the Pharmacy Guild of New Zealand (Inc) from time to time.
- #### **4.10 Conflict in Provisions**
- If any rules in Sections B-G of this Schedule conflict with the rules in Section A, the rules in Sections B-G apply.

## SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Antacids and Antiflatulants</b>				
<b>Antacids and Reflux Barrier Agents</b>				
ALGINIC ACID				
Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet .....	4.50	30	✓	Gaviscon Infant
CALCIUM CARBONATE WITH AMINOACETIC ACID				
* Tab 420 mg with aminoacetic acid 180 mg – Higher subsidy of \$38.73 per 1000 with Endorsement.....	30.00 (38.73)	1,000		Titralac
Additional subsidy by endorsement is available for pregnant women. The prescription must be endorsed accordingly.				
SIMETHICONE				
* Oral liq aluminium hydroxide 200 mg with magnesium hydrox- ide 200 mg and activated simethicone 20 mg per 5 ml .....	1.50 (4.05)	500 ml		Mylanta P
SODIUM ALGINATE				
* Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour .....	1.80 (7.97)	60		Gaviscon Double Strength
* Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml .....	1.50 (4.95)	500 ml		Acidex
* Oral liq 500 mg with sodium bicarbonate 267 mg per 10 ml (aniseed) .....	1.50 (8.08)	500 ml		Gaviscon
<b>Phosphate Binding Agents</b>				
ALUMINIUM HYDROXIDE				
Tab 600 mg .....	12.56	100	✓	Alu-Tab
<b>Antidiarrhoeals</b>				
<b>Agents Which Reduce Motility</b>				
DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE				
* Tab 2.5 mg with atropine sulphate 25 µg .....	3.90	100	✓	Diastop
LOPERAMIDE HYDROCHLORIDE – Up to 30 tab available on a PSO				
* Tab 2 mg .....	11.50	400	✓	Nodia
<b>Rectal and Colonic Anti-inflammatories</b>				
BUDESONIDE				
Cap 3 mg – Special Authority see SA0913 on the next page – Retail pharmacy .....	166.50	90	✓	Entocort CIR

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per	✓

►SA0913 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:  
Both:

- 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and
- 2 Any of the following:
  - 2.1 Diabetes; or
  - 2.2 Cushingoid habitus; or
  - 2.3 Osteoporosis where there is significant risk of fracture; or
  - 2.4 Severe acne following treatment with conventional corticosteroid therapy.

**Renewal** from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

The patient may not have had more than 1 prior approval in the last year.

Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.

**HYDROCORTISONE ACETATE**

Rectal foam 10 %, CFC-Free (14 applications) .....	21.10	21.1 g OP	✓ <u>Colifoam</u>
--	-------	-----------	-------------------

**MESALAZINE**

Tab 400 mg – Retail pharmacy-Specialist .....	49.50	100	✓ <u>Asacol</u>
Tab long-acting 500 mg – Retail pharmacy-Specialist .....	69.06	100	✓ <u>Pentasa</u>
Enema 1 g per 100 ml – Retail pharmacy-Specialist .....	46.90	7	✓ <u>Pentasa</u>
Suppos 500 mg .....	25.20	20	✓ <u>Asacol</u>
Suppos 1 g .....	50.96	28	✓ <u>Pentasa</u>

**OLSALAZINE**

Tab 500 mg .....	59.86	100	✓ <u>Dipentum</u>
Cap 250 mg .....	31.51	100	✓ <u>Dipentum</u>

**SODIUM CROMOGLYCATE**

Cap 100 mg .....	89.21	100	✓ <u>Nalcrom</u>
------------------	-------	-----	------------------

**SULPHASALAZINE**

* Tab 500 mg .....	8.42	100	✓ <u>Salazopyrin</u>
* Tab EC 500 mg .....	9.44	100	✓ <u>Salazopyrin EN</u>

**Antihaemorrhoidals**

**Corticosteroids**

**FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE**

Oint 950 µg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g .....	6.35	30 g OP	✓ <u>Ultraproct</u>
Suppos 630 µg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg .....	2.66	12	✓ <u>Ultraproct</u>

**Soothing Agents**

**ZINC OXIDE**

Oint zinc oxide with balsam peru .....	4.50	50 g OP	
	(6.50)		Anusol
Suppos zinc oxide with balsam peru .....	4.47	12	
	(6.35)		Anusol

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Antispasmodics and Other Agents Altering Gut Motility</b>				
ATROPINE SULPHATE				
* Inj 600 µg, 1 ml – Up to 5 inj available on a PSO .....	26.00	50	✓	<u>AstraZeneca</u>
* Inj 1200 µg, 1 ml – Up to 5 inj available on a PSO .....	32.00	50	✓	<u>AstraZeneca</u>
HYOSCINE N-BUTYLBROMIDE				
* Tab 10 mg .....	1.62	20	✓	<u>Gastrosoothe</u>
* Inj 20 mg, 1 ml – Up to 5 inj available on a PSO .....	8.04	5	✓	<u>Buscopan</u>
MEBEVERINE HYDROCHLORIDE				
* Tab 135 mg .....	18.00	90	✓	<u>Colofac</u>
<b>Antilucerants</b>				
<b>Antisecretory and Cytoprotective</b>				
MISOPROSTOL				
* Tab 200 µg .....	52.70	120	✓	<u>Cytotec</u>
<b>Helicobacter Pylori Eradication</b>				
OMEPRAZOLE, AMOXYCILLIN AND CLARITHROMYCIN				
Omeprazole cap 20 mg × 14, amoxicillin cap 500 mg × 28 and clarithromycin tab 500 mg × 14 .....	55.00	1 OP	✓	<u>Losec Hp7 OAC</u>
<b>H2 Antagonists</b>				
CIMETIDINE – Only on a prescription				
* Tab 200 mg .....	5.00 (7.50)	100		Apo-Cimetidine
* Tab 400 mg .....	10.00 (12.00)	100		Apo-Cimetidine
FAMOTIDINE – Only on a prescription				
* Tab 20 mg .....	8.10	250	✓	<u>Famox</u>
* Tab 40 mg .....	11.35	250	✓	<u>Famox</u>
RANITIDINE HYDROCHLORIDE – Only on a prescription				
* Tab 150 mg .....	7.99	250	✓	<u>Arrow-Ranitidine</u>
* Tab 300 mg .....	10.94	250	✓	<u>Arrow-Ranitidine</u>
* Oral liq 150 mg per 10 ml .....	7.95	300 ml	✓	<u>Peptisoothe</u>
* Inj 25 mg per ml, 2 ml .....	8.75	5	✓	<u>Zantac</u>
<b>Proton Pump Inhibitors</b>				
LANSOPRAZOLE				
* Cap 15 mg .....	4.30	28	✓	<u>Solox</u>
* Cap 30 mg .....	8.59	28	✓	<u>Solox</u>

## ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>OMEPRAZOLE</b>				
For omeprazole suspension refer, page 166				
* Cap 10 mg .....	2.14	30	✓	<b>Dr Reddy's Omeprazole</b>
	(8.43)			Losec
* Cap 20 mg .....	3.05	30	✓	<b>Dr Reddy's Omeprazole</b>
	(9.00)			Losec
* Cap 40 mg .....	3.59	30	✓	<b>Dr Reddy's Omeprazole</b>
	(11.25)			Losec
* Inj 40 mg .....	12.50	1	✓	<b>Losec</b>
<i>(Losec Cap 10 mg to be delisted 1 May 2009)</i>				
<i>(Losec Cap 20 mg to be delisted 1 May 2009)</i>				
<i>(Losec Cap 40 mg to be delisted 1 May 2009)</i>				
<i>(Losec Inj 40 mg to be delisted 1 May 2009)</i>				

<b>PANTOPRAZOLE</b>				
* Tab 20 mg .....	2.24	28	✓	<b>Dr Reddy's Pantoprazole</b>
* Tab 40 mg .....	3.36	28	✓	<b>Dr Reddy's Pantoprazole</b>

### Site Protective Agents

<b>SUCRALFATE</b>				
Tab 1 g .....	35.50	120		
	(48.28)			Carafate

### Diabetes

#### Hyperglycaemic Agents

<b>GLUCAGON HYDROCHLORIDE</b>				
Inj 1 mg syringe kit – Up to 5 kit available on a PSO.....	27.00	1	✓	<b>Glucagen Hypokit</b>

#### Insulin - Short-acting Preparations

<b>INSULIN NEUTRAL</b>				
▲ Inj human 100 u per ml .....	25.26	10 ml OP	✓	<b>Actrapid</b>
				✓ <b>Humulin R</b>
▲ Inj human 100 u per ml, 3 ml .....	42.66	5	✓	<b>Actrapid Penfill</b>
				✓ <b>Humulin R</b>

#### Insulin - Intermediate-acting Preparations

<b>INSULIN ISOPHANE</b>				
▲ Inj human 100 u per ml .....	17.68	10 ml OP	✓	<b>Humulin NPH</b>
				✓ <b>Protaphane</b>
▲ Inj human 100 u per ml, 3 ml .....	29.86	5	✓	<b>Humulin NPH</b>
				✓ <b>Protaphane Penfill</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>INSULIN ISOPHANE WITH INSULIN NEUTRAL</b>				
▲ Inj human with neutral insulin 100 u per ml .....	25.26	10 ml OP	✓	<b>Humulin 30/70</b>
▲ Inj human with neutral insulin 100 u per ml, 3 ml .....	42.66	5	✓	<b>Mixtard 30</b>
			✓	<b>Humulin 30/70</b>
			✓	<b>PenMix 30</b>
			✓	<b>PenMix 40</b>
			✓	<b>PenMix 50</b>
<b>INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE</b>				
▲ Inj lispro 25% with insulin lispro protamine 75% 100 u per ml, 3 ml .....	52.15	5	✓	<b>Humalog Mix 25</b>
▲ Inj lispro 50% with insulin lispro protamine 50% 100 u per ml,3 ml .....	52.15	5	✓	<b>Humalog Mix 50</b>

### Insulin - Long-acting Preparations

INSULIN GLARGINE – Special Authority see SA0834 below – Retail pharmacy

▲ Inj 100 u per ml, 10 ml .....	63.00	1	✓	<b>Lantus</b>
▲ Inj 100 u per ml, 3 ml .....	94.50	5	✓	<b>Lantus</b>
▲ Inj 100 u per ml, 3 ml disposable pen .....	94.50	5	✓	<b>Lantus SoloStar</b>

#### ►SA0834 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

1 Both:

1.1 Patient has type 1 diabetes and has received an intensive regimen (injections at least three times a day) of an intermediate acting insulin in combination with a rapid acting insulin analogue for at least three months; and

1.2 Either:

1.2.1 Patient has experienced more than one unexplained severe hypoglycaemic episode in the previous 12 months (severe defined as requiring the assistance of another person); or

1.2.2 Patient has experienced unexplained symptomatic nocturnal hypoglycaemia, biochemically documented at <3.0 mmol/L, more than once a month despite optimal management; or

2 Patient has documented severe, or continuing, systemic or local allergic reaction to existing insulins. Note this does not include hypoglycaemic episodes.

**Renewal** only from a relevant specialist or general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

1 Patient is continuing to derive benefit due to reduced hypoglycaemic events whilst maintaining similar or better glycaemic control; or

2 Patient's allergic reaction has significantly decreased, or resolved, following the change to long-acting insulin and patient is continuing to benefit from treatment.

### Insulin - Rapid Acting Preparations

INSULIN ASPART

▲ Inj 100 u per ml, 3 ml .....	53.57	5	✓	<b>NovoRapid Penfill</b>
▲ Inj 100 u per ml, 10 ml .....	31.43	1	✓	<b>NovoRapid</b>

INSULIN LISPRO

▲ Inj 100 u per ml, 10 ml .....	34.92	10 ml OP	✓	<b>Humalog</b>
▲ Inj 100 u per ml, 3 ml .....	59.52	5	✓	<b>Humalog</b>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

**Alpha Glucosidase Inhibitors**

ACARBOSE – Special Authority see SA0925 below – Retail pharmacy

* Tab 50 mg	22.00	90	✓	Glucobay
* Tab 100 mg	31.00	90	✓	Glucobay

**▶SA0925 Special Authority for Subsidy**

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has type 2 diabetes; and
- 2 Either:
  - 2.1 Metformin is not tolerated, or is contraindicated; or
  - 2.2 The patient has not responded to the maximum appropriate dose of metformin.

**Oral Hypoglycaemic Agents**

GLIBENCLAMIDE

* Tab 2.5 mg	3.78	100	✓	Gliben
* Tab 5 mg	3.31	100	✓	Gliben

GLICLAZIDE

* Tab 80 mg	22.24	500	✓	<u>Apo-Gliclazide</u>
-------------	-------	-----	---	-----------------------

GLIPIZIDE

* Tab 5 mg	3.50	100	✓	<u>Minidiab</u>
------------	------	-----	---	-----------------

METFORMIN HYDROCHLORIDE

* Tab 500 mg	9.75	500	✓	<u>Arrow-Metformin</u>
* Tab 850 mg	8.00	250	✓	<u>Arrow-Metformin</u>

PIOGLITAZONE – Special Authority see SA0859 below – Retail pharmacy

Tab 15 mg	61.04	28	✓	Actos
Tab 30 mg	93.90	28	✓	Actos
Tab 45 mg	119.18	28	✓	Actos

**▶SA0859 Special Authority for Subsidy**

**Initial application — (Patients with type 2 diabetes)** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

Monotherapy

- 1 All of the following:
  - 1.1 To be used as monotherapy for patients who after six months of diet and lifestyle changes have inadequate glycaemic control (defined as HbA1c > 7.0% in tests carried out at least two months apart); and
  - 1.2 Metformin is contraindicated or not tolerated after a minimum of a four-week trial period; and
  - 1.3 Sulphonylurea is contraindicated or not tolerated or the patient is obese; or

In combination with sulphonylurea

- 2 Both:
  - 2.1 For use in combination with a sulphonylurea for patients who after diet and lifestyle changes and a six-month trial of sulphonylurea have poor glycaemic control (defined as HbA1c > 7.5% measured within the last month of the six-month period); and
  - 2.2 Metformin is contraindicated or not tolerated after a minimum of a four-week trial period; or

In combination with metformin

- 3 Both:

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 3.1 For use in combination with metformin for patients who after diet and lifestyle changes and a six-month trial of the maximum tolerated dose of metformin have poor glycaemic control (defined as HbA1c > 7.5% measured within the last month of the six-month period); and
- 3.2 Sulphonylurea is contraindicated or not tolerated, or the patient is obese; or  
In combination with metformin after a trial of metformin and sulphonylurea
- 4 For use in combination with metformin for patients who after diet and lifestyle changes and a six-month trial of a combination of metformin and sulphonylurea at maximum tolerated doses have poor glycaemic control (defined as HbA1c > 7.5% measured within the last month of the six month period); or  
In combination with Insulin
- 5 For use in combination with insulin in patients requiring more than 1.5 units per kilogram of insulin a day for at least 6 months in conjunction with metformin if tolerated.

**Renewal — (Patients with type 2 diabetes)** from any relevant practitioner. Approvals valid for 1 year where patient is continuing to derive benefit from treatment.

Notes: Pioglitazone is not to be used in triple oral combination (defined as a combination of metformin, sulphonylurea and pioglitazone).

Pioglitazone should not be used in patients with heart failure.

Liver function tests should be performed at baseline.

Gastrointestinal side effects are relatively common when initiating metformin therapy. Upward titration of metformin dose over several weeks and taking metformin with food will help to minimize these side effects.

Intolerance and contraindications for metformin include: serum creatinine  $\geq$  0.15 or creatinine clearance < 60 ml/min; significant liver impairment; severe left ventricular dysfunction; and intolerable gastrointestinal side effects that persist beyond 4 weeks duration.

Intolerance for sulphonylurea includes: nausea; diarrhoea; rash; blood disorders (thrombocytopenia, agranulocytosis, aplastic anaemia); erythema multiforme, exfoliative dermatitis, hepatitis; and syndrome of inappropriate antidiuretic hormone secretion (SIADH) with water retention and hyponatraemia.

Maximum tolerated dose of metformin defined as: A dose up to a maximum of 3 g daily.

Maximum tolerated dose of sulphonylurea defined as: A dose up to a maximum of glibenclamide 20 mg daily or glipizide 20 mg daily or gliclazide 320 mg daily.

For the purposes of these criteria "obese" is defined as body mass index (BMI) greater than 33 kg/m<sup>2</sup>.

However, as ethnic differences between patients may vary BMI scores, practitioners may use discretion as to whether the patient meets this criterion.

It is considered that when applying, that the patient may have initiated "six months diet and lifestyle changes" from the date of diagnosis of type 2 diabetes.

## Diabetes Management

### Glucose/Urine Testing

#### COPPER

* Tab, diagnostic – Not on a BSO .....	5.02	36 OP	
	(30.25)		Clinitest

#### GLUCOSE OXIDASE

Urine diagnostic test – Not on a BSO.....	4.11	50 strip OP	
	(7.00)		Diabur 5000
Urine diagnostic test with peroxidase – Not on a BSO.....	4.13	50 strip OP	
	(6.05)		Clinistix
	4.11		
	(6.05)		Diastix

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

**Glucose &/or Ketones/Urine Testing**

**GLUCOSE OXIDASE**

Urine diagnostic test with peroxidase, sodium nitroprusside and aminoacetic acid – Not on a BSO.....	4.53 (8.00)	50 stick OP		Keto-Diabur 5000
Urine diagnostic test with peroxidase, potassium iodide, sodium nitroprusside and aminoacetic acid – Not on a BSO.....	4.53 (7.50)	50 strip OP		Keto-Diastix

**SODIUM NITROPRUSSIDE**

* Urine diagnostic strips, buffered – Not on a BSO.....	3.39 (6.00)	50 strip OP		Ketur-Test
	3.40 (7.15)			Ketostix

**Glucose/Blood Testing**

**GLUCOSE BLOOD DIAGNOSTIC TEST METER – Subsidy by endorsement**

- a) Maximum of 1 meter per prescription
- b) A diagnostic blood glucose test meter is subsidised for patients who begin insulin or sulphonylurea therapy after 1 March 2005. Only one meter per patient. No further prescriptions will be subsidised. The prescription must be endorsed accordingly.

Meter .....	9.00	1	✓	<b>Optium Xceed</b>
	19.00		✓	<b>Accu-Chek Performa</b>

**GLUCOSE DEHYDROGENASE**

The number of test strips available on a prescription is restricted to 50 unless:

- 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly;
- 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or
- 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly.

Blood/glucose test strips .....	22.00	50 test OP	✓	<b>Accu-Chek Performa</b>
			✓	<b>Optium</b>

**Insulin Syringes and Needles**

Subsidy is available for disposable insulin syringes, needles, and pen needles if prescribed on the same form as the one used for the supply of insulin or when prescribed for an insulin patient and the prescription is endorsed accordingly.

**INSULIN PEN NEEDLES – Maximum of 100 dev per prescription**

NovoFine pen needles 31 g x 6 mm are subsidised for children under 12 years of age.

* 29 g x 12.7 mm .....	11.75 13.09	100	✓	<b>ABM</b>
* 31 g x 5 mm .....	13.09	100	✓	<b>B-D Micro-Fine</b>
* 31 g x 6 mm .....	11.75 26.00	100	✓	<b>B-D Micro-Fine</b>
* 31 g x 8 mm .....	11.75 13.09	100	✓	<b>ABM</b>
			✓	<b>B-D Micro-Fine</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription				
* Syringe 0.3 ml with 29 g × 12.7 mm needle .....	14.45	100	✓	ABM
	15.92		✓	B-D Ultra Fine
* Syringe 0.3 ml with 31 g × 8 mm needle .....	14.45	100	✓	ABM
	15.92		✓	B-D Ultra Fine II
* Syringe 0.5 ml with 29 g × 12.7 mm needle .....	14.45	100	✓	ABM
	15.92		✓	B-D Ultra Fine
* Syringe 0.5 ml with 31 g × 8 mm needle .....	14.45	100	✓	ABM
	15.92		✓	B-D Ultra Fine II
* Syringe 1 ml with 29 g × 12.7 mm needle .....	14.45	100	✓	ABM
	15.92		✓	B-D Ultra Fine
* Syringe 1 ml with 31 g × 8 mm needle .....	14.45	100	✓	ABM
	15.92		✓	B-D Ultra Fine II

### Digestives Including Enzymes

#### PANCREATIC ENZYME

Tab EC 1,900 BP u lipase, 1,700 BP u amylase, 110 BP u protease .....	32.46	300	✓	Pancrex V
Tab EC 5,600 BP u lipase, 5,000 BP u amylase, 330 BP u protease .....	58.44	300	✓	Pancrex V Forte
Cap 8,000 BP u lipase, 9,000 BP u amylase, 430 BP u protease .....	67.26	300	✓	Pancrex V
Cap 8,000 USP u lipase, 30,000 USP u amylase, 30,000 USP u protease – Retail pharmacy-Specialist .....	85.00	250	✓	Cotazym ECS
Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease – Retail pharmacy-Specialist .....	34.93	100	✓	Creon 10000
Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease – Retail pharmacy-Specialist .....	94.38	100	✓	Creon Forte
Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease – Retail pharmacy-Specialist .....	94.40	100	✓	Panzytrat
URSODEOXYCHOLIC ACID – Special Authority see SA0914 below – Retail pharmacy				
Cap 300 mg .....	179.00	100	✓	Actigall

#### ►SA0914 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 170µmol/l; decompensated cirrhosis).

Note: Liver biopsy is not usually required for diagnosis but is helpful to stage the disease.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Actigall is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
--	---	-----	---------------------	-------------------------------------

**Laxatives**

**Bulk-forming Agents**

MUCILAGINOUS LAXATIVES – Only on a prescription

* Dry	5.72	325 g OP	✓	Konsyl-D
	6.69	380 g OP	✓	Mucilax
	7.92	450 g OP		
	(12.71)			Isogel
	8.80	500 g OP		
	(15.27)			Normacol
* Dry-original flavour, regular texture only	5.91	336 g OP		
	(12.38)			Metamucil
* Sugar Free	4.84	275 g OP		
	(10.60)			Mucilax
MUCILAGINOUS LAXATIVES WITH STIMULANTS				
* Dry	3.52	200 g OP		
	(7.69)			Normacol Plus
	8.80	500 g OP		
	(15.27)			Normacol Plus

**Faecal Softeners**

DOCUSATE SODIUM – Only on a prescription

* Tab 50 mg	4.89	100	✓	Coloxyl
* Tab 120 mg	6.73	100	✓	Coloxyl
* Enema conc 18%	5.40	100 ml OP	✓	Coloxyl

DOCUSATE SODIUM WITH SENNOSIDES

* Tab 50 mg with total sennosides 8 mg	7.98	200	✓	Laxsol
--	------	-----	---	--------

POLOXAMER – Only on a prescription

* Oral drops 10%	3.78	30 ml OP	✓	Coloxyl
------------------	------	----------	---	---------

**Osmotic Laxatives**

GLYCEROL

* Suppos 2.55 g – Only on a prescription	3.12	12	✓	Fleet Glycerin Suppositories
* Suppos 3.6 g – Only on a prescription	5.00	20	✓	PSM

LACTULOSE – Only on a prescription

* Oral liq 10 g per 15 ml	6.65	1,000 ml	✓	Duphalac
---------------------------	------	----------	---	----------

MACROGOL 3350 – Special Authority see SA0891 below – Retail pharmacy

Powder 13.125 g, sachets – Maximum of 60 sach per prescription	18.14	30	✓	Movicol
--	-------	----	---	---------

▶SA0891 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulose where lactulose is not contraindicated.

**Renewal** from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to gain benefit from treatment.

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>SODIUM ACID PHOSPHATE – Only on a prescription</b>				
Enema 16% with sodium phosphate 8% .....	2.50	1	✓	<b>Fleet Phosphate Enema</b>
<b>SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Only on a prescription</b>				
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml .....	7.30	12	✓	<b>Microlax</b>
<b>Stimulant Laxatives</b>				
<b>BISACODYL – Only on a prescription</b>				
* Tab 5 mg .....	5.09	200	✓	<b>Lax-Tabs</b>
* Suppos 5 mg .....	2.35 (3.00)	6		Dulcolax
* Suppos 10 mg .....	3.96	12	✓	<b>Fleet</b>
<b>SENNA – Only on a prescription</b>				
* Tab, standardised .....	2.17 (6.16)	100		Senkot

## Metabolic Disorder Agents

### Gaucher's Disease

<b>IMIGLUCERASE – Special Authority see SA0473 below – Hospital pharmacy [HP1]</b>				
Inj 40 iu per ml, 200 iu vial .....	1,072.00	1	✓	<b>Cerezyme</b>

#### ►SA0473 Special Authority for Subsidy

Special Authority approved by the Gaucher's Treatment Panel

Notes: Subject to a budgetary cap. Applications will be considered and approved subject to funding availability.

Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The Co-ordinator, Gaucher's Treatment Panel  
PHARMAC, PO Box 10 254  
Wellington

Phone: (04) 460 4990  
Facsimile: (04) 916 7571  
Email: [gaucherpanel@pharmac.govt.nz](mailto:gaucherpanel@pharmac.govt.nz)

## Mouth and Throat

### Agents Used in Mouth Ulceration

<b>BENZYDAMINE HYDROCHLORIDE</b>				
Soln 0.15% .....	9.00 (15.36)	500 ml		Difflam
<b>CHLORHEXIDINE GLUCONATE</b>				
Mouthwash 0.2% .....	3.06	200 ml OP	✓	<b>Orion</b>
<b>CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE</b>				
* Adhesive gel 8.7% with cetalkonium chloride 0.01% .....	2.06 (5.05)	15 g OP		Bonjela

## ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>SODIUM CARBOXYMETHYLCELLULOSE</b>				
With pectin and gelatin paste .....	17.20	56 g OP	✓	<b>Stomahesive</b>
	1.52 (3.60)	5 g OP		Orabase
	4.55 (7.90)	15 g OP		Orabase
With pectin and gelatin powder .....	8.48 (10.95)	28 g OP		Stomahesive
<b>TRIAMCINOLONE ACETONIDE</b>				
0.1% in Dental Paste USP .....	4.38	5 g OP	✓	<b>Oracort</b>

### Oropharyngeal Anti-infectives

<b>AMPHOTERICIN B</b>				
Lozenges 10 mg .....	5.86	20	✓	<b>Fungilin</b>
<b>MICONAZOLE</b>				
Oral gel 20 mg per g .....	8.95	40 g OP	✓	<b>Daktarin</b>
<b>NYSTATIN</b>				
Oral liq 100,000 u per ml .....	3.19	24 ml OP	✓	<b>Nilstat</b>

### Other Oral Agents

For folinic mouthwash, pilocarpine oral liquid or saliva substitute formula refer, page 166

<b>HYDROGEN PEROXIDE</b>				
* Solution 10 vol – Maximum of 200 ml per prescription .....	1.28	100 ml	✓	<b>PSM</b>
<b>THYMOL GLYCERIN</b>				
* Compound, BPC .....	9.15	500 ml	✓	<b>PSM</b>

### Vitamins

#### Vitamin A

##### VITAMIN A WITH VITAMINS D AND C

Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops .....	4.38 (5.51)	10 ml OP		Vitadol C
--	----------------	----------	--	-----------

#### Vitamin B Group

<b>HYDROXOCOBALAMIN</b>				
* Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO .....	9.21	3	✓	<b>ABM</b>
	10.84			Hydroxocobalamin ✓ <b>Neo-B12</b>
<b>PYRIDOXINE HYDROCHLORIDE</b>				
a) No more than 100 mg per dose				
b) Only on a prescription				
* Tab 25 mg – No patient co-payment payable .....	3.06	90	✓	<b>Healtheries</b>
* Tab 50 mg .....	17.63	500	✓	<b>Apo-Pyridoxine</b>
<b>THIAMINE HYDROCHLORIDE – Only on a prescription</b>				
* Tab 50 mg .....	5.62	100	✓	<b>Apo-Thiamine</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>VITAMIN B COMPLEX</b>				
* Tab, strong, BPC .....	12.10	500	✓	<b><u>Apo-B-Complex</u></b>
<b>Vitamin C</b>				
<b>ASCORBIC ACID</b>				
a) No more than 100 mg per dose				
b) Only on a prescription				
* Tab 100 mg .....	17.25	500	✓	<b><u>Apo-Ascorbic Acid</u></b>
<b>Vitamin D</b>				
<b>ALFACALCIDOL</b>				
Cap 0.25 µg .....	26.32	100	✓	<b><u>One-Alpha</u></b>
Cap 1 µg .....	87.98	100	✓	<b><u>One-Alpha</u></b>
Oral drops 2 µg per ml .....	60.68	20 ml OP	✓	<b><u>One-Alpha</u></b>
<b>CALCITRIOL</b>				
* Cap 0.25 µg .....	13.45	100	✓	<b><u>Calcitriol-AFT</u></b>
* Cap 0.5 µg .....	24.95	100	✓	<b><u>Calcitriol-AFT</u></b>
* Oral liq 1 µg per ml .....	39.40	10 ml OP	✓	<b><u>Rocaltrol solution</u></b>
<b>CHOLECALCIFEROL</b>				
* Tab 1.25 mg (50,000 iu) – Maximum of 12 tab per prescription .....	10.35	12	✓	<b><u>Cal-d-Forte</u></b>

### Vitamin E

<b>ALPHA TOCOPHERYL ACETATE</b> – Special Authority see SA0915 below – Hospital pharmacy [HP3]				
Water solubilised soln 156 iu/ml, with calibrated dropper .....	18.30	50 ml OP	✓	<b><u>Micelle E</u></b>

#### ►SA0915 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Cystic fibrosis patient; or
- 2 Both:
  - 2.1 Infant or child with liver disease or short gut syndrome; and
  - 2.2 Requires vitamin supplementation.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

### Multivitamin Preparations

<b>VITAMINS</b>				
* Tab (BPC cap strength) .....	14.80	1,000	✓	<b><u>Healtheries Multi-vitamin tablets</u></b>

## Minerals

### Calcium

<b>CALCIUM</b>				
* Tab eff 1 g (elemental) .....	6.54	30	✓	<b><u>Calsource</u></b>
<b>CALCIUM CARBONATE</b>				
* Tab 1.25 g .....	9.18	250	✓	<b><u>Calci-Tab 500</u></b>
* Tab 1.5 g .....	10.33	250	✓	<b><u>Calci-Tab 600</u></b>

## ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>CALCIUM GLUCONATE</b>				
* Inj 10%, 10 ml .....	21.40	10	✓	<b>Mayne</b>
<b>Fluoride</b>				
<b>SODIUM FLUORIDE</b>				
Tab 1.1 mg .....	4.00	100	✓	<b>PSM</b>
<b>Iron</b>				
<b>FERROUS FUMARATE</b>				
Tab 200 mg .....	3.75	100	✓	<b>Ferro-tab</b>
<b>FERROUS FUMARATE WITH FOLIC ACID</b>				
Tab 310 mg with folic acid 350 µg .....	3.95	60	✓	<b>Ferro-F-Tabs</b>
<b>FERROUS GLUCONATE WITH ASCORBIC ACID</b>				
* Tab 170 mg with ascorbic acid 40 mg .....	12.04	500	✓	<b>Healtheries Iron with Vitamin C</b>
<b>FERROUS SULPHATE</b>				
* Tab long-acting 325 mg .....	5.06 (13.55)	150		Ferro-Gradumet
* ‡ Oral liq 150 mg per 5 ml .....	10.30	500 ml	✓	<b>Ferodan</b>
<b>FERROUS SULPHATE WITH FOLIC ACID</b>				
* Tab long-acting 325 mg with folic acid 350 µg .....	1.80 (3.24)	30		Ferrograd-Folic
<b>IRON POLYMALTOSE</b>				
Inj 50 mg per ml, 2 ml .....	20.95	5	✓	<b>Ferrum H</b>
<b>Magnesium</b>				
For magnesium hydroxide mixture refer, page 166				
<b>MAGNESIUM SULPHATE</b>				
Inj 49.3% .....	26.60	10	✓	<b>Mayne</b>
<b>Zinc</b>				
<b>ZINC SULPHATE</b>				
* Cap 220 mg .....	10.00	100	✓	<b>Zincaps</b>

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## The Assessment and Management of Cardiovascular Risk

intervention and follow-up.

### Absolute Cardiovascular Risk

Treatment decisions are based on the likelihood an individual will have a cardiovascular (CV) event over a given period of time. This replaces decision-making based on single risk factor levels. By knowing the risk level, an individual and their practitioner can make decisions for prevention and treatment of cardiovascular disease, including lifestyle advice, diabetes care, the prescription of lipid-modifying and blood pressure lowering medication and/or medication after myocardial infarction (MI) or ischaemic stroke.

The following steps explain the actions taken at each stage.

### Step 1: Select people for risk assessment

#### Recommended ages for starting CV risk assessment

- Māori, Pacific peoples and people from the Indian subcontinent - age 35 years for men and age 45 years for women
- People with known cardiovascular risk factors or at high risk of developing diabetes - age 35 years for men and age 45 years for women
- Asymptomatic people, without known risk factors - age 45 years for men and age 55 years for women.

### Step 2: Measure and record risk factors

A comprehensive CV risk assessment includes measurement, and recording of: age, gender, ethnicity, smoking history, a fasting lipid profile, a fasting plasma glucose, the average of two sitting BPs, family history, waist circumference, BMI.

People with diabetes will require additional tests: HbA1c, albumin: creatinine ratio, creatinine and date of diagnosis.

The risk of MI and ischaemic stroke increases before diagnostic levels of plasma glucose for diabetes are reached. People with IGT, IFG or the metabolic syndrome need active

### Step 3: Risk Assessment

#### Who does not need their risk calculated using the CV risk tables?

5-year CV risk is assumed clinically to be more than 20% in:

- people who have had a previous cardiovascular event
- people with some genetic lipid disorders (familial hypercholesterolaemia, familial defective ApoB and familial combined dyslipidaemia)
- people with diabetes and overt nephropathy (albumin:creatinine ratio  $\geq 30$  mg/mmol) or diabetes with other renal disease.

#### Where risk may be underestimated using the cardiovascular risk tables

People with isolated elevated single risk factor levels will have at least greater than 15% CV risk over 5 years.

- TC greater than 8 mmol/L
- TC:HDL ratio greater than 8
- Blood pressure consistently greater than 170/100 mm Hg
- For age greater than 75 years the 5-year CV risk is greater than 15% in nearly all individuals.

5% may be added to CV risk for:

- a family history of premature coronary heart disease or ischaemic stroke in father or brother before the age of 55 years or mother or sister before the age of 65 years
- Māori
- Pacific or Indian people
- diabetes and microalbuminuria
- type 2 diabetes after 10 years
- type 2 diabetes with an HbA1c  $> 8\%$
- the metabolic syndrome

These adjustments should be made once only for people who have more than one criteria (the maximum adjustment is 5%).

Step 4: Intervention according to cardiovascular risk assessment

Cardiovascular risk	Lifestyle	Drug Therapy	Treatment goals	Follow-up
<b>CVD risk clinically determined more than 20%</b>	Intensive lifestyle advice on a cardioprotective dietary pattern with a dietitian, physical activity and smoking cessation interventions. Lifestyle advice should be given simultaneously with drug treatment	Aspirin, if not contraindicated, a beta blocker, statin and an ACE-inhibitor (after MI) or aspirin, statin and a new or increased dose of a blood pressure lowering agent (after stroke)	Efforts should be made to reach optimal risk factor levels	Cardiovascular risk assessments at least annually, risk factor monitoring every 3 to 6 months
<b>CVD risk calculated more than 20%</b>	Intensive lifestyle advice on a cardioprotective dietary pattern with a dietitian, physical activity and smoking cessation interventions. Lifestyle advice should be given simultaneously with drug treatment	Aspirin and drug treatment of all modifiable risk factors (blood pressure lowering, lipid modification and glycaemic control)	Risk factors treated to a level that will lower 5-year cardiovascular risk to less than 15% (by recalculating risk)	Cardiovascular risk assessments at least annually, risk factor monitoring every 3 to 6 months
<b>15% to 20%</b>	Specific individualised lifestyle advice on a cardioprotective dietary pattern, physical activity and smoking cessation. This lifestyle advice should be given by the primary health care team for 3 to 6 months prior to initiating drug treatment	Aspirin and drug treatment of all modifiable risk factors (blood pressure lowering, lipid modification and glycaemic control). Drug therapy indicated for people with extreme risk factor levels	Risk factors treated to a level that will lower 5-year cardiovascular risk to less than 15% (by recalculating risk)	Cardiovascular risk assessments at least annually, risk factor monitoring every 3 to 6 months
<b>10% to 15%</b>	Specific individualised lifestyle advice on a cardioprotective dietary pattern, physical activity and smoking cessation. This lifestyle advice should be given by the primary health care team	Non-pharmacological approach to treating multiple risk factors	Lifestyle advice aimed at reducing cardiovascular risk	Further cardiovascular risk assessment in 5 years
<b>less than 10%</b>	General lifestyle advice on a cardioprotective dietary pattern, physical activity and smoking cessation	Non-pharmacological approach to treating multiple risk factors	Lifestyle advice aimed at reducing cardiovascular risk	Further cardiovascular risk assessment in 5 to 10 years


Detail provided on the summary document of the evidence-based, best practice guideline, *The Assessment and Management of Cardiovascular Risk*. It is available for download at [www.nzgg.org.nz](http://www.nzgg.org.nz) - click on 'Guidelines/Publications' then 'Cardiology'.



# CARDIOVASCULAR DISEASE: BASELINE RISK AND TREATMENT BENEFITS

## Risk level women

### Risk level women




**Risk Level**  
5 year CVD risk (non-fatal and fatal)



#### How to use the Tables

- Identify the table relating the to person's sex, diabetic status, smoking history and age
- Within the table choose the cell nearest to the person's age, blood pressure and TC:HDL ratio. When the systolic and diastolic values fall in different risk levels, the higher category applies.
- For example, the lower left cell contains all non-smokers without diabetes who are less than 45 years and have a TC:HDL ratio less than 4.5 and a blood pressure less than 130/80 mm Hg. People who fall exactly on a threshold between cells are placed in the cell indicating higher risk.

Risk level men



**Benefits: NNT for 5 years to prevent one event**  
(CVD events prevented per 100 people treated for 5 years)

Risk level: 5 year CV risk (fatal and non-fatal)	Benefits: NNT for 5 years to prevent one event (CVD events prevented per 100 people treated for 5 years)		
	1 intervention (25% risk reduction)	2 interventions (45% risk reduction)	3 interventions (55% risk reduction)
30%	13 (7.5 per 100)	7 (14 per 100)	6 (16 per 100)
20%	20 (5 per 100)	11 (9 per 100)	9 (11 per 100)
15%	27 (4 per 100)	15 (7 per 100)	12 (8 per 100)
10%	40 (2.5 per 100)	22 (4.5 per 100)	18 (5.5 per 100)
5%	80 (1.25 per 100)	44 (2.25 per 100)	36 (3 per 100)

Based on the conservative estimate that each intervention: aspirin, blood pressure treatment (lowering systolic blood pressure by 10 mm Hg) or lipid modification (lowering LDL-C by 20%) reduces cardiovascular risk by about 25% over 5 years.

# BLOOD AND BLOOD FORMING ORGANS

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer ✓
---	----------------------------	--

## Antianaemics

### Hypoplastic and Haemolytic

#### ►SA0922 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:  
Both:

- 1 Both:
  - 1.1 patient in chronic renal failure; and
  - 1.2 Haemoglobin  $\leq$  100g/L; and
- 2 Any of the following:
  - 2.1 Both:
    - 2.1.1 patient is not diabetic; and
    - 2.1.2 glomerular filtration rate  $\leq$  30ml/min; or
  - 2.2 Both:
    - 2.2.1 patient is diabetic; and
    - 2.2.2 glomerular filtration rate  $\leq$  45ml/min; or
  - 2.3 patient is on haemodialysis or peritoneal dialysis.

**Renewal** only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Notes: Erythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

The Cockcroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:

GFR (ml/min) (male) =  $(140 - \text{age}) \times \text{Ideal Body Weight (kg)} / 814 \times \text{serum creatinine (mmol/l)}$

GFR (ml/min) (female) = Estimated GFR (male)  $\times$  0.85

ERYTHROPOIETIN ALPHA – Special Authority see SA0922 above – Hospital pharmacy [HP3]

Inj human recombinant 1,000 iu pre-filled syringe .....	48.68	6	✓ Eprex
Inj human recombinant 2,000 iu, pre-filled syringe .....	120.18	6	✓ Eprex
Inj human recombinant 3,000 iu, pre-filled syringe .....	166.87	6	✓ Eprex
Inj human recombinant 4,000 iu, pre-filled syringe .....	193.13	6	✓ Eprex
Inj human recombinant 5,000 iu, pre-filled syringe .....	243.26	6	✓ Eprex
Inj human recombinant 6,000 iu, pre-filled syringe .....	291.92	6	✓ Eprex
Inj human recombinant 10,000 iu, pre-filled syringe .....	395.18	6	✓ Eprex

ERYTHROPOIETIN BETA – Special Authority see SA0922 above – Hospital pharmacy [HP3]

Inj 1,000 iu, pre-filled syringe .....	48.68	6	✓ Recormon
Inj 2,000 iu, pre-filled syringe .....	120.18	6	✓ NeoRecormon
Inj 3,000 iu, pre-filled syringe .....	166.87	6	✓ NeoRecormon
Inj 4,000 iu, pre-filled syringe .....	193.13	6	✓ NeoRecormon
Inj 5,000 iu, pre-filled syringe .....	243.26	6	✓ NeoRecormon
Inj 6,000 iu, pre-filled syringe .....	291.29	6	✓ NeoRecormon
Inj 10,000 iu, pre-filled syringe .....	395.18	6	✓ NeoRecormon

*(Recormon Inj 1,000 iu, pre-filled syringe to be delisted 1 March 2009)*

### Megaloblastic

FOLIC ACID

* Tab 0.8 mg .....	16.50	1,000	✓ Apo-Folic Acid
* Tab 5 mg .....	6.59	500	✓ Apo-Folic Acid
Oral liq 50 µg per ml .....	21.05	25 ml OP	✓ Biomed

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

**Antifibrinolytics, Haemostatics and Local Sclerosants**

SODIUM TETRADECYL SULPHATE

* Inj 0.5% 2 ml	23.20 (45.52)	5		Fibro-vein
* Inj 1% 2 ml	25.00 (48.98)	5		Fibro-vein
* Inj 3% 2 ml	28.50 (55.91)	5		Fibro-vein

TRANEXAMIC ACID

Tab 500 mg	49.14	100	✓	Cyklokapron
------------	-------	-----	---	-------------

**Vitamin K**

MENADIONE SODIUM BISULPHITE

* Tab 10 mg	4.75	100	✓	K-Thrombin
-------------	------	-----	---	------------

PHYTOMENADIONE

Tab 10 mg	5.60	10	✓	Konaktion
Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO	8.00	5	✓	Konaktion MM
Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO	9.21	5	✓	Konaktion MM

**Antithrombotic Agents**

**Antiplatelet Agents**

ASPIRIN

* Tab 100 mg	16.83	990	✓	<u>Ethics Aspirin EC</u>
--------------	-------	-----	---	--------------------------

CLOPIDOGREL – Special Authority see SA0867 below – Retail pharmacy

Tab 75 mg	35.00 (73.38)	28	✓	Apo-Clopidogrel Plavix
-----------	------------------	----	---	---------------------------

**SA0867 Special Authority for Subsidy**

**Initial application — (aspirin allergic patients)** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient is allergic to aspirin (see definition below); and
- 2 Any of the following:
  - The patient has:
    - 2.1 suffered from a stroke, or transient ischaemic attack; or
    - 2.2 experienced an acute myocardial infarction; or
    - 2.3 experienced an episode of pain at rest of greater than 20 minutes duration due to coronary disease that required admission to hospital for at least 24 hours; or
    - 2.4 had a troponin T or troponin I test result greater than the upper limit of the reference range; or
    - 2.5 had a revascularisation procedure; or
    - 2.6 experienced symptomatic peripheral vascular disease of a severity that has required specialist consultation.

Note: Aspirin allergy is defined as a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates or NSAIDs.

**Initial application — (aspirin tolerant patients and aspirin naive patients)** from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Any of the following:

The patient has:

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## BLOOD AND BLOOD FORMING ORGANS

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1 experienced an acute myocardial infarction; or
- 2 had an episode of pain at rest of greater than 20 minutes duration due to coronary disease that required admission to hospital for at least 24 hours; or
- 3 had a troponin T or troponin I test result greater than the upper limit of the reference range; or
- 4 had a revascularisation procedure.

**Initial application — (patients awaiting revascularisation)** from any relevant practitioner. Approvals valid for 6 months where the patient is on a waiting list or active review list for stenting, coronary artery bypass grafting, or percutaneous coronary angioplasty following acute coronary syndrome.

**Initial application — (post stenting)** from any relevant practitioner. Approvals valid for 6 months where the patient has had a stent inserted in the previous 4 weeks.

**Initial application — (documented stent thrombosis)** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has, while on treatment with aspirin or clopidogrel, experienced documented stent thrombosis.

**Renewal — (aspirin tolerant patients)** from any relevant practitioner. Approvals valid without further renewal unless notified where while on treatment with aspirin the patient has experienced an additional vascular event following the recent cessation of clopidogrel.

**Renewal — (acute coronary syndrome - aspirin tolerant patients and aspirin naive patients)** from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Any of the following:

The patient has:

- 1 experienced an acute myocardial infarction; or
- 2 had an episode of pain at rest of greater than 20 minutes duration due to coronary disease that required admission to hospital for at least 24 hours; or
- 3 had a troponin T or troponin I test result greater than the upper limit of the reference range; or
- 4 had a revascularisation procedure.

**Renewal — (patients awaiting revascularisation)** from any relevant practitioner. Approvals valid for 6 months where the patient is on a waiting list or active review list for stenting, coronary artery bypass grafting or percutaneous coronary angioplasty following acute coronary syndrome.

**Renewal — (post stenting)** from any relevant practitioner. Approvals valid for 6 months where the patient has had a stent inserted in the previous 4 weeks.

**Renewal — (documented stent thrombosis)** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has, while on treatment with aspirin or clopidogrel, experienced documented stent thrombosis.

### DIPYRIDAMOLE

* Tab 25 mg – Additional subsidy by Special Authority see SA0930 below – Retail pharmacy .....	0.16 (8.36)	84	Persantin
* Tab long-acting 150 mg – Special Authority see SA0929 on the next page – Retail pharmacy .....	11.52	60	✓ <b>Pytazen SR</b>

### ►SA0930 Special Authority for Manufacturers Price

**Initial application — (Conditions other than transient ischaemic episodes)** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patients with prosthetic heart valves – as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or
- 2 Patients after coronary artery vein bypass graft – as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant.

Note: Aspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruising.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
		✓

continued...

**Initial application — (Transient ischaemic episodes)** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to have transient ischaemic episodes despite aspirin therapy or has transient ischaemic episodes and is aspirin intolerant.

Note: Aspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruising.

**Renewal — (Existing 2 year approvals)** from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

▶SA0929 | **Special Authority for Subsidy**

**Initial application — (Conditions other than transient ischaemic episodes)** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patients with prosthetic heart valves – as an adjunct to oral anticoagulation for prophylaxis of thromboembolism; or
- 2 Patients after coronary artery vein bypass graft – as an adjunct to aspirin or as monotherapy for patients who are aspirin intolerant.

Note: Aspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruising.

**Initial application — (Transient ischaemic episodes)** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to have transient ischaemic episodes despite aspirin therapy or has transient ischaemic episodes and is aspirin intolerant.

Note: Aspirin intolerant patients are defined as those with aspirin induced asthma, urticaria, or anaphylaxi, or those with significant aspirin induced bleeding, excluding bruising.

**Renewal — (Existing 2 year approvals)** from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

**Heparin and Antagonist Preparations**

HEPARIN SODIUM

Inj 1,000 iu per ml, 5 ml .....	66.80	50	✓ Mayne
Inj 1,000 iu per ml, 35 ml .....	12.10	1	✓ Mayne
Inj 5,000 iu per ml, 1 ml .....	10.32	5	✓ Mayne
Inj 5,000 iu per ml, 5 ml .....	37.45	10	✓ Multiparin
Inj 25,000 iu per ml, 0.2 ml .....	9.50	5	✓ Mayne

HEPARINISED SALINE

* Inj 100 iu per ml, 2 ml .....	8.30	10	✓ Hospira S29
* Inj 10 iu per ml, 5 ml .....	18.00	50	✓ AstraZeneca
* Inj 100 iu per ml, 5 ml .....	103.76	50	✓ Mayne

(Mayne Inj 100 iu per ml, 5 ml to be delisted 1 March 2009)

PROTAMINE SULPHATE

* Inj 10 mg per ml, 5 ml .....	22.40 (76.25)	10	Artex
--------------------------------	------------------	----	-------

**Oral Anticoagulants**

WARFARIN SODIUM

Note: Marevan and Coumadin are not interchangeable.

* Tab 1 mg .....	3.46	50	✓ Coumadin
	5.69	100	✓ Marevan
* Tab 2 mg .....	4.31	50	✓ Coumadin
* Tab 3 mg .....	8.00	100	✓ Marevan
* Tab 5 mg .....	5.93	50	✓ Coumadin
	9.64	100	✓ Marevan

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## BLOOD AND BLOOD FORMING ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Fluids and Electrolytes</b>				
<b>Intravenous Administration</b>				
<b>DEXTROSE</b>				
* Inj 50%, 10 ml – Up to 5 inj available on a PSO .....	22.75	5	✓	<b>Biomed</b>
* Inj 50%, 90 ml – Up to 5 inj available on a PSO .....	11.25	1	✓	<b>Biomed</b>
<b>POTASSIUM CHLORIDE</b>				
* Inj 75 mg per ml, 10 ml .....	26.00	50	✓	<b>AstraZeneca</b>
* Inj 150 mg per ml, 10 ml .....	26.00	50	✓	<b>AstraZeneca</b>
<b>SODIUM BICARBONATE</b>				
Inj 8.4%, 50ml .....	19.95	1	✓	<b>Biomed</b>
a) Up to 5 inj available on a PSO				
b) Not in combination				
Inj 8.4%, 100 ml .....	20.50	1	✓	<b>Biomed</b>
a) Up to 5 inj available on a PSO				
b) Not in combination				
<b>SODIUM CHLORIDE</b>				
Inf 0.9% – Up to 2000 ml available on a PSO .....	3.06	500 ml	✓	<b>Baxter</b>
	4.06	1,000 ml	✓	<b>Baxter</b>
Only if prescribed on a prescription for renal dialysis, maternity or post-natal care in the home of the patient, or on a PSO for emergency use. (500 ml and 1,000 ml packs)				
Inj 23.4%, 20 ml .....	26.50	5	✓	<b>Biomed</b>
Inj 0.9%, 5 ml – Up to 5 inj available on a PSO .....	11.50	50	✓	<b>AstraZeneca</b>
Inj 0.9%, 10 ml – Up to 5 inj available on a PSO .....	11.50	50	✓	<b>AstraZeneca</b>
Inj 0.9%, 20 ml .....	7.86	20	✓	<b>Multichem</b>
	11.79	30	✓	<b>Pharmacia</b>
<b>TOTAL PARENTERAL NUTRITION (TPN) – Hospital pharmacy [HP1]-Specialist</b>				
Infusion .....	CBS	1 OP	✓	<b>TPN</b>
<b>WATER</b>				
1) On a prescription or Practitioner's Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or				
2) On a bulk supply order; or				
3) When used in the extemporaneous compounding of eye drops.				
Purified for inj 2 ml – Up to 5 inj available on a PSO .....	21.90	50	✓	<b>Baxter</b>
Purified for inj 5 ml – Up to 5 inj available on a PSO .....	9.31	50	✓	<b>Multichem</b>
Purified for inj 10 ml – Up to 5 inj available on a PSO .....	10.38	50	✓	<b>Multichem</b>
Purified for inj 20 ml – Up to 5 inj available on a PSO .....	5.04	20	✓	<b>Multichem</b>
<i>(Baxter Purified for inj 2 ml to be delisted 1 July 2009)</i>				
<b>Oral Administration</b>				
<b>CALCIUM POLYSTYRENE SULPHONATE</b>				
Powder .....	169.85	300 g OP	✓	<b>Calcium Resonium</b>
<b>COMPOUND ELECTROLYTES</b>				
Powder for soln for oral use 5 g – Up to 10 sach available on a PSO .....	2.86	10	✓	<b>Enerlyte</b>

## BLOOD AND BLOOD FORMING ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>DEXTROSE WITH ELECTROLYTES</b>				
Soln with electrolytes .....	6.66	1,000 ml OP	✓	<b><u>Pedialyte - Bubblegum</u></b>
	6.78		✓	<b><u>Pedialyte - Fruit</u></b>
			✓	<b><u>Pedialyte - Plain</u></b>
<b>POTASSIUM BICARBONATE</b>				
Tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg .....	82.50	100	✓	<b><u>Phosphate-Sandoz</u></b>
For phosphate supplementation				
<b>POTASSIUM CHLORIDE</b>				
* Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq) .....	5.26 (11.85)	60		Chlorvescent
* Tab long-acting 600 mg .....	5.20	200	✓	<b><u>Span-K</u></b>
<b>SODIUM POLYSTYRENE SULPHONATE</b>				
Powder .....	89.10	450 g OP	✓	<b><u>Resonium-A</u></b>

### Lipid Modifying Agents

#### Fibrates

<b>BEZAFIBRATE</b>				
* Tab 200 mg .....	9.75	90	✓	<b><u>Fibalip</u></b>
* Tab long-acting 400 mg .....	7.60	30	✓	<b><u>Bezalip Retard</u></b>

#### Other Lipid Modifying Agents

<b>ACIPIMOX</b>				
* Cap 250 mg .....	18.75	30	✓	<b><u>Olbetam</u></b>
<b>NICOTINIC ACID</b>				
* Tab 50 mg .....	5.08	100	✓	<b><u>Apo-Nicotinic Acid</u></b>
* Tab 500 mg .....	17.60	100	✓	<b><u>Apo-Nicotinic Acid</u></b>

#### Resins

<b>CHOLESTYRAMINE WITH ASPARTAME</b>				
Sachets 4 g with aspartame .....	19.25 (28.88)	50		Questran-Lite
<b>COLESTIPOL HYDROCHLORIDE</b>				
Sachets 5 g .....	16.17	30	✓	<b><u>Colestid</u></b>

### HMG CoA Reductase Inhibitors (Statins)

#### Prescribing Guidelines

Treatment with HMG CoA Reductase Inhibitors (statins) is recommended for patients with dyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater.

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## BLOOD AND BLOOD FORMING ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
ATORVASTATIN – Additional subsidy by Special Authority see SA0788 below – Retail pharmacy See prescribing guideline on the preceding page				
* Tab 10 mg .....	4.03 (18.32)	30		Lipitor
* Tab 20 mg .....	5.87 (26.70)	30		Lipitor
* Tab 40 mg .....	8.14 (37.02)	30		Lipitor

### ►SA0788 Special Authority for Manufacturers Price

**Initial application** only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Either:
  - 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or
  - 2.2 Both:
    - 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and
    - 2.2.2 Either:
      - 2.2.2.1 All of the following:
        - 2.2.2.1.1 Patient has venous CABG; and
        - 2.2.2.1.2 LDL cholesterol test 1  $\geq$  2.0 mmol/litre; and
        - 2.2.2.1.3 LDL cholesterol test 2  $\geq$  2.0 mmol/litre (at least 1 week after test 1); or
      - 2.2.2.2 All of the following:
        - 2.2.2.2.1 Patient does not have venous CABG; and
        - 2.2.2.2.2 LDL cholesterol test 1  $\geq$  2.5 mmol/litre; and
        - 2.2.2.2.3 LDL cholesterol test 2  $\geq$  2.5 mmol/litre (at least 1 week after test 1).

Notes: To confirm that cholesterol levels are not still improving, two lipid tests must be carried out during treatment with simvastatin 80 mg, and have results for LDL cholesterol that have reduced by <10% in the second test. The tests must be carried out while the patient is in a fasted state (with the exception of patients with IDDM).

The following indications of intolerance to simvastatin, are known as class effects for all statins, and hence are likely to mean that the patient may also be intolerant of atorvastatin:

- Constipation, flatulence (may occur in >1% of patients)
- Asthenia, abdominal pain, headache (may occur in >1% of patients)
- Myopathy, rhabdomyolysis (may occur in <3% of patients)
- Elevated serum transaminase levels (may occur in <1% of patients)

Statins have been shown to be generally well tolerated in clinical studies, with the rate of discontinuation due to adverse reactions being less than 5%, and similar to the discontinuation rate for patients taking a placebo.

PRAVASTATIN – Special Authority see SA0932 below – Retail pharmacy

See prescribing guideline on the preceding page

Tab 10 mg .....	27.46	30	✓ Pravachol
Tab 20 mg .....	42.58	30	✓ Pravachol
Tab 40 mg .....	65.31	30	✓ Pravachol

### ►SA0932 Special Authority for Subsidy

**Initial application — (Confirmed HIV/AIDS)** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has dyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater; and
- 2 Confirmed HIV infection; and
- 3 Patient is being treated with an HIV protease inhibitor.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
SIMVASTATIN – See prescribing guideline on page 49				
* Tab 10 mg .....	1.27	30	✓	SimvaRex
	8.33		✓	Lipex
* Tab 20 mg .....	1.54	30	✓	SimvaRex
	10.13		✓	Lipex
* Tab 40 mg .....	2.74	30	✓	SimvaRex
	18.00		✓	Lipex
* Tab 80 mg .....	3.18	30	✓	SimvaRex
	21.00		✓	Lipex

**Selective Cholesterol Absorption Inhibitors**

EZETIMIBE – Special Authority see SA0796 below – Retail pharmacy

Tab 10 mg .....	57.60	30	✓	Ezetol
-----------------	-------	----	---	--------

**SA0796 | Special Authority for Subsidy**

**Initial application** only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 Either:

- 1.1 ezetimibe is to be used in combination with simvastatin; or
- 1.2 ezetimibe is to be used without a statin; and

2 Either:

2.1 All of the following:

- 2.1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and
- 2.1.2 Patient cannot tolerate statin therapy at a dose of ≥ 40 mg per day; and
- 2.1.3 Either:

2.1.3.1 All of the following:

- 2.1.3.1.1 Patient has venous CABG; and
- 2.1.3.1.2 LDL cholesterol ≥ 2.0 mmol/litre (see note); and
- 2.1.3.1.3 LDL cholesterol ≥ 2.0 mmol/litre (at least 1 week after test 1 – see note); or

2.1.3.2 All of the following:

- 2.1.3.2.1 Patient does not have venous CABG; and
- 2.1.3.2.2 LDL cholesterol ≥ 2.5 mmol/litre (see note); and
- 2.1.3.2.3 LDL cholesterol ≥ 2.5 mmol/litre (at least 1 week after test 1 – see note); or

2.2 All of the following:

- 2.2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholesterolemia; and
- 2.2.2 Patient has been compliant for at least two months with maximum dose statin therapy; and
- 2.2.3 LDL cholesterol ≥ 5 mmol/litre (see note); and
- 2.2.4 LDL cholesterol ≥ 5 mmol/litre (at least 1 week after test 1 – see note).

Note: Two lipid tests are required to assess LDL cholesterol levels, the tests must be at least one week apart, and be carried out in a fasted state (other than for patients with IDDM). The results for LDL cholesterol levels in both tests must be above those specified.

**Renewal** only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and

2 Either:

- 2.1 ezetimibe is to be used in combination with simvastatin; or
- 2.2 ezetimibe is to be used without a statin.

EZETIMIBE WITH SIMVASTATIN – Special Authority see SA0826 on the next page – Retail pharmacy

Tab 10 mg with simvastatin 10 mg .....	69.00	30	✓	Vytorin
Tab 10 mg with simvastatin 20 mg .....	75.00	30	✓	Vytorin
Tab 10 mg with simvastatin 40 mg .....	103.50	30	✓	Vytorin
Tab 10 mg with simvastatin 80 mg .....	123.00	30	✓	Vytorin

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## BLOOD AND BLOOD FORMING ORGANS

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

### SA0826 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:  
Either:

- 1 All of the following:
  - 1.1 Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years; and
  - 1.2 Patient cannot tolerate statin therapy at a dose of  $\geq 40$  mg per day; and
  - 1.3 Either:
    - 1.3.1 All of the following:
      - 1.3.1.1 Patient has venous CABG; and
      - 1.3.1.2 LDL cholesterol  $\geq 2.0$  mmol/litre (see note); and
      - 1.3.1.3 LDL cholesterol  $\geq 2.0$  mmol/litre (at least 1 week after test 1 – see note); or
    - 1.3.2 All of the following:
      - 1.3.2.1 Patient does not have venous CABG; and
      - 1.3.2.2 LDL cholesterol  $\geq 2.5$  mmol/litre (see note); and
      - 1.3.2.3 LDL cholesterol  $\geq 2.5$  mmol/litre (at least 1 week after test 1 – see note); or
- 2 All of the following:
  - 2.1 Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholesterolemia; and
  - 2.2 Patient has been compliant for at least two months with maximum dose statin therapy; and
  - 2.3 LDL cholesterol  $\geq 5$  mmol/litre (see note); and
  - 2.4 LDL cholesterol  $\geq 5$  mmol/litre (at least 1 week after test 1 – see note).

Note: Two lipid tests are required to assess LDL cholesterol levels, the tests must be at least one week apart, and be carried out in a fasted state (other than for patients with IDDM). The results for LDL cholesterol levels in both tests must be above those specified.

**Renewal** only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Alpha Adrenoceptor Blockers</b>				
<b>DOXAZOSIN MESYLATE</b>				
* Tab 2 mg .....	22.85	500	✓	<b>Apo-Doxazosin</b>
* Tab 4 mg .....	30.26	500	✓	<b>Apo-Doxazosin</b>
<b>PHENOXYBENZAMINE HYDROCHLORIDE</b>				
* Cap 10 mg .....	7.82	30	✓	<b>Dibenyline S29</b>
<b>PHENTOLAMINE MESYLATE</b>				
* Inj 10 mg per ml, 1 ml .....	17.97 (31.65)	5		Regitine
<b>PRAZOSIN HYDROCHLORIDE</b>				
* Tab 0.5 mg .....	9.50	100	✓	<b>Hyprosin</b>
* Tab 1 mg .....	5.53	100	✓	<b>Apo-Prazo</b>
* Tab 2 mg .....	7.00	100	✓	<b>Apo-Prazo</b>
* Tab 5 mg .....	11.70	100	✓	<b>Apo-Prazo</b>
<i>(Hyprosin Tab 0.5 mg to be delisted 1 February 2009)</i>				
<b>TERAZOSIN HYDROCHLORIDE</b>				
* Tab 7 × 1 mg and 7 × 2 mg .....	0.74	14 OP	✓	<b>Hytrin Starter Pack</b>
* Tab 2 mg .....	1.48 (4.66)	28		Hytrin
* Tab 5 mg .....	1.91 (5.60)	28		Hytrin

**Agents Affecting the Renin-Angiotensin System**

Perindopril andtrandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are “certified condition” or an appropriate description of the patient such as “congestive heart failure”, “CHF”, “congestive cardiac failure” or “CCF”. **Definition of Congestive Heart Failure** At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer’s surcharge: “Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include patients post myocardial infarction with an ejection fraction of less than 40%.”

**ACE Inhibitors**

<b>CAPTOPRIL</b>				
* Tab 12.5 mg .....	10.40	500	✓	<b>Apo-Captopril</b>
* Tab 25 mg .....	13.40	500	✓	<b>Apo-Captopril</b>
* Tab 50 mg .....	19.00	500	✓	<b>Apo-Captopril</b>
* ‡ Oral liq 5 mg per ml .....	51.04	95 ml OP	✓	<b>Capoten</b>
Oral liquid restricted to children under 12 years of age.				
<b>CILAZAPRIL</b>				
* Tab 0.5 mg .....	2.20	30	✓	<b>Inhibace</b>
* Tab 2.5 mg .....	4.39	30	✓	<b>Inhibace</b>
* Tab 5 mg .....	6.44	30	✓	<b>Inhibace</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

## CARDIOVASCULAR SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>ENALAPRIL</b>				
* Tab 5 mg .....	2.19	90	✓	<b>m-Enalapril</b>
* Tab 10 mg .....	2.76	90	✓	<b>m-Enalapril</b>
* Tab 20 mg .....	3.68	90	✓	<b>m-Enalapril</b>
<b>LISINAPRIL</b>				
* Tab 5 mg .....	2.78	30	✓	<b>Arrow-Lisinopril</b>
* Tab 10 mg .....	3.16	30	✓	<b>Arrow-Lisinopril</b>
* Tab 20 mg .....	3.91	30	✓	<b>Arrow-Lisinopril</b>
<b>PERINDOPRIL</b>				
* Tab 2 mg – Higher subsidy of \$18.50 per 30 with Endorsement .....	3.00 (18.50)	30		Coversyl
* Tab 4 mg – Higher subsidy of \$25.00 per 30 with Endorsement .....	4.05 (25.00)	30		Coversyl
<b>QUINAPRIL</b>				
* Tab 5 mg .....	1.60	30	✓	<b>Accupril</b>
* Tab 10 mg .....	1.75	30	✓	<b>Accupril</b>
* Tab 20 mg .....	2.35	30	✓	<b>Accupril</b>
<b>TRANDOLAPRIL</b>				
* Cap 1 mg – Higher subsidy of \$18.67 per 28 with Endorsement .....	3.06 (18.67)	28		Gopten
* Cap 2 mg – Higher subsidy of \$27.00 per 28 with Endorsement .....	4.43 (27.00)	28		Gopten

### ACE Inhibitors with Diuretics

<b>CILAZAPRIL WITH HYDROCHLOROTHIAZIDE</b>				
* Tab 5 mg with hydrochlorothiazide 12.5 mg .....	6.30	28	✓	<b>Inhibace Plus</b>
<b>ENALAPRIL WITH HYDROCHLOROTHIAZIDE</b>				
* Tab 20 mg with hydrochlorothiazide 12.5 mg .....	3.32 (8.70)	30		Co-Renitec
<b>QUINAPRIL WITH HYDROCHLOROTHIAZIDE</b>				
* Tab 10 mg with hydrochlorothiazide 12.5 mg .....	3.37	30	✓	<b>Accuretic 10</b>
* Tab 20 mg with hydrochlorothiazide 12.5 mg .....	4.57	30	✓	<b>Accuretic 20</b>

### Angiotension II Antagonists

<b>CANDESARTAN – Special Authority see SA0933 below – Retail pharmacy</b>				
* Tab 4 mg – No more than 1.5 tab per day .....	16.22	30	✓	<b>Atacand</b>
* Tab 8 mg – No more than 1.5 tab per day .....	19.30	30	✓	<b>Atacand</b>
* Tab 16 mg – No more than 1 tab per day .....	23.54	30	✓	<b>Atacand</b>
* Tab 32 mg – No more than 1 tab per day .....	38.50	30	✓	<b>Atacand</b>

#### ►SA0933 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Both:
  - 1.1 Patient with congestive heart failure; and
  - 1.2 Either:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
1.2.1	Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or			
1.2.2	Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years; or			
2	All of the following:			
2.1	Patient with raised blood pressure; and			
2.2	Use of fully funded beta blockers or diuretics are contraindicated; or not well tolerated; or insufficient to control blood pressure adequately at appropriate doses; and			
2.3	Either:			
2.3.1	Has been treated with, and cannot tolerate, two ACE inhibitors, due to persistent cough; or			
2.3.2	Has experienced angioedema on an ACE inhibitor at any time in the past or who have experienced angioedema (even if not using an ACE inhibitor) in the last 2 years.			
LOSARTAN – Special Authority see SA0911 below – Retail pharmacy				
* Tab 12.5 mg	17.40	30	✓	Cozaar
* Tab 25 mg	21.76	30	✓	Cozaar
* Tab 50 mg	23.10	30	✓	Cozaar
Tab 50 mg with hydrochlorothiazide 12.5 mg	30.00	30	✓	Hyzaar
* Tab 100 mg	35.40	30	✓	Cozaar

►SA0911 Special Authority for Subsidy

**Initial application — (ACE inhibitor intolerance)** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor); or
- or
- 2 Patient has a history of angioedema.

**Initial application — (Unsatisfactory response to ACE inhibitor)** from any relevant practitioner. Approvals valid without further renewal unless notified where patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.

**Initial application — (Patient had an approval for Losartan with hydrochlorothiazide prior to 1 May 2008)** from any relevant practitioner. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

**Antiarrhythmics**

For lignocaine hydrochloride refer to NERVOUS SYSTEM, Anaesthetics, Local, page 110

AMIODARONE HYDROCHLORIDE

▲ Tab 100 mg – Retail pharmacy-Specialist	18.65	30	✓	Aratac
▲ Tab 200 mg – Retail pharmacy-Specialist	30.52	30	✓	Cordarone-X
Inj 50 mg per ml, 3 ml – Up to 5 inj available on a PSO	60.84	10	✓	Aratac
			✓	Cordarone-X
			✓	Cordarone-X

DIGOXIN

* Tab 62.5 µg – Up to 30 tab available on a PSO	6.94	250	✓	Lanoxin PG
* Tab 250 µg – Up to 30 tab available on a PSO	15.13	250	✓	Lanoxin
*‡ Oral liq 50 µg per ml	16.60	60 ml	✓	Lanoxin

DISOPYRAMIDE PHOSPHATE

▲ Cap 100 mg	15.00 (23.87)	100		Rythmodan
▲ Cap 150 mg	26.21	100	✓	Rythmodan

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## CARDIOVASCULAR SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>FLECAINIDE ACETATE – Retail pharmacy-Specialist</b>				
▲ Tab 50 mg .....	42.82	60	✓	Tambocor
▲ Tab 100 mg .....	75.63	60	✓	Tambocor
▲ Cap long-acting 100 mg .....	42.82	30	✓	Tambocor CR
▲ Cap long-acting 200 mg .....	75.63	30	✓	Tambocor CR
Inj 10 mg per ml, 15 ml .....	49.02	5	✓	Tambocor
<b>MEXILETINE HYDROCHLORIDE</b>				
▲ Cap 50 mg .....	23.52	100	✓	Mexitil
▲ Cap 200 mg .....	55.05	100	✓	Mexitil
<b>PROPAFENONE HYDROCHLORIDE – Retail pharmacy-Specialist</b>				
▲ Tab 150 mg .....	40.90	50	✓	Rytmonorm

### Antihypotensives

**MIDODRINE – Special Authority** see SA0934 below – Hospital pharmacy [HP3]

Tab 2.5 mg .....	53.00	100	✓	Gutron
Tab 5 mg .....	79.00	100	✓	Gutron

#### ►SA0934 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:  
All of the following:

- 1 Disabling orthostatic hypotension not due to drugs; and
- 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and
- 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night.

Notes: Treatment should be started with small doses and titrated upwards as necessary.

Hypertension should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

### Beta Adrenoceptor Blockers

**ACEBUTOLOL**

* Cap 100 mg .....	9.50	100	✓	ACB
* Cap 200 mg .....	15.94	100	✓	ACB

**ATENOLOL**

* Tab 50 mg .....	0.39	30	✓	Noten <sup>S29</sup>
	6.50	500	✓	Loten
			✓	Pacific Atenolol
* Tab 100 mg .....	11.30	500	✓	Loten
			✓	Pacific Atenolol

(Loten Tab 50 mg to be delisted 1 March 2009)

(Loten Tab 100 mg to be delisted 1 March 2009)

**CARVEDILOL**

Tab 6.25 mg .....	21.00	30	✓	Dilatrend
Tab 12.5 mg .....	27.00	30	✓	Dilatrend
Tab 25 mg .....	33.75	30	✓	Dilatrend

**CELIPROLOL**

* Tab 200 mg .....	19.00	180	✓	Celol
--------------------	-------	-----	---	-------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>LABETALOL</b>				
* Tab 50 mg .....	8.66	100	✓	<b>Hybloc</b>
* Tab 100 mg .....	10.59	100	✓	<b>Hybloc</b>
* Tab 200 mg .....	18.47	100	✓	<b>Hybloc</b>
* Tab 400 mg .....	34.44	100	✓	<b>Hybloc</b>
* Inj 5 mg per ml, 5 ml .....	14.77	5		
	(22.15)			Trandate <del>\$29</del>
* Inj 5 mg per ml, 20 ml .....	59.06	5		Trandate
	(88.60)			
<b>METOPROLOL SUCCINATE</b>				
Additional subsidy by endorsement is available for patients who:				
1) were being prescribed metoprolol succinate prior to 1 October 2007; or				
2) have experienced a myocardial infarction; or				
3) have experienced heart failure and are either intolerant of carvedilol or it is contra-indicated.				
Pharmacists may annotate prescriptions for patients who were being prescribed metoprolol succinate prior to 1 October 2007 in which case the prescription is deemed to be endorsed. The pharmacist must be able to show a clear documented dispensing history for the patient. The prescription must be endorsed accordingly.				
* Tab long-acting 23.75 mg – Higher subsidy of \$6.20 per 30 with Endorsement .....	5.20	30		
	(6.20)			Betaloc CR
* Tab long-acting 47.5 mg – Higher subsidy of \$7.80 per 30 with Endorsement .....	6.50	30		
	(7.80)			Betaloc CR
* Tab long-acting 95 mg – Higher subsidy of \$13.20 per 30 with Endorsement .....	11.20	30		
	(13.20)			Betaloc CR
* Tab long-acting 190 mg – Higher subsidy of \$21.00 per 30 with Endorsement .....	20.25	30		
	(21.00)			Betaloc CR
<b>METOPROLOL TARTRATE</b>				
* Tab 50 mg .....	16.50	100	✓	<b>Lopressor</b>
* Tab 100 mg .....	21.80	60	✓	<b>Lopressor</b>
* Tab long-acting 200 mg .....	18.40	28	✓	<b>Slow-Lopressor</b>
* Inj 1 mg per ml 5 ml .....	24.08	5		
	(34.00)			Betaloc
<b>NADOLOL</b>				
* Tab 40 mg .....	14.97	100	✓	<b>Apo-Nadolol</b>
* Tab 80 mg .....	22.19	100	✓	<b>Apo-Nadolol</b>
<b>PINDOLOL</b>				
* Tab 5 mg .....	4.50	100	✓	<b>Pindol</b>
* Tab 10 mg .....	8.35	100	✓	<b>Pindol</b>
* Tab 15 mg .....	12.00	100	✓	<b>Pindol</b>
<b>PROPRANOLOL</b>				
* Tab 10 mg .....	3.55	100	✓	<b>Cardinol</b>
* Tab 40 mg .....	4.65	100	✓	<b>Cardinol</b>
* Cap long-acting 160 mg .....	16.90	100	✓	<b>Cardinol LA</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

# CARDIOVASCULAR SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>SOTALOL</b>				
* Tab 80 mg .....	27.50	500	✓	<b>Pacific</b>
* Tab 160 mg .....	10.50	100	✓	<b>Pacific</b>
* Inj 10 mg per ml, 4 ml .....	41.34	5	✓	<b>Sotacor</b>
<b>TIMOLOL MALEATE</b>				
* Tab 10 mg .....	10.55	100	✓	<b>Apo-Timol</b>

## Calcium Channel Blockers

### Dihydropyridine Calcium Channel Blockers (DHP CCBs)

<b>AMLODIPINE</b>				
* Tab 5 mg .....	7.33	100	✓	<b>Apo-Amlodipine</b>
	7.85	30	✓	<b>Calvasc</b>
* Tab 10 mg .....	11.79	100	✓	<b>Apo-Amlodipine</b>
	13.60	30	✓	<b>Calvasc</b>
<i>(Calvasc Tab 5 mg to be delisted 1 May 2009)</i>				
<i>(Calvasc Tab 10 mg to be delisted 1 May 2009)</i>				
<b>FELODIPINE</b>				
* Tab long-acting 2.5 mg – No more than 1 tab per day .....	10.38	30	✓	<b>Plendil ER</b>
* Tab long-acting 5 mg .....	16.50	90	✓	<b>Felo 5 ER</b>
* Tab long-acting 10 mg .....	24.00	90	✓	<b>Felo 10 ER</b>
<b>ISRADIPINE</b>				
Cap long-acting 2.5 mg .....	7.50	30	✓	<b>Dynacirc-SRO</b>
Cap long-acting 5 mg .....	7.85	30	✓	<b>Dynacirc-SRO</b>
<b>NIFEDIPINE</b>				
* Tab long-acting 10 mg .....	17.72	60	✓	<b>Adalat 10</b>
* Tab long-acting 20 mg .....	7.30	100	✓	<b>Nyefax Retard</b>
* Tab long-acting 30 mg .....	10.70	30	✓	<b>Adefin XL</b>
	5.50		✓	<b>Arrow-Nifedipine XR</b>
	(19.90)			Adalat Oros
* Tab long-acting 60 mg .....	15.35	30	✓	<b>Adefin XL</b>
	8.00		✓	<b>Arrow-Nifedipine XR</b>
	(29.50)			Adalat Oros

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Other Calcium Channel Blockers</b>				
<b>DILTIAZEM HYDROCHLORIDE</b>				
* Tab 30 mg	4.60	100	✓	Dilzem
* Tab 60 mg	8.50	100	✓	Dilzem
* Tab long-acting 180 mg	7.65	30	✓	Dilzem LA
* Tab long-acting 240 mg	10.20	30	✓	Dilzem LA
* Cap long-acting 90 mg	7.65	60	✓	Dilzem SR
* Cap long-acting 120 mg (once per day)	4.72	30	✓	Cardizem CD
* Cap long-acting 120 mg (twice per day)	18.00	100	✓	Dilzem SR
* Cap long-acting 180 mg	7.08	30	✓	Cardizem CD
* Cap long-acting 240 mg	9.44	30	✓	Cardizem CD

*(Dilzem LA Tab long-acting 180 mg to be delisted 1 June 2009)*  
*(Dilzem LA Tab long-acting 240 mg to be delisted 1 June 2009)*  
*(Dilzem SR Cap long-acting 90 mg to be delisted 1 June 2009)*  
*(Dilzem SR Cap long-acting 120 mg (twice per day) to be delisted 1 June 2009)*

PERHEXILINE MALEATE – Special Authority see SA0256 below – Hospital pharmacy [HP3]

* Tab 100 mg	62.90	100	✓	Pexsig
--------------	-------	-----	---	--------

**SA0256 Special Authority for Subsidy**

**Initial application** only from a cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Refractory angina; and
- 2 Patient is already on maximal anti-anginal therapy.

**Renewal** only from a cardiologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

<b>VERAPAMIL HYDROCHLORIDE</b>				
* Tab 40 mg	4.75	100	✓	Verpamil
	7.01		✓	Isoptin
* Tab 80 mg	11.74	100	✓	Isoptin
* Tab long-acting 120 mg	15.20	250	✓	Verpamil SR
* Tab long-acting 240 mg	25.00	250	✓	Verpamil SR
* Inj 2.5 mg per ml, 2 ml – Up to 5 inj available on a PSO	7.54	5	✓	Isoptin

*(Verpamil Tab 40 mg to be delisted 1 March 2009)*

**Centrally Acting Agents**

<b>CLONIDINE</b>				
* TDDS 2.5 mg, 100 µg per day – Only on a prescription	21.29	4	✓	Catapres-TTS-1
* TDDS 5 mg, 200 µg per day – Only on a prescription	30.79	4	✓	Catapres-TTS-2
* TDDS 7.5 mg, 300 µg per day – Only on a prescription	39.10	4	✓	Catapres-TTS-3
<b>CLONIDINE HYDROCHLORIDE</b>				
* Tab 150 µg	30.33	100	✓	Catapres
* Inj 150 µg per ml, 1 ml	14.00	5	✓	Catapres
<b>METHYLDOPA</b>				
* Tab 125 mg	12.00	100	✓	Prodopa
* Tab 250 mg	13.10	100	✓	Prodopa
* Tab 500 mg	20.85	100	✓	Prodopa

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## CARDIOVASCULAR SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Diuretics</b>				
<b>Loop Diuretics</b>				
<b>BUMETANIDE</b>				
* Tab 1 mg .....	16.36	100	✓	<b>Burinex</b>
* Inj 500 µg per ml, 4 ml .....	7.95	5	✓	<b>Burinex</b>
<b>FRUSEMIDE</b>				
* Tab 40 mg – Up to 30 tab available on a PSO.....	11.50	1,000	✓	<b>Diurin 40</b>
* Tab 500 mg .....	12.00	100	✓	<b>Diurin 500</b>
*‡ Oral liq 10 mg per ml .....	10.66	30 ml OP	✓	<b>Lasix</b>
* Infusion 10 mg per ml, 25 ml .....	48.14	5	✓	<b>Lasix</b>
* Inj 10 mg per ml, 2 ml – Up to 5 inj available on a PSO .....	29.50	50	✓	<b>Mayne</b>
<b>Potassium Sparing Diuretics</b>				
<b>AMILORIDE</b>				
‡ Oral liq 1 mg per ml .....	26.20	25 ml OP	✓	<b>Biomed</b>
<b>SPIRONOLACTONE</b>				
* Tab 25 mg .....	8.50	100	✓	<b>Spirotone</b>
* Tab 100 mg .....	21.70	100	✓	<b>Spirotone</b>
‡ Oral liq 5 mg per ml .....	26.80	25 ml OP	✓	<b>Biomed</b>
<b>Potassium Sparing Combination Diuretics</b>				
<b>AMILORIDE WITH FRUSEMIDE</b>				
* Tab 5 mg with frusemide 40 mg .....	4.67 (8.63)	28		Frumil
<b>AMILORIDE WITH HYDROCHLOROTHIAZIDE</b>				
* Tab 5 mg with hydrochlorothiazide 50 mg .....	13.00	500	✓	<b>Amizide</b>
<b>TRIAMTERENE WITH HYDROCHLOROTHIAZIDE</b>				
* Tab 50 mg with hydrochlorothiazide 25 mg .....	5.00	100	✓	<b>Triamizide</b>
<b>Thiazide and Related Diuretics</b>				
<b>BENDROFLUAZIDE</b>				
* Tab 2.5 mg – Up to 150 tab available on a PSO..... May be supplied on a PSO for reasons other than emergency.	13.50	500	✓	<b>Neo-Naclex</b>
* Tab 5 mg .....	21.50	500	✓	<b>Neo-Naclex</b>
<b>CHLOROTHIAZIDE</b>				
‡ Oral liq 50 mg per ml .....	22.60	25 ml OP	✓	<b>Biomed</b>
<b>CHLORTHALIDONE</b>				
* Tab 25 mg .....	8.00	50	✓	<b>Hygroton</b>
<b>INDAPAMIDE</b>				
* Tab 2.5 mg .....	4.00	100	✓	<b>Napamide</b>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
<b>Nitrates</b>				
GLYCERYL TRINITRATE				
* Tab 600 µg – Up to 100 tab available on a PSO.....	8.00	100 OP	✓	Lycinate S29
* Oral pump spray 400 µg per dose – Up to 250 dose available on a PSO.....	5.16	250 dose OP	✓	Nitrolingual Pumpspray
* TDDS 5 mg .....	16.56	30	✓	Nitroderm TTS
* TDDS 10 mg .....	19.60	30	✓	Nitroderm TTS
ISOSORBIDE MONONITRATE				
* Tab 20 mg .....	18.00	100	✓	Ismo 20
* Tab long-acting 40 mg .....	14.84	30	✓	Corangin
* Tab long-acting 60 mg .....	4.15	90	✓	Duride

<b>Sympathomimetics</b>				
ADRENALINE				
Inj 1 in 1,000, 1 ml – Up to 5 inj available on a PSO .....	4.98	5	✓	Aspen Adrenaline
	5.25		✓	Mayne
Inj 1 in 10,000, 10 ml – Up to 5 inj available on a PSO .....	27.00	5	✓	Mayne
ISOPRENALINE HYDROCHLORIDE				
* Inj 200 µg per ml, 1 ml .....	36.80	25		Isuprel
	(135.00)			

<b>Vasodilators</b>				
AMYL NITRITE				
* Ampoule, 0.3 ml crushable .....	62.92	12		Baxter
	(73.40)			
HYDRALAZINE				
* Inj 20 mg per ml, 1 ml .....	25.90	5	✓	Apresoline
OXYPENTIFYLLINE – Hospital pharmacy [HP3]				
Tab 400 mg .....	36.94	50		Trental 400
	(42.26)			
PAPAVERINE HYDROCHLORIDE				
* Inj 12 mg per ml, 10 ml .....	73.12	5	✓	Mayne

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Smoking Cessation</b>				
NICOTINE – Only on a Quitcard				
Patch 7 mg .....	10.53	7	✓	Habitrol
Patch 14 mg .....	11.63	7	✓	Habitrol
Patch 21 mg .....	12.32	7	✓	Habitrol
Lozenge 1 mg .....	11.08	36	✓	Habitrol
Lozenge 2 mg .....	11.08	36	✓	Habitrol
Gum 2 mg (Fruit) .....	14.97	96	✓	Habitrol
	23.41		✓	Nicotinell
Gum 2 mg (Mint) .....	14.97	96	✓	Habitrol
	23.41		✓	Nicotinell
Gum 4 mg (Fruit) .....	20.02	96	✓	Habitrol
	23.41		✓	Nicotinell
Gum 4 mg (Mint) .....	20.02	96	✓	Habitrol
	23.41		✓	Nicotinell

*(Nicotinell Gum 2 mg (Fruit) to be delisted 1 March 2009)*

*(Nicotinell Gum 2 mg (Mint) to be delisted 1 March 2009)*

*(Nicotinell Gum 4 mg (Fruit) to be delisted 1 March 2009)*

*(Nicotinell Gum 4 mg (Mint) to be delisted 1 March 2009)*

Subsidy (Manufacturer's Price) \$ Per Fully Subsidised Per Brand or Generic Manufacturer

**Antiacne Preparations**

For systemic antibacterials, refer to INFECTIONS, Antibacterials, page 88

ISOTRETINOIN – Hospital pharmacy [HP3]-Specialist prescription

Specialist must be a dermatologist.

Cap 10 mg .....	36.00	100	✓ <b>Isotane 10</b>
Cap 20 mg .....	47.50	100	✓ <b>Isotane 20</b>

**Antibacterials Topical**

For systemic antibacterials, refer to INFECTIONS, Antibacterials, page 88

FUSIDIC ACID

Crm 2 % .....	3.95	15 g OP	✓ <b>Foban</b>
a) Maximum of 15 g per prescription			
b) Only on a prescription			
c) Not in combination			

Oint 2 % .....	3.95	15 g OP	✓ <b>Foban</b>
a) Maximum of 15 g per prescription			
b) Only on a prescription			
c) Not in combination			

HYDROGEN PEROXIDE

* Crm 1% .....	8.56	10 g OP	✓ <b>Crystacide</b>
----------------	------	---------	---------------------

MUPIROICIN

Oint 2% .....	6.60 (9.26)	15 g OP	Bactroban
a) Only on a prescription			
b) Not in combination			

SILVER SULPHADIAZINE

Crm 1% with chlorhexidine digluconate 0.2% .....	15.04	100 g OP	✓ <b>Silvazine</b>
a) Up to 500 g available on a PSO			
b) Not in combination			

**Antifungals Topical**

For systemic antifungals, refer to INFECTIONS, Antifungals, page 92

AMOROLFINE

a) Only on a prescription			
b) Not in combination			
Nail soln 5% .....	37.86 (61.87)	5 ml OP	Loceryl

CICLOPIROX OLAMINE

a) Only on a prescription			
b) Not in combination			
Crm 1% .....	1.00 (12.82)	20 g OP	Batrafen
Nail soln 8% .....	37.81 (42.84)	3.5 ml OP	Batrafen
Soln 1% .....	4.36 (11.54)	20 ml OP	Batrafen

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## DERMATOLOGICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>CLOTRIMAZOLE</b>				
* Crm 1% .....	0.50	20 g OP	✓	<b>Clomazol</b>
a) Only on a prescription				
b) Not in combination				
* Soln 1% .....	4.36 (7.55)	20 ml OP		Canesten
a) Only on a prescription				
b) Not in combination				
<b>ECONAZOLE NITRATE</b>				
Crm 1% .....	1.00 (6.50)	20 g OP		Pevaryl
a) Only on a prescription				
b) Not in combination				
Foaming soln 1%, 10 ml sachets .....	9.89 (15.66)	3		Pevaryl
a) Only on a prescription				
b) Not in combination				
<b>KETOCONAZOLE</b>				
Crm 2% .....	1.00 (10.00)	15 g OP		Nizoral
a) Only on a prescription				
b) Not in combination				
<b>MICONAZOLE NITRATE</b>				
* Crm 2% .....	0.42	15 g OP	✓	<b>Multichem</b>
a) Only on a prescription				
b) Not in combination				
* Lotn 2% .....	4.36 (10.32)	30 ml OP		Daktarin
a) Only on a prescription				
b) Not in combination				
* Tincture 2% .....	4.36 (12.46)	30 ml OP		Daktarin
a) Only on a prescription				
b) Not in combination				
<b>NYSTATIN</b>				
Crm 100,000 u per g .....	1.00 (5.10)	15 g OP		Mycostatin
a) Only on a prescription				
b) Not in combination				

## Antipruritic Preparations

### CALAMINE

- a) Only on a prescription  
b) Not in combination

Crm, aqueous, BP .....	3.02	100 ml	✓	<b>ABM</b>
Lotn, BP .....	19.44	2,000 ml	✓	<b>ABM</b>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>CROTAMITON</b>				
a) Only on a prescription				
b) Not in combination				
Crm 10% .....	4.26 (4.45)	20 g OP		Eurax
Lotn 10% .....	7.56 (7.70)	50 ml		Eurax

(Eurax Lotn 10% to be delisted 1 July 2009)

<b>MENTHOL – Only in combination</b>				
Only in combination with aqueous cream, 10% urea cream, wool fat with mineral oil lotion, 1% hydrocortisone with wool fat and mineral oil lotion, and glycerol, paraffin and cetyl alcohol lotion				
Crystals .....	7.40	25 g	✓ PSM	
	29.60	100 g	✓ MidWest	

**Corticosteroids Topical**

For systemic corticosteroids, refer to CORTICOSTEROIDS AND RELATED AGENTS, page 79

**Corticosteroids - Plain**

<b>BETAMETHASONE DIPROPIONATE</b>				
Crm 0.05% .....	2.96 (6.91)	15 g OP		Diprosone
	8.97 (18.36)	50 g OP		Diprosone
Crm 0.05% in propylene glycol base .....	4.33 (13.83)	30 g OP		Diprosone OV
Oint 0.05% .....	2.96 (6.51)	15 g OP		Diprosone
	8.97 (17.11)	50 g OP		Diprosone
Oint 0.05% in propylene glycol base .....	4.33 (13.83)	30 g OP		Diprosone OV
<b>BETAMETHASONE VALERATE</b>				
* Crm 0.1% .....	2.00	50 g OP	✓ Beta Cream	
* Oint 0.1% .....	2.20	50 g OP	✓ Beta Ointment	
* Lotn 0.1% .....	10.05	50 ml OP	✓ Betnovate	
<b>CLOBETASOL PROPIONATE</b>				
* Crm 0.05% .....	2.35	30 g OP	✓ Dermol	
* Oint 0.05% .....	1.60	30 g OP	✓ Dermol	
<b>CLOBETASONE BUTYRATE</b>				
Crm 0.05% .....	5.38 (7.09)	30 g OP		Eumovate
	16.13 (22.00)	100 g OP		Eumovate
<b>DIFLUCORTOLONE VALERATE</b>				
Crm 0.1% .....	8.97 (15.23)	50 g OP		Nerisone
Fatty oint 0.1% .....	8.97 (15.23)	50 g OP		Nerisone

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## DERMATOLOGICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>HYDROCORTISONE</b>				
* Crm 1% – Only on a prescription .....	2.44	100 g	✓	<b>Lemnis Fatty Cream HC</b>
	12.20	500 g	✓	<b>PSM</b>
* Powder – Only in combination .....	37.64	25 g	✓	<b>m-Hydrocortisone</b>
Up to 5% in a dermatological base (not proprietary Topical Corticosteroid – Plain) with or without other dermatological galenicals. Refer, page 163				
<b>HYDROCORTISONE BUTYRATE</b>				
Crm 0.1% .....	5.00	30 g OP	✓	<b>Locoid</b>
	15.00	100 g OP	✓	<b>Locoid</b>
Lipocream 0.1% .....	5.00	30 g OP	✓	<b>Locoid Lipocream</b>
	15.00	100 g OP	✓	<b>Locoid Lipocream</b>
Oint 0.1% .....	15.00	100 g OP	✓	<b>Locoid</b>
Milky Emulsion 0.1% .....	5.00	30 ml OP	✓	<b>Locoid Crelo</b>
	15.00	100 ml OP	✓	<b>Locoid Crelo</b>
<i>(Locoid Crm 0.1% to be delisted 1 May 2009)</i>				
<b>HYDROCORTISONE WITH WOOL FAT AND MINERAL OIL</b>				
Lotn 1% with wool fat hydrous 3% and mineral oil – Only on a prescription .....	9.95	250 ml	✓	<b>DP Lotn HC</b>
<b>METHYLPREDNISOLONE ACEPONATE</b>				
Crm 0.1% .....	4.95	15 g OP	✓	<b>Advantan</b>
Oint 0.1% .....	4.95	15 g OP	✓	<b>Advantan</b>
<b>MOMETASONE FUROATE</b>				
Crm 0.1% .....	3.96	15 g OP	✓	<b>Elocon</b>
	10.82	45 g OP	✓	<b>Elocon</b>
Oint 0.1% .....	3.96	15 g OP	✓	<b>Elocon</b>
	10.82	45 g OP	✓	<b>Elocon</b>
Lotn 0.1% .....	4.80	30 ml OP	✓	<b>Elocon</b>
<b>TRIAMCINOLONE ACETONIDE</b>				
Crm 0.02% .....	6.63	100 g OP	✓	<b>Aristocort</b>
Oint 0.02% .....	6.69	100 g OP	✓	<b>Aristocort</b>
<b>Corticosteroids - Combination</b>				
<b>BETAMETHASONE VALERATE WITH CLIOQUINOL – Only on a prescription</b>				
Crm 0.1% with clioquinol 3% .....	3.49	15 g OP		
	(4.90)			<b>Betnovate-C</b>
Oint 0.1% with clioquinol 3% .....	3.49	15 g OP		
	(4.90)			<b>Betnovate-C</b>
<b>BETAMETHASONE VALERATE WITH FUSIDIC ACID</b>				
Crm 0.1% with fusidic acid 2% .....	3.49	15 g OP		
	(8.84)			<b>Fucicort</b>
a) Maximum of 15 g per prescription				
b) Only on a prescription				
<b>HYDROCORTISONE BUTYRATE WITH CHLORQUINALDOL – Only on a prescription</b>				
Crm 0.1% with chlorquinaldol 3% .....	3.49	15 g OP	✓	<b>Locoid C</b>
<b>HYDROCORTISONE WITH MICONAZOLE – Only on a prescription</b>				
* Crm 1% with miconazole nitrate 2% .....	2.20	15 g OP	✓	<b>Micreme H</b>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN – Only on a prescription</b>				
Crm 1% with natamycin 1% and neomycin sulphate 0.5% .....	4.40	15 g OP	✓	<b>Pimafucort</b>
Oint 1% with natamycin 1% and neomycin sulphate 0.5% .....	4.40	15 g OP	✓	<b>Pimafucort</b>
<b>TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN</b>				
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g – Only on a prescription .....	3.49 (4.49)	15 g OP		Viaderm KC
Oint 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g – Only on a prescription .....	3.00	15 g OP	✓	<b>Kenacomb</b>

**Disinfecting and Cleansing Agents**

<b>CHLORHEXIDINE GLUCONATE – Subsidy by endorsement</b>				
a) No more than 500 ml per month				
b) Only if prescribed for a dialysis patient and the prescription is endorsed accordingly.				
* Handrub 1% with ethanol 70% .....	5.40	500 ml	✓	<b>Orion</b>
* Soln 4% .....	7.20	500 ml	✓	<b>Orion</b>
<b>SODIUM HYPOCHLORITE – Subsidy by endorsement</b>				
Only if prescribed for a dialysis patient and the prescription is endorsed accordingly.				
* Soln .....	2.71	2,500 ml	✓	<b>Janola</b>

**Dusting Powders**

<b>DIPHEMANIL METHYLSULPHATE – Subsidy by endorsement</b>				
Only if prescribed for an amputee with an artificial limb, or for a paraplegic patient and the prescription endorsed accordingly.				
Powder 2% .....	6.81 (13.54)	50 g OP		Prantal

**Barrier Creams and Emollients**

**Barrier Creams**

<b>ZINC</b>				
Crm BP .....	6.55 (9.79)	500 g		PSM
<b>ZINC AND CASTOR OIL</b>				
Oint BP .....	5.11	500 g	✓	<b>PSM</b>

**Emollients**

<b>AQUEOUS CREAM</b>				
* Crm .....	2.28 (2.37)	500 g	✓	<b>AFT</b> Multichem
<i>(Multichem Crm to be delisted 1 April 2009)</i>				
<b>CETOMACROGOL</b>				
* Crm BP .....	3.50	500 g	✓	<b>PSM</b>
<b>EMULSIFYING OINTMENT</b>				
* Oint BP .....	3.69	500 g	✓	<b>AFT</b>
<b>GLYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription</b>				
* Lotn 5% with paraffin liq 5% and cetyl alcohol 2% .....	1.40 (8.10)	250 ml		QV

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## DERMATOLOGICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>OIL IN WATER EMULSION</b>				
* Crm .....	2.80	500 g	✓	<b>Lemnis Fatty Cream</b>
<b>OILY CREAM</b>				
* Crm BP .....	2.80 (13.60) (15.40)	500 g		David Craig PSM
<b>UREA</b>				
* Crm 10% .....	2.52	100 g OP	✓	<b>Nutraplus</b>
<b>WOOL FAT WITH MINERAL OIL – Only on a prescription</b>				
* Lotn hydrous 3% with mineral oil .....	1.40 (2.92) 5.60 (9.54) 1.40 (3.50) 5.60 (10.90) 1.12 (5.00) 2.10 (9.38) 5.60 (18.43) 1.40 (7.73) 5.60 (23.91)	250 ml OP  1,000 ml  250 ml OP  1,000 ml  200 ml OP  375 ml OP  1,000 ml  250 ml OP  1,000 ml		Hydroderm Lotion  Hydroderm Lotion  DP Lotion  DP Lotion  Alpha-Keri Lotion  Alpha-Keri Lotion  Alpha-Keri Lotion  BK Lotion  BK Lotion

### Other Dermatological Bases

#### PARAFFIN

White soft – Only in combination .....	20.20 3.58 (8.69)	2,500 g 500 g	✓	<b>IPW</b>  PSM
--	-------------------------	------------------	---	-----------------------

Only in combination with a dermatological galenical or as a diluent for a proprietary Topical Corticosteroid – Plain.

### Minor Skin Infections

#### POVIDONE IODINE

Oint 10% .....	2.88 (3.27)	25 g OP		Betadine
a) Maximum of 100 g per prescription				
b) Only on a prescription				
Antiseptic soln 10% .....	6.20	500 ml	✓	<b>Betadine</b>
			✓	<b>Riodine</b>
Skin preparation, povidone iodine 10% with 30% alcohol .....	8.13	500 ml	✓	<b>Betadine Skin Prep</b>
Skin preparation, povidone iodine 10% with 70% alcohol .....	8.13 (18.63)	500 ml		Orion

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

**Parasiticial Preparations**

**GAMMA BENZENE HEXACHLORIDE**

Crm 1% .....3.50 50 g OP ✓ **Benhex**

**MALATHION**

Liq 0.5% .....4.99 200 ml ✓ **Derbac-M**

Shampoo 1% .....2.83 30 ml OP ✓ **A-Lices**

**PERMETHRIN**

1) Should be strictly reserved for use as second line therapy in:

1) patients unable to tolerate the other medications, such as infants, young children and patients with allergies or eczema;

2) cases of scabies which are resistant to gamma benzene hexachloride and resistant to malathion.

2) Verification of drug resistance is dependent on the persistence of the condition after treatment. In order to establish whether there is drug resistance, the following criteria should be fulfilled:

1) a definite diagnosis of scabies should be made;

2) it should be ascertained that the medication was administered properly;

3) the possibility of reinfestation should have been excluded.

Crm 5% .....4.20 30 g OP ✓ **Lyderm**

**Psoriasis and Eczema Preparations**

**ACITRETIN – Hospital pharmacy [HP3]-Specialist prescription**

Specialist must be a dermatologist.

Cap 10 mg .....94.75 100 ✓ **Neotigason**

Cap 25 mg .....203.70 100 ✓ **Neotigason**

**CALCIPOTRIOL**

Crm 50 µg per g .....20.76 30 g OP ✓ **Daivonex**

57.89 100 g OP ✓ **Daivonex**

Oint 50 µg per g .....20.76 30 g OP ✓ **Daivonex**

57.89 100 g OP ✓ **Daivonex**

Soln 50 µg per ml .....20.78 30 ml OP ✓ **Daivonex**

34.72 60 ml OP ✓ **Daivonex**

**COAL TAR**

Solution BP – Only in combination .....36.48 500 ml ✓ **PSM**

12.98 200 ml

(16.20) David Craig

Up to 10 % Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain, refer, page 163  
With or without other dermatological galenicals.

**COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULPHUR**

Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and

allantoin crm 2.5% .....3.43 30 g OP

(4.35) Egopsoryl TA

6.59 75 g OP

(8.00) Egopsoryl TA

**COAL TAR WITH SALICYLIC ACID AND SULPHUR**

Soln 12% with salicylic acid 2% and sulphur 4% ointment .....7.95 40 g OP ✓ **Coco-Scalp**

**DITHRANOL**

Crm 1% .....27.50 50 g OP ✓ **Micanol**

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## DERMATOLOGICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>SALICYLIC ACID</b>				
Powder – Only in combination .....	15.00	500 g	✓	<b>ABM</b>
	18.88	250 g	✓	<b>PSM</b>
1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain or collodion flexible, refer, page 163				
2) With or without other dermatological galenicals.				
3) Maximum 20 g or 20 ml per prescription when prescribed with white soft paraffin or collodion flexible.				
<b>SULPHUR</b>				
Precipitated – Only in combination .....	6.50	100 g	✓	<b>ABM</b>
	(9.25)			<b>PSM</b>
1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain, refer, page 163				
2) With or without other dermatological galenicals.				
<b>TAR WITH CADE OIL</b>				
Bath emulsion 7.5% coal tar, 2.5% cade oil, 7.5% compound .....	9.70	350 ml		
	(29.60)			<b>Polytar Emollient</b>
<b>TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLUORESCEIN</b> – Only on a prescription				
* Soln 2.3% with triethanolamine lauryl sulphate and fluo- cein sodium .....	2.90	500 ml	✓	<b>Pinetarsol</b>

### Scalp Preparations

<b>BETAMETHASONE VALERATE</b>				
* Scalp app 0.1% .....	5.25	100 ml OP	✓	<b>Beta Scalp</b>
<b>CLOBETASOL PROPIONATE</b>				
* Scalp app 0.05% .....	3.20	30 ml OP	✓	<b>Dermol</b>
<b>HYDROCORTISONE BUTYRATE</b>				
Scalp lotn 0.1% .....	7.52	100 ml OP	✓	<b>Locoid</b>
<b>KETOCONAZOLE</b>				
Shampoo 2% .....	3.48	100 ml OP	✓	<b>Sebizole</b>
a) Maximum of 100 ml per prescription				
b) Only on a prescription				

### Sunscreens

<b>SUNSCREENS, PROPRIETARY</b> – Subsidy by endorsement				
Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly.				
Crm .....	2.55	100 g OP		
	(5.89)			<b>Hamilton Sunscreen</b>
	1.28	50 g OP		
	(5.84)			<b>Aquasun Oil Free Faces SPF30+</b>
Lotn .....	2.55	100 ml OP	✓	<b>Marine Blue Lotion SPF 30+</b>
	5.10	200 ml OP	✓	<b>Marine Blue Lotion SPF 30+</b>
	3.19	125 ml OP		
	(8.82)			<b>Aquasun Sensitive SPF 30+</b>
	(9.38)			<b>Aquasun 30+</b>

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per	✓

### Wart Preparations

For salicylic acid preparations refer to PSORIASIS AND ECZEMA PREPARATIONS, page 69

IMIQUIMOD – Special Authority see SA0923 below – Retail pharmacy

Crm 5% sachet .....	110.40	12	✓ Aldara
---------------------	--------	----	----------

#### ▶▶SA0923 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has external anogenital warts and podophyllotoxin has been tried and failed (or is contraindicated); or
- 2 The patient has external anogenital warts and podophyllotoxin is unable to be applied accurately to the site; or
- 3 The patient has confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate.

Notes: Superficial basal cell carcinoma

- Surgical excision remains first-line treatment for superficial basal cell carcinoma as it has a higher cure rate than imiquimod and allows histological assessment of tumour clearance.
- Imiquimod has not been evaluated for the treatment of superficial basal cell carcinoma within 1 cm of the hairline, eyes, nose, mouth or ears.
- Imiquimod is not indicated for recurrent, invasive, infiltrating, or nodular basal cell carcinoma.

External anogenital warts

- Imiquimod is only indicated for external genital and perianal warts (condyloma acuminata).

**Renewal** from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria:

Any of the following:

- 1 Inadequate response to initial treatment for anogenital warts; or
- 2 New confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate; or
- 3 Inadequate response to initial treatment for superficial basal cell carcinoma.

Note: Confirmation that the lesion is a superficial basal cell carcinoma should be obtained using a biopsy

PODOPHYLLOTOXIN

Soln 0.5% .....	33.60	3.5 ml OP	✓ Condylone
a) Maximum of 3.5 ml per prescription			
b) Only on a prescription			

### Other Skin Preparations

#### Antineoplastics

FLUOROURACIL SODIUM

Crm 5% .....	26.49	20 g OP	✓ Efudix
--------------	-------	---------	----------

#### Topical Analgesia

For aspirin & chloroform application refer, page 166

CAPSAICIN – Subsidy by endorsement

Subsidised only if prescribed for post-herpetic neuralgia or diabetic peripheral neuropathy and the prescription is endorsed accordingly.

Crm 0.075% .....	12.50	45 g OP	✓ Zostrix HP
------------------	-------	---------	--------------

### Wound Management Products

HYDROGEN PEROXIDE

* Solution 20 vol – Maximum of 500 ml per prescription .....	3.13 (7.00)	500 ml	PSM
--	----------------	--------	-----

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## DERMATOLOGICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
MAGNESIUM SULPHATE				
Paste .....	2.98 (4.90)	80 g		PSM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Contraceptives - Non-hormonal</b>				
<b>Condoms</b>				
CONDOMS				
* 49 mm – Up to 144 dev available on a PSO.....	13.36	144	✓	Gold Knight ✓ MarquisTantiliza ✓ Shield 49
* 52 mm – Up to 144 dev available on a PSO.....	13.36	144	✓	Marquis Selecta ✓ Marquis SensoLite ✓ Marquis Supalite
* 52 mm extra strength – Up to 144 dev available on a PSO.....	13.36	144	✓	Marquis Protecta
* 53 mm – Up to 144 dev available on a PSO.....	13.36	144	✓	Gold Knight ✓ Marquis Black ✓ Marquis Titillata
* 53 mm (chocolate) – Up to 144 dev available on a PSO.....	13.36	144	✓	Shield Blue
* 53 mm (strawberry) – Up to 144 dev available on a PSO.....	13.36	144	✓	Gold Knight
* 53 mm extra strength – Up to 144 dev available on a PSO.....	13.36	144	✓	Gold Knight
* 54 mm, shaped – Up to 144 dev available on a PSO.....	13.36	144		
	(14.84)			Lifestyles Flared
* 55 mm – Up to 144 dev available on a PSO.....	13.36	144	✓	Gold Knight ✓ Marquis Conforma
* 56 mm, shaped – Up to 144 dev available on a PSO.....	13.36	144	✓	Durex Confidence
* 60 mm – Up to 144 pack available on a PSO.....	13.36	144	✓	Shield XL

**Spermicidal Agents**

APPLICATOR

When ordered with a spermicide.

* Applicator – Up to 1 dev available on a PSO.....	4.34	1	✓	Ortho
--	------	---	---	-------

NONOXYNOL-9

Jelly 2% – Up to 108 g available on a PSO.....	10.95	108 g OP	✓	Gynol II
--	-------	----------	---	----------

**Contraceptive Devices**

DIAPHRAGM

* Diaphragm – Up to 1 dev available on a PSO.....	42.90	1	✓	Ortho All-flex ✓ Ortho Coil
---	-------	---	---	--------------------------------

One of each size is permitted on a PSO.

INTRA-UTERINE DEVICE – Only on a WSO

* IUD .....	39.50	1	✓	Multiload Cu 375 ✓ Multiload Cu 375 SL
-------------	-------	---	---	---

Distributed by Pharmaco NZ Ltd, PO Box 4079, Auckland Ph 09 377 3336

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) Fully Subsidised Brand or Generic Manufacturer  
 \$ Per ✓

**Contraceptives - Hormonal**

**Combined Oral Contraceptives**

**▶SA0500 Special Authority for Alternate Subsidy**

**Initial application** from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
  - 1.1 Patient is on a Social Welfare benefit; or
  - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

**Renewal** from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon, Marvelon, Minulet and Femodene.

The additional subsidy will fund Mercilon, Marvelon, Minulet and Femodene up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

**ETHINYLOESTRADIOL WITH DESOGESTREL**

* Tab 20 µg with desogestrel 150 µg .....	6.62	63	
	(16.50)		Mercilon 21
a) Higher subsidy of \$13.80 per 63 with Special Authority see SA0500 above			
b) Up to 63 tab available on a PSO			
* Tab 20 µg with desogestrel 150 µg and 7 inert tab .....	6.62	84	
	(16.50)		Mercilon 28
a) Higher subsidy of \$13.80 per 84 with Special Authority see SA0500 above			
b) Up to 84 tab available on a PSO			
* Tab 30 µg with desogestrel 150 µg .....	6.62	63	
	(16.50)		Marvelon 21
a) Higher subsidy of \$13.80 per 63 with Special Authority see SA0500 above			
b) Up to 63 tab available on a PSO			
* Tab 30 µg with desogestrel 150 µg and 7 inert tab .....	6.62	84	
	(16.50)		Marvelon 28
a) Higher subsidy of \$13.80 per 84 with Special Authority see SA0500 above			
b) Up to 84 tab available on a PSO			
<b>ETHINYLOESTRADIOL WITH GESTODENE</b>			
* Tab 30 µg with gestodene 75 µg and 7 inert tab .....	6.62	84	
	(14.49)		Minulet 28
	(16.50)		Femodene 28
a) Higher subsidy of \$14.49 per 84 with Special Authority see SA0500 above			
b) Up to 84 tab available on a PSO			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>ETHINYLOESTRADIOL WITH LEVONORGESTREL</b>				
* Tab ethinyloestradiol 30 µg with levonorgestrel 50 µg (6) and tab ethinyloestradiol 40 µg with levonorgestrel 75 µg (5), and tab ethinyloestradiol 30 µg with levonorgestrel 125 µg (10) and 7 inert tab .....	6.62 (9.45) (14.49)	84	✓	<b>Trifeme</b> Triquilar ED Triphasil 28
a) Higher subsidy of up to \$14.49 per 84 with Special Authority see SA0500 on the preceding page				
b) Up to 84 tab available on a PSO				
* Tab 50 µg with levonorgestrel 125 µg and 7 inert tab – Up to 84 tab available on a PSO .....	9.45	84	✓	<b>Microgynon 50 ED</b>
* Tab 30 µg with levonorgestrel 150 µg .....	6.62 (16.50)	63		Microgynon 30
a) Higher subsidy of \$15.00 per 63 with Special Authority see SA0500 on the preceding page				
b) Up to 63 tab available on a PSO				
* Tab 30 µg with levonorgestrel 150 µg and 7 inert tab .....	6.62 (14.49) (16.50)	84	✓ ✓	<b>Leven ED</b> <b>Monofeme</b> Nordette 28 Microgynon 30 ED
a) Higher subsidy of up to \$15.00 per 84 with Special Authority see SA0500 on the preceding page				
b) Up to 84 tab available on a PSO				
<b>ETHINYLOESTRADIOL WITH NORETHISTERONE</b>				
* Tab 35 µg with norethisterone 1 mg – Up to 63 tab available on a PSO .....	6.62	63	✓	<b>Brevinor 1/21</b>
* Tab 35 µg with norethisterone 1 mg and 7 inert tab – Up to 84 tab available on a PSO .....	6.62	84	✓	<b>Brevinor 1/28</b>
* Tab 35 µg with norethisterone 500 µg – Up to 63 tab available on a PSO .....	6.62	63	✓	<b>Brevinor 21</b>
* Tab 35 µg with norethisterone 500 µg and 7 inert tab – Up to 84 tab available on a PSO .....	6.62	84	✓	<b>Norimin</b>
<b>NORETHISTERONE WITH MESTRANOL</b>				
* Tab 1 mg with mestranol 50 µg and 7 inert tab .....	6.62 (13.80)	84		Norinyl-1/28
a) Higher subsidy of \$13.80 per 84 with Special Authority see SA0500 on the preceding page				
b) Up to 84 tab available on a PSO				

**Combined Oral Contraceptives - Other**

<b>ETHINYLOESTRADIOL WITH LEVONORGESTREL</b>				
* Tab 20 µg with levonorgestrel 100 µg and 7 inert tab – Up to 84 tab available on a PSO .....	6.62 (16.50) (16.50)	84		Loette Microgynon 20 ED

‡ safety cap

\* Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$ Per Fully Subsidised ✓ Brand or Generic Manufacturer

**Progestogen-only Contraceptives**

▶▶SA0500 **Special Authority for Alternate Subsidy**

**Initial application** from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Either:
  - 1.1 Patient is on a Social Welfare benefit; or
  - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

**Renewal** from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon, Marvelon, Minulet and Femodene.

The additional subsidy will fund Mercilon, Marvelon, Minulet and Femodene up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

**LEVONORGESTREL**

* Tab 30 µg .....	6.62	84	
	(16.50)		Microlut
a) Higher subsidy of \$13.80 per 84 with Special Authority see SA0500 above			
b) Up to 84 tab available on a PSO			

**MEDROXYPROGESTERONE ACETATE**

* Inj 150 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	8.05	1	✓ Depo-Provera
* Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a PSO .....	8.05	1	✓ Depo-Provera

**NORETHISTERONE**

* Tab 350 µg – Up to 84 tab available on a PSO.....	7.15	84	✓ <u>Noriday 28</u>
---	------	----	---------------------

**Emergency Contraceptives**

**LEVONORGESTREL**

* Tab 1.5 mg .....	12.50	1	✓ Postinor-1
a) Maximum of 2 tab per prescription			
b) Up to 5 tab available on a PSO			

**Antiandrogen Oral Contraceptives**

Prescribers may code prescriptions "contraceptive" (code "O") when used as indicated for contraception. The period of supply and prescription charge will be as per other contraceptives, as follows:

- \$3.00 prescription charge (patient co-payment) will apply.
- prescription may be written for up to six months supply.

Prescriptions coded in any other way are subject to the non contraceptive prescription charges, and the non-contraceptive period of supply. ie. Prescriptions may be written for up to three months supply.

**CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL**

* Tab 2 mg with ethinyloestradiol 35 µg and 7 inert tabs .....	6.30	84	✓ Estelle 35-ED
--	------	----	-----------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

**Gynaecological Anti-infectives**
**ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC ACID**

Jelly with glacial acetic acid 0.94%, hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator .....

8.43 100 g OP  
(11.32)

Aci-Jel

**CLOTRIMAZOLE**

\* Vaginal crm 1% with applicator(s) .....

1.45 35 g OP

✓ **Clomazol**

\* Vaginal crm 2% with applicators .....

2.75 20 g OP

✓ **Clomazol**

3.44 25 g  
(3.99)

Clotrimaderm 2%

*(Clotrimaderm 2% Vaginal crm 2% with applicators to be delisted 1 April 2009)*

**MICONAZOLE NITRATE**

\* Vaginal crm 2% with applicator .....

2.75 40 g OP

(3.70)

Micreme

**NYSTATIN**

Vaginal crm 100,000 u per 5 g with applicator(s) .....

4.71 75 g OP

✓ **Nilstat**

**Myometrial and Vaginal Hormone Preparations**
**ERGOMETRINE MALEATE**

Inj 500 µg per ml, 1 ml – Up to 5 inj available on a PSO .....

11.60 5

✓ **Mayne**

**METHYLERGOMETRINE**

Inj 200 µg per ml, 1 ml – Up to 10 inj available on a PSO .....

9.28 10

✓ **Hospira S29**

**OESTRIOL**

\* Crm 1 mg per g with applicator .....

7.00 15 g OP

✓ **Ovestin**

\* Pessaries 500 µg .....

7.25 15

✓ **Ovestin**

**OXYTOCIN – Up to 5 inj available on a PSO**

Inj 5 iu per ml, 1 ml .....

5.40 5

✓ **Syntocinon**

Inj 10 iu per ml, 1 ml .....

6.80 5

✓ **Syntocinon**

Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml .....

9.20 5

✓ **Syntometrine**

**Pregnancy Tests - HCG Urine**
**PREGNANCY TESTS - HCG URINE – Only on a WSO**

Cassette .....

19.00 25 test

✓ **MDS Quick Card**

Distributed by MDS Diagnostics, PO Box 24-162, Royal Oak, Auckland. Ph 09 570 5761

**Urinary Agents**

For urinary tract Infections refer to INFECTIONS, Antibacterials, page 99

**5-Alpha Reductase Inhibitors**
**FINASTERIDE – Special Authority see SA0928 on the next page – Retail pharmacy**

Tab 5 mg .....

19.20 30

✓ **Fintral**

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## GENITO-URINARY SYSTEM

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

### SA0928 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 Either:
  - 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
  - 2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

Note: Patients with enlarged prostates are the appropriate candidates for therapy with finasteride.

### Other Urinary Agents

#### OXYBUTYNIN

* Tab 5 mg .....	44.79	500	✓ <u>Apo-Oxybutynin</u>
* Oral liq 5 mg per 5 ml .....	50.40	473 ml OP	✓ <u>Apo-Oxybutynin</u>

#### SODIUM CITRO-TARTRATE

* Grans eff 4 g sachets .....	2.75	28	✓ <u>Ural</u>
-------------------------------	------	----	---------------

## HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer ✓
<b>Anabolic Agents</b>			
NANDROLONE DECANOATE – Retail pharmacy-Specialist			
Inj 50 mg per ml, 1 ml .....	21.15	1	✓ <b>Deca-Durabolin Orgaject</b>
<b>Corticosteroids and Related Agents for Systemic Use</b>			
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE			
* Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1ml .....	19.20 (33.60)	5	Celestone Chronodose
DEXAMETHASONE			
* Tab 1 mg – Retail pharmacy-Specialist .....	16.08	100	✓ <b>Douglas</b>
Up to 30 tab available on a PSO			
* Tab 4 mg – Retail pharmacy-Specialist .....	61.89	100	✓ <b>Douglas</b>
Up to 30 tab available on a PSO			
Oral liq 1 mg per ml – Retail pharmacy-Specialist .....	39.90	25 ml OP	✓ <b>Biomed</b>
Oral liq prescriptions:			
1) Must be written by a Paediatrician or Paediatric Cardiologist; or			
2) On the recommendation of a Paediatrician or Paediatric Cardiologist.			
DEXAMETHASONE SODIUM PHOSPHATE			
* Inj 4 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	21.50	5	✓ <b>Mayne</b>
* Inj 4 mg per ml, 2 ml – Up to 5 inj available on a PSO .....	31.00	5	✓ <b>Mayne</b>
FLUDROCORTISONE ACETATE			
* Tab 100 µg .....	7.62	100	✓ <b>Florinef</b>
HYDROCORTISONE			
* Tab 5 mg .....	7.95	100	✓ <b>Douglas</b>
* Tab 20 mg .....	19.95	100	✓ <b>Douglas</b>
* Inj 50 mg per ml, 2 ml .....	3.72	1	✓ <b>Solu-Cortef</b>
a) Up to 5 inj available on a PSO			
b) Only on a PSO			
METHYLPREDNISOLONE – Retail pharmacy-Specialist			
* Tab 4 mg .....	48.57	100	✓ <b>Medrol</b>
* Tab 100 mg .....	166.52	20	✓ <b>Medrol</b>
METHYLPREDNISOLONE ACETATE			
Inj 40 mg per ml, 1 ml .....	6.03	1	✓ <b>Depo-Medrol</b>
METHYLPREDNISOLONE ACETATE WITH LIGNOCAINE			
Inj 40 mg per ml with lignocaine 1 ml .....	6.03	1	✓ <b>Depo-Medrol with lidocaine</b>
METHYLPREDNISOLONE SODIUM SUCCINATE – Retail pharmacy-Specialist			
Inj 40 mg per ml, 1 ml .....	151.40	25	✓ <b>Solu-Medrol</b>
Inj 62.5 mg per ml, 2 ml .....	412.59	25	✓ <b>Solu-Medrol</b>
Inj 500 mg .....	16.45	1	✓ <b>Solu-Medrol</b>
Inj 1 g .....	42.57	1	✓ <b>Solu-Medrol</b>
PREDNISOLONE SODIUM PHOSPHATE			
* Oral liq 5 mg per ml – Up to 30 ml available on a PSO .....	9.95	30 ml OP	✓ <b>Redipred</b>
Restricted to children under 12 years of age.			

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>PREDNISONE</b>				
* Tab 1 mg .....	10.68	500	✓	<u>Apo-Prednisone</u>
* Tab 2.5 mg .....	12.09	500	✓	<u>Apo-Prednisone</u>
* Tab 5 mg – Up to 30 tab available on a PSO.....	11.09	500	✓	<u>Apo-Prednisone</u>
* Tab 20 mg .....	29.03	500	✓	<u>Apo-Prednisone</u>
<b>TETRACOSACTRIN</b>				
* Inj 250 µg .....	177.18	10	✓	<u>Synacthen</u>
* Inj 1 mg per ml, 1 ml .....	26.88	1	✓	<u>Synacthen Depot</u>
<b>TRIAMCINOLONE ACETONIDE</b>				
Inj 10 mg per ml, 1 ml .....	11.11	5	✓	<u>Kenacort-A</u>
Inj 10 mg per ml, 5 ml .....	10.31	1	✓	<u>Kenacort-A</u>
Inj 40 mg per ml, 1 ml .....	28.09	5	✓	<u>Kenacort-A40</u>

### Sex Hormones Non Contraceptive

#### Androgen Agonists and Antagonists

<b>CYPROTERONE ACETATE – Hospital pharmacy [HP3]-Specialist</b>				
Tab 50 mg .....	23.50	50	✓	<u>Siterone</u>
<b>TESTOSTERONE</b>				
Transdermal patch 2.5 mg per day .....	80.00	60	✓	<u>Androderm</u>
<b>TESTOSTERONE CYPIONATE – Retail pharmacy-Specialist</b>				
Inj long-acting 100 mg per ml, 10 ml .....	61.41	1	✓	<u>Depo-Testosterone</u>
<b>TESTOSTERONE ESTERS – Retail pharmacy-Specialist</b>				
Inj 250 mg per ml, 1 ml .....	12.98	1	✓	<u>Sustanon Ampoules</u>
<b>TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist</b>				
Cap 40 mg .....	60.71	60	✓	<u>Panteston</u>

### Hormone Replacement Therapy - Systemic

#### ►SA0312 Special Authority for Alternate Subsidy

**Initial application** only from an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years for applications meeting the following criteria:

Any of the following:

- 1 acute or significant liver disease – where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record; or
- 2 oestrogen induced hypertension requiring antihypertensive therapy – documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens; or
- 3 hypertriglyceridaemia – documented evidence must be kept on file that triglyceride levels increased to at least 2 × normal triglyceride levels post oral oestrogens.

Note: Prescriptions with a valid Special Authority (CHEM) number will be reimbursed at the level of the lowest priced TDDS product within the specified dose group.

**Renewal** only from an obstetrician, gynaecologist, general practitioner or general physician. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment.

#### Prescribing Guideline

HRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG "Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004".

## HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Oestrogens</b>				
OESTRADIOL – See prescribing guideline on the preceding page				
* Tab 1 mg .....	4.12	28 OP		
	(6.50)			Estrofem
* Tab 2 mg .....	4.12	28 OP		
	(7.00)			Estrofem
* TDDS 25 µg per day .....	3.01	8		
	(10.86)			Estraderm TTS 25
a) Higher subsidy of \$10.86 per 8 with Special Authority see SA0312 on the preceding page				
b) No more than 2 patch per week				
c) Only on a prescription				
* TDDS 3.9 mg (releases 50 µg of oestradiol per day) .....	4.12	4		
	(14.50)			Climara 50
	(32.50)			Femtran 50
a) Higher subsidy of \$13.18 per 4 with Special Authority see SA0312 on the preceding page				
b) No more than 1 patch per week				
c) Only on a prescription				
* TDDS 50 µg per day .....	4.12	8		
	(13.18)			Estraderm TTS 50
a) Higher subsidy of \$13.18 per 8 with Special Authority see SA0312 on the preceding page				
b) No more than 2 patch per week				
c) Only on a prescription				
* TDDS 7.8 mg (releases 100 µg of oestradiol per day) .....	7.05	4		
	(17.75)			Climara 100
	(35.00)			Femtran 100
a) Higher subsidy of \$16.14 per 4 with Special Authority see SA0312 on the preceding page				
b) No more than 1 patch per week				
c) Only on a prescription				
* TDDS 100 µg per day .....	7.05	8		
	(16.14)			Estraderm TTS 100
a) Higher subsidy of \$16.14 per 8 with Special Authority see SA0312 on the preceding page				
b) No more than 2 patch per week				
c) Only on a prescription				
OESTRADIOL VALERATE – See prescribing guideline on the preceding page				
* Tab 1 mg .....	8.24	56	✓	<b>Progynova</b>
* Tab 2 mg .....	8.24	56	✓	<b>Progynova</b>
OESTROGENS – See prescribing guideline on the preceding page				
* Conjugated, equine tab 300 µg .....	3.01	28		
	(3.75)			Premarin
* Conjugated, equine tab 625 µg .....	4.12	28		
	(5.14)			Premarin
<b>Progestogens</b>				
MEDROXYPROGESTERONE ACETATE – See prescribing guideline on the preceding page				
* Tab 2.5 mg .....	2.07	30	✓	<b>Provera</b>
* Tab 5 mg .....	13.75	100	✓	<b>Provera</b>
* Tab 10 mg .....	7.57	30	✓	<b>Provera</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

### Progestogen and Oestrogen Combined Preparations

OESTRADIOL WITH LEVONORGESTREL – See prescribing guideline on page 80

\* Tab 2 mg with 75 µg levonorgestrel (36) and tab 2 mg oestradiol (48) ..... 16.20 84 ✓ Nuvelle

OESTRADIOL WITH NORETHISTERONE – See prescribing guideline on page 80

\* Tab 1 mg with 0.5 mg norethisterone acetate ..... 5.40 28 OP  
(11.45) Kliovance

\* Tab 2 mg with 1 mg norethisterone acetate ..... 5.40 28 OP  
(11.45) Kliogest

\* Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg oestradiol tab (12) and 1 mg oestradiol tab (6) ..... 5.40 28 OP  
(10.00) Trisequens

OESTROGENS WITH MEDROXYPROGESTERONE – See prescribing guideline on page 80

\* Tab 625 µg conjugated equine with 2.5 mg medroxyprogesterone acetate tab (28) ..... 5.40 28 OP  
(11.45) Premia 2.5 Continuous

\* Tab 625 µg conjugated equine with 5 mg medroxyprogesterone acetate tab (28) ..... 5.40 28 OP  
(11.45) Premia 5 Continuous

### Other Oestrogen Preparations

ETHINYLOESTRADIOL

\* Tab 10 µg ..... 17.60 100 ✓ NZ Medical and Scientific

OESTRIOL

\* Tab 2 mg ..... 7.00 30 ✓ Ovestin

### Other Progestogen Preparations

DYDROGESTERONE

Tab 10 mg ..... 27.50 50  
(29.90) Duphaston

LEVONORGESTREL

\* Levonorgestrel - releasing intrauterine system 20µg/24 hr – Special Authority see SA0782 below – Retail pharmacy ..... 269.50 1 ✓ Mirena

#### ►SA0782 Special Authority for Subsidy

**Initial application — (No previous use)** only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and
- 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and
- 3 Either:
  - 3.1 serum ferritin level < 16 µg/l (within the last 12 months); or
  - 3.2 haemoglobin level < 120 g/l.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

continued...

## HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

**Initial application** — (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and
- 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and
- 3 Applicant to state date of the previous insertion.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

**Renewal** only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
  - 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or
  - 1.2 Previous insertion was removed or expelled within 3 months of insertion; and
- 2 Applicant to state date of the previous insertion.

### MEDROXYPROGESTERONE ACETATE

* Tab 100 mg – Retail pharmacy-Specialist .....	104.26	100	✓ <b>Provera</b>
* Tab 200 mg – Retail pharmacy-Specialist .....	78.06	30	✓ <b>Provera</b>

### NORETHISTERONE

* Tab 5 mg – Up to 30 tab available on a PSO.....	25.00	100	✓ <b>Primolut N</b>
---	-------	-----	---------------------

## Thyroid and Antithyroid Agents

### CARBIMAZOLE

* Tab 5 mg .....	10.80	100	✓ <b>Neo-Mercazole</b>
------------------	-------	-----	------------------------

### LEVOTHYROXINE

* Tab 50 µg .....	1.71	28	✓ <b>Goldshield</b>
	64.28	1,000	✓ <b>Eltroxin</b>

‡ Safety cap for extemporaneously compounded oral liquid preparations.

* Tab 100 µg .....	1.78	28	✓ <b>Goldshield</b>
	66.78	1,000	✓ <b>Eltroxin</b>

‡ Safety cap for extemporaneously compounded oral liquid preparations.

## Trophic Hormones

### Growth Hormones

#### ►SA0755 Special Authority for Subsidy

Special Authority approved by the Growth Hormone Committee

Notes: Subject to budgetary cap. Applications will be considered and approved subject to funding availability.

Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

NZGHC Coordinator

PHARMAC, PO Box 10-254, WELLINGTON

Tel: 0800 808 476, Fax: (09) 939 3221, Email: [growthhormone@pharmac.govt.nz](mailto:growthhormone@pharmac.govt.nz)

GROWTH HORMONE BIOSYNTHETIC HUMAN – Special Authority see SA0755 above

* Cartridge 16 iu per vial .....	1,600.00	5	✓ <b>Genotropin</b>
* Cartridge 36 iu per vial .....	3,600.00	5	✓ <b>Genotropin</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
RECOMBINANT HUMAN GROWTH HORMONE – Special Authority see SA0755 on the preceding page				
* Inj 5 mg .....	300.00	1	✓	Norditropin SimpleXx 5mg
* Inj 10 mg .....	600.00	1	✓	Norditropin SimpleXx 10mg
* Inj 15 mg .....	900.00	1	✓	Norditropin SimpleXx 15mg

### GnRH Analogues

BUSERELIN ACETATE – Special Authority see SA0835 below – Hospital pharmacy [HP3]

Inj 1 mg per ml, 5.5 ml .....	195.00	2		Suprefact
	(272.53)			

#### ►SA0835 Special Authority for Subsidy

**Initial application — (Breast cancer)** from any medical practitioner. Approvals valid for 1 year where the patient is a pre-menopausal woman with breast cancer.

**Initial application — (Prostate cancer)** only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where the patient has advanced prostatic cancer.

Note: Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated.

**Initial application — (Endometriosis)** only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

1 Endometriosis; and

2 Either:

2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetrisone has proven ineffective; or

2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrisone for 6 months.

Note: The maximum treatment period for a GnRH analogue is:

- 3 months to assess whether surgery is appropriate
- 3 months for infertile patients after surgery
- 6 months for patients with symptoms of endometriosis After the first 3 months patients should be assessed to determine whether there has been a satisfactory response to the first 3 months treatment.

**Initial application — (Precocious puberty)** only from a paediatrician or endocrinologist. Approvals valid for 1 year where the patient is affected by gonadotropin dependent precocious puberty.

**Renewal — (Breast or prostate cancer)** from any medical practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application.

**Renewal — (Endometriosis)** from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Either:

1 Both:

1.1 There has been a satisfactory response to the first 3 months treatment; and

1.2 Surgery is inappropriate; or

2 The first three months of therapy did not follow surgery for infertility.

Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application.

**Renewal — (Precocious puberty)** only from a paediatrician or endocrinologist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application.

## HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
GOSERELIN ACETATE – Special Authority see SA0839 below – Hospital pharmacy [HP3]				
Inj 3.6 mg .....	221.60	1	✓	Zoladex
Inj 10.8 mg .....	554.70	1	✓	Zoladex

### ▶SA0839 Special Authority for Subsidy

**Initial application — (Breast cancer)** from any medical practitioner. Approvals valid for 1 year where the patient is a pre-menopausal woman with breast cancer.

**Initial application — (Prostate cancer)** only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Advanced prostatic cancer; or
- 2 Neoadjuvant or adjuvant treatment of locally advanced prostatic cancer.

Note: Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated.

**Initial application — (Endometriosis)** only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Endometriosis; and
- 2 Either:
  - 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetrisone has proven ineffective; or
  - 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrisone for 6 months.

Note: The maximum treatment period for a GnRH analogue is:

- 3 months to assess whether surgery is appropriate
- 3 months for infertile patients after surgery
- 6 months for patients with symptoms of endometriosis After the first 3 months patients should be assessed to determine whether there has been a satisfactory response to the first 3 months treatment.

**Initial application — (Precocious puberty)** only from a paediatrician or endocrinologist. Approvals valid for 1 year where the patient is affected by gonadotropin dependent precocious puberty.

**Renewal — (Breast or prostate cancer)** from any medical practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application.

**Renewal — (Endometriosis)** from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Either:

- 1 Both:
  - 1.1 There has been a satisfactory response to the first 3 months treatment; and
  - 1.2 Surgery is inappropriate; or
- 2 The first three months of therapy did not follow surgery for infertility.

Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application.

**Renewal — (Precocious puberty)** only from a paediatrician or endocrinologist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application.

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
LEUPRORELIN – Special Authority see SA0837 below – Hospital pharmacy [HP3]				
Inj 3.75 mg .....	221.60	1	✓	Lucrin Depot
Inj 7.5 mg .....	184.90	1	✓	Eligard
Inj 11.25 mg .....	591.68	1	✓	Lucrin Depot
Inj 22.5 mg .....	554.70	1	✓	Eligard
Inj 30 mg .....	739.60	1	✓	Eligard
Inj 45 mg .....	1,109.40	1	✓	Eligard

### ▶SA0837 Special Authority for Subsidy

**Initial application — (Breast cancer)** from any medical practitioner. Approvals valid for 1 year where the patient is a pre-menopausal woman with breast cancer.

**Initial application — (Prostate cancer)** only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year where the patient has advanced prostatic cancer.

Note: Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is initiated

**Initial application — (Endometriosis)** only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Endometriosis; and
- 2 Either:
  - 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetrisone has proven ineffective; or
  - 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetrisone for 6 months.

Note: The maximum treatment period for a GnRH analogue is:

- 3 months to assess whether surgery is appropriate
- 3 months for infertile patients after surgery
- 6 months for patients with symptoms of endometriosis After the first 3 months patients should be assessed to determine whether there has been a satisfactory response to the first 3 months treatment

**Initial application — (Precocious puberty)** only from a paediatrician or endocrinologist. Approvals valid for 1 year where the patients is affected by gonadotropin dependent precocious puberty.

**Renewal — (Breast or prostate cancer)** from any medical practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application.

**Renewal — (Endometriosis)** from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Either:

- 1 Both:
  - 1.1 There has been a satisfactory response to the first 3 months treatment; and
  - 1.2 Surgery is inappropriate; or
- 2 The first three months of therapy did not follow surgery for infertility.

Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application.

**Renewal — (Precocious puberty)** only from a paediatrician or endocrinologist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application.

## HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
--	---	----------------------------	-------------------------------------

### Vasopressin Agonists

#### DESMOPRESSIN

▲ Nasal drops 100 µg per ml – Retail pharmacy-Specialist .....	39.03	2.5 ml OP	✓ <b>Minirin</b>
▲ Nasal spray 10 µg per dose – Retail pharmacy-Specialist .....	29.94	6 ml OP	✓ <b><u>Desmopressin- PH&amp;T</u></b>
Inj 4 µg per ml, 1 ml – Special Authority see SA0090 below – Hospital pharmacy [HP3].....	67.18	10	✓ <b>Minirin</b>

#### ▶SA0090 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid for 2 years where the patient cannot use desmopressin nasal spray or nasal drops.

**Renewal** only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

### Other Endocrine Agents

#### CABERGOLINE

Tab 0.5 mg – Maximum of 2 tab per prescription; can be waived by Special Authority see SA0175 below .....	105.03	8	✓ <b>Dostinex</b>
--	--------	---	-------------------

#### ▶SA0175 Special Authority for Waiver of Rule

**Initial application** only from an obstetrician, endocrinologist or gynaecologist. Approvals valid for 2 years where the patient has pathological hyperprolactinemia.

**Renewal** only from an obstetrician, endocrinologist or gynaecologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

#### CLOMIPHENE CITRATE – Retail pharmacy-Specialist

Only a prescription for a female patient.

Tab 50 mg .....	2.50	5	✓ <b>Phenate</b>
-----------------	------	---	------------------

#### DANAZOL – Retail pharmacy-Specialist

Cap 100 mg .....	17.00	30	✓ <b>D-Zol</b>
Cap 200 mg .....	25.00	30	✓ <b>D-Zol</b>

#### GESTRINONE – Retail pharmacy-Specialist

Cap 2.5 mg .....	101.87	8 OP	✓ <b>Dimetriose</b>
------------------	--------	------	---------------------

#### METYRAPONE

Cap 250 mg – Hospital pharmacy [HP3]-Specialist .....	238.00	50	✓ <b><u>Metopirone</u></b>
---	--------	----	----------------------------

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Anthelmintics</b>				
MEBENDAZOLE – Only on a prescription				
Tab 100 mg .....	3.79 (7.59)	6		Vermox
Oral liq 100 mg per 5 ml .....	2.18 (7.17)	15 ml		Vermox
PYRANTEL EMBONATE				
Tab 125 mg .....	5.31 (7.00)	18		Combantrin
Tab 250 mg .....	3.76 (4.95)	6		Combantrin

(Combantrin Tab 125 mg to be delisted 1 February 2009)

(Combantrin Tab 250 mg to be delisted 1 February 2009)

## Antibacterials

- a) For topical antibacterials, refer to DERMATOLOGICALS, page 63  
 b) For anti-infective eye preparations, refer to SENSORY ORGANS, page 157

## Cephalosporins and Cephamycins

CEFACLOR MONOHYDRATE				
Cap 250 mg .....	28.90	100	✓	<u>Ranbaxy-Cefaclor</u>
Grans for oral liq 125 mg per 5 ml .....	3.92	100 ml	✓	<u>Ranbaxy-Cefaclor</u>
CEFAZOLIN SODIUM – Hospital pharmacy [HP3] – Subsidy by endorsement				
Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.				
Inj 500 mg .....	5.00	5	✓	Hospira
	10.00	10	✓	m-Cefazolin
Inj 1 g .....	8.00	5	✓	Hospira
	16.00	10	✓	m-Cefazolin
(m-Cefazolin Inj 500 mg to be delisted 1 March 2009)				
(m-Cefazolin Inj 1 g to be delisted 1 March 2009)				
CEFOXITIN SODIUM – Hospital pharmacy [HP3]-Specialist – Subsidy by endorsement				
Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.				
Inj 1 g .....	48.48	5	✓	Mayne
CEFTRIAOXONE SODIUM – Hospital pharmacy [HP3] – Subsidy by endorsement				
a) Up to 5 inj available on a PSO				
b) Subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of confirmed ciprofloxacin-resistant gonorrhoea, or the treatment of suspected meningitis in patients who have a known allergy to penicillin, and the prescription or PSO is endorsed accordingly.				
Inj 500 mg .....	3.99	1	✓	AFT
Inj 1 g .....	5.40	1	✓	AFT
CEFUROXIME AXETIL – Subsidy by endorsement				
Only if prescribed for prophylaxis of endocarditis and the prescription is endorsed accordingly.				
Tab 250 mg .....	29.40	50	✓	Zinnat

## INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
<b>CEFUROXIME SODIUM – Hospital pharmacy [HP3]</b>			
Inj 250 mg – Maximum of 3 inj per prescription; can be waived by endorsement.....	20.97	10	✓ <b>Mayne</b>
Inj 750 mg – Maximum of 1 inj per prescription; can be waived by endorsement.....	10.71	5	✓ <b>Zinacef</b>
Inj 1.5 g – Hospital pharmacy [HP3]-Specialist – Subsidy by endorsement.....	4.04	1	✓ <b>Zinacef</b>
Only if prescribed for a dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.			

### Macrolides

**AZITHROMYCIN – Subsidy by endorsement**

a) Maximum of 2 tab per prescription

b) Up to 4 tab available on a PSO

c) Subsidised only if prescribed for patients with uncomplicated urethritis or cervicitis proven or presumed to be due to chlamydia trachomatis and their sexual contacts and prescription or PSO is endorsed accordingly.

Tab 500 mg .....9.90      2 OP      ✓ **Arrow-Azithromycin**

**CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see SA0657 below**

Tab 250 mg .....7.75      14      ✓ **Klamycin**

Grans for oral liquid 125 mg per 5 ml .....23.12      70 ml      ✓ **Klacid**

#### ▶SA0657 Special Authority for Waiver of Rule

**Initial application — (Helicobacter pylori infections)** only from a general practitioner or relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Eradication of *Helicobacter pylori* in patient with proven infection; and
- 2 Peptic ulcer disease proven by endoscopy.

Note: Maximum of two prescriptions (two courses) per patient.

**Initial application — (Mycobacterial infections)** only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 *Mycobacterium Avium* Intracellulare Complex infections in patient with AIDS; or
- 2 Atypical and drug-resistant mycobacterial infection; or
- 3 All of the following:
  - 3.1 Prophylaxis against disseminated *Mycobacterium Avium* Intracellulare Complex infection; and
  - 3.2 HIV infection; and
  - 3.3 CD4 count  $\leq 50$  cells/mm<sup>3</sup>.

**Renewal — (Mycobacterial infections)** only from a respiratory specialist, infectious disease specialist or paediatrician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

**ERYTHROMYCIN ETHYL SUCCINATE**

Tab 400 mg – Up to 30 tab available on a PSO.....18.95      100      ✓ **E-Myacin**

Grans for oral liq 200 mg per 5 ml – Up to 200 ml available on a PSO.....4.35      100 ml      ✓ **E-Myacin**

Grans for oral liq 400 mg per 5 ml – Up to 200 ml available on a PSO.....5.85      100 ml      ✓ **E-Myacin**

**ERYTHROMYCIN LACTOBIONATE**

Inj 300 mg .....70.97      5      ✓ **Mayne**

Inj 1 g .....6.50      1      ✓ **Erythrocin IV**

(*Mayne Inj 300 mg to be delisted 1 March 2009*)

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>ERYTHROMYCIN STEARATE</b>				
Tab 250 mg – Up to 30 tab available on a PSO.....	14.95 (22.29)	100		ERA
Tab 500 mg .....	29.90 (44.58)	100		ERA
<b>ROXITHROMYCIN</b>				
Tab 150 mg .....	9.50	50	✓	<b>Arrow- Roxithromycin</b>
Tab 300 mg .....	18.00	50	✓	<b>Arrow- Roxithromycin</b>
<b>Penicillins</b>				
<b>AMOXYCILLIN</b>				
Cap 250 mg – Up to 30 cap available on a PSO.....	17.30	500	✓	<b>Apo-Amoxi</b>
Cap 500 mg .....	27.25	500	✓	<b>Apo-Amoxi</b>
Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO.....	1.00	100 ml	✓	<b>Ranbaxy Amoxicillin</b>
Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO.....	1.27	100 ml	✓	<b>Ranbaxy Amoxicillin</b>
Drops 125 mg per 1.25 ml .....	4.00	30 ml OP	✓	<b>Ospamox Paediatric Drops</b>
	2.67 (7.25)	20 ml OP		Amoxil Paediatric Drops
Inj 250 mg .....	12.42	10	✓	<b>Ibiamox</b>
Inj 500 mg .....	14.24	10	✓	<b>Ibiamox</b>
Inj 1 g – Up to 5 inj available on a PSO.....	21.62	10	✓	<b>Ibiamox</b>
<b>AMOXYCILLIN CLAVULANATE</b>				
Tab amoxicillin 500 mg with potassium clavulanate 125 mg – Up to 30 tab available on a PSO .....	6.40	20	✓	<b>Augmentin</b>
Grans for oral liq amoxicillin 125 mg with potassium clavu- lanate 31.25 mg per 5 ml – Up to 200 ml available on a PSO.....	2.75	100 ml	✓	<b>Augmentin</b>
Grans for oral liq amoxicillin 250 mg with potassium clavu- lanate 62.5 mg per 5 ml – Up to 200 ml available on a PSO.....	4.75	100 ml	✓	<b>Augmentin</b>
<i>(Augmentin Tab amoxicillin 500 mg with potassium clavulanate 125 mg to be delisted 1 June 2009)</i>				
<b>BENZATHINE BENZYL PENICILLIN</b>				
Inj 1.2 mega u per 2 ml – Up to 5 inj available on a PSO.....	200.00	10	✓	<b>Bicillin LA</b>
<b>BENZYL PENICILLIN SODIUM (PENICILLIN G)</b>				
Inj 1 mega u – Up to 5 inj available on a PSO.....	10.49	10	✓	<b>Sandoz</b>
<b>DICLOXACILLIN</b>				
Cap 250 mg .....	2.47 (4.35)	24		Diclocil
Cap 500 mg .....	3.83 (8.65)	24		Diclocil

## INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
<b>FLUCLOXACILLIN SODIUM</b>			
Cap 250 mg – Up to 30 cap available on a PSO .....	18.50	250	✓ <b>Staphlex</b>
Cap 500 mg .....	57.90	500	✓ <b>Staphlex</b>
Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO .....	2.05	100 ml	✓ <b>AFT</b>
Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO .....	2.72	100 ml	✓ <b>AFT</b>
Inj 250 mg .....	9.00	10	✓ <b>Flucloxin</b>
Inj 500 mg .....	10.40	10	✓ <b>Flucloxin</b>
Inj 1 g – Up to 5 inj available on a PSO .....	14.00	10	✓ <b>Flucloxin</b>
<b>PHENOXYMETHYLPENICILLIN (PENICILLIN V)</b>			
Cap potassium salt 250 mg – Up to 30 cap available on a PSO .....	4.29	50	✓ <b>Cilicaine VK</b>
Cap potassium salt 500 mg .....	8.15	50	✓ <b>Cilicaine VK</b>
Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO .....	1.68	100 ml	✓ <b>AFT</b>
Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO .....	1.82	100 ml	✓ <b>AFT</b>
<b>PROCAINE PENICILLIN</b>			
Inj 1.5 mega u – Up to 5 inj available on a PSO .....	50.86	5	✓ <b>Cilicaine</b>

### Tetracyclines

<b>DOXYCYCLINE HYDROCHLORIDE</b>			
* Tab 50 mg – Up to 30 tab available on a PSO .....	2.90	30	
	(6.00)		Doxy-50
* Tab 100 mg – Up to 30 tab available on a PSO .....	8.10	250	✓ <b>Doxine</b>
<b>MINOCYCLINE HYDROCHLORIDE</b>			
* Tab 50 mg .....	5.79	60	
	(12.05)		Mino-tabs
* Cap 100 mg .....	19.32	100	
	(52.04)		Minomycin

### Other Antibiotics

For topical antibiotics, refer to DERMATOLOGICALS, page 63

<b>CIPROFLOXACIN</b>			
Tab 250 mg – Up to 5 tab available on a PSO .....	3.13	28	✓ <b>Cipflox</b>
	3.35	30	✓ <b>Rex Medical</b>
Tab 500 mg – Up to 5 tab available on a PSO .....	4.90	30	✓ <b>Rex Medical</b>
	4.57	28	
	(8.31)		Cipflox
Tab 750 mg – Retail pharmacy-Specialist .....	7.04	28	✓ <b>Cipflox</b>
	7.54	30	✓ <b>Rex Medical</b>

*(Cipflox Tab 250 mg to be delisted 1 April 2009)*

*(Cipflox Tab 500 mg to be delisted 1 April 2009)*

*(Cipflox Tab 750 mg to be delisted 1 April 2009)*

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>CLINDAMYCIN</b>				
Cap hydrochloride 150 mg – Maximum of 4 cap per prescription; can be waived by endorsement - Retail pharmacy - Specialist .....	11.39	16	✓	<b>Dalacin C</b>
Inj phosphate 150 mg per ml, 4 ml – Retail pharmacy - Specialist .....	19.45	1	✓	<b>Dalacin C</b>
<b>CO-TRIMOXAZOLE</b>				
* Tab trimethoprim 80 mg and sulphamethoxazole 400 mg – Up to 30 tab available on a PSO .....	17.00	500	✓	<b>Trisul</b>
* Oral liq sugar-free trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml – Up to 200 ml available on a PSO .....	5.90	500 ml	✓	<b>Trisul</b>
<b>COLISTIN SULPHOMETHATE – Hospital pharmacy [HP3]-Specialist – Subsidy by endorsement</b> Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.				
Inj 150 mg .....	65.00	1	✓	<b>Colistin-Link</b>
<b>FUSIDIC ACID</b>				
Tab 250 mg – Hospital pharmacy [HP3]-Specialist .....	34.50	12	✓	<b>Fucidin</b>
Inj 500 mg sodium fusidate per 40 ml – Hospital pharmacy [HP3]-Specialist – Subsidy by endorsement .....	12.87 (17.80)	1		Fucidin
Only if prescribed for a dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.				
<b>GENTAMICIN SULPHATE</b>				
Inj 10 mg per ml, 1 ml – Hospital pharmacy [HP3] – Subsidy by endorsement .....	8.56	5	✓	<b>Mayne</b>
Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis and the prescription is endorsed accordingly.				
Inj 40 mg per ml, 2 ml – Hospital pharmacy [HP3] – Subsidy by endorsement .....	4.56	10	✓	<b>Pfizer</b>
Only if prescribed for a dialysis or cystic fibrosis patient or for prophylaxis of endocarditis and the prescription is endorsed accordingly.				
<b>TOBRAMYCIN</b>				
Inj 40 mg per ml, 2 ml – Hospital pharmacy [HP3] – Subsidy by endorsement .....	27.50	5	✓	<b>Mayne</b>
Only if prescribed for dialysis or cystic fibrosis patient and the prescription is endorsed accordingly.				
<b>TRIMETHOPRIM</b>				
* Tab 300 mg – Up to 30 tab available on a PSO .....	8.69	50	✓	<b>TMP</b>
<b>VANCOMYCIN HYDROCHLORIDE – Hospital pharmacy [HP3] – Subsidy by endorsement</b> Only if prescribed for a dialysis or cystic fibrosis patient or in the treatment of pseudomembranous colitis or for prophylaxis of endocarditis and the prescription is endorsed accordingly.				
Inj 50 mg per ml, 10 ml .....	5.04	1	✓	<b>Pacific</b>

### Antifungals

- a) For topical antifungals refer to DERMATOLOGICALS, page 63  
b) For topical antifungals refer to GENITO URINARY, page 77

**FLUCONAZOLE – Hospital pharmacy [HP3]-Specialist**

Cap 50 mg .....	6.82	28	✓	<b>Pacific</b>
Cap 150 mg .....	1.30	1	✓	<b>Pacific</b>
Cap 200 mg .....	19.05	28	✓	<b>Pacific</b>

## INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>ITRACONAZOLE – Hospital pharmacy [HP3]-Specialist</b>				
Cap 100 mg .....	23.70	15	✓	<b>Sporanox</b>
<b>KETOCONAZOLE</b>				
Tab 200 mg – Retail pharmacy-Specialist .....	38.12	30	✓	<b>Nizoral</b>
<b>NYSTATIN</b>				
Tab 500,000 u .....	9.60	50	✓	<b>Nilstat</b> §29
Cap 500,000 u .....	11.64	50	✓	<b>Nilstat</b>
<b>TERBINAFINE</b>				
Tab 250 mg .....	25.50	100	✓	<b>Apo-Terbinafine</b>

### Antimalarials

<b>HYDROXYCHLOROQUINE SULPHATE</b>				
* Tab 200 mg .....	31.09	100	✓	<b>Plaquenil</b>

### Antitrichomonal Agents

<b>METRONIDAZOLE</b>				
Tab 200 mg – Up to 30 tab available on a PSO.....	9.50	100	✓	<b>Trichozole</b>
Tab 400 mg .....	17.50	100	✓	<b>Trichozole</b>
Oral liq benzoate 200 mg per 5 ml .....	25.00	100 ml	✓	<b>Flagyl-S</b>
Suppos 500 mg .....	24.48	10	✓	<b>Flagyl</b>
Suppos 1 g .....	33.31	10	✓	<b>Flagyl</b>

*(Flagyl Suppos 1 g to be delisted 1 February 2009)*

<b>ORNIDAZOLE</b>				
Tab 500 mg .....	12.38	10	✓	<b>Tiberal</b>

### Antituberculotics and Antileprotics

Note: There is no co-payment charge for all pharmaceuticals listed in the Antituberculotics and Antileprotics group regardless of immigration status.

<b>DAPSONE – No patient co-payment payable</b>				
Tab 25 mg .....	95.00	100	✓	<b>Dapsone</b>
Tab 100 mg .....	110.00	100	✓	<b>Dapsone</b>
<b>ETHAMBUTOL HYDROCHLORIDE – No patient co-payment payable</b>				
Tab 400 mg .....	10.98	56	✓	<b>Myambutol</b> §29
<b>ISONIAZID – Retail pharmacy-Specialist</b>				
No patient co-payment payable				
* Tab 100 mg .....	20.50	100	✓	<b>PSM</b>
* Tab 100 mg with rifampicin 150 mg .....	90.04	100	✓	<b>Rifinah</b>
* Tab 150 mg with rifampicin 300 mg .....	179.57	100	✓	<b>Rifinah</b>
<b>PYRAZINAMIDE – Retail pharmacy-Specialist</b>				
No patient co-payment payable				
* Tab 500 mg .....	59.00	100	✓	<b>AFT-Pyrazinamide</b>
<b>RIFABUTIN – Hospital pharmacy [HP3]-Specialist</b>				
No patient co-payment payable				
* Cap 150 mg .....	213.19	30	✓	<b>Mycobutin</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>RIFAMPICIN – Retail pharmacy-Specialist</b>				
No patient co-payment payable				
* Tab 600 mg .....	114.40	30	✓	Rifadin
* Cap 150 mg .....	58.66	100	✓	Rifadin
* Cap 300 mg .....	122.36	100	✓	Rifadin
* Oral liq 100 mg per 5 ml .....	12.66	60 ml	✓	Rifadin

### Antivirals

For eye preparations refer to Eye Preparations, Anti-Infective Preparations, page 157

#### First Episode Genital Herpes

ACICLOVIR

\* Tab dispersible 200 mg ..... 1.98 25 ✓ Lovir

#### Recurrent Episodes of Genital Herpes

ACICLOVIR

\* Tab dispersible 400 mg ..... 6.64 56 ✓ Lovir

#### Acute Herpes Zoster

ACICLOVIR

\* Tab dispersible 800 mg ..... 7.38 35 ✓ Lovir

#### Hepatitis B Treatment

ADEFOVIR DIPVOXIL – Special Authority see SA0829 below – Retail pharmacy

Tab 10 mg ..... 670.00 30 ✓ Hepsera

#### ►SA0829 Special Authority for Subsidy

**Initial application** only from a gastroenterologist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine, defined as:
- 2 Patient has raised serum ALT ( $> 1 \times$  ULN); and
- 3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load  $\geq 10$  fold over nadir; and
- 4 Detection of M204I or M204V mutation; and
- 5 Either:
  - 5.1 Both:
    - 5.1.1 Patient is cirrhotic; and
    - 5.1.2 adefovir dipivoxil to be used in combination with lamivudine; or
  - 5.2 Both:
    - 5.2.1 Patient is not cirrhotic; and
    - 5.2.2 adefovir dipivoxil to be used as monotherapy.

**Renewal** only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatment.

Notes: Lamivudine should be added to adefovir dipivoxil if a patient develops documented resistance to adefovir dipivoxil, defined as:

- i) raised serum ALT ( $> 1 \times$  ULN); and
- ii) HBV DNA greater than 100,000 copies per mL, or viral load  $\geq 10$  fold over nadir; and

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
		✓

continued...

iii) Detection of N236T or A181T/V mutation.

Adefovir dipivoxil should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg+ prior to commencing adefovir dipivoxil.

The recommended dose of adefovir dipivoxil is no more than 10mg daily.

In patients with renal insufficiency adefovir dipivoxil dose should be reduced in accordance with the datasheet guidelines.

Adefovir dipivoxil should be avoided in pregnant women and children.

LAMIVUDINE – Special Authority see SA0832 below – Retail pharmacy

Tab 100mg .....	143.00	28	✓ Zeffix
Oral liq 5 mg per ml .....	90.00	240 ml	✓ Zeffix

▶SA0832 Special Authority for Subsidy

**Initial application** only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
  - 1.1 All of the following:
    - 1.1.1 HBsAg positive for more than 6 months; and
    - 1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and
    - 1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology clinical/radiological evidence of cirrhosis; or
  - 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or
  - 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or
  - 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and
- 2 All of the following:
  - 2.1 No continuing alcohol abuse or intravenous drug use; and
  - 2.2 Not coinfectd with HCV or HDV; and
  - 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and
  - 2.4 No history of hypersensitivity to lamivudine; and
  - 2.5 No previous lamivudine therapy with genotypically proven lamivudine resistance.

**Renewal** only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

Renewal for patients who have maintained continuous treatment and response to lamivudine

- 1 All of the following:
  - 1.1 Have maintained continuous treatment with lamivudine; and
  - 1.2 Most recent test result shows continuing biochemical response (normal ALT); and
  - 1.3 HBV DNA <100,00 copies per ml by quantitative PCR at a reference laboratory; or

Renewal when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine

- 2 All of the following:
  - 2.1 Lamivudine to be used in combination with adefovir dipivoxil; and
  - 2.2 Patient is cirrhotic; and  
Documented resistance to lamivudine, defined as:
    - 2.3 Patient has raised serum ALT (> 1 × ULN); and
    - 2.4 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
    - 2.5 Detection of M204I or M204V mutation; or

Renewal when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil

- 3 All of the following:

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

- 3.1 Lamivudine to be used in combination with adefovir dipivoxil; and Documented resistance to adefovir, defined as:
- 3.2 Patient has raised serum ALT ( $> 1 \times \text{ULN}$ ); and
- 3.3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
- 3.4 Detection of N236T or A181T/V mutation.

## Antiretrovirals

### ▶SA0779 Special Authority for Subsidy

**Initial application — (Confirmed HIV/AIDS)** only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
  - 2.1 Symptomatic patient; or
  - 2.2 Patient aged 12 months and under; or
  - 2.3 Both:
    - 2.3.1 Patient aged 1 to 5 years; and
    - 2.3.2 Any of the following:
      - 2.3.2.1 CD4 counts  $< 1000 \text{ cells/mm}^3$ ; or
      - 2.3.2.2 CD4 counts  $< 0.25 \times \text{total lymphocyte count}$ ; or
      - 2.3.2.3 Viral load counts  $> 100000 \text{ copies per ml}$ ; or
    - 2.3.3 Viral load counts  $> 100000 \text{ copies per ml}$ ; or
  - 2.4 Both:
    - 2.4.1 Patient aged 6 years and over; and
    - 2.4.2 CD4 counts  $< 350 \text{ cells/mm}^3$ .

Note: Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including ritonavir plus indinavir or saquinavir or atazanavir will be counted as one protease inhibitor for the purpose of accessing funding to anti-retrovirals.

**Initial application — (Percutaneous exposure)** only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Note: Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including ritonavir plus indinavir or saquinavir or atazanavir will be counted as one protease inhibitor for the purpose of accessing funding to anti-retrovirals.

**Initial application — (Prevention of maternal transmission)** only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Notes: Subsidies for a combination of up to three anti-retroviral medications, including a maximum of two protease inhibitors. Combinations including ritonavir plus indinavir or saquinavir or atazanavir will be counted as one protease inhibitor for the purpose of accessing funding to anti-retrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

**Renewal — (Confirmed HIV/AIDS)** only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

### Non-nucleosides Reverse Transcriptase Inhibitors

EFAVIRENZ – Special Authority see SA0779 on the preceding page – Hospital pharmacy [HP1]

Tab 50 mg .....	158.33	30	✓	Stocrin
Tab 200 mg .....	474.99	90	✓	Stocrin
Tab 600 mg .....	474.99	30	✓	Stocrin
Cap 50 mg .....	158.33	30	✓	Stocrin
Cap 100 mg .....	158.33	30	✓	Stocrin
Cap 200 mg .....	474.99	90	✓	Stocrin

(Stocrin Cap 100 mg to be delisted 1 June 2009)

NEVIRAPINE – Special Authority see SA0779 on the preceding page – Hospital pharmacy [HP1]

Tab 200 mg .....	319.80	60	✓	Viramune
Oral suspension 10 mg per ml .....	134.55	240 ml	✓	Viramune Suspension

### Nucleosides Reverse Transcriptase Inhibitors

ABACAVIR SULPHATE – Special Authority see SA0779 on the preceding page – Hospital pharmacy [HP1]

Tab 300 mg .....	458.00	60	✓	Ziagen
Oral liq 20 mg per ml .....	100.00	240 ml OP	✓	Ziagen

ABACAVIR SULPHATE WITH LAMIVUDINE – Special Authority see SA0779 on the preceding page – Hospital pharmacy [HP1]

Note: Kivexa counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.

Tab 600 mg with lamivudine 300 mg .....	630.00	30	✓	Kivexa
---	--------	----	---	--------

DIDANOSINE [DDI] – Special Authority see SA0779 on the preceding page – Hospital pharmacy [HP1]

Cap 125 mg .....	115.05	30	✓	Videx EC
Cap 200 mg .....	184.08	30	✓	Videx EC
Cap 250 mg .....	230.10	30	✓	Videx EC
Cap 400 mg .....	368.16	30	✓	Videx EC

EMTRICITABINE – Special Authority see SA0779 on the preceding page – Hospital pharmacy [HP1]

Cap 200 mg .....	307.20	30	✓	Emtriva
------------------	--------	----	---	---------

LAMIVUDINE – Special Authority see SA0779 on the preceding page – Hospital pharmacy [HP1]

Tab 150 mg .....	307.20	60	✓	3TC
Oral liq 10 mg per ml .....	100.00	240 ml OP	✓	3TC

STAVUDINE [D4T] – Special Authority see SA0779 on the preceding page – Hospital pharmacy [HP1]

Cap 20 mg .....	317.10	60	✓	Zerit
Cap 30 mg .....	377.80	60	✓	Zerit
Cap 40 mg .....	503.80	60	✓	Zerit
Powder for oral soln 1 mg per ml .....	100.76	200 ml OP	✓	Zerit

TENOFOVIR DISOPROXIL FUMARATE – Special Authority see SA0779 on the preceding page – Hospital pharmacy [HP1]

Tab 300 mg .....	531.00	30	✓	Viread
------------------	--------	----	---	--------

ZIDOVUDINE [AZT] – Special Authority see SA0779 on the preceding page – Hospital pharmacy [HP1]

Cap 100 mg .....	290.00	100	✓	Retrovir
Oral liq 10 mg per ml .....	58.00	200 ml OP	✓	Retrovir

ZIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority see SA0779 on the preceding page – Hospital pharmacy [HP1]

Combivir counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.

Tab 300 mg with lamivudine 150 mg .....	667.20	60	✓	Combivir
---	--------	----	---	----------

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Protease Inhibitors</b>				
ATAZANAVIR SULPHATE – Special Authority see SA0779 on page 96 – Hospital pharmacy [HP1]				
Cap 150 mg .....	568.34	60	✓	Reyataz
Cap 200 mg .....	757.79	60	✓	Reyataz
INDINAVIR – Special Authority see SA0779 on page 96 – Hospital pharmacy [HP1]				
Cap 200 mg .....	519.75	360	✓	Crixivan
Cap 400 mg .....	519.75	180	✓	Crixivan
LOPINAVIR WITH RITONAVIR – Special Authority see SA0779 on page 96 – Hospital pharmacy [HP1]				
Tab 200 mg with ritonavir 50 mg .....	735.00	120	✓	Kaletra
Oral liq 80 mg with ritonavir 20 mg per ml .....	735.00	300 ml OP	✓	Kaletra
RITONAVIR – Special Authority see SA0779 on page 96 – Hospital pharmacy [HP1]				
Cap 100 mg .....	121.27	84	✓	Norvir
Oral liq 80 mg per ml .....	103.98	90 ml OP	✓	Norvir
SAQUINAVIR – Special Authority see SA0779 on page 96 – Hospital pharmacy [HP1]				
Tab 500 mg .....	556.59	120	✓	Invirase
Cap 200 mg .....	519.75	270	✓	Invirase
<i>(Invirase Cap 200 mg to be delisted 1 March 2009)</i>				

## Antiretrovirals - Additional Therapies

### HIV Fusion Inhibitors

ENFUVIRTIDE – Special Authority see SA0845 below – Hospital pharmacy [HP1]				
Powder for inj 90 mg per ml × 60 .....	2,380.00	1	✓	Fuzeon

#### SA0845 Special Authority for Subsidy

**Initial application** only from a named specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Confirmed HIV infection; and
- 2 Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure; and
- 3 Either:
  - 3.1 Patient has evidence of HIV replication, despite ongoing therapy; or
  - 3.2 Patient has treatment-limiting toxicity to previous antiretroviral agents; and
- 4 Previous treatment with 3 different antiretroviral regimens has failed; and
- 5 All of the following:
  - 5.1 Previous treatment with a non-nucleoside reverse transcriptase inhibitor has failed; and
  - 5.2 Previous treatment with a nucleoside reverse transcriptase inhibitor has failed; and
  - 5.3 Previous treatment with a protease inhibitor has failed.

**Renewal** only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Evidence of at least a 10 fold reduction in viral load at 12; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
		✓

## Immune Modulators

### Guidelines for the use of interferon in the treatment of hepatitis C:

Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects.

Patients should be otherwise fit.

Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level.

### Criteria for Treatment

- 1) Diagnosis
  - Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or
  - PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or
  - Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following.
- 2) Establishing Active Chronic Liver Disease
  - Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six months averaging  $> 1.5 \times$  upper limit of normal. (ALT is the preferable enzyme); or
  - Liver biopsy showing significant inflammatory activity (active hepatitis) with or without cirrhosis. This is not a necessary requirement for those patients with coagulopathy. (Some patients have active disease on histology with normal transaminase enzymes).

### Exclusion Criteria

- 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease).
- 2) Pregnancy.
- 3) Neutropenia ( $< 2.0 \times 10^9$ ) and/or thrombocytopenia.
- 4) Continuing alcohol abuse and/or continuing intravenous drug users.

### Dosage

The current recommended dosage is 3 million units of interferon alpha-2a or interferon alpha-2b administered subcutaneously 3 times a week for 52 weeks (twelve months)

### Exit Criteria

The patient's response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment ALT level at this stage.

### INTERFERON ALPHA-2A – PCT – Hospital pharmacy [HP3]-Specialist

- a) See prescribing guideline above
- b) Only one multidose cartridge starter pack to be prescribed and dispensed per patient.

Inj 3 m iu prefilled syringe .....	31.32	1	✓ Roferon-A
Inj 4.5 m iu prefilled syringe .....	46.98	1	✓ Roferon-A
Inj 6 m iu prefilled syringe .....	62.64	1	✓ Roferon-A
Inj 9 m iu prefilled syringe .....	93.96	1	✓ Roferon-A
Inj 18 m iu multidose cartridge .....	187.92	1	✓ Roferon-A
Inj 18 m iu multidose cartridge × 2 starter pack .....	375.84	1	✓ Roferon-A

### INTERFERON ALPHA-2A WITH RIBAVIRIN – Special Authority see SA0784 on the next page – Hospital pharmacy [HP3]

See prescribing guideline above

Inj 18 m iu multidose cartridge × 2 with ribavirin tab 200 mg × 168 .....	1,375.84	1 OP	✓ Roferon RBV Combination Pack
Inj 18 m iu multidose cartridge × 2 with with pen and needles with ribavirin tab 200 mg × 168 .....	1,375.84	1 OP	✓ Roferon RBV Combination Pack Starter Kit

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

### ▶SA0784 Special Authority for Subsidy

**Initial application** from any specialist. Approvals valid for 12 months where patient has chronic hepatitis C (all genotypes).

INTERFERON ALPHA-2B – PCT – Hospital pharmacy [HP3]-Specialist

See prescribing guideline on the preceding page

Inj 18 m iu, 1.2 ml multidose pen .....	187.92	1	✓	Intron-A
Inj 30 m iu, 1.2 ml multidose pen .....	313.20	1	✓	Intron-A
Inj 60 m iu, 1.2 ml multidose pen .....	626.40	1	✓	Intron-A

PEGYLATED INTERFERON ALPHA-2A – Special Authority see SA0802 below – Hospital pharmacy [HP3]

See prescribing guideline on the preceding page

Inj 135 µg prefilled syringe .....	362.00	1	✓	Pegasys
Inj 180 µg prefilled syringe .....	450.00	1	✓	Pegasys
Inj 135 µg prefilled syringe × 4 with ribavirin tab 200 mg × 112 .....	1,799.68	1 OP	✓	Pegasys RBV Combination Pack
Inj 135 µg prefilled syringe × 4 with ribavirin tab 200 mg × 168 .....	1,975.00	1 OP	✓	Pegasys RBV Combination Pack
Inj 180 µg prefilled syringe × 4 with ribavirin tab 200 mg × 112 .....	2,059.84	1 OP	✓	Pegasys RBV Combination Pack
Inj 180 µg prefilled syringe × 4 with ribavirin tab 200 mg × 168 .....	2,190.00	1 OP	✓	Pegasys RBV Combination Pack

### ▶SA0802 Special Authority for Subsidy

**Initial application** — (genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 11 months for applications meeting the following criteria:

Either:

- 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
- 2 Patient has chronic hepatitis C and is co-infected with HIV.

Note: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

**Initial application** — (genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Either:
  - 2.1 Patient has bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent); or
  - 2.2 is unsuitable for liver biopsy due to coagulopathy.

## INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>PEGYLATED INTERFERON ALPHA-2B WITH RIBAVIRIN – Special Authority see SA0846 below – Hospital pharmacy [HP3]</b>				
See prescribing guideline on page 99				
Inj 50 µg × 4 with ribavirin cap 200 mg × 112 .....	1,080.40	1 OP	✓	<b>Pegatron Combination Therapy</b>
Inj 50 µg × 4 with ribavirin cap 200 mg × 84 .....	976.80	1 OP	✓	<b>Pegatron Combination Therapy</b>
Inj 80 µg × 4 with ribavirin cap 200 mg × 140 .....	1,583.60	1 OP	✓	<b>Pegatron Combination Therapy</b>
Inj 80 µg × 4 with ribavirin cap 200 mg × 168 .....	1,687.20	1 OP	✓	<b>Pegatron Combination Therapy</b>
Inj 80 µg × 4 with ribavirin cap 200 mg × 84 .....	1,376.40	1 OP	✓	<b>Pegatron Combination Therapy</b>
Inj 100 µg × 4 with ribavirin cap 200 mg × 112 .....	1,746.40	1 OP	✓	<b>Pegatron Combination Therapy</b>
Inj 100 µg × 4 with ribavirin cap 200 mg × 84 .....	1,642.80	1 OP	✓	<b>Pegatron Combination Therapy</b>
Inj 120 µg × 4 with ribavirin cap 200 mg × 140 .....	2,116.40	1 OP	✓	<b>Pegatron Combination Therapy</b>
Inj 120 µg × 4 with ribavirin cap 200 mg × 84 .....	1,909.20	1 OP	✓	<b>Pegatron Combination Therapy</b>
Inj 150 µg × 4 with ribavirin cap 200 mg × 140 .....	2,516.00	1 OP	✓	<b>Pegatron Combination Therapy</b>
Inj 150 µg × 4 with ribavirin cap 200 mg × 168 .....	2,619.60	1 OP	✓	<b>Pegatron Combination Therapy</b>
Inj 150 µg × 4 with ribavirin cap 200 mg × 84 .....	2,308.80	1 OP	✓	<b>Pegatron Combination Therapy</b>

### ▶SA0846 Special Authority for Subsidy

**Initial application** from any specialist. Approvals valid for 11 months for applications meeting the following criteria:

Either:

- 1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
- 2 Both:
  - 2.1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
  - 2.2 Either:
    - 2.2.1 has bridging fibrosis or cirrhosis (Metavir stage 3 or 4, or equivalent); or
    - 2.2.2 is unsuitable for liver biopsy due to coagulopathy.

Note: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Urinary Tract Infections</b>				
<b>HEXAMINE HIPPURATE</b>				
* Tab 1 g .....	18.40	100		
	(38.10)			Hiprex
<b>NITROFURANTOIN</b>				
* Tab 50 mg .....	17.90	100	✓	Nifuran
* Tab 100 mg .....	30.25	100	✓	Nifuran
<b>NORFLOXACIN</b>				
Tab 400 mg – Maximum of 6 tab per prescription; can be waived by endorsement - Retail pharmacy - Specialist.....	22.50	100	✓	Arrow-Norfloxacine

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer ✓
---	----------------------------	--

## Vaccines

### Influenza vaccine

INFLUENZA VACCINE – Hospital pharmacy [Xpharm]

A) is available between 1 March and 30 June each year for patients who meet the following criteria, as set by the Ministry of Health:

- a) all people 65 years of age and over;
- b) people under 65 years of age with:
  - i) the following cardiovascular disease:
    - 1) ischaemic heart disease,
    - 2) congestive heart disease,
    - 3) rheumatic heart disease,
    - 4) congenital heart disease, or
    - 5) cerebo-vascular disease;
  - ii) the following chronic respiratory disease:
    - 1) asthma, if on a regular preventative therapy, or
    - 2) other chronic respiratory disease with impaired lung function;
  - iii) diabetes;
  - iv) chronic renal disease;
  - v) any cancer, excluding basal and squamous skin cancers if not invasive;
  - vi) the following other conditions:
    - a) autoimmune disease,
    - b) immune suppression,
    - c) HIV,
    - d) transplant recipients,
    - e) neuromuscular and CNS diseases,
    - f) haemoglobinopathies, or
    - g) children on long term aspirin.

The following conditions are excluded from funding:

- a) asthma not requiring regular preventative therapy,
  - b) hypertension and/or dyslipidaemia without evidence of end-organ disease,
  - c) pregnancy in the absence of another risk factor.
- B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.
- C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor.
- D) Influenza Vaccine does not fall within the definition Community Pharmaceutical as it is not funded directly from the Pharmaceutical Budget. Pharmacists are unable to claim for the dispensing of influenza vaccine from the Funder.

Inj .....	9.00	1	✓ <b>Fluvax</b>
	90.00	10	✓ <b>Vaxigrip</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## MUSCULO-SKELETAL SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Anticholinesterases</b>				
NEOSTIGMINE				
Inj 2.5 mg per ml, 1 ml .....	20.30	50	✓	<u>AstraZeneca</u>
PYRIDOSTIGMINE BROMIDE				
▲ Tab 60 mg .....	40.08	100	✓	<u>Mestinon</u>
<b>Anti-inflammatory Non Steroidal Drugs (NSAIDs)</b>				
▶SA0291 Special Authority for Manufacturers Price				
Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria:				
Both:				
1 Inflammatory arthritis (including osteoarthritis with an inflammatory component); and				
2 Stabilised and are well controlled on the particular NSAID medication.				
Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.				
DICLOFENAC SODIUM				
* Tab EC 25 mg .....	3.51	100	✓	<u>Apo-Diclo</u>
* Tab 50 mg dispersible – Additional subsidy by Special Authority see SA0291 above – Retail pharmacy .....	1.50	20		Voltaren D
	(8.00)			
* Tab EC 50 mg .....	25.88	500	✓	<u>Apo-Diclo</u>
* Tab long-acting 75 mg .....	22.78	500	✓	<u>Apo-Diclo SR</u>
* Tab long-acting 100 mg .....	34.32	500	✓	<u>Apo-Diclo SR</u>
* Inj 25 mg per ml, 3 ml .....	12.00	5	✓	<u>Voltaren</u>
Up to 5 inj available on a PSO				
* Suppos 12.5 mg .....	1.85	10	✓	<u>Voltaren</u>
* Suppos 25 mg .....	2.22	10	✓	<u>Voltaren</u>
* Suppos 50 mg .....	3.84	10	✓	<u>Voltaren</u>
Up to 10 supp available on a PSO				
* Suppos 100 mg .....	6.36	10	✓	<u>Voltaren</u>
IBUPROFEN – Additional subsidy by Special Authority see SA0291 above – Retail pharmacy				
* Tab 200 mg .....	1.78	100	✓	<u>I-Profen</u>
* Tab 400 mg .....	1.07	30		Brufen
	(4.56)			
* Tab 600 mg .....	1.60	30		Brufen
	(6.84)			
* Tab long-acting 800 mg .....	1.50	30		Brufen Retard
	(9.12)			
*‡ Oral liq 100 mg per 5 ml .....	3.49	200 ml	✓	<u>Fenpaed</u>
KETOPROFEN – Additional subsidy by Special Authority see SA0291 above – Retail pharmacy				
* Cap long-acting 100 mg .....	6.72	100		Oruvail 100
	(21.56)			
* Cap long-acting 200 mg .....	13.44	100		Oruvail 200
	(43.12)			
MEFENAMIC ACID – Additional subsidy by Special Authority see SA0291 above – Retail pharmacy				
* Cap 250 mg .....	2.50	100		Ponstan
	(18.33)			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>NAPROXEN</b>				
* Tab 250 mg .....	21.00	500	✓	<b>Noflam 250</b>
* Tab 500 mg .....	17.95	250	✓	<b>Noflam 500</b>
* Tab long-acting 750 mg .....	18.00	90	✓	<b>Naprosyn SR 750</b>
* Tab long-acting 1,000 mg .....	21.00	90	✓	<b>Naprosyn SR 1000</b>
<b>NAPROXEN SODIUM</b>				
* Tab 275 mg .....	6.00	120	✓	<b>Sonaflam</b>
* Tab 550 mg .....	12.80	100	✓	<b>Synflex</b>
<b>SULINDAC – Additional subsidy by Special Authority see SA0291 on the preceding page – Retail pharmacy</b>				
* Tab 100 mg .....	5.32 (12.00)	100		Daclin
* Tab 200 mg .....	6.72 (20.00)	100		Daclin
	3.36 (15.87)	50		Clinoril
<b>TENOXICAM</b>				
* Tab 20 mg .....	23.75	100	✓	<b>Tilcotil</b>
<b>TIAPROFENIC ACID – Additional subsidy by Special Authority see SA0291 on the preceding page – Retail pharmacy</b>				
* Tab 300 mg .....	4.03 (19.26)	60		Surgam
<b>NSAIDs Other</b>				
<b>INDOMETHACIN</b>				
* Cap 25 mg .....	5.90	100	✓	<b>Rheumacin</b>
* Cap 50 mg .....	6.95	100	✓	<b>Rheumacin</b>
* Cap long-acting 75 mg .....	13.30	100	✓	<b>Rheumacin SR</b>
* Suppos 100 mg .....	14.50	30	✓	<b>Arthrexin</b>
<b>PIROXICAM</b>				
* Tab dispersible 10 mg .....	3.25	50	✓	<b>Piram-D</b>
* Tab dispersible 20 mg .....	5.50	100	✓	<b>Piram-D</b>
<b>Antirheumatoid Agents</b>				
<b>AURANOFIN – Retail pharmacy-Specialist</b>				
Tab 3 mg .....	68.99 (70.97)	60		Ridaura
<b>LEFLUNOMIDE</b>				
Tab 10 mg .....	55.00 79.27	30	✓	<b>AFT-Leflunomide</b>
Tab 20 mg .....	76.00 108.60	30	✓	<b>Arava</b>
Tab 100 mg .....	54.44	3	✓	<b>AFT-Leflunomide</b>
			✓	<b>Arava</b>
<b>PENICILLAMINE – Retail pharmacy-Specialist</b>				
Tab 125 mg .....	61.93	100	✓	<b>D-Penaminate</b>
Tab 250 mg .....	98.98	100	✓	<b>D-Penaminate</b>
<b>SODIUM AUROTHIOMALATE – Retail pharmacy-Specialist</b>				
Inj 10 mg per 0.5 ml .....	76.87	10	✓	<b>Myocrisin</b>
Inj 20 mg per 0.5 ml .....	113.17	10	✓	<b>Myocrisin</b>
Inj 50 mg per 0.5 ml .....	217.23	10	✓	<b>Myocrisin</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## MUSCULO-SKELETAL SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Tumour Necrosis Factor (TNF) Inhibitors</b>				
ADALIMUMAB – Special Authority see SA0812 below – Retail pharmacy				
Inj 40 mg per 0.8 ml pre-filled pen .....	1,799.92	2	✓	HumiraPen
Inj 40 mg per 0.8 ml prefilled syringe .....	1,799.92	2	✓	Humira

### ►SA0812 Special Authority for Subsidy

**Initial application** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient is an adult who has had severe and active erosive Rheumatoid Arthritis for six months duration or longer; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Either:
  - 5.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of Cyclosporin alone or in combination with another agent; or
  - 5.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of Leflunomide alone or in combination with another agent; and
- 6 Either:
  - 6.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 active, swollen, tender joints; or
  - 6.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 7 Either:
  - 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
- 8 The patient consents to details of their treatment being held on a central registry and has signed a consent form outlining the conditions of ongoing treatment.

Notes: A patient declaration form [http://www.pharmac.govt.nz/special\\_authority\\_forms/SA0812-declaration.pdf](http://www.pharmac.govt.nz/special_authority_forms/SA0812-declaration.pdf) must be signed by the legal guardian of the patient and the prescriber in the presence of a witness (over 18 years of age).

Applicants are requested to register the treatment with the New Zealand Rheumatology Association by completing the forms and questionnaire [http://www.pharmac.govt.nz/special\\_authority\\_forms/SA0812-survey.pdf](http://www.pharmac.govt.nz/special_authority_forms/SA0812-survey.pdf).

**Renewal** only from a rheumatologist or general physician on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
  - 2.1 Following 4 months initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
  - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

ETANERCEPT – Retail pharmacy-Specialist prescription – Special Authority see SA0868 on the next page  
Inj 25 mg ..... 949.96 4 ✓ **Enbrel**

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

►SA0868 Special Authority for Subsidy

**Initial application** only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
- 3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20mg/m<sup>2</sup> weekly or at the maximum tolerated dose) in combination with oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose); and
- 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15mg/m<sup>2</sup> weekly or at the maximum tolerated dose) in combination with one other disease-modifying agent; and
- 6 Both:
  - 6.1 Either:
    - 6.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 active, swollen, tender joints; or
    - 6.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
  - 6.2 Physician's global assessment indicating severe disease; and
- 7 The patient or their legal guardian consents to details of their treatment being held on a central registry and has signed a consent form outlining conditions of ongoing treatment.

Note: A patient declaration form [http://www.pharmac.govt.nz/special\\_authority\\_forms/SA0667-declaration.pdf](http://www.pharmac.govt.nz/special_authority_forms/SA0667-declaration.pdf) must be signed by the legal guardian of the patient and the prescriber in the presence of a witness (over 18 years of age)

**Renewal** only from a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
  - 2.1 Following 4 months initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
  - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Calcium Homeostasis

Alendronate for Osteoporosis

►SA0797 Special Authority for Subsidy

**Initial application** — (Underlying cause – Osteoporosis) only from a relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score ≤ -3.0.

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

# MUSCULO-SKELETAL SYSTEM

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

**Initial application — (Underlying cause – glucocorticosteroid therapy)** only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is receiving systemic glucocorticosteroid therapy ( $\geq 5$  mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months and has either; and
- 2 Either:
  - 2.1 documented BMD  $\geq 1.5$  standard deviations below the mean normal value in young adults (i.e. T-Score  $\leq -1.5$ ); or
  - 2.2 history of one significant osteoporotic fracture demonstrated radiologically.

**Renewal** only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteroid therapy ( $\geq 5$  mg per day prednisone equivalents).

Notes:

- a) Evidence used by National institute for Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score  $\leq -2.5$ , and therefore do not require BMD measurement for treatment with bisphosphonates.
- b) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- c) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALENDRONATE SODIUM – Special Authority see SA0797 on the preceding page – Retail pharmacy

Tab 70 mg .....	35.91	4	✓ Fosamax
-----------------	-------	---	-----------

ALENDRONATE SODIUM WITH CHOLECALCIFEROL – Special Authority see SA0797 on the preceding page – Retail pharmacy

Tab 70 mg with cholecalciferol 2800 iu .....	35.91	4	✓ Fosamax Plus
--	-------	---	----------------

## Alendronate for Pagets Disease

►SA0467 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Paget's disease; and
- 2 Any of the following:
  - 2.1 Bone or articular pain; or
  - 2.2 Bone deformity; or
  - 2.3 Bone, articular or neurological complications; or
  - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
  - 2.5 Preparation for orthopaedic surgery.

**Renewal** only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

ALENDRONATE SODIUM – Special Authority see SA0467 above – Retail pharmacy

Tab 40 mg .....	133.00	30	✓ Fosamax
-----------------	--------	----	-----------

## Other Treatments

CALCITONIN – Hospital pharmacy [HP3]-Specialist

* Inj 100 iu per ml, 1 ml .....	110.00	5	✓ Miacalcic
---------------------------------	--------	---	-------------

ETIDRONATE DISODIUM

* Tab 200 mg .....	22.80	60	✓ Didronel
	38.00	100	✓ Etidrate

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
---	-----	---------------------	-------------------------------------

**Prescribing Guidelines**

Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose – 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water.

PAMIDRONATE DISODIUM – Special Authority see SA0091 below – Hospital pharmacy [HP3]

Inj 3 mg per ml, 5 ml .....	18.75	1	✓ <b>Pamisol</b>
Inj 3 mg per ml, 10 ml .....	37.50	1	✓ <b>Pamisol</b>
Inj 6 mg per ml, 10 ml .....	75.00	1	✓ <b>Pamisol</b>

**SA0091 Special Authority for Subsidy**

**Initial application** only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Paget's disease; or
- 2 Both:
  - 2.1 Patients under hospice care; and
  - 2.2 Either:
    - 2.2.1 Tumour-induced hypercalcaemia; or
    - 2.2.2 Tumour-induced osteolysis without hypercalcaemia.

**Renewal** only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

**Enzymes**

**HYALURONIDASE**

Inj 1,500 iu per ml .....	18.32	10	
	(194.40)		Hyalase

**Hyperuricaemia and Antigout**

**ALLOPURINOL**

* Tab 100 mg .....	5.44	250	✓ <b>Apo-Allopurinol</b>
	11.45	500	✓ <b>Progout</b>
* Tab 300 mg .....	4.03	100	✓ <b>Apo-Allopurinol</b>
	21.20	500	✓ <b>Progout</b>

**COLCHICINE**

* Tab 500 µg .....	9.60	100	✓ <b>Colgout</b>
--------------------	------	-----	------------------

**PROBENECID**

* Tab 500 mg .....	55.00	100	✓ <b>AFT</b>
--------------------	-------	-----	--------------

**Muscle Relaxants**

**BACLOFEN – Retail pharmacy-Specialist**

* Tab 10 mg .....	3.75	100	✓ <b>Pacifen</b>
-------------------	------	-----	------------------

**DANTROLENE SODIUM – Retail pharmacy-Specialist**

* Cap 25 mg .....	32.96	100	✓ <b>Dantrium</b>
* Cap 50 mg .....	51.70	100	✓ <b>Dantrium</b>

**ORPHENADRINE CITRATE**

Tab 100 mg .....	18.54	100	✓ <b>Norfex</b>
------------------	-------	-----	-----------------

**QUININE SULPHATE**

* Tab 200 mg .....	15.95	250	✓ <b>Q 200</b>
‡ Safety cap for extemporaneously compounded oral liquid preparations.			
* Tab 300 mg .....	34.75	500	✓ <b>Q 300</b>
‡ Safety cap for extemporaneously compounded oral liquid preparations.			

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Anaesthetics</b>				
<b>Local</b>				
BUPIVACAINE HYDROCHLORIDE – Hospital pharmacy [HP3]				
Inj 0.5%, 4 ml .....	29.35	5	✓	<u>Marcaïn Isobaric</u>
Inj 0.5%, 8% glucose, 4 ml .....	24.50	5	✓	<u>Marcaïn Heavy</u>
LIGNOCAINE HYDROCHLORIDE				
Inj 0.5%, 5 ml – Up to 5 inj available on a PSO .....	44.10	50	✓	<u>Xylocaine</u>
Only if prescribed on prescription for a dialysis patient or child with rheumatic fever or on a PSO for emergency use.				
Inj 1%, 5 ml – Up to 5 inj available on a PSO .....	42.00	50	✓	<u>Xylocaine</u>
Only if prescribed on prescription for a dialysis patient or child with rheumatic fever or on a PSO for emergency use.				
Inj 1%, 20 ml – Up to 5 inj available on a PSO .....	23.50	5	✓	<u>Xylocaine</u>
Only if prescribed on prescription for a dialysis patient or child with rheumatic fever or on a PSO for emergency use.				
LIGNOCAINE WITH CHLORHEXIDINE				
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes .....	43.26	10	✓	<u>Pfizer</u>
LIGNOCAINE WITH PRILOCAINE – Special Authority see SA0906 below – Hospital pharmacy [HP3]				
Crn 2.5% with prilocaine 2.5% .....	41.00	30 g OP	✓	<u>EMLA</u>
Crn 2.5% with prilocaine 2.5% (5 g tubes) .....	41.00	5	✓	<u>EMLA</u>

### ►SA0906 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years where the patient is a child with a chronic medical condition requiring frequent injections or venepuncture.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

## Analgesics

For Anti-inflammatory NSAIDs refer to MUSCULO-SKELETAL, page 104

### Non-Opioid Analgesics

ASPIRIN				
* Tab EC 300 mg .....	7.25 (8.10)	100		Aspec 300
* Tab dispersible 300 mg – Up to 30 tab available on a PSO .....	2.15	100	✓	<u>Ethics Aspirin</u>
NEFOPAM HYDROCHLORIDE				
Tab 30 mg .....	23.40	90	✓	<u>Acupan</u>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>PARACETAMOL</b>				
* Tab 500 mg – Up to 30 tab available on a PSO.....	9.60	1,000	✓	Pharmacare
	1.38	150		
	(14.67)			Panadol
*‡ Oral liq 120 mg per 5 ml .....	6.80	1,000 ml	✓	<u>Paracare Junior</u>
a) Up to 200 ml available on a PSO				
b) Not in combination				
*‡ Oral liq 250 mg per 5 ml .....	7.00	1,000 ml	✓	<u>Paracare Double Strength</u>
a) Up to 100 ml available on a PSO				
b) Not in combination				
* Suppos 125 mg .....	6.51	20	✓	Panadol
* Suppos 250 mg .....	12.52	20	✓	Panadol
* Suppos 500 mg .....	20.50	50	✓	Paracare
<i>(Panadol Tab 500 mg to be delisted 1 May 2009)</i>				

**Opioid Analgesics**

<b>BUPRENORPHINE HYDROCHLORIDE – Only on a controlled drug form</b>				
Inj 0.3 mg per ml, 1 ml .....	7.42	5		Temgesic
	(9.38)			
<b>CODEINE PHOSPHATE</b>				
Tab 15 mg .....	5.50	100	✓	<u>PSM</u>
Tab 30 mg .....	8.50	100	✓	<u>PSM</u>
Tab 60 mg .....	18.50	100	✓	<u>PSM</u>
<b>DEXTROPROPOXYPHENE WITH PARACETAMOL</b>				
Tab napsylate 50 mg with paracetamol 325 mg .....	14.50	500		Paradex
	(22.50)			
Cap hydrochloride 32.5 mg with paracetamol 325 mg .....	19.91	500		Capadex
	(24.50)			
<b>DIHYDROCODEINE TARTRATE</b>				
Tab long-acting 60 mg .....	30.30	60	✓	DHC Continus
<b>FENTANYL – Special Authority see SA0935 below – Retail pharmacy</b>				
a) Only on a controlled drug form				
b) No patient co-payment payable				
Transdermal patch, matrix 25 µg per hour .....	55.23	5	✓	Durogesic
Transdermal patch, matrix 50 µg per hour .....	100.52	5	✓	Durogesic
Transdermal patch, matrix 75 µg per hour .....	139.18	5	✓	Durogesic
Transdermal patch, matrix 100 µg per hour .....	171.22	5	✓	Durogesic

**▶▶SA0935 | Special Authority for Subsidy**

**Initial application** from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is terminally ill and is opioid-responsive; and
- 2 Either:
  - 2.1 is unable to take oral medication; or
  - 2.2 is intolerant to morphine, or morphine is contraindicated.

**Renewal** from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>METHADONE HYDROCHLORIDE</b>				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets).				
d) For methadone hydrochloride oral liquid refer, page 166				
Tab 5 mg .....	2.10	10	✓	<u>Methatabs</u>
‡ Oral liq 2 mg per ml .....	6.55	200 ml	✓	<u>Biodone</u>
‡ Oral liq 5 mg per ml .....	6.52	200 ml	✓	<u>Biodone Forte</u>
‡ Oral liq 10 mg per ml .....	9.50	200 ml	✓	<u>Biodone Extra Forte</u>
Inj 10 mg per ml, 1 ml .....	52.00	10	✓	<u>AFT</u>
<b>MORPHINE HYDROCHLORIDE</b>				
a) Only on a controlled drug form				
b) No patient co-payment payable				
‡ Oral liq 1 mg per ml .....	8.06	200 ml	✓	<u>RA-Morph</u>
‡ Oral liq 2 mg per ml .....	8.56	200 ml	✓	<u>RA-Morph</u>
‡ Oral liq 5 mg per ml .....	9.61	200 ml	✓	<u>RA-Morph</u>
‡ Oral liq 10 mg per ml .....	12.56	200 ml	✓	<u>RA-Morph</u>
<b>MORPHINE SULPHATE</b>				
a) Only on a controlled drug form				
b) No patient co-payment payable				
Tab immediate-release 10 mg .....	2.64	10	✓	<u>Sevredol</u>
Tab long-acting 10 mg .....	1.80	10	✓	<u>LA-Morph</u>
Tab immediate-release 20 mg .....	5.10	10	✓	<u>Sevredol</u>
Tab long-acting 30 mg .....	3.60	10	✓	<u>LA-Morph</u>
Tab long-acting 60 mg .....	7.20	10	✓	<u>LA-Morph</u>
Tab long-acting 100 mg .....	8.50	10	✓	<u>LA-Morph</u>
Cap long-acting 10 mg .....	1.80	10	✓	<u>m-Eslon</u>
Cap long-acting 30 mg .....	2.64	10	✓	<u>m-Eslon</u>
Cap long-acting 60 mg .....	7.20	10	✓	<u>m-Eslon</u>
Cap long-acting 100 mg .....	7.85	10	✓	<u>m-Eslon</u>
Cap long-acting 200 mg .....	17.00	10	✓	<u>m-Eslon</u>
Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	5.17	5	✓	<u>Mayne</u>
Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	4.50	5	✓	<u>Mayne</u>
Inj 15 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	4.70	5	✓	<u>Mayne</u>
Inj 30 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	4.98	5	✓	<u>Mayne</u>
Suppos 30 mg .....	31.39	12	✓	<u>Martindale S29</u>
<i>(Martindale S29 Suppos 30 mg to be delisted 1 May 2009)</i>				
<b>MORPHINE TARTRATE</b>				
a) Only on a controlled drug form				
b) No patient co-payment payable				
Inj 80 mg per ml, 1.5 ml .....	20.20	5	✓	<u>Mayne</u>
Inj 80 mg per ml, 5 ml .....	67.37	5	✓	<u>Mayne</u>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
<b>OXYCODONE HYDROCHLORIDE</b>				
a) Only on a controlled drug form				
b) No patient co-payment payable				
Tab controlled-release 5 mg .....	7.51	20	✓	OxyContin
Tab controlled-release 10 mg .....	11.14	20	✓	OxyContin
Tab controlled-release 20 mg .....	18.93	20	✓	OxyContin
Tab controlled-release 40 mg .....	33.29	20	✓	OxyContin
Tab controlled-release 80 mg .....	58.03	20	✓	OxyContin
Cap 5 mg .....	2.83	20	✓	OxyNorm
Cap 10 mg .....	5.58	20	✓	OxyNorm
Cap 20 mg .....	9.77	20	✓	OxyNorm
‡ Oral liq 5 mg per 5 ml .....	11.20	250 ml	✓	OxyNorm
Inj 10 mg per ml, 1 ml .....	14.40	5	✓	OxyNorm
Inj 10 mg per ml, 2 ml .....	28.80	5	✓	OxyNorm

**Prescribing Guideline**

Prescribers should note that oxycodone is significantly more expensive than long-acting morphine sulphate and clinical advice suggests that it is reasonable to consider this as a second-line agent to be used after morphine.

**PARACETAMOL WITH CODEINE**

* Tab paracetamol 500 mg with codeine phosphate 8 mg .....	3.24	100	✓	Codalgin
--	------	-----	---	----------

**PETHIDINE HYDROCHLORIDE**

a) Only on a controlled drug form				
b) No patient co-payment payable				
Tab 50 mg .....	3.00	10	✓	PSM
Tab 100 mg .....	4.00	10	✓	PSM
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	3.75	5	✓	Mayne
Inj 50 mg per ml, 1.5 ml – Up to 5 inj available on a PSO .....	4.35	5	✓	Mayne
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO .....	4.18	5	✓	Mayne

**Antidepressants**

**Cyclic and Related Agents**

**AMITRIPTYLINE**

Tab 10 mg .....	2.77	50	✓	Amirol
	3.00	100	✓	Amitrip
Tab 25 mg .....	3.40	100	✓	Amitrip
Tab 50 mg .....	5.20	100	✓	Amitrip

(Amitrip Tab 10 mg to be delisted 1 March 2009)

**CLOMIPRAMINE HYDROCHLORIDE**

Tab 10 mg .....	10.00	100	✓	Clopress
Tab 25 mg .....	26.00	500	✓	Clopress

**DOTHIEPIN HYDROCHLORIDE**

Tab 75 mg .....	8.75	100	✓	Dopress
Cap 25 mg .....	4.75	100	✓	Dopress

**DOXEPIN HYDROCHLORIDE**

Cap 10 mg .....	5.24	100	✓	Anten
Cap 25 mg .....	5.46	100	✓	Anten
Cap 50 mg .....	7.34	100	✓	Anten
Cap 75 mg .....	10.99	100	✓	Anten

(Anten Cap 75 mg to be delisted 1 April 2009)

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>IMIPRAMINE HYDROCHLORIDE</b>				
Tab 10 mg .....	5.48	50	✓	<b>Tofranil</b>
Tab 25 mg .....	8.80	50	✓	<b>Tofranil</b>
<b>MAPROTILINE HYDROCHLORIDE</b>				
Tab 25 mg .....	25.06	100	✓	<b>Ludiomil</b>
Tab 75 mg .....	21.01	30	✓	<b>Ludiomil</b>
<b>MIANSERIN HYDROCHLORIDE</b> – Special Authority see SA0864 below – Retail pharmacy				
Tab 30 mg .....	29.25	30	✓	<b>Tolvon</b>

### ►SA0864 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Depression; and
- 2 Either:
  - 2.1 Co-existent bladder neck obstruction; or
  - 2.2 Cardiovascular disease.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

<b>NORTRIPTYLINE HYDROCHLORIDE</b>				
Tab 10 mg .....	5.94	100	✓	<b>Norpress</b>
Tab 25 mg .....	20.06	250	✓	<b>Norpress</b>
<b>TRIMIPRAMINE MALEATE</b>				
Cap 25 mg .....	5.50	100	✓	<b>Tripres</b>
Cap 50 mg .....	10.20	100	✓	<b>Tripres</b>

### Monoamine-Oxidase Inhibitors (MAOIs) - Non Selective

<b>PHENELZINE SULPHATE</b>				
Tab 15 mg .....	95.00	100	✓	<b>Nardil</b>
<b>TRANLYCYPROMINE SULPHATE</b>				
Tab 10 mg .....	22.94	50	✓	<b>Parnate</b>

### Monoamine-Oxidase Type A Inhibitors

#### MOCLOBEMIDE

Note: There is a significant cost differential between moclobemide and fluoxetine (moclobemide being about three times more expensive). For depressive syndromes it is therefore more cost-effective to start treatment with fluoxetine first before considering prescribing moclobemide.

Tab 150 mg .....	49.45	500	✓	<b>Apo-Moclobemide</b>
Tab 300 mg .....	26.11	100	✓	<b>Apo-Moclobemide</b>

### Selective Serotonin Reuptake Inhibitors

<b>CITALOPRAM HYDROBROMIDE</b>				
* Tab 20 mg .....	1.26	28	✓	<b>Citalopram - Rex</b>
	3.78	84	✓	<b>Arrow-Citalopram</b>
	1.26	28		
	(3.50)			Celapram

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>FLUOXETINE HYDROCHLORIDE</b>				
* Tab dispersible 20 mg, scored – Subsidy by endorsement .....	5.50	30	✓	<b>Fluox</b>
Subsidised by endorsement				
1) When prescribed for a patient who cannot swallow whole tablets or capsules and the prescription is endorsed accordingly; or				
2) When prescribed in a daily dose that is not a multiple of 20 mg in which case the prescription is deemed to be endorsed. Note: Tablets should be combined with capsules to facilitate incremental 10 mg doses.				
* Cap 20 mg .....	4.39	90	✓	<b>Fluox</b>
<b>PAROXETINE HYDROCHLORIDE</b>				
Tab 20 mg .....	5.90	30	✓	<b>Loxamine</b>

**Other Antidepressants**

<b>VENLAFAXINE – Special Authority see SA0789 below – Retail pharmacy</b>				
Cap 37.5 mg .....	18.64	28	✓	<b>Efexor XR</b>
Cap 75 mg .....	37.27	28	✓	<b>Efexor XR</b>
Cap 150 mg .....	45.68	28	✓	<b>Efexor XR</b>

**SA0789 Special Authority for Subsidy**

**Initial application** only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has “treatment resistant” depression; and
- 2 Either:
  - 2.1 The patient must have had a trial of two different antidepressants and failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or
  - 2.2 Both:
    - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
    - 2.2.2 The patient must have had a trial of one other antidepressant and failed to respond to an adequate dose over an adequate period of time.

**Renewal** from any medical practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

**Antiepilepsy Drugs**

**Agents for Control of Status Epilepticus**

<b>CLONAZEPAM</b>				
Inj 1 mg per ml, 1 ml .....	19.00	5	✓	<b>Rivotril</b>
<b>DIAZEPAM</b>				
Inj 5 mg per ml, 2 ml – Subsidy by endorsement .....	9.24	5	✓	<b>Mayne</b>
a) Up to 5 inj available on a PSO				
b) Only on a PSO				
c) PSO must be endorsed “not for anaesthetic procedures”.				
Rectal tubes 5 mg – Up to 5 tube available on a PSO .....	27.83	5	✓	<b>Stesolid</b>
Rectal tubes 10 mg – Up to 5 tube available on a PSO .....	33.89	5	✓	<b>Stesolid</b>
<b>PARALDEHYDE</b>				
* Inj 5 ml .....	1,500.00	5	✓	<b>AFT</b>
<b>PHENYTOIN SODIUM</b>				
* Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO .....	69.24	5	✓	<b>Mayne</b>
* Inj 50 mg per ml, 5 ml – Up to 5 inj available on a PSO .....	77.27	5	✓	<b>Mayne</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Control of Epilepsy</b>				
<b>CARBAMAZEPINE</b>				
* Tab 200 mg .....	14.53	100	✓	<b>Tegretol</b>
* Tab long-acting 200 mg .....	16.98	100	✓	<b>Tegretol CR</b>
* Tab 400 mg .....	34.58	100	✓	<b>Tegretol</b>
* Tab long-acting 400 mg .....	39.17	100	✓	<b>Tegretol CR</b>
*‡ Oral liq 100 mg per 5 ml .....	26.37	250 ml	✓	<b>Tegretol</b>
<b>CLOBAZAM</b>				
Tab 10 mg .....	9.12	50	✓	<b>Frisium</b>
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
<b>CLONAZEPAM</b>				
Tab 500 µg .....	6.26	100	✓	<b>Paxam</b>
Tab 2 mg .....	11.15	100	✓	<b>Paxam</b>
‡ Oral drops 2.5 mg per ml .....	7.38	10 ml OP	✓	<b>Rivotril</b>
<b>ETHOSUXIMIDE</b>				
* Cap 250 mg .....	32.90	200	✓	<b>Zarontin</b>
*‡ Oral liq 250 mg per 5 ml .....	11.96	200 ml	✓	<b>Zarontin</b>
<b>GABAPENTIN – Special Authority see SA0936 below – Retail pharmacy</b>				
▲ Tab 600 mg .....	79.79	100	✓	<b>Neurontin</b>
▲ Cap 100 mg .....	13.26	100	✓	<b>Nupentin</b>
	15.67		✓	<b>Neurontin</b>
▲ Cap 300 mg .....	39.76	100	✓	<b>Nupentin</b>
	47.00		✓	<b>Neurontin</b>
▲ Cap 400 mg .....	53.01	100	✓	<b>Nupentin</b>
	62.66		✓	<b>Neurontin</b>

**SA0936 Special Authority for Subsidy**

**Initial application — (Epilepsy - new patients)** from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Either:

- 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
- 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

**Initial application — (Epilepsy - patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007)** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life from gabapentin, topiramate, vigabatrin and/or lamotrigine.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

**Initial application — (Neuropathic pain - new patients)** from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant.

**Initial application — (Neuropathic pain - patient has had an approval for gabapentin for neuropathic pain prior to 1 August 2007)** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

**Renewal — (Epilepsy)** from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application.

**Renewal — (Neuropathic pain)** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or
- 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

Note: If the patient had an approval for gabapentin for neuropathic pain prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application.

LAMOTRIGINE

▲ Tab dispersible 2 mg .....	6.74	30	✓	Lamictal
▲ Tab dispersible 5 mg .....	9.64	30	✓	Lamictal
	15.00	56	✓	Arrow-Lamotrigine
▲ Tab dispersible 25 mg .....	19.38	56	✓	Logem
	20.40		✓	Arrow-Lamotrigine
	29.09		✓	Mogine
▲ Tab dispersible 50 mg .....	32.97	56	✓	Lamictal
	34.70		✓	Logem
			✓	Arrow-Lamotrigine
	47.89		✓	Mogine
▲ Tab dispersible 100 mg .....	56.91	56	✓	Lamictal
	59.90		✓	Logem
			✓	Arrow-Lamotrigine
			✓	Mogine
	79.16		✓	Lamictal
▲ Tab dispersible 200 mg .....	101.80	56	✓	Arrow-Lamotrigine
			✓	Mogine

LEVETIRACETAM – Special Authority see SA0921 below – Retail pharmacy

Tab .....	CBS	60	✓	Keppra
-----------	-----	----	---	--------

**SA0921 Special Authority for Subsidy**

Subsidy by application to the Levetiracetam Special Access Panel

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The Coordinator, Levetiracetam Special Access Panel      Phone: (04) 916-7553  
 PHARMAC, PO Box 10 254      Facsimile: (09) 929-3226  
 Wellington      Email: [lsacoordinator@pharmac.govt.nz](mailto:lsacoordinator@pharmac.govt.nz)

PHENOBARBITONE

For phenobarbitone oral liquid refer, page 166

* Tab 15 mg .....	23.68	500	✓	PSM
* Tab 30 mg .....	24.59	500	✓	PSM

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>PHENYTOIN SODIUM</b>				
* Tab 50 mg .....	15.63	200	✓	Dilantin Infatab
* Cap 30 mg .....	15.50	200	✓	Dilantin
* Cap 100 mg .....	14.69	200	✓	Dilantin
*‡ Oral liq 30 mg per 5 ml .....	11.19	500 ml	✓	Dilantin
<b>PRIMIDONE</b>				
* Tab 250 mg .....	17.25	100	✓	Apo-Primidone
<b>SODIUM VALPROATE</b>				
* Tab 100 mg .....	13.65	100	✓	Epilim Crushable
* Tab 200 mg EC .....	27.44	100	✓	Epilim
* Tab 500 mg EC .....	52.24	100	✓	Epilim
*‡ Oral liq 200 mg per 5 ml .....	20.48	300 ml	✓	Epilim S/F Liquid
			✓	Epilim Syrup
			✓	Epilim IV
* Inj 100 mg per ml, 4 ml .....	41.50	1		
<b>TOPIRAMATE</b>				
▲ Tab 25 mg .....	26.04	60	✓	Topamax
▲ Tab 50 mg .....	44.26	60	✓	Topamax
▲ Tab 100 mg .....	75.25	60	✓	Topamax
▲ Tab 200 mg .....	129.85	60	✓	Topamax
▲ Sprinkle cap 15 mg .....	20.84	60	✓	Topamax
▲ Sprinkle cap 25 mg .....	26.04	60	✓	Topamax
<b>VIGABATRIN – Special Authority see SA0937 below – Retail pharmacy</b>				
▲ Tab 500 mg .....	119.30	100	✓	Sabril

### ▶SA0937 Special Authority for Subsidy

**Initial application — (new patients)** from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Both:

1 Either:

1.1 Patient has infantile spasms; or

1.2 Both:

1.2.1 Patient has epilepsy; and

1.2.2 Either:

1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or

1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and

2 Either:

2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or

2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

**Initial application — (patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007)** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1 Patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life from gabapentin, topiramate, vigabatrin and or lamotrigine; and
- 2 Either:
  - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for the duration of treatment with vigabatrin; or
  - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

**Renewal** from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
- 2 Either:
  - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
  - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application.

### Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULO-SKELETAL, page 104

#### Acute Migraine Treatment

<b>ERGOTAMINE TARTRATE WITH CAFFEINE</b>				
Tab 1 mg with caffeine 100 mg .....	31.00	100	✓	<b>Cafergot</b>
<b>METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL</b>				
Tab 5 mg with paracetamol 500 mg .....	6.77	60	✓	<b>Paramax</b>
<b>RIZATRIPTAN BENZOATE</b>				
Wafer 10 mg .....	25.32	3	✓	<b>Maxalt Melt</b>
<b>SUMATRIPTAN</b>				
Tab 50 mg .....	12.00	4	✓	<b>Arrow-Sumatriptan</b>
	22.00		✓	<b>Sumagran</b>
Tab 100 mg .....	12.00	2	✓	<b>Imigran</b>
	22.00		✓	<b>Arrow-Sumatriptan</b>
			✓	<b>Sumagran</b>
			✓	<b>Imigran</b>
Inj 12 mg per ml, 0.5 ml – Hospital pharmacy [HP3]-Specialist .....	80.00	2 OP	✓	<b>Imigran</b>
Maximum of 10 inj per prescription				

#### Prophylaxis of Migraine

For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYSTEM, page 56

<b>CLONIDINE HYDROCHLORIDE</b>				
* Tab 25 µg .....	17.53	100	✓	<b>Dixarit</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
PIZOTIFEN				
* Tab 500 µg .....	21.10 (24.10)	100		Sandomigran

### Antinausea and Vertigo Agents

For Antispasmodics refer to ALIMENTARY TRACT, page 28

#### BETAHISTINE DIHYDROCHLORIDE

\* Tab 16 mg ..... 7.56 84 ✓ **Vergo 16**

#### CYCLIZINE HYDROCHLORIDE

Tab 50 mg ..... 1.99 10 ✓ **Nausicalm**

#### CYCLIZINE LACTATE

Inj 50 mg per ml, 1 ml ..... 14.95 5 ✓ **Valoid (AFT)**

DOMPERIDONE – Additional subsidy by Special Authority see SA0938 below – Retail pharmacy

\* Tab 10 mg ..... 3.90 100  
(7.99) Motilium

#### ►SA0938 Special Authority for Manufacturers Price

**Initial application** from any relevant practitioner. Approvals valid for 6 months where the patient is terminally ill and requires control of nausea and vomiting.

**Renewal** from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

HYOSCINE (SCOPOLAMINE) – Special Authority see SA0939 below – Hospital pharmacy [HP3]

Patches, 1.5 mg ..... 11.95 2 ✓ **Scopoderm TTS**

#### ►SA0939 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease; and
- 2 Patient cannot tolerate or does not adequately respond to oral anti-nausea agents; and
- 3 The applicant must specify the underlying malignancy or chronic disease.

**Renewal** from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

#### HYOSCINE HYDROBROMIDE

\* Inj 400 µg per ml, 1 ml ..... 6.66 5 ✓ **Mayne**

#### METOCLOPRAMIDE HYDROCHLORIDE

\* Tab 10 mg ..... 5.15 100 ✓ **Metamide**

\* Inj 5 mg per ml, 2 ml – Up to 5 inj available on a PSO ..... 4.50 10 ✓ **Pfizer**

ONDANSETRON – Retail pharmacy-Specialist

a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 below

b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 below

c) Not more than one prescription per month; can be waived by Special Authority see SA0887 below.

Tab 4 mg ..... 17.18 10 ✓ **Zofran**

Tab disp 4 mg ..... 17.18 10 ✓ **Zofran Zydys**

Tab 8 mg ..... 33.89 20 ✓ **Zofran**

Tab disp 8 mg ..... 20.43 10 ✓ **Zofran Zydys**

#### ►SA0887 Special Authority for Waiver of Rule

**Initial application** from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy.

**Renewal** from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>PROCHLORPERAZINE</b>				
* Tab 3 mg buccal .....	5.97 (15.00)	50		Buccastem
* Tab 5 mg – Up to 30 tab available on a PSO.....	16.85	500	✓	<b>Antinaus</b>
* Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	25.81	10	✓	<b>Stemetil</b>
* Suppos 25 mg .....	23.87	5	✓	<b>Stemetil</b>
<b>PROMETHAZINE THEOCLATE</b>				
* Tab 25 mg .....	1.20 (6.24)	10		Avomine
<b>TROPISETRON – Hospital pharmacy [HP3]-Specialist</b>				
a) Maximum of 6 cap per prescription				
b) Maximum of 3 cap per dispensing				
c) Not more than one prescription per month.				
Cap 5 mg .....	77.41	5	✓	<b>Navoban</b>
<b>Antiparkinson Agents</b>				
<b>Dopamine Agonists and Related Agents</b>				
<b>AMANTADINE HYDROCHLORIDE</b>				
▲ Cap 100 mg .....	47.81	60	✓	<b>Symmetrel</b>
<b>APOMORPHINE HYDROCHLORIDE</b>				
▲ Inj 10 mg per ml, 2 ml .....	50.43	5	✓	<b>AP0-go <sup>S29</sup></b>
▲ Inj 10 mg per ml, 1 ml .....	50.43	5	✓	<b>Mayne</b>
<b>BROMOCRIPTINE MESYLATE</b>				
* Tab 2.5 mg .....	32.08	100	✓	<b>Alpha-Bromocriptine</b>
* Tab 10 mg .....	120.86	100	✓	<b>Alpha-Bromocriptine</b>
<b>ENTACAPONE</b>				
▲ Tab 200 mg .....	129.00	100	✓	<b>Comtan</b>
<b>LEVODOPA WITH BENSERAZIDE</b>				
* Tab dispersible 50 mg with benserazide 12.5 mg .....	10.00	100	✓	<b>Madopar Dispersible</b>
* Cap 50 mg with benserazide 12.5 mg .....	8.00	100	✓	<b>Madopar 62.5</b>
* Cap 100 mg with benserazide 25 mg .....	12.50	100	✓	<b>Madopar 125</b>
* Cap long-acting 100 mg with benserazide 25 mg .....	17.00	100	✓	<b>Madopar HBS</b>
* Cap 200 mg with benserazide 50 mg .....	25.00	100	✓	<b>Madopar 250</b>
<b>LEVODOPA WITH CARBIDOPA</b>				
* Tab 100 mg with carbidopa 25 mg .....	10.00 20.00	50 100	✓ ✓	<b>Sindopa</b> <b>Sinemet</b>
* Tab long-acting 200 mg with carbidopa 50 mg – Retail pharmacy-Specialist .....	70.00	100	✓	<b>Sinemet CR</b>
* Tab 250 mg with carbidopa 25 mg .....	57.50	100	✓	<b>Sinemet</b>
<b>LISURIDE HYDROGEN MALEATE</b>				
▲ Tab 200 µg .....	27.50	30	✓	<b>Dopergin</b>
<b>PERGOLIDE</b>				
▲ Tab 0.25 mg .....	48.00	100	✓	<b>Permax</b>
▲ Tab 1 mg .....	170.00	100	✓	<b>Permax</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>ROPINIROLE HYDROCHLORIDE – Retail pharmacy-Specialist</b>				
▲ Tab 0.25 mg .....	31.50	210	✓	Requip
▲ Tab 0.25 mg × 42, 0.5 mg × 42 and 1 mg × 21 .....	35.70	105 OP	✓	Requip Starter Pack
▲ Tab 0.5 mg × 42, 1 mg × 42 and 2 mg × 63 .....	122.11	147 OP	✓	Requip Follow-on Pack
▲ Tab 1 mg .....	67.20	84	✓	Requip
▲ Tab 2 mg .....	101.21	84	✓	Requip
▲ Tab 5 mg .....	150.00	84	✓	Requip
<b>SELEGILINE HYDROCHLORIDE</b>				
* Tab 5 mg .....	16.06	100	✓	<u>Apo-Selegiline</u>
<b>TOLCAPONE – Retail pharmacy-Specialist prescription</b>				
Specialist must be a neurologist, geriatrician or general physician.				
▲ Tab 100 mg .....	128.75	100	✓	Tasmar
<b>Anticholinergics</b>				
<b>BENZTROPINE MESYLATE</b>				
Tab 2 mg .....	7.25	60	✓	Benztrop
Inj 1 mg per ml, 2 ml .....	36.35	5	✓	Cogentin
a) Up to 5 inj available on a PSO				
b) Only on a PSO				
<b>ORPHENADRINE HYDROCHLORIDE</b>				
Tab 50 mg .....	31.93	250	✓	Disipal
<b>PROCYCLIDINE HYDROCHLORIDE</b>				
Tab 5 mg .....	7.40	100	✓	Kemadrin

## Antipsychotics

### Guidelines for the use of atypical antipsychotic agents

Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical antipsychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional antipsychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.

### General

<b>AMISULPRIDE</b>				
Tab 100 mg .....	22.52	30	✓	Solian
Tab 200 mg .....	97.03	60	✓	Solian
Tab 400 mg .....	185.44	60	✓	Solian
Oral liq 100 mg per ml .....	55.44	60 ml	✓	Solian
<b>ARIPIPRAZOLE – Special Authority see SA0920 on the next page – Retail pharmacy</b>				
Tab 10 mg .....	123.54	30	✓	Abilify
Tab 15 mg .....	175.28	30	✓	Abilify
Tab 20 mg .....	213.42	30	✓	Abilify
Tab 30 mg .....	260.07	30	✓	Abilify

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>SA0920   Special Authority for Subsidy</b>				
<b>Initial application</b> from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:				
Both:				
1 Patient is suffering from schizophrenia or related psychoses; and				
2 Either:				
2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or				
2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.				
<b>Renewal</b> from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.				
<b>CHLORPROMAZINE HYDROCHLORIDE</b>				
Tab 10 mg – Up to 30 tab available on a PSO.....	12.36	100	✓	Largactil
Tab 25 mg – Up to 30 tab available on a PSO.....	13.02	100	✓	Largactil
Tab 100 mg – Up to 30 tab available on a PSO.....	30.61	100	✓	Largactil
Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO.....	25.66	10	✓	Largactil
<b>CLOZAPINE – Hospital pharmacy [HP4]</b>				
Tab 25 mg .....	13.37	50	✓	Clopine
	26.74	100	✓	Clopine
	13.37	50	✓	Clozaril
Tab 50 mg .....	17.33	50	✓	Clopine
	34.65	100	✓	Clopine
Tab 100 mg .....	34.65	50	✓	Clozaril
	35.65		✓	Clopine
	69.30	100	✓	Clopine
Tab 200 mg .....	55.45	50	✓	Clopine
	110.90	100	✓	Clopine
Suspension 50 mg/ml .....	34.65	100 ml	✓	Clopine
<b>HALOPERIDOL</b>				
Tab 500 µg – Up to 30 tab available on a PSO.....	4.93	100	✓	Serenace
Tab 1.5 mg – Up to 30 tab available on a PSO.....	7.45	100	✓	Serenace
Tab 5 mg – Up to 30 tab available on a PSO.....	23.49	100	✓	Serenace
Oral liq 2 mg per ml – Up to 200 ml available on a PSO.....	18.06	100 ml	✓	Serenace
Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO.....	17.04	10	✓	Serenace
<b>LITHIUM CARBONATE</b>				
Tab 250 mg .....	25.45	500	✓	Lithicarb
Tab 400 mg .....	9.17	100	✓	Lithicarb
Tab long-acting 400 mg .....	16.05	100	✓	Priadel
Cap 250 mg .....	7.22	100	✓	Douglas
<b>METHOTRIMEPRAZINE</b>				
Tab 25 mg .....	16.93	100	✓	Nozinan
Tab 100 mg .....	43.96	100	✓	Nozinan
Inj 25 mg per ml, 1 ml .....	73.68	10	✓	Nozinan
<b>OLANZAPINE – Special Authority see SA0741 on the next page – Retail pharmacy</b>				
Tab 2.5 mg .....	51.07	28	✓	Zyprexa
Tab 5 mg .....	101.21	28	✓	Zyprexa
Tab 10 mg .....	204.49	28	✓	Zyprexa

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>SA0741 Special Authority for Subsidy</b>				
<b>Initial application</b> only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria:				
Any of the following:				
1 Patient presents with first episode schizophrenia or related psychoses; or				
2 Both:				
2.1 Patient suffering from schizophrenia and related psychoses or acute mania in bipolar disorder who is likely to benefit from antipsychotic treatment; and				
2.2 Either:				
2.2.1 An effective dose of risperidone had been trialled and has been discontinued because of unacceptable side effects; or				
2.2.2 An effective dose of risperidone had been trialled and has been discontinued because of inadequate clinical response after 4 weeks; or				
3 The patient has suffered from an acute episode of schizophrenia or bipolar mania and has been treated with olanzapine short-acting intra-muscular injection.				
<b>Renewal</b> only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.				
Note: Initial prescriptions to be written by psychiatrists or psychiatric registrars and subsequent prescriptions can be written by General Practitioners.				
<b>PERICYAZINE</b>				
Tab 2.5 mg .....	12.49	100	✓	Neulactil
Tab 10 mg .....	44.45	100	✓	Neulactil
<b>QUETIAPINE</b>				
Tab 25 mg .....	20.62	90	✓	Quetapel
	46.20	60	✓	Seroquel
Tab 100 mg .....	41.25	90	✓	Quetapel
	92.40	60	✓	Seroquel
Tab 200 mg .....	70.88	90	✓	Quetapel
	158.76	60	✓	Seroquel
Tab 300 mg .....	119.25	90	✓	Quetapel
	267.12	60	✓	Seroquel
<b>RISPERIDONE</b>				
Tab 0.5 mg .....	5.20	20	✓	Ridal
	15.60	60	✓	Ridal
	5.20	20	✓	Risperdal
Tab 1 mg .....	30.77	60	✓	Ridal
			✓	Risperdal
Tab 2 mg .....	61.53	60	✓	Ridal
			✓	Risperdal
Tab 3 mg .....	92.32	60	✓	Ridal
			✓	Risperdal
Tab 4 mg .....	123.05	60	✓	Ridal
			✓	Risperdal
Oral liquid 1 mg per ml .....	45.92	30 ml	✓	Risperdal
<b>TRIFLUOPERAZINE HYDROCHLORIDE</b>				
Tab 1 mg .....	9.83	100		
	(10.22)			Stelazine S29
Tab 2 mg .....	13.63	100		
	(15.61)			Stelazine S29
Tab 5 mg .....	15.79	100		
	(17.77)			Stelazine S29

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>ZIPRASIDONE – Subsidy by endorsement</b>				
Ziprasidone is subsidised for patients suffering from schizophrenia or related psychoses after a trial of an effective dose of risperidone or quetiapine that has been discontinued, or is in the process of being discontinued, because of unacceptable side effects or inadequate response, and the prescription is endorsed accordingly.				
Cap 20 mg .....	87.88	60	✓	Zeldox
Cap 40 mg .....	164.78	60	✓	Zeldox
Cap 60 mg .....	247.17	60	✓	Zeldox
Cap 80 mg .....	329.56	60	✓	Zeldox
<b>Depot Injections</b>				
<b>FLUPENTHIXOL DECANOATE</b>				
Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	13.14	5	✓	Fluanxol
Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO .....	20.90	5	✓	Fluanxol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	40.87	5	✓	Fluanxol
<b>FLUPHENAZINE DECANOATE</b>				
Inj 12.5 mg per 0.5 ml, 0.5 ml – Up to 5 inj available on a PSO .....	17.60	5	✓	Modecate
Inj 25 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	27.90	5	✓	Modecate
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	154.50	5	✓	Modecate
<b>HALOPERIDOL DECANOATE</b>				
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	28.39	5	✓	Haldol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	55.90	5	✓	Haldol Concentrate
<b>PIPOTHIAZINE PALMITATE</b>				
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	178.48	10	✓	Piportil
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO .....	353.32	10	✓	Piportil
<b>RISPERIDONE – Special Authority see SA0926 below – Retail pharmacy</b>				
Microspheres for injection 25 mg .....	175.00	1	✓	Risperdal Consta
Microspheres for injection 37.5 mg .....	230.00	1	✓	Risperdal Consta
Microspheres for injection 50 mg .....	280.00	1	✓	Risperdal Consta

**SA0926 Special Authority for Subsidy**

**Initial application** from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:  
All of the following:

- 1 The patient has schizophrenia or other psychotic disorder; and
- 2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
- 3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

**Renewal** from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:  
Either:

- 1 Both:
  - 1.1 The patient has had less than 12 months treatment with risperidone microspheres; and
  - 1.2 There is no clinical reason to discontinue treatment; or
- 2 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres.

Note: Risperidone microspheres should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone microspheres.

ZUCLOPENTHIXOL DECANOATE				
Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO .....	19.80	5	✓	Clopixol

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Orodispersible Antipsychotics</b>				
OLANZAPINE – Special Authority see SA0739 below – Retail pharmacy				
Wafer 5 mg .....	102.19	28	✓	Zyprexa Zydys
Wafer 10 mg .....	204.37	28	✓	Zyprexa Zydys

### ▶▶SA0739 Special Authority for Subsidy

**Initial application** only from a psychiatrist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient meets the current criteria for standard olanzapine tablets; and
- 2 The patient is unable to take standard olanzapine tablets, or once stabilized refuses to take olanzapine tablets; or the patient is non-adherent to oral therapy with standard olanzapine tablets; and
- 3 The patient is under direct supervision for administration of medicine.

**Renewal** only from a psychiatrist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard olanzapine tablets, or once stabilized refuses to take olanzapine tablets; and
- 2 The patient is under direct supervision for administration of medicine.

Note: Initial prescriptions to be written by psychiatrists and subsequent prescriptions can be written by psychiatric registrars or General Practitioners.

RISPERIDONE – Special Authority see SA0927 below – Retail pharmacy

Orally-disintegrating tablets 0.5 mg .....	21.42	28	✓	Risperdal Quicklet
Orally-disintegrating tablets 1 mg .....	42.84	28	✓	Risperdal Quicklet
Orally-disintegrating tablets 2 mg .....	85.71	28	✓	Risperdal Quicklet

### ▶▶SA0927 Special Authority for Subsidy

**Initial application — (Acute situations)** from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

**Initial application — (Chronic situations)** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

**Renewal** from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Note: Risperdal Quicklets cost significantly more than risperidone tablets and should only be used where necessary.

## Anxiolytics

ALPRAZOLAM – Month Restriction

Tab 250 µg .....	3.25	50	✓	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 500 µg .....	4.30	50	✓	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 1 mg .....	7.85	50	✓	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.				

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>BUSPIRONE HYDROCHLORIDE – Special Authority see SA0863 below – Retail pharmacy</b>				
Month Restriction				
Tab 5 mg .....	28.00	100	✓	<b>Pacific Buspirone</b>
Tab 10 mg .....	17.00	100	✓	<b>Pacific Buspirone</b>

**SA0863 Special Authority for Subsidy**

**Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:  
Both:

- 1 For use only as an anxiolytic; and
- 2 Other agents are contraindicated or have failed.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

**DIAZEPAM**

Tab 2 mg – Month Restriction.....	8.40	500	✓	<b>Pro-Pam</b>
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 5 mg – Month Restriction.....	5.00	250	✓	<b>Pro-Pam</b>
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 10 mg – Month Restriction.....	3.45	100	✓	<b>Pro-Pam</b>
‡ Safety cap for extemporaneously compounded oral liquid preparations.				

**LORAZEPAM – Month Restriction**

Tab 1 mg .....	6.28	250	✓	<b>Ativan</b>
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 2.5 mg .....	4.12	100	✓	<b>Ativan</b>
‡ Safety cap for extemporaneously compounded oral liquid preparations.				

**OXAZEPAM – Month Restriction**

Tab 10 mg .....	1.98 (5.50)	100		Ox-Pam
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 15 mg .....	2.45 (7.60)	100		Ox-Pam
‡ Safety cap for extemporaneously compounded oral liquid preparations.				

**Multiple Sclerosis Treatments**

**SA0855 Special Authority for Subsidy**

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC).

Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: <a href="mailto:mstacordinator@pharmac.govt.nz">mstacordinator@pharmac.govt.nz</a>
Wellington	

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

These agents will NOT be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their clinicians by courier.

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

Prescribers must send quarterly prescriptions for approved patients to the MSTAC coordinator.

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, or 20 mg glatiramer acetate daily will be subsidised.

Appeals against MSTAC's decision and/or the processing of any application may be lodged with the MSTAC coordinator. Concerns that cannot be or have not been adequately addressed by MSTAC will be forwarded to a separate Appeal Committee if necessary. Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. The MSTAC coordinator should be notified of the change and a new prescription provided.

### Entry Criteria

- 1) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis should as a rule include MRI confirmation. For patients diagnosed before MRI was widely utilised in New Zealand, confirmation of diagnosis via clinical assessment and laboratory/ancillary data must be provided; and
- 2) patients must have active relapsing MS (confirmed by MR scan where necessary) with or without underlying progression; and
- 3) patients must have either:
  - a) EDSS score 2.5 - 5.5 with 2+ relapses:
    - experienced at least 2 significant relapses of MS in the previous 12 months, and
    - an EDSS score of between 2.5 and 5.5 inclusive; or
  - b) EDSS score 2.0 with 3+ relapses:
    - experienced at least 3 significant relapses of MS in the previous 12 months, and
    - an EDSS score of 2.0; and
- 4) Each relapse must:
  - a) be confirmed by a neurologist or general physician (the patient may not necessarily have been seen during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
  - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
  - c) last at least one week;
  - d) follow a period of stability of at least one month;
  - e) be severe enough to change either the EDSS or at least one of the Kurtzke functional systems scores by at least 1 point;
  - f) be distinguishable from the effects of general fatigue; and
  - g) not be associated with a fever ( $T > 37.5^{\circ}\text{C}$ ); and
- 5) applications must be made at least four weeks after the date of the onset of the last known relapse; and
- 6) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate (see criteria for stopping).
- 7) applications must be submitted to the Multiple Sclerosis Treatment Assessment Committee (MSTAC) by the patient's neurologist or a general physician; and
- 8) patients must agree (via informed consent) to co-operate if as a result of their meeting the stopping criteria, funding is withdrawn. Patients must agree to the collection of clinical data relating to their MS and use of those data by PHARMAC; and
- 9) patients must agree to allow clinical data to be collected and reviewed by MSTAC annually for each year in which they receive funding for beta-interferon or glatiramer acetate.

### Stopping Criteria

- 1) Confirmed progression of disability that is sustained for three months after a minimum of one year of treatment. Progression of disability is defined as either an increase of 1 EDSS point from the starting EDSS or an increase in EDSS score to 6.0 or more; or
- 2) stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment); or
- 3) pregnancy and/or lactation; or
- 4) within the 12 month approval year, intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
5) non-compliance with treatment, including refusal to undergo annual assessment or refusal to allow the results of the assessment to be submitted to MSTAC; or				
6) patients may, subject to conclusions drawn from published evidence available at the time, be excluded if they develop a high titre of neutralising anti-bodies to beta-interferon or glatiramer acetate.				
GLATIRAMER ACETATE – Special Authority see SA0855 on page 127				
Inj 20 mg pre-filled syringe .....	1,089.25	28	✓	Copaxone
INTERFERON BETA-1-ALPHA – Special Authority see SA0855 on page 127				
Inj 6 million iu prefilled syringe .....	1,245.13	4	✓	Avonex
Inj 6 million iu per vial .....	1,245.13	4	✓	Avonex
INTERFERON BETA-1-BETA – Special Authority see SA0855 on page 127				
Inj 8 million iu per 1 ml .....	1,378.71	15	✓	Betaferon

**Sedatives and Hypnotics**

LORMETAZEPAM – Month Restriction				
Tab 1 mg .....	3.11 (23.50)	30		Noctamid
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
MIDAZOLAM				
Tab 7.5 mg – Month Restriction.....	10.38 (25.00)	100		Hypnovel
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Inj 1 mg per ml, 5 ml .....	12.65 (14.73)	10	✓	Hypnovel Pfizer
Inj 5 mg per ml, 3 ml .....	14.00 (19.64)	5	✓	Hypnovel Pfizer
NITRAZEPAM – Month Restriction				
Tab 5 mg .....	2.00 (3.90) (4.65)	100		Insoma Nitrados
‡ Safety cap for extemporaneously compounded oral liquid preparations. (Insoma Tab 5 mg to be delisted 1 March 2009)				
TEMAZEPAM – Month Restriction				
Tab 10 mg .....	0.83	25	✓	Normison
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
TRIAZOLAM – Month Restriction				
Tab 125 µg .....	5.10	100	✓	Hypam
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
Tab 250 µg .....	4.10	100	✓	Hypam
‡ Safety cap for extemporaneously compounded oral liquid preparations.				
ZOPICLONE – Month Restriction				
Tab 7.5 mg .....	21.02	500	✓	Apo-Zopiclone

**Other CNS Agents**

DEXAMPHETAMINE SULPHATE – Special Authority see SA0907 on the next page – Retail pharmacy Only on a controlled drug form				
Tab 5 mg .....	17.00	100	✓	PSM

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

## ►SA0907 Special Authority for Subsidy

**Initial application — (ADHD in patients 5 or over – new patients)** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
  - 3.1 Applicant is a paediatrician or psychiatrist; or
  - 3.2 Both:
    - 3.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
    - 3.2.2 Provide name of the recommending specialist.

**Initial application — (ADHD in patients 5 or over - patient has had an approval for dexamphetamine for ADHD prior to 1 April 2008)** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 Applicant is a paediatrician or psychiatrist; or
  - 2.2 Both:
    - 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
    - 2.2.2 Provide name of the recommending specialist.

**Initial application — (ADHD in patients under 5 – new patients)** only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

**Initial application — (ADHD in patients under 5 - patient has had an approval for dexamphetamine for ADHD in patients under 5 prior to 1 April 2008)** only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

**Initial application — (Narcolepsy – new patients)** only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

**Initial application — (Narcolepsy - patient has had an approval for dexamphetamine for narcolepsy prior to 1 April 2008)** only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

**Renewal — (ADHD in patients 5 or over)** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 Applicant is a paediatrician or psychiatrist; or
  - 2.2 Both:
    - 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
    - 2.2.2 Provide name of the recommending specialist.

Note: If the patient had an approval for dexamphetamine for ADHD prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

continued...

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
---	----------------------------	-------------------------------------

continued...

**Renewal — (ADHD in patients under 5)** only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If the patient had an approval for dexamphetamine for ADHD in patients under 5 prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

**Renewal — (Narcolepsy)** only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If the patient had an approval for dexamphetamine for narcolepsy prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

**DISULFIRAM**

Tab 200 mg .....	24.30	100	✓ <b>Antabuse</b>
------------------	-------	-----	-------------------

**METHYLPHENIDATE HYDROCHLORIDE** – Special Authority see SA0908 below – Retail pharmacy

Only on a controlled drug form

Tab immediate-release 5 mg .....	3.20	30	✓ <b>Rubifen</b>
Tab immediate-release 10 mg .....	4.29	30	✓ <b>Rubifen</b>
Tab immediate-release 20 mg .....	7.85	30	✓ <b>Rubifen</b>
Tab sustained-release 20 mg .....	10.95	30	✓ <b>Rubifen SR</b>

**SA0908 Special Authority for Subsidy**

**Initial application — (ADHD in patients 5 or over – new patients)** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
  - 3.1 Applicant is a paediatrician or psychiatrist; or
  - 3.2 Both:
    - 3.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
    - 3.2.2 Provide name of the recommending specialist.

**Initial application — (ADHD in patients 5 or over - patient has had an approval for methylphenidate for ADHD prior to 1 April 2008)** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 Applicant is a paediatrician or psychiatrist; or
  - 2.2 Both:
    - 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
    - 2.2.2 Provide name of the recommending specialist.

**Initial application — (ADHD in patients under 5 – new patients)** only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

**Initial application — (ADHD in patients under 5 - patient has had an approval for methylphenidate for ADHD in patients under 5 prior to 1 April 2008)** only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

**Initial application — (Narcolepsy – new patients)** only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

**Initial application — (Narcolepsy - patient has had an approval for methylphenidate for narcolepsy prior to 1 April 2008)** only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

**Renewal — (ADHD in patients 5 or over)** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 Applicant is a paediatrician or psychiatrist; or
  - 2.2 Both:
    - 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
    - 2.2.2 Provide name of the recommending specialist.

Note: If the patient had an approval for methylphenidate for ADHD prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

**Renewal — (ADHD in patients under 5)** only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If the patient had an approval for methylphenidate for ADHD in patients under 5 prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

**Renewal — (Narcolepsy)** only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: If the patient had an approval for methylphenidate for narcolepsy prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed.

**METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE** – Special Authority see SA0924 below – Retail pharmacy

Only on a controlled drug form

Tab extended-release 18 mg .....	58.96	30	✓ Concerta
Tab extended-release 27 mg .....	65.44	30	✓ Concerta
Tab extended-release 36 mg .....	71.93	30	✓ Concerta
Tab extended-release 54 mg .....	86.24	30	✓ Concerta

**▶SA0924 Special Authority for Subsidy**

**Initial application** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
  - 3.1 Applicant is a paediatrician or psychiatrist; or
  - 3.2 Both:
    - 3.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
--	---	-----	---------------------	-------------------------------------

continued...

- 3.2.2 Provide name of the recommending specialist; and
- 4 Either:
  - 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
  - 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

**Renewal** only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 Applicant is a paediatrician or psychiatrist; or
  - 2.2 Both:
    - 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
    - 2.2.2 Provide name of the recommending specialist.

NALTREXONE HYDROCHLORIDE – Special Authority see SA0909 below – Retail pharmacy

Tab 50 mg .....	180.00	30	✓	ReVia
-----------------	--------	----	---	-------

**SA0909 Special Authority for Subsidy**

**Initial application** from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in a community Alcohol and Drug Service contracted to one of the 21 District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard.

**Renewal** from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
  - 2.1 Patient is still unstable and requires further treatment; or
  - 2.2 Patient achieved significant improvement but requires further treatment; or
  - 2.3 Patient is well controlled but requires maintenance therapy.

The patient may not have had more than 1 prior approval in the last 12 months.

TETRABENAZINE

Tab 25 mg .....	243.00	112	✓	Xenazine 25
-----------------	--------	-----	---	-------------

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Chemotherapeutic Agents</b>				
<b>Alkylating Agents</b>				
BUSULPHAN – PCT – Retail pharmacy-Specialist				
Tab 2 mg .....	47.89	100	✓	Myleran
CARBOPLATIN – PCT only – Specialist				
Inj 10 mg per ml, 5 ml .....	12.00	1	✓	Carboplatin Ebewe
Inj 10 mg per ml, 15 ml .....	18.70	1	✓	Carboplatin Ebewe
Inj 10 mg per ml, 45 ml .....	55.50	1	✓	Carboplatin Ebewe
Inj 10 mg per ml, 100 ml .....	135.65	1	✓	Carboplatin Ebewe
Inj 1 mg for ECP .....	0.13	1 mg	✓	Baxter Biomed
CARMUSTINE – PCT only – Specialist				
Inj 100 mg .....	204.13	1	✓	BiCNU
Inj 100 mg for ECP .....	204.13	100 mg OP	✓	Baxter Biomed
CHLORAMBUCIL – PCT – Retail pharmacy-Specialist				
Tab 2 mg .....	22.35	25	✓	Leukeran FC
CISPLATIN – PCT only – Specialist				
Inj 1 mg per ml, 50 ml .....	19.00	1	✓	Cisplatin Ebewe Mayne
Inj 1 mg per ml, 100 ml .....	38.00	1	✓	Cisplatin Ebewe Mayne
Inj 1 mg for ECP .....	0.46	1 mg	✓	Baxter Biomed
CYCLOPHOSPHAMIDE				
Tab 50 mg – PCT – Retail pharmacy-Specialist .....	25.71	50	✓	Cycloblastin
Inj 1 g – PCT – Retail pharmacy-Specialist .....	21.51	1	✓	Endoxan
	127.80	6	✓	Cytoxan
Inj 2 g – PCT only – Specialist .....	43.00	1	✓	Endoxan
Inj 1 mg for ECP – PCT only – Specialist .....	0.02	1 mg	✓	Baxter Biomed
IFOSFAMIDE – PCT only – Specialist				
Inj 1 g .....	87.26	1	✓	Holoxan
Inj 2 g .....	162.80	1	✓	Holoxan
Inj 1 mg for ECP .....	0.09	1 mg	✓	Baxter Biomed
LOMUSTINE – PCT only – Specialist				
Cap 10 mg .....	132.59	20	✓	CeeNU
Cap 40 mg .....	399.15	20	✓	CeeNU
MELPHALAN				
Tab 2 mg – PCT – Retail pharmacy-Specialist .....	31.31	25	✓	Alkeran
Inj 50 mg – PCT only – Specialist .....	52.15	1	✓	Alkeran

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>OXALIPLATIN – PCT only – Specialist – Special Authority see SA0900 below</b>				
Inj 50 mg .....	200.00	1	✓	<b>Eloxatin</b>
Inj 100 mg .....	400.00	1	✓	<b>Eloxatin</b>
Inj 1 mg for ECP .....	4.36	1 mg	✓	<b>Baxter</b>
	8.74		✓	<b>Biomed</b>

**SA0900 | Special Authority for Subsidy**

**Initial application** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 Both:
  - 1.1 The patient has metastatic colorectal cancer; and
  - 1.2 To be used for first or second line use as part of a combination chemotherapy regimen; or
- 2 Both:
  - 2.1 The patient has stage III (Duke's C) colorectal\* cancer; and
  - 2.2 Adjuvant oxaliplatin to be given in combination with a fluoropyrimidine (fluorouracil or capecitabine).

**Renewal** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

Note: Indications marked with \* are Unapproved Indications, oxaliplatin is indicated for adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of the primary tumour.

**Antimetabolites**

**CALCIUM FOLINATE**

Tab 15 mg – PCT – Hospital pharmacy [HP3]-Specialist .....	63.89	10	✓	<b>Mayne</b>
Inj 3 mg per ml, 1 ml – PCT – Hospital pharmacy [HP1]- Specialist .....	17.10	5	✓	<b>Mayne</b>
Inj 50 mg – PCT – Hospital pharmacy [HP1]-Specialist .....	24.50	5	✓	<b>Calcium Folate Ebewe</b>
Inj 100 mg – PCT only – Specialist .....	15.00	1	✓	<b>Calcium Folate Ebewe</b>
Inj 300 mg – PCT only – Specialist .....	45.00	1	✓	<b>Calcium Folate Ebewe</b>
Inj 1 g – PCT only – Specialist .....	152.00	1	✓	<b>Calcium Folate Ebewe</b>
Inj 1 mg for ECP – PCT only – Specialist .....	0.10	1 mg	✓	<b>Baxter</b>
			✓	<b>Biomed</b>

**CAPECITABINE – Hospital pharmacy [HP1]-Specialist – Special Authority see SA0869 below**

Tab 150 mg .....	115.00	60	✓	<b>Xeloda</b>
Tab 500 mg .....	705.00	120	✓	<b>Xeloda</b>

**SA0869 | Special Authority for Subsidy**

**Initial application** only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has advanced gastrointestinal malignancy; or
- 2 The patient has metastatic breast cancer\*; or
- 3 The patient has stage III (Duke's stage C) colorectal\*# cancer and undergone surgery; or
- 4 Both:

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 4.1 The patient has poor venous access or needle phobia\*; and  
4.2 The patient requires a substitute for single agent fluoropyrimidine\*.

**Renewal** only from a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

Note: Indications marked with \* are Unapproved Indications, # capecitabine is approved for stage III (Duke's stage C) colon cancer.

### CLADRIBINE – PCT only – Specialist

Inj 2 mg per ml, 5 ml .....	873.00	1	✓	Litak <sup>S29</sup>
Inj 1 mg per ml, 10 ml .....	5,249.72	7	✓	Leustatin
Inj 10 mg for ECP .....	749.96	10 mg OP	✓	Baxter
			✓	Biomed

### CYTARABINE

Inj 100 mg – PCT – Retail pharmacy-Specialist.....	80.00	5	✓	Mayne
			✓	Pharmacia
Inj 100 mg per ml, 5 ml – PCT – Retail pharmacy-Specialist .....	95.36	5	✓	Mayne
Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist .....	42.65	1	✓	Mayne
Inj 100 mg per ml, 20 ml – PCT only – Specialist.....	34.47	1	✓	Mayne
Inj 1 mg for ECP – PCT only – Specialist.....	0.03	1 mg	✓	Baxter
			✓	Biomed
Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist .....	16.00	100 mg OP	✓	Baxter
			✓	Biomed

### FLUDARABINE PHOSPHATE – PCT only – Specialist

Tab 10 mg .....	650.25	15	✓	Fludara
Inj 50 mg .....	1,430.00	5	✓	Fludara
Inj 50 mg for ECP .....	286.00	50 mg OP	✓	Baxter
			✓	Biomed

### FLUOROURACIL SODIUM

Inj 50 mg per ml, 10 ml – PCT only – Specialist.....	4.95	1	✓	Fluorouracil Ebewe
Inj 500 mg per 20 ml – PCT – Retail pharmacy-Specialist.....	55.60	10	✓	Mayne
Inj 50 mg per ml, 20 ml – PCT only – Specialist.....	8.60	1	✓	Fluorouracil Ebewe
Inj 25 mg per ml, 100 ml – PCT only – Specialist.....	13.55	1	✓	Mayne
Inj 50 mg per ml, 50 ml – PCT only – Specialist.....	21.50	1	✓	Fluorouracil Ebewe
Inj 50 mg per ml, 100 ml – PCT only – Specialist.....	43.00	1	✓	Fluorouracil Ebewe
Inj 1 mg for ECP – PCT only – Specialist.....	0.01	1 mg	✓	Baxter
			✓	Biomed

(Mayne Inj 500 mg per 20 ml to be delisted 1 July 2009)

### GEMCITABINE HYDROCHLORIDE – PCT only – Specialist – Special Authority see SA0877 on the next page

Inj 1 g .....	349.20	1	✓	Gemzar
Inj 200 mg .....	78.00	1	✓	Gemzar
Inj 1 mg for ECP .....	0.38	1 mg	✓	Baxter
			✓	Biomed

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

▶SA0877 Special Authority for Subsidy

**Initial application** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or
- 2 The patient has advanced malignant mesothelioma\*; or
- 3 The patient has advanced pancreatic carcinoma; or
- 4 The patient has ovarian, fallopian tube\* or primary peritoneal carcinoma\*; or
- 5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic).

**Renewal** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

Note: Indications marked with a \* are Unapproved Indications.

IRINOTECAN – PCT only – Specialist – Special Authority see SA0878 below

Inj 20 mg per ml, 2 ml .....	124.00	1	✓ Camptosar
Inj 20 mg per ml, 5 ml .....	310.00	1	✓ Camptosar
Inj 1 mg for ECP .....	3.19	1 mg	✓ Baxter ✓ Biomed

▶SA0878 Special Authority for Subsidy

**Initial application** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has metastatic colorectal cancer; and
- 2 Either:
  - 2.1 To be used for first or second line use as part of a combination chemotherapy regimen; or
  - 2.2 As single agent chemotherapy in fluropyrimidine-relapsed disease.

**Renewal** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

MERCAPTOPURINE – PCT – Retail pharmacy-Specialist

Tab 50 mg .....	47.06	25	✓ Purinethol
-----------------	-------	----	--------------

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>METHOTREXATE</b>				
* Tab 2.5 mg – PCT – Hospital pharmacy [HP3]-Specialist .....	5.80	30	✓	<b>Methoblastin</b>
* Tab 10 mg – PCT – Hospital pharmacy [HP3]-Specialist .....	40.93	50	✓	<b>Methoblastin</b>
* Inj 2.5 mg per ml, 2 ml – PCT – Hospital pharmacy [HP1]- Specialist .....	23.65	5	✓	<b>Mayne</b>
* Inj 25 mg per ml, 2 ml – PCT – Hospital pharmacy [HP1]- Specialist .....	46.10	5	✓	<b>Mayne</b>
* Inj 100 mg per ml, 5 ml – PCT – Hospital pharmacy [HP1]- Specialist .....	18.00	1	✓	<b>Methotrexate Ebewe</b>
* Inj 25 mg per ml, 20 ml – PCT – Hospital pharmacy [HP1]- Specialist .....	80.25	1	✓	<b>Mayne</b>
* Inj 100 mg per ml, 10 ml – PCT – Hospital pharmacy [HP1]- Specialist .....	27.50	1	✓	<b>Methotrexate Ebewe</b>
* Inj 100 mg per ml, 50 ml – PCT – Hospital pharmacy [HP1]- Specialist .....	135.00	1	✓	<b>Methotrexate Ebewe</b>
* Inj 1 mg for ECP – PCT only – Specialist .....	0.09	1 mg	✓	<b>Baxter</b>
	0.10		✓	<b>Biomed</b>
* Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist .....	4.73	5 mg OP	✓	<b>Baxter</b>
			✓	<b>Biomed</b>
<i>(Methotrexate Ebewe Inj 100 mg per ml, 5 ml to be delisted 1 February 2009)</i>				
<b>THIOGUANINE – PCT – Hospital pharmacy [HP3]-Specialist</b>				
Tab 40 mg .....	97.16	25	✓	<b>Lanvis</b>

### Other Cytotoxic Agents

<b>ANAGRELIDE HYDROCHLORIDE – PCT only – Specialist – Special Authority see SA0879 below</b>				
Cap 0.5 mg .....	CBS	100	✓	<b>Agrylin S29</b>
			✓	<b>Teva S29</b>

#### SA0879 Special Authority for Subsidy

**Initial application** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has primary thrombocythaemia; and
- 2 Either:
  - 2.1 is at high risk (previous thromboembolic disease, bleeding or platelet count >1500/ml); or
  - 2.2 is intolerant or refractory to hydroxyurea or interferon.

**Renewal** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: It is recommended that treatment with anagrelide be initiated only on the recommendation of a haematologist.

<b>ARSENIC TRIOXIDE – PCT only – Specialist</b>				
Inj 10 mg .....	2,475.55	10	✓	<b>AFT S29</b>
<b>BLEOMYCIN SULPHATE – PCT only – Specialist</b>				
Inj 15,000 iu .....	680.00	10	✓	<b>Blenoxane</b>
Inj 1,000 iu for ECP .....	5.26	1,000 iu	✓	<b>Baxter</b>
			✓	<b>Biomed</b>
<b>COLASPASE (L-ASPARAGINASE) – PCT only – Specialist</b>				
Inj 10,000 iu .....	102.32	1	✓	<b>Leunase</b>
Inj 10,000 iu for ECP .....	102.32	10,000 iu OP	✓	<b>Baxter</b>
			✓	<b>Biomed</b>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>DACARBAZINE – PCT only – Specialist</b>				
Inj 200 mg .....	43.86	1	✓	Mayne
Inj 200 mg for ECP .....	43.86	200 mg OP	✓	Baxter
			✓	Biomed
<b>DACTINOMYCIN (ACTINOMYCIN D) – PCT only – Specialist</b>				
Inj 0.5 mg .....	13.52	1	✓	Cosmegen
Inj 0.5 mg for ECP .....	13.52	0.5 mg OP	✓	Baxter
			✓	Biomed
<b>DAUNORUBICIN – PCT only – Specialist</b>				
Inj 5 mg per ml, 4 ml .....	99.00	1	✓	Mayne
Inj 20 mg for ECP .....	99.00	20 mg OP	✓	Baxter
			✓	Biomed
<b>DOCETAXEL – PCT only – Specialist – Special Authority see SA0880 below</b>				
Inj 20 mg .....	460.00	1	✓	Taxotere
Inj 80 mg .....	1,650.00	1	✓	Taxotere
Inj 1 mg for ECP .....	23.81	1 mg	✓	Baxter
			✓	Biomed

**SA0880 Special Authority for Subsidy**

**Initial application** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
  - 1.1 The patient has ovarian\*, fallopian\* or primary peritoneal cancer\*; and
  - 1.2 Either:
    - 1.2.1 Has not received prior chemotherapy; or
    - 1.2.2 Has received prior chemotherapy but has not previously been treated with taxanes; or
- 2 The patient has metastatic breast cancer; or
- 3 Both:
  - 3.1 The patient has early breast cancer; and
  - 3.2 Docetaxel is to be given concurrently with trastuzumab; or
- 4 Both:
  - 4.1 The patient has non small-cell lung cancer; and
  - 4.2 Either:
    - 4.2.1 Has advanced disease (stage IIIa or above); or
    - 4.2.2 Is receiving combined chemotherapy and radiotherapy; or
- 5 Both:
  - 5.1 The patient has small-cell lung cancer\*; and
  - 5.2 Docetaxel is to be used as second-line therapy.

**Renewal** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has metastatic breast cancer, non small-cell lung cancer, or small-cell lung cancer\*; and
- 2 Either:
  - 2.1 The patient requires continued therapy; or
  - 2.2 The tumour has relapsed and requires re-treatment.

Note: indications marked with \* are Unapproved Indications.

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>DOXORUBICIN – PCT only – Specialist</b>				
Inj 10 mg .....	8.80	1	✓	Doxorubicin Ebewe
Inj 50 mg .....	39.40	1	✓	Doxorubicin Ebewe
Inj 100 mg .....	81.00	1	✓	Doxorubicin Ebewe
Inj 200 mg .....	162.00	1	✓	Doxorubicin Ebewe
Inj 1 mg for ECP .....	0.87	1 mg	✓	Baxter ✓ Biomed
<b>EPIRUBICIN – PCT only – Specialist</b>				
Inj 2 mg per ml, 5 ml .....	24.70	1	✓	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml .....	123.50	1	✓	Epirubicin Ebewe
Inj 2 mg per ml, 50 ml .....	247.00	1	✓	Epirubicin Ebewe
Inj 2 mg per ml, 100 ml .....	494.00	1	✓	Epirubicin Ebewe
Inj 1 mg for ECP .....	2.74	1 mg	✓	Baxter ✓ Biomed
<b>ETOPOSIDE</b>				
Cap 50 mg – PCT – Hospital pharmacy [HP3]-Specialist .....	340.73	20	✓	<u>Vepesid</u>
Cap 100 mg – PCT – Hospital pharmacy [HP3]-Specialist .....	340.73	10	✓	<u>Vepesid</u>
Inj 20 mg per ml, 5 ml – PCT – Hospital pharmacy [HP1]- Specialist .....	25.00	1	✓	Mayne
	612.20	10	✓	Vepesid
Inj 1 mg for ECP – PCT only – Specialist .....	0.30	1 mg	✓	Baxter ✓ Biomed
<b>ETOPOSIDE PHOSPHATE – PCT only – Specialist</b>				
Inj 100 mg (of etoposide base) .....	40.00	1	✓	Etopophos
Inj 1 mg (of etoposide base) for ECP .....	0.47	1 mg	✓	Baxter ✓ Biomed
<b>HYDROXYUREA – PCT – Retail pharmacy-Specialist</b>				
Cap 500 mg .....	31.76	100	✓	Hydrea
<b>IDARUBICIN HYDROCHLORIDE – PCT only – Specialist</b>				
Cap 5 mg .....	80.75	1	✓	Zavedos
Cap 10 mg .....	144.50	1	✓	Zavedos
Inj 5 mg .....	170.00	1	✓	Zavedos
Inj 10 mg .....	340.00	1	✓	Zavedos
Inj 1 mg for ECP .....	37.74	1 mg	✓	Baxter ✓ Biomed
<b>MESNA – PCT only – Specialist</b>				
Tab 400 mg .....	168.30	50	✓	Uromitexan
Tab 600 mg .....	251.35	50	✓	Uromitexan
Inj 100 mg per ml, 4 ml .....	109.63	15	✓	Uromitexan
Inj 100 mg per ml, 10 ml .....	251.73	15	✓	Uromitexan
Inj 1 mg for ECP .....	0.02	1 mg	✓	Baxter ✓ Biomed
<b>MITOMYCIN C – PCT only – Specialist</b>				
Inj 2 mg .....	283.00	10	✓	Mitomycin-C <sup>S29</sup>
Inj 10 mg .....	531.30	5	✓	Mitomycin-C <sup>S29</sup>
Inj 1 mg for ECP .....	11.85	1 mg	✓	Baxter ✓ Biomed

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>MITOZANTRONE – PCT only – Specialist</b>				
Inj 2 mg per ml, 5 ml .....	110.00	1	✓	<b>Mitozantrone Ebewe</b>
Inj 2 mg per ml, 10ml .....	220.00	1	✓	<b>Mitozantrone Ebewe</b>
Inj 2 mg per ml, 12.5 ml .....	407.50	1	✓	<b>Onkotrone</b>
Inj 1 mg for ECP .....	12.43	1 mg	✓	<b>Baxter</b>
			✓	<b>Biomed</b>
<b>PACLITAXEL – PCT only – Specialist</b>				
Inj 30 mg .....	37.95	1	✓	<b>Paclitaxel Ebewe</b>
Inj 100 mg .....	125.35	1	✓	<b>Paclitaxel Ebewe</b>
Inj 150 mg .....	188.03	1	✓	<b>Paclitaxel Ebewe</b>
Inj 300 mg .....	376.05	1	✓	<b>Paclitaxel Ebewe</b>
Inj 600 mg .....	724.50	1	✓	<b>Paclitaxel Ebewe</b>
Inj 1 mg for ECP .....	1.32	1 mg	✓	<b>Baxter</b>
			✓	<b>Biomed</b>
<b>PENTOSTATIN (DEOXYCOFORMYCIN) – PCT only – Specialist</b>				
Inj 10 mg .....	CBS	1	✓	<b>Nipent S29</b>
<b>PROCARBAZINE HYDROCHLORIDE – PCT only – Specialist</b>				
Cap 50 mg .....	133.00	50	✓	<b>Natulan S29</b>
<b>TEMOZOLOMIDE – Special Authority see SA0831 below – Hospital pharmacy [HP3]</b>				
Cap 5 mg .....	50.00	5	✓	<b>Temodal</b>
Cap 20 mg .....	170.00	5	✓	<b>Temodal</b>
Cap 100 mg .....	840.00	5	✓	<b>Temodal</b>
Cap 250 mg .....	2,100.00	5	✓	<b>Temodal</b>
<b>▶SA0831 Special Authority for Subsidy</b>				
<b>Initial application</b> only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: All of the following:				
1 Patient has newly diagnosed glioblastoma multiforme; and				
2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and				
3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m <sup>2</sup> .				
Notes: Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Reapplications will not be approved. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.				
<b>TENIPOSIDE – PCT only – Specialist</b>				
Inj 10 mg per ml, 5 ml .....	845.11	10	✓	<b>Vumon</b>
Inj 50 mg for ECP .....	84.51	50 mg OP	✓	<b>Baxter</b>
			✓	<b>Biomed</b>
<b>THALIDOMIDE – PCT only – Specialist – Special Authority see SA0882 on the next page</b>				
Only on a controlled drug form				
Cap 50 mg .....	490.00	28	✓	<b>Thalidomide Pharmion</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

### ►SA0882 Special Authority for Subsidy

**Initial application — (for new patients)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has refractory, progressive or relapsed multiple myeloma; and
- 2 The patient has received prior chemotherapy.

**Initial application — (for patients receiving thalidomide prior to 1 January 2006)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient was receiving treatment with thalidomide for multiple myeloma on or before 31 December 2005.

**Renewal** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

TRETINOIN – PCT only – Specialist

Cap 10 mg .....	435.90	100	✓ Vesainoid
-----------------	--------	-----	-------------

VINBLASTINE SULPHATE

Inj 10 mg – PCT – Retail pharmacy-Specialist .....	137.50	5	✓ Mayne
Inj 1 mg for ECP – PCT only – Specialist .....	3.05	1 mg	✓ Baxter ✓ Biomed

VINCRIStINE SULPHATE

Inj 1 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist .....	99.00	5	✓ <u>Mayne</u>
Inj 1 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist .....	199.00	5	✓ <u>Mayne</u>
Inj 1 mg for ECP – PCT only – Specialist .....	21.46	1 mg	✓ Baxter ✓ Biomed

VINOReLBINE – PCT only – Specialist – Special Authority see SA0901 below

Inj 10 mg per ml, 1 ml .....	42.00	1	✓ Vinorelbine Ebewe
Inj 10 mg per ml, 5 ml .....	210.00	1	✓ Vinorelbine Ebewe
Inj 1 mg for ECP .....	4.75	1 mg	✓ Baxter ✓ Biomed

### ►SA0901 Special Authority for Subsidy

**Initial application** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has metastatic breast cancer; or
- 2 The patient has non-small cell lung cancer (stage IIIa, or above); or
- 3 All of the following:
  - 3.1 The patient has stage IB-IIIa non-small cell lung cancer; and
  - 3.2 Vinorelbine is to be given as adjuvant treatment in combination with cisplatin; and
  - 3.3 The patient has good performance status (WHO/ECOG grade 0-1).

**Renewal** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

## Protein-tyrosine Kinase Inhibitors

IMATINIB MESYLATE – Special Authority see SA0643 on the next page

Tab 100 mg .....	2,400.00	60	✓ Glivec
------------------	----------	----	----------

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per	✓

►SA0643 Special Authority for Subsidy

Special Authority approved by the Glivec Co-ordinator

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz>, and prescriptions should be sent to:

The Glivec Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: <a href="mailto:mary.chesterfield@pharmac.govt.nz">mary.chesterfield@pharmac.govt.nz</a>
Wellington	

**Special Authority criteria for CML – access by application**

- Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.
- Maximum dose of 600 mg/day for accelerated or blast phase, and 400 mg/day for chronic phase CML.
- Subsidised for use as monotherapy only.
- Initial approvals valid seven months.
- Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

**Guideline on discontinuation of treatment for patients with CML**

- Prescribers should consider discontinuation of treatment if after 6 months from initiating therapy a patient did not obtain a haematological response as defined as any one of the following three levels of response:
  - complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5 × 10<sup>9</sup>/L, platelets > 100 × 10<sup>9</sup>/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
  - no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0 × 10<sup>9</sup>/L, platelets > 20 × 10<sup>9</sup>/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
  - return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).
- Prescribers should consider discontinuation of treatment if after 18 months from initiating therapy a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

**Special Authority criteria for GIST – access by application**

- Funded for patients:
  - with a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
  - who have immunohistochemical documentation of c-kit (CD117) expression by the tumour.
- Maximum dose of 400 mg/day.
- Applications to be made and subsequent prescriptions can be written by an oncologist.
- Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined).

**Endocrine Therapy**

For GnRH ANALOGUES – refer to HORMONE PREPARATIONS, Tropic Hormones, page 83

**ANASTROZOLE**

Tab 1 mg – Higher subsidy of \$240.00 per 30 with Special

Authority see SA0942 on the next page .....	146.46	30	
	(240.00)		Arimidex

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>▶▶SA0942 Special Authority for Alternate Subsidy</b>				
<b>Initial application — (New patients)</b> only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal woman; and 2 Patient has hormone receptor positive early breast cancer; and 3 Either: 3.1 The patient has a very clear history of intolerance to tamoxifen; or 3.2 The use of tamoxifen is contraindicated due to a history of thromboembolic disease.				
<b>Initial application — (Patient has had a Special Authority approval for anastrozole prior to 1 December 2008)</b> only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.				
<b>Renewal</b> only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.				
Note: If the patient had an approval for anastrozole prior to 1 December 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone Ministry of Health Sector Services on 0800 243 666 for clarification if needed.				
ANASTROZOLE-DP – Subsidy by endorsement Subsidised only for patients with hormone receptor positive advanced breast cancer and the prescription is endorsed accordingly.				
Tab 1 mg .....	29.50	30	✓	DP-Anastrozole
BICALUTAMIDE – Special Authority see SA0941 below – Retail pharmacy				
Tab 50 mg .....	27.10	30	✓	Bicalox
<b>▶▶SA0941 Special Authority for Subsidy</b>				
<b>Initial application</b> from any medical practitioner. Approvals valid without further renewal unless notified where the patient has advanced prostate cancer.				
EXEMESTANE				
Tab 25 mg .....	175.00	30	✓	Aromasin
FLUTAMIDE – Hospital pharmacy [HP3]-Specialist				
Tab 250 mg .....	39.50	100	✓	Flutamin
LETROZOLE				
Tab 2.5 mg – Higher subsidy of \$200.00 per 30 with Special Authority see SA0943 below .....	146.46 (200.00)	30		Femara

### ▶▶SA0943 Special Authority for Alternate Subsidy

**Initial application — (New patients)** only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria:

All of the following:

- 1 Patient is a postmenopausal woman; and
- 2 Patient has hormone receptor positive early breast cancer; and
- 3 Either:
  - 3.1 The patient has a very clear history of intolerance to tamoxifen; or
  - 3.2 The use of tamoxifen is contraindicated due to a history of thromboembolic disease.

**Initial application — (Patient has had a Special Authority approval for letrozole prior to 1 December 2008)** only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

**Renewal** only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

Note: If the patient had an approval for letrozole prior to 1 December 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone Ministry of Health Sector Services on 0800 243 666 for clarification if needed.

**MEGESTROL ACETATE – Retail pharmacy-Specialist**

Tab 160 mg .....74.25 30 ✓ **Megace**

**OCTREOTIDE (SOMATOSTATIN ANALOGUE) – Special Authority see SA0563 below – Hospital pharmacy [HP3]**

Inj 50 µg per ml, 1 ml .....25.65 5 ✓ **Hospira**

(43.50) Sandostatin

Inj 100 µg per ml, 1 ml .....48.50 5 ✓ **Hospira**

(81.00) Sandostatin

Inj 500 µg per ml, 1 ml .....175.00 5 ✓ **Hospira**

(399.00) Sandostatin

LAR 10 mg pre-filled syringe .....1,772.50 1 ✓ **Sandostatin LAR**

LAR 20 mg pre-filled syringe .....2,358.75 1 ✓ **Sandostatin LAR**

LAR 30 mg pre-filled syringe .....2,951.25 1 ✓ **Sandostatin LAR**

**SA0563 Special Authority for Subsidy**

**Initial application** only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 Both:
  - 1.1 Acromegaly; and
  - 1.2 Patient has failed surgery, radiotherapy, bromocriptine and other oral therapies; or
- 2 VIPomas and Glucagonomas – for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 3 Both:
  - 3.1 Gastrinoma; and
  - 3.2 Either:
    - 3.2.1 Patient has failed surgery; or
    - 3.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
- 4 Both:
  - 4.1 Insulinomas; and
  - 4.2 Surgery is contraindicated or has failed; or
- 5 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 6 Both:
  - 6.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
  - 6.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item

**Renewal** only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

**TAMOXIFEN CITRATE**

\* Tab 10 mg .....9.00 100 ✓ **Genox**

\* Tab 20 mg .....9.25 100 ✓ **Genox**

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

# ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

## Immunosuppressants

### Cytotoxic Immunosuppressants

AZATHIOPRINE – Retail pharmacy-Specialist

* Tab 50 mg	25.00	100	✓	Azamun
	(34.90)		✓	Thioprine
* Inj 50 mg	46.33	1		Imuran
	(47.72)			Imuran

MYCOPHENOLATE MOFETIL – Special Authority see SA0893 below – Hospital pharmacy [HP3]

Tab 500 mg	206.66	50	✓	Cellcept
Cap 250 mg	206.66	100	✓	Cellcept
Powder for oral liq 1 g per 5 ml – Subsidy by endorsement	285.00	165 ml OP	✓	Cellcept

Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.

#### ►SA0893 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Renal transplant recipient; or
- 2 Heart transplant recipient; or
- 3 Patient has an organ transplant and has severe tophaceous gout making azathioprine unsuitable.

### Immune Modulators

ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist

Inj 50 mg per ml, 5 ml	2,137.50	5	✓	ATGAM
------------------------	----------	---	---	-------

RITUXIMAB – PCT only – Specialist – Special Authority see SA0884 below

Inj 100 mg per 10 ml vial	1,195.00	2	✓	Mabthera
Inj 500 mg per 50 ml vial	2,987.00	1	✓	Mabthera
Inj 1 mg for ECP	6.27	1 mg	✓	Baxter
			✓	Biomed

#### ►SA0884 Special Authority for Subsidy

**Initial application — (Post-transplant)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where the patient has B-cell post-transplant lymphoproliferative disorder\*.

Note: For no more than 8 treatment cycles.

**Initial application — (Low-grade lymphomas)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where the patient has low grade NHL — relapsed disease following prior chemotherapy.

Note: For no more than 4 treatment cycles.

**Initial application — (Large cell lymphomas)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has treatment naive large B-cell NHL; and
- 2 To be used with CHOP (or alternative anthracycline containing multi-agent chemotherapy regimen given with curative intent).

Note: For no more than 8 treatment cycles.

**Renewal — (Low-grade lymphomas)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per	✓

continued...

Both:

- 1 The patient has had a treatment-free interval of 6 months or more; and
- 2 Either:
  - 2.1 Has B-cell post-transplant lymphoproliferative disorder\*; or
  - 2.2 Has low grade NHL – relapsed disease following prior chemotherapy.

Notes: For no more than 4 treatment cycles for low grade NHL.

Indications marked with \* are Unapproved Indications.

TRASTUZUMAB – PCT only – Specialist – Special Authority see SA0885 below

Inj 150 mg vial .....	1,350.00	1	✓ Herceptin
Inj 440 mg vial .....	3,875.00	1	✓ Herceptin
Inj 1 mg for ECP .....	9.36	1 mg	✓ Baxter ✓ Biomed

**SA0885 Special Authority for Subsidy**

**Initial application — (metastatic breast cancer)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months where the patient has metastatic breast cancer expressing HER-2 IHC 3+ or FISH+.

**Renewal — (metastatic breast cancer)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has metastatic breast cancer; and
- 2 The cancer has not progressed.

**Initial application — (early breast cancer)** only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or FISH +; and
- 2 Maximum cumulative dose of 20mg/kg (9 weeks treatment)\*; and
- 3 Trastuzumab is to be given concurrently with adjuvant taxane chemotherapy\*; and
- 4 Trastuzumab is not to be given concurrently with anthracycline chemotherapy.

Notes: indications marked with \* are Unapproved Indications.

It is recommended that for early breast cancer trastuzumab be administered concurrently with docetaxel prior to anthracyclines as per the FinHer regimen (Joensuu H, Kellokumpu-Lehtinen P, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20).

**Other Immunosuppressants**

CYCLOSPORIN A – Special Authority see SA0470 below – Hospital pharmacy [HP3]

Cap 25 mg .....	85.00	50	✓ Neoral
Cap 50 mg .....	169.34	50	✓ Neoral
Cap 100 mg .....	338.69	50	✓ Neoral
Oral liq 100 mg per ml .....	377.38	50 ml OP	✓ Neoral

**SA0470 Special Authority for Subsidy**

**Initial application — (Organ transplant)** only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.

**Initial application — (Bone marrow transplant or Graft v host disease)** only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Bone marrow transplant; or
- 2 Graft v host disease.

continued...

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

continued...

**Initial application — (Psoriasis)** only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Psoriasis; and
- 2 Applicant must state which systemic and topical therapies have failed.

**Initial application — (Severe atopic dermatitis)** only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Severe atopic dermatitis; and
- 2 Not responsive to topical therapy, oral antihistamines and other commonly used orthodox therapies.

**Initial application — (Nephrotic Syndrome)** only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Nephrotic Syndrome; and
- 2 Corticosteroid dependent patients who have failed on cytotoxic therapy.

**Initial application — (Endogenous uveitis)** only from a relevant specialist. Approvals valid for 2 years where the patient suffers from endogenous uveitis.

**Initial application — (Severe rheumatoid arthritis)** only from a rheumatologist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Severe rheumatoid arthritis; and
- 2 The patient must be either unresponsive to or unable to tolerate, both sulphasalazine and methotrexate; and
- 3 Patients must have 2 serum creatinine test results within the normal range within the three months prior to initiation of therapy.

**Renewal — (Severe atopic dermatitis)** only from a dermatologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

**Renewal — (Indications other than severe atopic dermatitis)** only from a dermatologist, rheumatologist or relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

### Guidelines for use of cyclosporin A in rheumatoid arthritis

#### Monitoring:

All patients require frequent monitoring for creatinine levels and blood pressure:

- fortnightly, in the first three months of therapy and then monthly, if results are stable;
- if dose is increased or there is a rise in serum creatinine or blood pressure, then more frequent monitoring is required.

#### Contraindications:

Cyclosporin A is contraindicated in patients with the following conditions:

- current or past malignancy;
- uncontrolled hypertension;
- renal dysfunction (abnormal serum creatinine for age and sex);
- immunodeficiency and neutropenia;
- abnormally low white blood cell count or platelet count; or
- liver function tests more than twice the upper limit of normal.

#### Caution in use:

- age above 65 years;
- controlled hypertension;
- use of anti-epileptic medications;
- use of ketoconazole, fluconazole, trimethoprim, erythromycin, verapamil, and diltiazem;
- concurrent or previous use of alkylating agents such as cyclophosphamide;
- use of any experimental drug within the past three months;

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- premalignant conditions such as leukoplakia, monoclonal paraproteinaemia, myelodysplastic syndrome and dysplastic naevi;
- active infection may necessitate temporary discontinuation;
- pregnancy and lactation.

Therapy should be discontinued if there has been no improvement after 6 months with the patient on the maximum tolerated dose. For further information please consult the data sheet.

SIROLIMUS – Special Authority see SA0866 below – Hospital pharmacy [HP3]

Tab 1 mg .....	813.00	100	✓	Rapamune
Tab 2 mg .....	1,626.00	100	✓	Rapamune
Oral liq 1 mg per ml .....	487.80	60 ml OP	✓	Rapamune

▶SA0866 Special Authority for Subsidy

**Initial application** from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR<30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease

TACROLIMUS – Special Authority see SA0669 below – Hospital pharmacy [HP3]

Cap 0.5 mg .....	214.00	100	✓	Prograf
Cap 1 mg .....	428.00	100	✓	Prograf
Cap 5 mg .....	1,070.00	50	✓	Prograf

▶SA0669 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.

Note: Subsidy applies for either primary or rescue therapy.

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## RESPIRATORY SYSTEM AND ALLERGIES

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

### Antiallergy Preparations

BEE VENOM ALLERGY TREATMENT – Special Authority see SA0053 below – Hospital pharmacy [HP3]

Maintenance kit - 6 vials 120 µg freeze dried venom, 6 diluent			
1.8 ml .....	154.30	1 OP	✓ Albay
Treatment kit - 1 vial 550 µg freeze dried venom, 1 diluent			
9 ml, 3 diluent 1.8 ml .....	154.30	1 OP	✓ Albay

#### ▶SA0053 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

**Renewal** only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

WASP VENOM ALLERGY TREATMENT – Special Authority see SA0053 below – Hospital pharmacy [HP3]

Treatment kit (Paper wasp venom) - 1 vial 550 µg freeze dried			
polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml .....	154.30	1 OP	✓ Albay
Treatment kit (Yellow jacket venom) - 1 vial 550 µg freeze			
dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml .....	154.30	1 OP	✓ Albay

#### ▶SA0053 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 RAST or skin test positive; and
- 2 Patient has had severe generalised reaction to the sensitising agent.

**Renewal** only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

### Antihistamines

AZATADINE MALEATE

* Tab 1 mg .....	6.94	50	
	(16.90)		Zadine

CETIRIZINE HYDROCHLORIDE

* Tab 10 mg .....	2.21	100	✓ Zetop
	3.32	90	✓ Razene
*‡ Oral liq 1 mg per ml .....	2.75	100 ml OP	✓ Allerid C
	3.50	200 ml	✓ Cetirizine - AFT

*(Razene Tab 10 mg to be delisted 1 May 2009)*

*(Allerid C Oral liq 1 mg per ml to be delisted 1 May 2009)*

CHLORPHENIRAMINE MALEATE

*‡ Oral liq 2 mg per 5 ml .....	3.74	500 ml	
	(7.26)		Histafen

CYPROHEPTADINE HYDROCHLORIDE

* Tab 4 mg .....	6.27	100	✓ Periactin
------------------	------	-----	-------------

## RESPIRATORY SYSTEM AND ALLERGIES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>DEXTROCHLORPHENIRAMINE MALEATE</b>				
* Tab 2 mg .....	2.52 (9.99)	50		
* Tab long-acting 6 mg .....	5.40 (12.56)	40		Polaramine
*‡ Oral liq 2 mg per 5 ml .....	1.77 (10.29)	100 ml		Polaramine Repetab Polaramine
<b>FEXOFENADINE HYDROCHLORIDE</b>				
* Tab 60 mg .....	4.34 (11.53)	20		Telfast
* Tab 120 mg .....	14.22 (29.81)	30		Telfast
<b>KETOTIFEN</b>				
* Oral liq 1 mg per 5 ml .....	4.90 (5.90)	200 ml		Asmafen
<i>(Asmafen Oral liq 1 mg per 5 ml to be delisted 1 February 2009)</i>				
<b>LORATADINE</b>				
* Tab 10 mg .....	3.58	100	✓	<b>Loraclear Hayfever Relief</b>
* Oral liq 1 mg per ml .....	3.65	100 ml	✓	<b>Lorapaed</b>
<b>PROMETHAZINE HYDROCHLORIDE</b>				
* Tab 10 mg .....	2.72	50	✓	<b>Allersoothe</b>
* Tab 25 mg .....	4.44	50	✓	<b>Allersoothe</b>
*‡ Oral liq 5 mg per 5 ml .....	3.53 (8.51)	100 ml		Phenergan
* Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO .....	8.05	5	✓	<b>Mayne</b>
<b>TRIMEPAZINE TARTRATE</b>				
‡ Oral liq 30 mg per 5 ml .....	2.79 (8.06)	100 ml OP		Vallergan Forte

### Inhaled Corticosteroids

<b>BECLOMETHASONE DIPROPIONATE</b>				
Aerosol inhaler, 50 µg per dose .....	8.54	200 dose OP	✓	<b>Beclazone 50</b>
Aerosol inhaler, 100 µg per dose .....	12.50	200 dose OP	✓	<b>Beclazone 100</b>
Aerosol inhaler, 250 µg per dose .....	22.67	200 dose OP	✓	<b>Beclazone 250</b>
<b>BUDESONIDE</b>				
Powder for inhalation, 100 µg per dose .....	17.00	200 dose OP	✓	<b>Pulmicort Turbuhaler</b>
Powder for inhalation, 200 µg per dose .....	19.00	200 dose OP	✓	<b>Pulmicort Turbuhaler</b>
Powder for inhalation, 400 µg per dose .....	32.00	200 dose OP	✓	<b>Pulmicort Turbuhaler</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## RESPIRATORY SYSTEM AND ALLERGIES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>FLUTICASONE</b>				
Aerosol inhaler, 50 µg per dose CFC-free .....	7.50	120 dose OP	✓	<b>Flixotide</b>
Powder for inhalation, 50 µg per dose .....	5.10	60 dose OP		
	(8.67)			Flixotide Accuhaler
Powder for inhalation, 100 µg per dose .....	7.50	60 dose OP		
	(13.87)			Flixotide Accuhaler
Aerosol inhaler, 125 µg per dose CFC-free .....	13.60	120 dose OP	✓	<b>Flixotide</b>
Aerosol inhaler, 250 µg per dose CFC-free .....	27.20	120 dose OP	✓	<b>Flixotide</b>
Powder for inhalation, 250 µg per dose .....	13.60	60 dose OP		
	(24.51)			Flixotide Accuhaler

### Inhaled Long-acting Beta-adrenoceptor Agonists

#### Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor Agonists

The addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended:

- For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 µg beclomethasone or budesonide (or 100 µg fluticasone).
- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 µg beclomethasone or budesonide (or 200 µg fluticasone).

Note:

Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults ([www.nzgg.org.nz](http://www.nzgg.org.nz)) and in the New Zealand guidelines for asthma in children aged 1-15 ([www.paediatrics.org.nz](http://www.paediatrics.org.nz)).

EFORMOTEROL FUMARATE – See prescribing guideline above

Powder for inhalation, 6 µg per dose, breath activated .....	16.90	60 dose OP	✓	<b>Oxis Turbuhaler</b>
Powder for inhalation, 12 µg per dose, and monodose device .....	35.80	60 dose	✓	<b>Foradil</b>

SALMETEROL – See prescribing guideline above

Aerosol inhaler CFC-free, 25 µg per dose .....	26.46	120 dose OP	✓	<b>Serevent</b>
Powder for inhalation, 50 µg per dose, breath activated .....	26.46	60 dose OP	✓	<b>Serevent Accuhaler</b>

### Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

#### ►SA0838 Special Authority for Subsidy

**Initial application** only from a relevant specialist or general practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- All of the following:
  - Patient is a child under the age of 12; and
  - All of the following:
    - Has, for 3 months or more, been treated with:
      - An inhaled long-acting beta adrenoceptor agonist; and
      - Inhaled corticosteroids at a dose of at least 400 µg per day beclomethasone or budesonide, or 200 µg per day fluticasone; and
  - The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product; or
- All of the following:
  - Patient is over the age of 12; and
  - All of the following:
    - Has, for 3 months or more, been treated with:
      - An inhaled long-acting beta adrenoceptor agonist; and

continued...

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
continued...			
2.2.2 Inhaled corticosteroids at a dose of at least 800 µg per day beclomethasone or budesonide, or 500 µg per day fluticasone; and			
2.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product.			
<b>Renewal</b> only from a relevant specialist or general practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.			
<b>BUDESONIDE WITH EFORMOTEROL</b> – Special Authority see SA0838 on the preceding page – Retail pharmacy			
Aerosol inhaler 100 µg with eformoterol fumarate 6 µg .....	55.00	120 dose OP	✓ <b>Vannair</b>
Powder for inhalation 100 µg with eformoterol fumarate 6 µg .....	55.00	120 dose OP	✓ <b>Symbicort</b> <b>Turbuhaler 100/6</b>
Aerosol inhaler 200 µg with eformoterol fumarate 6 µg .....	60.00	120 dose OP	✓ <b>Vannair</b>
Powder for inhalation 200 µg with eformoterol fumarate 6 µg .....	60.00	120 dose OP	✓ <b>Symbicort</b> <b>Turbuhaler 200/6</b>
Powder for inhalation 400 µg with eformoterol fumarate 12 µg – No more than 2 dose per day .....	60.00	60 dose OP	✓ <b>Symbicort</b> <b>Turbuhaler 400/12</b>
<b>FLUTICASONE WITH SALMETEROL</b> – Special Authority see SA0838 on the preceding page – Retail pharmacy			
Aerosol inhaler 50 µg with salmeterol 25 µg .....	37.48	120 dose OP	✓ <b>Seretide</b>
Aerosol inhaler 125 µg with salmeterol 25 µg .....	49.69	120 dose OP	✓ <b>Seretide</b>
Powder for inhalation 100 µg with salmeterol 50 µg – No more than 2 dose per day .....	37.48	60 dose OP	✓ <b>Seretide Accuhaler</b>
Powder for inhalation 250 µg with salmeterol 50 µg – No more than 2 dose per day .....	49.69	60 dose OP	✓ <b>Seretide Accuhaler</b>

**Beta-Adrenoceptor Agonists**

**SALBUTAMOL**

Tab long-acting 4 mg .....	11.18	56	✓ <b>Volmax</b>
‡ Oral liq 2 mg per 5 ml .....	2.25	150 ml	✓ <b>Salapin</b>
Infusion 1 mg per ml, 5 ml .....	118.38 (130.21)	10	Ventolin
Inj 500 µg per ml, 1 ml – Up to 5 inj available on a PSO .....	12.90	5	✓ <b>Ventolin</b>

*(Volmax Tab long-acting 4 mg to be delisted 1 March 2009)*

**Inhaled Beta-Adrenoceptor Agonists**

**SALBUTAMOL**

Aerosol inhaler, 100 µg per dose CFC free – Up to 1000 dose available on a PSO .....	3.80	200 dose OP	✓ <b>Respigen</b> ✓ <b>Salamol</b> Ventolin
	(6.00)		
Nebuliser soln, 1 mg per ml, 2.5 ml – Up to 30 neb available on a PSO .....	3.70	20	✓ <b>Asthalin</b>
Nebuliser soln, 2 mg per ml, 2.5 ml – Up to 30 neb available on a PSO .....	3.85	20	✓ <b>Asthalin</b>
<b>TERBUTALINE SULPHATE</b>			
Powder for inhalation, 250 µg per dose, breath activated .....	18.20	200 dose OP	✓ <b>Bricanyl Turbuhaler</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Inhaled Anticholinergic agents</b>				
<b>IPRATROPIUM BROMIDE</b>				
Aerosol inhaler, 20 µg per dose CFC-free .....	16.20	200 dose OP	✓	<b>Atrovent</b>
Nebuliser soln, 250 µg per ml, 1 ml – Up to 40 neb available on a PSO .....	4.30	20	✓	<b>Ipratropium Steri-Neb</b>
Nebuliser soln, 250 µg per ml, 2 ml – Up to 40 neb available on a PSO .....	5.25	20	✓	<b>Ipratropium Steri-Neb</b>
<b>TIOTROPIUM BROMIDE – Special Authority see SA0872 below – Retail pharmacy</b>				
Powder for inhalation, 18 µg per dose .....	70.00	30 dose	✓	<b>Spiriva</b>
<b>▶SA0872 Special Authority for Subsidy</b>				
<b>Initial application</b> only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:				
All of the following:				
1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and				
2 In addition to standard treatment, the patient has trialled a dose of at least 40 µg ipratropium q.i.d for one month; and				
3 Any of the following:				
The patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:				
3.1 Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or				
3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and				
4 Actual FEV <sub>1</sub> (litres) < 0.6 × predicted (litres); and				
5 Either:				
5.1 Patient is not a smoker (for reporting purposes only); or				
5.2 Patient is a smoker and has been offered smoking cessation counselling; and				
6 The patient has been offered annual influenza immunisation.				
<b>Renewal</b> only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:				
All of the following:				
1 Patient is compliant with the medication; and				
2 Patient has experienced improved COPD symptom control (prescriber determined); and				
3 Applicant must state recent measurement of FEV <sub>1</sub> (% of predicted).				
<b>Inhaled Beta-Adrenoceptor Agonists with Anticholinergic Agents</b>				
<b>SALBUTAMOL WITH IPRATROPIUM BROMIDE</b>				
Aerosol inhaler, 100 µg with ipratropium bromide, 20 µg per dose .....	13.50	200 dose OP	✓	<b>Combivent</b>
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml – Up to 20 neb available on a PSO .....	5.30	20	✓	<b>Duolin</b>
<b>Mast cell stabilisers</b>				
<b>NEDOCROMIL</b>				
Aerosol inhaler, 2 mg per dose CFC-free .....	23.20 (28.07)	112 dose OP		Tilade
<b>SODIUM CROMOGLYCATE</b>				
Powder for inhalation, 20 mg per dose .....	16.31 (17.94)	50 dose		Intal Spincaps
Aerosol inhaler, 5 mg per dose CFC-free .....	23.20 (28.07)	112 dose OP		Vicrom

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

**Methylxanthines**

<b>AMINOPHYLLINE</b>				
* Inj 25 mg per ml, 10 ml – Up to 5 inj available on a PSO .....	12.84	5	✓	Mayne
<b>THEOPHYLLINE</b>				
* Tab long-acting 250 mg .....	21.51	100	✓	Nuelin-SR
*‡ Oral liq 80 mg per 15 ml .....	4.06	500 ml		Nuelin
	(15.50)			

**Cystic Fibrosis**

<b>DORNASE ALFA – Special Authority see SA0611 below – Hospital pharmacy [HP1]</b>				
Nebuliser soln, 2.5 mg per 2.5 ml ampoule .....	294.30	6	✓	Pulmozyme

**▶▶SA0611 Special Authority for Subsidy**

Special Authority approved by the Cystic Fibrosis Advisory Panel

Notes: Application details may be obtained from PHARMAC's website <http://www.pharmac.govt.nz> or:

The Co-ordinator, Cystic Fibrosis Advisory Panel	Phone: (04) 460 4990
PHARMAC, PO Box 10 254	Facsimile: (04) 916 7571
Wellington	Email: <a href="mailto:CFPanel@pharmac.govt.nz">CFPanel@pharmac.govt.nz</a>

Prescriptions for patients approved for treatment must be written by respiratory physicians or paediatricians who have experience and expertise in treating cystic fibrosis.

**Nasal Preparations**

**Allergy Prophylactics**

<b>BECLOMETHASONE DIPROPIONATE</b>				
Metered aqueous nasal spray, 50 µg per dose .....	2.35	200 dose OP	✓	<u>Alanase</u>
Metered aqueous nasal spray, 100 µg per dose .....	2.46	200 dose OP	✓	<u>Alanase</u>
<b>BUDESONIDE</b>				
Metered aqueous nasal spray, 50 µg per dose .....	2.35	200 dose OP		Butacort Aqueous
	(2.95)			
Metered aqueous nasal spray, 100 µg per dose .....	2.61	200 dose OP		Butacort Aqueous
	(3.30)			
<b>IPRATROPIUM BROMIDE</b>				
Aqueous nasal spray, 0.03% .....	12.66	30 ml OP	✓	<u>Apo-Ipravent</u>
<b>SODIUM CROMOGLYCATE</b>				
Nasal spray, 4% .....	13.50	22 ml OP	✓	<u>Rex</u>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

## Respiratory Devices

### MASK FOR SPACER DEVICE

- a) Maximum of 20 dev per WSO
- b) Only on a WSO
- c)

- 1) Spacer devices and masks also available to paediatricians employed by a DHB on a wholesale supply order signed by the paediatrician. Limited to one pack of 20 per order. Orders via a hospital pharmacy.
- 2) Only available for children aged six years and under.
- 3) For Space Chamber and Foremount Child's Silicone Mask wholesale supply order must indicate clearly if either the spacer device, the mask, or both are required.
- 4) Distributed by Airflow Products. Forward orders to:  
Airflow Products Telephone: 04 499 1240 or 0800 AIR FLOW  
PO Box 1485, Wellington Facsimile: 04 499 1245 or 0800 323 270

Size 2 .....	3.28	1	✓ Foremount Child's Silicone Mask
--------------	------	---	--------------------------------------

### PEAK FLOW METER

- a) Maximum of 10 dev per WSO
- b) Only on a WSO

Low range .....	13.75	1	✓ Breath-Alert
Normal range .....	13.75	1	✓ Breath-Alert

### SPACER DEVICE

- a) Maximum of 20 dev per WSO
- b) Only on a WSO
- c)

- 1) Spacer devices and masks also available to paediatricians employed by a DHB on a wholesale supply order signed by the paediatrician. Limited to one pack of 20 per order. Orders via a hospital pharmacy.
- 2) Only available for children aged six years and under.
- 3) For Space Chamber and Foremount Child's Silicone Mask wholesale supply order must indicate clearly if either the spacer device, the mask, or both are required.
- 4) Distributed by Airflow Products. Forward orders to:  
Airflow Products Telephone: 04 499 1240 or 0800 AIR FLOW  
PO Box 1485, Wellington Facsimile: 04 499 1245 or 0800 323 270

230 ml (autoclavable) – Subsidy by endorsement .....	11.60	1	✓ Space Chamber
Available where the prescriber requires a spacer device that is capable of sterilisation in an autoclave and the WSO is endorsed accordingly.			
230 ml (single patient) .....	8.38	1	✓ Space Chamber

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
<b>Ear Preparations</b>			
<b>ACETIC ACID WITH 1, 2-PROPANEDIOL DIACETATE AND BENZETHONIUM</b>			
For Vosol ear drops with hydrocortisone powder refer, page 166			
Ear drops 2% with 1, 2-Propanediol diacetate 3% and benzethonium chloride 0.02 % .....	6.97	35 ml OP	✓ Vosol
<b>CHLORAMPHENICOL</b>			
Ear drops 0.5% .....	1.87	5 ml OP	✓ Chloromycetin
<b>FLUMETASONE PIVALATE</b>			
Ear drops 0.02% with cloquinol 1% .....	4.46	7.5 ml OP	✓ Locorten-Vioform
<b>TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN</b>			
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g .....	3.35	7.5 ml OP	✓ Kenacomb

**Ear/Eye Preparations**

<b>DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN</b>			
Ear/Eye drops 500 µg with framycetin sulphate 5 mg and gramicidin 50 µg per ml .....	4.50 (9.27)	8 ml OP	Sofradex
<b>FRAMYCETIN SULPHATE</b>			
Ear/Eye drops 0.5% .....	4.13 (8.65)	8 ml OP	Soframycin

**Eye Preparations**

**Anti-Infective Preparations**

<b>ACICLOVIR</b>			
* Eye oint 3% .....	37.53	4.5 g OP	✓ Zovirax
<b>CHLORAMPHENICOL</b>			
Eye oint 1% .....	2.48	4 g OP	✓ Chlorsig
Eye drops 0.5% .....	1.40	10 ml OP	✓ Chlorsig
<b>CIPROFLOXACIN</b>			
Eye Drops 0.3% .....	12.43	5 ml OP	✓ Ciloxan
For treatment of bacterial keratitis or severe bacterial conjunctivitis resistant to chloramphenicol.			
<b>DIBROMOPROPAMIDINE ISETHIONATE</b>			
* Eye oint 0.15% .....	2.97 (7.99)	5 g OP	Brolene
<i>(Brolene Eye oint 0.15% to be delisted 1 March 2009)</i>			
<b>FUSIDIC ACID</b>			
Eye drops 1% .....	4.50 (9.83)	5 g OP	Fucithalmic
<b>GENTAMICIN SULPHATE</b>			
Eye drops 0.3% .....	11.40	5 ml OP	✓ Genoptic
<b>PROPAMIDINE ISETHIONATE</b>			
* Eye drops 0.1 % .....	2.97 (7.99)	10 ml OP	Brolene

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## SENSORY ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>SULPHACETAMIDE SODIUM</b>				
* Eye drops 10% .....	4.41	15 ml OP	✓	<b>Bleph 10</b>
<b>TOBRAMYCIN</b>				
Eye oint 0.3% .....	10.45	3.5 g OP	✓	<b>Tobrex</b>
Eye drops 0.3% .....	11.48	5 ml OP	✓	<b>Tobrex</b>
<b>Corticosteroids and Other Anti-Inflammatory Preparations</b>				
<b>DEXAMETHASONE</b>				
* Eye oint 0.1% .....	5.86	3.5 g OP	✓	<b>Maxidex</b>
* Eye drops 0.1 % .....	4.50	5 ml OP	✓	<b>Maxidex</b>
<b>DEXAMETHASONE WITH NEOMYCIN AND POLYMYXIN B SULPHATE</b>				
* Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g .....	5.39	3.5 g OP	✓	<b>Maxitrol</b>
* Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml .....	4.50	5 ml OP	✓	<b>Maxitrol</b>
<b>DICLOFENAC SODIUM</b>				
* Eye drops 1 mg per ml .....	13.80	5 ml OP	✓	<b>Voltaren Ophtha</b>
<b>FLUOROMETHOLONE</b>				
* Eye drops 0.1% .....	4.30	5 ml OP	✓	<b>Flucon</b>
<b>LEVOCABASTINE</b>				
Eye drops 0.5 mg per ml .....	8.71 (11.26)	4 ml OP		Livostin
<b>LODOXAMIDE TROMETAMOL</b>				
Eye drops 0.1% .....	8.71	10 ml OP	✓	<b>Lomide</b>
<b>PREDNISOLONE ACETATE</b>				
* Eye drops 0.12% .....	4.50 (7.53)	5 ml OP		Pred Mild
* Eye drops 1% .....	4.50 (9.44)	5 ml OP		Pred Forte
<b>SODIUM CROMOGLYCAT</b>				
Eye drops 2% .....	3.95	10 ml OP	✓	<b>Cromolux</b>

### Glaucoma Preparations - Beta Blockers

<b>BETAXOLOL HYDROCHLORIDE</b>				
* Eye drops 0.25% .....	11.80	5 ml OP	✓	<b>Betoptic S</b>
* Eye drops 0.5% .....	7.50	5 ml OP	✓	<b>Betoptic</b>
<b>LEVOBUNOLOL</b>				
* Eye drops 0.25% .....	7.00	5 ml OP	✓	<b>Betagan</b>
* Eye drops 0.5 % .....	7.00	5 ml OP	✓	<b>Betagan</b>
<b>TIMOLOL MALEATE</b>				
* Eye drops 0.25% .....	2.37	5 ml OP	✓	<b>Apo-Timop</b>
* Eye drops 0.25%, gel forming .....	3.30	2.5 ml OP	✓	<b>Timoptol XE</b>
* Eye drops 0.5% .....	2.29	5 ml OP	✓	<b>Apo-Timop</b>
* Eye drops 0.5%, gel forming .....	3.78	2.5 ml OP	✓	<b>Timoptol XE</b>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

**Glaucoma Preparations - Carbonic Anhydrase Inhibitors**

**Prescribing Guidelines**

Trusopt, Cosopt and Azopt are subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Trusopt, Cosopt and Azopt should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless:

- 1) that person has previously trialled all other such subsidised agents (except brimonidine tartrate); and
- 2) those trials have indicated that that person does not respond adequately to treatment with those other agents.

**ACETAZOLAMIDE**

\* Tab 250 mg ..... 10.40      100      ✓ **Diamox**

**BRINZOLAMIDE**

▲ Eye Drops 1% ..... 9.77      5 ml OP      ✓ **Azopt**

**DORZOLAMIDE HYDROCHLORIDE**

\* Eye drops 2% ..... 9.77      5 ml OP  
(13.95)      Trusopt

**DORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEATE**

\* Eye drops 2% with timolol maleate 0.5% ..... 18.50      5 ml OP      ✓ **Cosopt**

**Glaucoma Preparations - Prostaglandin Analogues**

**Prescribing Guideline**

Bimatoprost, lantanoprost and travoprost are subsidised for use in the treatment of glaucoma as either monotherapy or as an adjunctive agent for patients in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure. Bimatoprost, lantanoprost and travoprost should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless:

- 1) That person has previously trialled all other such subsidised agents (beta-blockers, pilocarpine, carbonic anhydrase inhibitors); and
- 2) Those trials have indicated that that person does not respond adequately to treatment with those other agents.

**BIMATOPROST – Retail pharmacy-Specialist**

See prescribing guideline above

▲ Eye Drops 0.03% ..... 19.50      3 ml OP      ✓ **Lumigan**

**LATANOPROST – Retail pharmacy-Specialist**

See prescribing guideline above

▲ Eye drops 50 µg per ml, 2.5ml ..... 19.50      2.5 ml OP      ✓ **Xalatan**

**TRAVOPROST – Retail pharmacy-Specialist**

See prescribing guideline above

▲ Eye drops 0.004% ..... 19.50      2.5 ml OP      ✓ **Travatan**

**Glaucoma Preparations - Other**

**BRIMONIDINE TARTRATE**

\* Eye Drops 0.2% ..... 7.93      5 ml OP      ✓ **AFT**

**Prescribing Guidelines**

Brimonidine tartrate is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma.

Brimonidine tartrate should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless:

- that person has previously trialled all other such subsidised agents (except dorzolamide hydrochloride); and
- those trials have indicated that that person does not respond adequately to or does not tolerate treatment with those other agents.

**BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE**

▲ Eye drops 0.2% with timolol maleate 0.5% ..... 18.50      5 ml OP      ✓ **Combigan**

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## SENSORY ORGANS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

### Prescribing Guidelines

Combigan is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma.

Combigan should only be prescribed when:

- 1) less expensive first line agents for the treatment of glaucoma are contraindicated; or
- 2) the response to such subsidised agents is inadequate; or
- 3) the patient cannot tolerate such subsidised agents.

### PILOCARPINE

* Eye drops 0.5% .....	3.19	15 ml OP	✓	<b>Piloft</b>
* Eye drops 1% .....	3.24	15 ml OP	✓	<b>Piloft</b>
* Eye drops 2% .....	4.32	15 ml OP	✓	<b>Piloft</b>
* Eye drops 4% .....	6.57	15 ml OP	✓	<b>Piloft</b>
* Eye drops 6% .....	8.56	15 ml OP	✓	<b>Piloft</b>
* Eye drops 2% single dose – Special Authority see SA0895 below – Hospital pharmacy [HP3] .....	31.95 (32.72)	20 dose		Minims

### SA0895 Special Authority for Subsidy

**Initial application** from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or
- 2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be “tools of trade” and are not approved as special authority items.

**Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

## Mydriatics and Cycloplegics

### ATROPINE SULPHATE

* Eye drops 1% .....	4.40	15 ml OP	✓	<b>Atropt</b>
----------------------	------	----------	---	---------------

### CYCLOPENTOLATE HYDROCHLORIDE

* Eye drops 1% .....	8.76	15 ml OP	✓	<b>Cyclogyl</b>
----------------------	------	----------	---	-----------------

### HOMATROPINE HYDROBROMIDE

* Eye drops 2% .....	7.18	15 ml OP	✓	<b>Isopto Homatropine</b>
----------------------	------	----------	---	---------------------------

### TROPICAMIDE

* Eye drops 0.5% .....	7.15	15 ml OP	✓	<b>Mydriacyl</b>
* Eye drops 1% .....	8.66	15 ml OP	✓	<b>Mydriacyl</b>

## Preparations for Tear Deficiency

For acetylcysteine eye drops refer, page 166

### HYPROMELLOSE

* Eye drops 0.3% .....	2.62	15 ml OP	✓	<b>Poly-Tears</b>
* Eye drops 0.5% .....	2.00	15 ml OP	✓	<b>Methopt</b>

### POLYVINYL ALCOHOL

* Eye drops 1.4% .....	2.68	15 ml OP	✓	<b>Liquifilm Tears</b>
			✓	<b>Vistil</b>
* Eye drops 3% .....	3.75	15 ml OP	✓	<b>Liquifilm Forte</b>
			✓	<b>Vistil Forte</b>

### TYLOXAPOL

* Eye drops 0.25% .....	8.63	15 ml OP	✓	<b>Enuclene</b>
-------------------------	------	----------	---	-----------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>Other Eye Preparations</b>				
NAPHAZOLINE HYDROCHLORIDE				
* Eye drops 0.1% .....	4.15	15 ml OP	✓	<b>Naphcon Forte</b>
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN				
* Eye oint with soft white paraffin .....	3.63	3.5 g OP	✓	<b>Lacri-Lube</b>
PARAFFIN LIQUID WITH WOOL FAT LIQUID				
* Eye oint 3% with wool fat liq 3% .....	3.63	3.5 g OP	✓	<b>Poly-Visc</b>
PHENYLEPHRINE HYDROCHLORIDE				
* Eye drops 0.12% .....	4.47	15 ml OP	✓	<b>Prefrin</b>
PHENYLEPHRINE HYDROCHLORIDE WITH ZINC SULPHATE				
* Eye drops 0.12% with zinc sulphate 0.25% .....	4.51	15 ml OP	✓	<b>Zincfrin</b>

‡ safety cap

\*Three months or six months, as applicable, dispensed all-at-once

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

## VARIOUS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

### Agents Used in the Treatment of Poisonings

See also to MUSCULO-SKELETAL, Anticholinesterases, page 104

#### CHARCOAL

* Tab 300 mg .....	7.13	100	✓	Red Seal
* Oral liq 50 g per 250 ml .....	37.75	250 ml OP	✓	Carbosorb-X
a) Up to 250 ml available on a PSO				
b) Only on a PSO				

#### DESFERRIOXAMINE MESYLATE – Hospital pharmacy [HP3]

* Inj 500 mg .....	99.00	10	✓	Mayne
--------------------	-------	----	---	-------

#### IPECACUANHA

* Tincture .....	41.20 (43.40)	500 ml		PSM
------------------	------------------	--------	--	-----

#### NALOXONE HYDROCHLORIDE

- a) Up to 5 inj available on a PSO  
b) Only on a PSO

* Inj 400 µg per ml, 1 ml .....	33.00	5	✓	Mayne
---------------------------------	-------	---	---	-------

#### SODIUM CALCIUM EDETATE

* Inj 200 mg per ml, 5 ml .....	53.31 (156.71)	6		Calcium Disodium Versenate
---------------------------------	-------------------	---	--	-------------------------------

### Detection of Substances in Urine

#### ORTHO-TOLIDINE

* Compound diagnostic sticks .....	7.50 (8.25)	50 test OP		Hemastix
------------------------------------	----------------	------------	--	----------

#### TETRABROMOPHENOL

* Blue diagnostic strips .....	7.02 (13.92)	100 test OP		Albustix
--------------------------------	-----------------	-------------	--	----------

## INTRODUCTION

The following extemporaneously compounded products are eligible for subsidy:

- The “Standard Formulae”.
- Oral liquid mixtures for patients unable to swallow subsidised solid dose oral formulations.
- The preparation of syringe drivers when prescribed by a general practitioner.
- Dermatological preparations
  - a) One or more subsidised dermatological galenical(s) in a subsidised dermatological base.
  - b) Dilution of proprietary Topical Corticosteroid-Plain preparations with a dermatological base (Retail pharmacy-specialist).
  - c) Menthol crystals only in the following bases:
    - Aqueous cream
    - Urea cream 10%
    - Wool fat with mineral oil lotion
    - Hydrocortisone 1% with wool fat and mineral oil lotion
    - Glycerol, paraffin and cetyl alcohol lotion.

## Glossary

**Dermatological base:** The products listed in the Barrier creams and Emollients section and the Topical Corticosteroids-Plain section of the Pharmaceutical Schedule are classified as dermatological bases for the purposes of extemporaneous compounding and are the bases to which the dermatological galenicals can be added. Also the dermatological bases in the Barrier Creams and Emollients section of the Pharmaceutical Schedule can be used for diluting proprietary Topical Corticosteroid-Plain preparations. The following products are dermatological bases:

- Aqueous cream
- Cetomacrogol cream BP
- Collodion flexible
- Emulsifying ointment BP
- Glycerol with paraffin and cetyl alcohol lotion
- Hydrocortisone with wool fat and mineral oil lotion
- Oil in water emulsion
- Oily cream
- Urea cream 10%
- White soft paraffin
- Wool fat with mineral oil lotion
- Zinc cream BP
- Zinc and castor oil ointment BP
- Proprietary Topical Corticosteroid-Plain preparations

**Dermatological galenical:** Dermatological galenicals will only be subsidised when added to a dermatological base. More than one dermatological galenical can be added to a dermatological base.

The following are dermatological galenicals:

- Coal tar solution BP - up to 10%
- Hydrocortisone powder - up to 5%
- Salicylic acid powder
- Sulphur precipitated powder

**Standard formulae:** Standard formulae are a list of formulae for ECPs that are subsidised. Their ingredients are listed under the appropriate therapeutic heading in Section B of the Pharmaceutical Schedule and also in Section C.

## **Explanatory notes**

### **Oral liquid mixtures**

Oral liquid mixtures are subsidised for patients unable to swallow subsidised solid oral dose forms where no suitable alternative proprietary formulation is subsidised. Suitable alternatives include dispersible and sublingual formulations, oral liquid formulations or rectal formulations. Before extemporaneously compounding an oral liquid mixture, other alternatives such as dispersing the solid dose form (if appropriate) or crushing the solid dose form in jam, honey or soft foods such as yoghurt should be explored.

Subsidy for extemporaneously compounded oral liquid mixtures is based on:

Solid dose form	qs
Preservative	qs
Suspending agent	qs
Water	to 100%

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients such as flavouring and colouring agents, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The majority of extemporaneously compounded oral liquid mixtures should contain a preservative and suspending agent. Methylcellulose 3% is considered a suitable suspending agent and compound hydroxybenzoate solution or methyl hydroxybenzoate 10% solution are considered to be suitable preservatives. Usually 1 ml of these preservative solutions is added to 100 ml of oral liquid mixture.

Some solid oral dose forms are not appropriate for compounding into oral liquid mixtures and should therefore not be used/considered for extemporaneously compounded oral liquid mixtures. This includes long-acting solid dose formulations, enteric coated tablets or capsules, sugar coated tablets, hard gelatin capsules and chemotherapeutic agents.

The following practices will not be subsidised:

- Mixing one or more proprietary oral liquids (eg an antihistamine with pholcodine linctus).
- Extemporaneously compounding an oral liquid with more than one solid dose chemical.
- Mixing more than one extemporaneously compounded oral liquid mixture.
- Mixing one or more extemporaneously compounded oral liquid mixtures with one or more proprietary oral liquids.
- The addition of a chemical/powder/agent/solution to a proprietary oral liquid or extemporaneously compounded oral mixture.

### **Standard formulae**

A list of standard formulae is contained in this section. All ingredients associated with a standard formula will be subsidised and an appropriate compounding fee paid.

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

### **Dermatological Preparations**

Proprietary topical corticosteroid preparations may be diluted with a dermatological base (see page 163) from the Barrier Creams and Emollients section of the Pharmaceutical Schedule (Retail pharmacy-Specialist). Dilution of proprietary topical corticosteroid preparations should only be prescribed for withdrawing patients off higher strength proprietary topical corticosteroid products where there is no suitable proprietary product of a lower strength available or an extemporaneously compounded product with up to 5% hydrocortisone is not appropriate. (In general proprietary topical corticosteroid preparations should not be diluted because dilution effects can be unpredictable and may not be linear, and usually there is no stability data available for diluted products).


One or more dermatological galenicals may be added to a dermatological base (including proprietary topical corticosteroid preparations). Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The addition of dermatological galenicals to diluted proprietary Topical Corticosteroids-Plain will not be subsidised.

The flow diagram on page 165 may assist you in deciding whether or not a dermatological ECP is subsidised.

# Dermatological ECPs

Is it subsidised?



**Standard Formulae**

**ACETYLCYSTEINE EYE DROPS**

Acetylcysteine inj 200 mg per ml, 10 ml	qs
Suitable eye drop base	qs

**ASPIRIN AND CHLOROFORM APPLICATION**

Aspirin Soluble tabs 300 mg	12 tabs
Chloroform	to 100 ml

**CODEINE LINCTUS PAEDIATRIC (3 mg per 5 ml)**

Codeine phosphate	60 mg
Glycerol	40 ml
Preservative	qs
Water	to 100 ml

**CODEINE LINCTUS DIABETIC (15 mg per 5 ml)**

Codeine phosphate	300 mg
Glycerol	40 ml
Preservative	qs
Water	to 100 ml

**FOLINIC MOUTHWASH**

Calcium folinate 15 mg tab	1 tab
Preservative	qs
Water	to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.)

**MAGNESIUM HYDROXIDE MIXTURE**

Magnesium hydroxide paste	275 g
Methyl hydroxybenzoate	1.5 g
Water	770 ml

**METHADONE MIXTURE**

Methadone powder	qs
Glycerol	qs
Water	to 100 ml

**METHYL HYDROXYBENZOATE 10% SOLUTION**

Methyl hydroxybenzoate	10 g
Propylene glycol	to 100 ml

(Use 1 ml of the 10% solution per 100 ml of oral liquid mixture)

**OMEPRAZOLE SUSPENSION**

Omeprazole capules	qs
Sodium bicarbonate powder BP	8.4 g
Water	to 100 ml

**PHENOBARBITONE ORAL LIQUID**

Phenobarbitone Sodium	1 g
Glycerol BP	70 ml
Water	to 100 ml

**PILOCARPINE ORAL LIQUID**

Pilocarpine 6% eye drops	qs
Preservative	qs
Water	to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days.)

**SALIVA SUBSTITUTE FORMULA**

Methylcellulose	5 g
Preservative	qs
Water	to 500 ml

(Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.)

**VOSOL EAR DROPS**

**WITH HYDROCORTISONE POWDER 1%**

Hydrocortisone powder	1%
Vosol Ear Drops	to 35 ml

## EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
<b>Extemporaneously Compounded Preparations and Galenicals</b>			
ACETYLCYSTEINE – Hospital pharmacy [HP1]-Specialist			
Inj 200 mg per ml, 10 ml .....	137.06 (255.35)	10	Hospira
BENZOIN			
Tincture compound BP .....	24.42 (38.00)	500 ml	PSM
CHLOROFORM – Only in combination			
Only in aspirin and chloroform application.			
Chloroform BP .....	25.50	500 ml	✓ PSM
CODEINE PHOSPHATE			
Powder – Only in combination .....	63.09 (84.20)	25 g	Douglas
a) Only in extemporaneously compounded codeine linctus diabetic or codeine linctus paediatric.			
b) ‡ Safety cap for extemporaneously compounded oral liquid preparations.			
COLLODION FLEXIBLE			
Collodion flexible .....	19.30	100 ml	✓ PSM
COMPOUND HYDROXYBENZOATE – Only in combination			
Only in extemporaneously compounded oral mixtures.			
Soln .....	34.18	100 ml	✓ David Craig
GLYCEROL			
* Liquid – Only in combination .....	19.80 24.75 19.80 (24.75)	2,000 ml	✓ ABM ✓ PSM MidWest
Only in extemporaneously compounded oral liquid preparations.			
MAGNESIUM HYDROXIDE			
Paste .....	22.61	500 g	✓ PSM
METHADONE HYDROCHLORIDE			
a) Only on a controlled drug form			
b) No patient co-payment payable			
c) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets).			
Powder .....	7.84	1 g	✓ AFT
‡ Safety cap for extemporaneously compounded oral liquid preparations.			
METHYL HYDROXYBENZOATE			
Powder .....	10.00 (18.45)	25 g	✓ ABM PSM
METHYLCELLULOSE			
Powder .....	14.00 (17.72)	100 g	✓ ABM MidWest
PHENOBARBITONE SODIUM			
Powder – Only in combination .....	325.00	100 g	✓ MidWest
a) Only in children up to 12 years			
b) ‡ Safety cap for extemporaneously compounded oral liquid preparations.			

## EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>PROPYLENE GLYCOL</b>				
Only in extemporaneously compounded methyl hydroxybenzoate 10% solution.				
Liq .....	12.00	500 ml	✓	<b>ABM</b>
	17.70		✓	<b>PSM</b>
<b>SODIUM BICARBONATE</b>				
Powder BP – Only in combination .....	9.80	500 g	✓	<b>ABM</b>
	(11.99)			Biomed
	(29.50)			David Craig
Only in extemporaneously compounded omeprazole suspension.				
<b>SYRUP (PHARMACEUTICAL GRADE) – Only in combination</b>				
Only in extemporaneously compounded oral liquid preparations.				
Liq .....	21.75	2,000 ml	✓	<b>Midwest</b>
<b>WATER</b>				
Tap – Only in combination .....	0.00	1 ml	✓	<b>Tap water</b>

## EXPLANATORY NOTES

The list of special foods to which Subsidies apply is contained in this section. The list of available products, guidelines for use, subsidies and charges is reviewed as required. Applications for new listings and changes to subsidies and access criteria will be considered by the special foods sub-committee of PTAC which meets as and when required. In all cases, subsidies are available by Special Authority only. This means that, unless a patient has a valid Special Authority number for their special food requirements, they must pay the full cost of the products themselves.

### Eligibility for Special Authority

Special Authorities will be approved for patients meeting conditions specified under the *Conditions and Guidelines* for each product. In some cases there are also limits to how products can be prescribed (for example quantity, use or duration). Only those brands, presentations and flavours of special foods listed in this section are subsidised.

### Who can apply for Special Authority?

*Initial Applications:* Only Specialists

*Reapplications:* Specialist or general practitioner on recommendation of specialist. Reapplications by general practitioners on specialist recommendation must include the name of the specialist and the date the specialist was contacted.

All applications must be made on an official form available from the PHARMAC website [www.pharmac.govt.nz](http://www.pharmac.govt.nz). All applications must include specific details as requested on the form relating to the application. A supporting letter may be included if desired. Applications must be forwarded to:

HealthPAC  
Special Authorities Section  
Private Bag 3015  
Wanganui  
Freefax 0800 100 131

### Subsidies and manufacturer's surcharges

The Subsidies for some special foods are based on the lowest priced product within each group. Where this is so, or where special foods are otherwise not fully subsidised, a manufacturer's surcharge may be payable by the patient. The manufacturer's surcharge is the difference between the price of the product and the subsidy attached to it and may be subject to mark-ups applied at a pharmacy level. As a result the manufacturer's surcharge may vary. Fully subsidised alternatives are available in most cases (as indicated by a tick in the left hand column). Patients should only have to pay a co-payment on these products.

### Where are special foods available from?

Distribution arrangements for special foods vary from region to region. Special foods are available from hospital pharmacies providing an outpatient dispensing service as well as retail pharmacies in the Northern, Midland and Central (including Nelson and Blenheim) regions.

### Definitions

*Failure to thrive* An inability to gain or maintain weight resulting in physiological impairment.  
*Growth deficiency* Where the weight of the child is less than the fifth or possibly third percentile for their age, with evidence of malnutrition

Subsidy (Manufacturer's Price) \$ Per Fully Subsidised ✓ Brand or Generic Manufacturer

**Nutrient Modules**

**Carbohydrate**

**▶▶SA0912 Special Authority for Subsidy**

**Initial application — (Cystic fibrosis or renal failure)** only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Either:

- 1 cystic fibrosis; or
- 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient.

**Initial application — (Indications other than cystic fibrosis or renal failure)** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 cancer in children; or
- 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 3 failure to thrive; or
- 4 growth deficiency; or
- 5 bronchopulmonary dysplasia; or
- 6 premature and post premature infant; or
- 7 inborn errors of metabolism.

**Renewal — (Cystic fibrosis or renal failure)** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

**Renewal — (Indications other than cystic fibrosis or renal failure)** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

**CARBOHYDRATE SUPPLEMENT – Special Authority see SA0912 above – Hospital pharmacy [HP3]**

Powder .....	36.50	5,000 g	✓ <b>Morrex Maltodextrin</b>
	1.30	400 g OP	
	(5.29)		Polycal
	1.14	350 g OP	
	(7.85)		Polycose
	1.30	368 g OP	
	(12.00)		Moducal

**Carbohydrate And Fat**

**▶▶SA0581 Special Authority for Subsidy**

**Initial application — (Cystic fibrosis)** only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 infant aged four years or under; and
- 2 cystic fibrosis.

**Initial application — (Indications other than cystic fibrosis)** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

- 1 infant aged four years or under; and
- 2 Any of the following:
  - 2.1 cancer in children; or
  - 2.2 failure to thrive; or
  - 2.3 growth deficiency; or
  - 2.4 bronchopulmonary dysplasia; or
  - 2.5 premature and post premature infants.

**Renewal — (Cystic fibrosis)** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

**Renewal — (Indications other than cystic fibrosis)** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

**CARBOHYDRATE AND FAT SUPPLEMENT** – Special Authority see SA0581 on the preceding page – Hospital pharmacy [HP3]

Powder (neutral) .....	60.31	400 g OP	✓ Duocal Super Soluble Powder
------------------------	-------	----------	-------------------------------

**Fat**

**SA0899 Special Authority for Subsidy**

**Initial application — (Inborn errors of metabolism)** only from a relevant specialist. Approvals valid for 3 years where the patient has inborn errors of metabolism.

**Initial application — (Indications other than inborn errors of metabolism)** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 failure to thrive where other high calorie products are inappropriate or inadequate; or
- 2 growth deficiency; or
- 3 bronchopulmonary dysplasia; or
- 4 fat malabsorption; or
- 5 lymphangiectasia; or
- 6 short bowel syndrome; or
- 7 infants with necrotising enterocolitis; or
- 8 biliary atresia.

**Renewal — (Inborn errors of metabolism)** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

**Renewal — (Indications other than inborn errors of metabolism)** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

## SPECIAL FOODS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>FAT SUPPLEMENT – Special Authority see SA0899 on the preceding page – Hospital pharmacy [HP3]</b>				
Emulsion (neutral) .....	12.30	200 ml OP	✓	<b>Calogen</b>
	30.75	500 ml OP	✓	<b>Calogen</b>
Emulsion (strawberry) .....	12.30	200 ml OP	✓	<b>Calogen</b>
Oil .....	28.73	250 ml OP	✓	<b>Liquigen</b>
	30.00	500 ml OP	✓	<b>MCT oil (Nutricia)</b>

### Protein

#### ▶▶SA0582 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 protein losing enteropathy; or
- 2 high protein needs (eg burns).

**Renewal** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

**PROTEIN SUPPLEMENT – Special Authority see SA0582 above – Hospital pharmacy [HP3]**

Powder .....	7.90	225 g OP	✓	<b>Protifar 90</b>
Powder (vanilla) .....	12.90	275 g OP	✓	<b>Promod</b>

### Oral Supplements

These products are to be used only as supplements to a person's dietary needs. Subsidy for up to 500 ml a day. Amounts prescribed in excess of this amount must be paid for by the patient.

#### ▶▶SA0583 Special Authority for Subsidy

**Initial application – (Cystic fibrosis)** only from a relevant specialist. Approvals valid for 3 years where the patient has cystic fibrosis.

**Initial application – (Indications other than cystic fibrosis)** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 cancer in children; or
- 2 inflammatory bowel disease; or
- 3 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 4 malnutrition requiring nutritional support.

**Renewal – (Cystic fibrosis)** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

**Renewal – (Indications other than cystic fibrosis)** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>ORAL SUPPLEMENT 1KCAL/ML – Special Authority see SA0583 on the preceding page – Hospital pharmacy [HP3]</b>				
Powder (chocolate) .....	9.22	900 g OP	✓	<b>Sustagen Hospital Formula</b>
	4.75 (7.22)	400 g OP		Ensure
Powder (strawberry) .....	4.75 (7.22)	400 g OP		Ensure
Powder (vanilla) .....	9.22	900 g OP	✓	<b>Sustagen Hospital Formula</b>
	11.50 4.75 (7.22)	400 g OP	✓	<b>Fortisip Powder</b>
				Ensure

(Fortisip Powder Powder (vanilla) to be delisted 1 February 2009)

**Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed)**

**Respiratory Products**

**▶▶SA0588 | Special Authority for Subsidy**

**Initial application** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:  
Both:

1. CORD patients who have hypercapnia; and
2. Either:
  - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 2.2 The product is to be used as a complete diet.

**Renewal** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. Either:
  - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 2.2 The product is to be used as a complete diet; and
3. General Practitioners must include the name of the specialist and date contacted.

**CORD ORAL FEED 1.5KCAL/ML – Special Authority see SA0588 above – Hospital pharmacy [HP3]**

Liquid .....	1.66	237 ml OP	✓	<b>Pulmocare</b>
--------------	------	-----------	---	------------------

**Diabetic Products**

**▶▶SA0594 | Special Authority for Subsidy**

**Initial application** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:  
Both:

1. Type I and II diabetics who require nutritional supplementation; and
2. Either:
  - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 2.2 The product is to be used as a complete diet.

**Renewal** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

1. The treatment remains appropriate and the patient is benefiting from treatment; and
2. Either:

continued...

## SPECIAL FOODS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
continued...				
2.1	The product is to be used as a supplement (maximum 500 ml per day); or			
2.2	The product is to be used as a complete diet; and			
3	General Practitioners must include the name of the specialist and date contacted.			
DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0594 on the preceding page – Hospital pharmacy [HP3]				
Liquid .....	7.50	1,000 ml OP	✓	Diason RTH ✓ Glucerna Select RTH ✓ Resource Diabetic TF RTH
ORAL FEED 1KCAL/ML – Special Authority see SA0594 on the preceding page – Hospital pharmacy [HP3]				
Liquid (chocolate) .....	1.78	237 ml OP	✓	Resource Diabetic
Liquid (strawberry) .....	1.50	200 ml OP	✓	Diasip
	1.78	237 ml OP	✓	Resource Diabetic
Liquid (vanilla) .....	1.50	200 ml OP	✓	Diasip
	1.78	237 ml OP	✓	Resource Diabetic
	1.88	250 ml OP	✓	Glucerna Select

### Fat Modified Products

#### ►SA0615 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The product is to be used as a complete diet; and
- 2 Either:
  - 2.1 Patient has metabolic disorders of fat metabolism; or
  - 2.2 Patient has chylothorax.

**Renewal** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

FAT MODIFIED FEED – Special Authority see SA0615 above – Hospital pharmacy [HP3]

Powder .....60.48 400 g OP ✓ Monogen

### High Protein Products

#### ►SA0589 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Anorexia and weight loss; and
- 2 Either:
  - 2.1 decompensating liver disease without encephalopathy; or
  - 2.2 protein losing gastro-enteropathy; and
- 3 Either:
  - 3.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 3.2 The product is to be used as a complete diet.

**Renewal** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

continued...

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

ORAL FEED 1KCAL/ML – Special Authority see SA0589 on the preceding page – Hospital pharmacy [HP3]

Liquid ..... 1.50 200 ml OP ✓ **Fortimel**

**Paediatric Products For Children Awaiting Liver Transplant**

**▶SA0607 Special Authority for Subsidy**

**Initial application** only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 Child (up to 18 years) who is awaiting liver transplant; and
- 2 Either:
  - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 2.2 The product is to be used as a complete diet.

**Renewal** only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 2.2 The product is to be used as a complete diet.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA0607 above – Hospital pharmacy [HP3]

Powder ..... 78.97 400 g OP ✓ **Generaid Plus**

**Paediatric Products For Children With Chronic Renal Failure**

**▶SA0606 Special Authority for Subsidy**

**Initial application** only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 child (up to 18 years) with chronic renal failure; and
- 2 Either:
  - 2.1 The product is to be used as a supplement; or
  - 2.2 The product is to be used as a complete diet.

**Renewal** only from a paediatrician. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 The product is to be used as a supplement; or
  - 2.2 The product is to be used as a complete diet.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA0606 above – Hospital pharmacy [HP3]

Liquid ..... 54.00 400 g OP ✓ **Kindergen**

Subsidy (Manufacturer's Price) \$ Per Fully Subsidised ✓ Brand or Generic Manufacturer

**Paediatric Products**

**▶SA0896 Special Authority for Subsidy**

**Initial application** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 infant aged one to eight years; and
- 2 Any of the following:
  - 2.1 any condition causing malabsorption; or
  - 2.2 failure to thrive; or
  - 2.3 increased nutritional requirements; and
- 3 Either:
  - 3.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 3.2 The product is to be used as a complete diet.

**Renewal** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

PAEDIATRIC ENTERAL FEED 1.5KCAL/ML – Special Authority see SA0896 above – Hospital pharmacy [HP3]

Liquid .....	1.60	200 ml OP	✓ Nutrini Energy RTH
	6.00	500 ml OP	✓ Nutrini Energy RTH

PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0896 above – Hospital pharmacy [HP3]

Liquid .....	1.07	200 ml OP	✓ Nutrini RTH
	2.68	500 ml OP	✓ Nutrini RTH
			✓ Pediasure RTH

PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see SA0896 above – Hospital pharmacy [HP3]

Liquid (strawberry) .....	1.60	200 ml OP	✓ Fortini
Liquid (vanilla) .....	1.60	200 ml OP	✓ Fortini

PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA0896 above – Hospital pharmacy [HP3]

Liquid (chocolate) .....	1.07	200 ml OP	✓ Pediasure
	1.27	237 ml OP	✓ Pediasure
			✓ Resource Just for Kids
Liquid (strawberry) .....	1.07	200 ml OP	✓ Pediasure
	1.27	237 ml OP	✓ Pediasure
Liquid (vanilla) .....	1.27	237 ml OP	✓ Pediasure
			✓ Resource Just for Kids

*(Resource Just for Kids Liquid (chocolate) to be delisted 1 July 2009)*

*(Resource Just for Kids Liquid (vanilla) to be delisted 1 July 2009)*

PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA0896 above – Hospital pharmacy [HP3]

Liquid (chocolate) .....	1.60	200 ml OP	✓ Fortini Multifibre
Liquid (strawberry) .....	1.60	200 ml OP	✓ Fortini Multifibre
Liquid (vanilla) .....	1.60	200 ml OP	✓ Fortini Multifibre

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per	✓

**Renal Products**

**▶▶SA0587 Special Authority for Subsidy**

**Initial application** only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:  
Both:

- 1 acute or chronic renal failure; and
- 2 Either:
  - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 2.2 The product is to be used as a complete diet.

**Renewal** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

ENTERAL FEED 2KCAL/ML – Special Authority see SA0587 above – Hospital pharmacy [HP3]

Liquid .....	6.08	500 ml OP	✓ <b>Nutrison Concentrated</b>
--------------	------	-----------	------------------------------------

RENAL ORAL FEED 2KCAL/ML – Special Authority see SA0587 above – Hospital pharmacy [HP3]

Liquid .....	2.43	200 ml OP	✓ <b>Nepro (vanilla)</b>
	2.88	237 ml OP	✓ <b>NovaSource Renal</b>
Liquid (apricot) .....	2.88	125 ml OP	✓ <b>Renilon 7.5</b>
Liquid (caramel) .....	2.88	125 ml OP	✓ <b>Renilon 7.5</b>

**Specialised And Elemental Products**

**▶▶SA0592 Special Authority for Subsidy**

**Initial application** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:  
Both:

- 1 Any of the following:
  - 1.1 malabsorption; or
  - 1.2 short bowel syndrome; or
  - 1.3 enterocutaneous fistulas; or
  - 1.4 pancreatitis; and
- 2 Either:
  - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 2.2 The product is to be used as a complete diet.

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

**Renewal** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

## SPECIAL FOODS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>ENTERAL/ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA0592 on the preceding page – Hospital pharmacy [HP3]</b>				
Powder .....	4.40	79 g OP	✓	<b>Vital HN</b>
	7.50	76 g OP	✓	<b>Alitraq</b>
<b>ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority see SA0592 on the preceding page – Hospital pharmacy [HP3]</b>				
Liquid (grapefruit) .....	9.50	250 ml OP	✓	<b>Elemental 028 Extra</b>
Liquid (pineapple & orange) .....	9.50	250 ml OP	✓	<b>Elemental 028 Extra</b>
Liquid (summer fruit) .....	9.50	250 ml OP	✓	<b>Elemental 028 Extra</b>
<b>ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA0592 on the preceding page – Hospital pharmacy [HP3]</b>				
Powder (unflavoured) .....	4.00	80.4 g OP	✓	<b>Vivonex TEN</b>
<b>SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Authority see SA0592 on the preceding page – Hospital pharmacy [HP3]</b>				
Liquid .....	6.02	500 ml OP	✓	<b>Peptisorb</b>
	12.04	1,000 ml OP	✓	<b>Peptisorb</b>

### Undialysed End Stage Renal Failure

#### ▶SA0586 Special Authority for Subsidy

**Initial application** only from a gastroenterologist or renal physician. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 undialysed end stage renal patients; and
- 2 Either:
  - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 2.2 The product is to be used as a complete diet.

Note: Where possible, the requirements for oral supplementation should be established in conjunction with assessment by a dietician.

**Renewal** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 The product is to be used as a supplement (maximum 500 ml per day); or
  - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

**RENAL ORAL FEED 1KCAL/ML – Special Authority see SA0586 above – Hospital pharmacy [HP3]**

Liquid ..... 3.80 237 ml OP ✓ **Suplena**

### Adult Products Standard

#### ▶SA0702 Special Authority for Subsidy

**Initial application — (Oral feed for cystic fibrosis patient)** only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 Cystic fibrosis; and
- 2 Either:
  - 2.1 The product is to be used as a supplement; or
  - 2.2 The product is to be used as a complete diet.

**Initial application — (Oral feed for indications other than cystic fibrosis)** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
---	-----	--------------------------	-------------------------------------

continued...

Both:

- 1 Any of the following:
  - 1.1 any condition causing malabsorption; or
  - 1.2 failure to thrive; or
  - 1.3 increased nutritional requirements; and
- 2 Either:
  - 2.1 The product is to be used as a supplement; or
  - 2.2 The product is to be used as a complete diet.

**Renewal — (Oral feed cystic fibrosis patient)** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 The product is to be used as a supplement; or
  - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

**Initial application — (Enteral feed)** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
  - 1.1 enteral feeding; or
  - 1.2 nasogastric; or
  - 1.3 nasoduodenal; or
  - 1.4 nasojejunal; or
  - 1.5 gastrostomy/jejunostomy; and
- 2 Either:
  - 2.1 The product is to be used as a supplement; or
  - 2.2 The product is to be used as a complete diet.

**Renewal — (Enteral feed or Oral feed for indications other than cystic fibrosis)** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
  - 2.1 The product is to be used as a supplement; or
  - 2.2 The product is to be used as a complete diet; and
- 3 General Practitioners must include the name of the specialist and date contacted.

Notes: This group of products can be used either as a supplement or as a complete diet.

If a product is being used as a supplement, the limit is 500 ml per day.

Cystic fibrosis patients are exempt the 500 ml per day volume restriction when using Ensure Plus, Fortisip or Resource Plus as a supplement.

## SPECIAL FOODS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>ENTERAL FEED 1KCAL/ML – Special Authority see SA0702 on page 178 – Hospital pharmacy [HP3]</b>				
Liquid .....	1.24	250 ml OP	✓	<b>Isosource HN</b>
			✓	<b>Isosource Standard</b>
	2.65	500 ml OP	✓	<b>Nutrison Standard RTH</b>
	5.29	1,000 ml OP	✓	<b>Nutrison Standard RTH</b>
			✓	<b>Isosource HN RTH</b>
			✓	<b>Isosource Standard RTH</b>
			✓	<b>Osmolite RTH</b>
<b>ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA0702 on page 178 – Hospital pharmacy [HP3]</b>				
Liquid .....	1.24	250 ml OP	✓	<b>Fibresource</b>
			✓	<b>Fibresource HN</b>
	2.65	500 ml OP	✓	<b>Nutrison Multi Fibre</b>
	5.29	1,000 ml OP	✓	<b>Nutrison Multi Fibre</b>
			✓	<b>Fibresource HN RTH</b>
			✓	<b>Fibresource RTH</b>
			✓	<b>Jevity RTH</b>
<b>ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA0702 on page 178 – Hospital pharmacy [HP3]</b>				
Liquid .....	7.00	1,000 ml OP	✓	<b>Ensure Plus RTH</b>
	1.75	250 ml OP	✓	<b>Isosource 1.5</b>
	7.00	1,000 ml OP	✓	<b>Isosource 1.5</b>
			✓	<b>Nutrison Energy Multi Fibre</b>
<b>ORAL FEED 1.5KCAL/ML – Special Authority see SA0702 on page 178 – Hospital pharmacy [HP3]</b>				
Liquid (banana) .....	1.12	200 ml OP	✓	<b>Fortisip</b>
	(1.45)			Ensure Plus
Liquid (chocolate) .....	1.12	200 ml OP	✓	<b>Fortisip</b>
	1.33	237 ml OP	✓	<b>Resource Plus</b>
	1.12	200 ml OP		Ensure Plus
	(1.45)			Ensure Plus
	1.33	237 ml OP	✓	<b>Ensure Plus</b>
Liquid (coffee) .....	1.33	237 ml OP	✓	<b>Ensure Plus</b>
Liquid (fruit of the forest) .....	1.12	200 ml OP		Ensure Plus
	(1.45)			Ensure Plus
Liquid (strawberry) .....	1.12	200 ml OP	✓	<b>Fortisip</b>
	1.33	237 ml OP	✓	<b>Resource Plus</b>
	1.12	200 ml OP		Ensure Plus
	(1.45)			Ensure Plus
	1.33	237 ml OP	✓	<b>Ensure Plus</b>
Liquid (toffee) .....	1.12	200 ml OP	✓	<b>Fortisip</b>
Liquid (tropical fruit) .....	1.12	200 ml OP	✓	<b>Fortisip</b>
Liquid (vanilla) .....	1.12	200 ml OP	✓	<b>Fortisip</b>
	1.33	237 ml OP	✓	<b>Resource Plus</b>
	1.12	200 ml OP		Ensure Plus
	(1.45)			Ensure Plus
	1.33	237 ml OP	✓	<b>Ensure Plus</b>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see SA0702 on page 178 – Hospital pharmacy [HP3]</b>				
Liquid (chocolate) .....	1.12	200 ml OP	✓	<b>Fortisip Multi Fibre</b>
Liquid (strawberry) .....	1.12	200 ml OP	✓	<b>Fortisip Multi Fibre</b>
Liquid (vanilla) .....	1.12	200 ml OP	✓	<b>Fortisip Multi Fibre</b>

**Adult Products High Calorie**

**SA0585 Special Authority for Subsidy**

**Initial application — (Cystic fibrosis)** only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements; and
- 4 Either:
  - 4.1 The product is to be used as a supplement; or
  - 4.2 The product is to be used as a complete diet.

**Initial application — (Indications other than cystic fibrosis)** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
  - 1.1 any condition causing malabsorption; or
  - 1.2 failure to thrive; or
  - 1.3 increased nutritional requirements; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements; and
- 4 Either:
  - 4.1 The product is to be used as a supplement; or
  - 4.2 The product is to be used as a complete diet.

**Renewal — (Cystic fibrosis)** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted; and
- 3 Either:
  - 3.1 The product is to be used as a supplement; or
  - 3.2 The product is to be used as a complete diet.

**Renewal — (Indications other than cystic fibrosis)** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted; and
- 3 Either:
  - 3.1 The product is to be used as a supplement; or
  - 3.2 The product is to be used as a complete diet.

Notes: This product can be used either as a supplement or as a complete diet.

If it is being used as a supplement, the limit is 500 ml per day.

<b>ORAL FEED 2KCAL/ML – Special Authority see SA0585 above – Hospital pharmacy [HP3]</b>				
Liquid (vanilla) .....	2.25	237 ml OP	✓	<b>Two Cal HN</b>

## SPECIAL FOODS

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

### Food Thickeners

#### ▶▶SA0595 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid for 1 year where the patient has motor neurone disease with swallowing disorder.

**Renewal** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

FOOD THICKENER – Special Authority see SA0595 above – Hospital pharmacy [HP3]

Powder .....	3.80	250 g OP	✓ Resource Thicken Up
	4.56 (7.25)	380 g	Karicare Food Thickener

### Gluten Free Foods

#### ▶▶SA0722 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Gluten enteropathy has been diagnosed by biopsy; or
- 2 Patient suffers from dermatitis herpetiformis.

GLUTEN FREE BAKING MIX – Special Authority see SA0722 above – Hospital pharmacy [HP3]

Powder .....	2.81	1,000 g OP	Healtheries Simple Baking Mix
	(5.15)		

GLUTEN FREE BREAD MIX – Special Authority see SA0722 above – Hospital pharmacy [HP3]

Powder .....	3.93	1,000 g OP	NZB Low Gluten Bread Mix
	(6.73)		
	4.77		Bakels Gluten Free Health Bread Mix
	(8.97)		

GLUTEN FREE FLOUR – Special Authority see SA0722 above – Hospital pharmacy [HP3]

Powder .....	5.62	2,000 g OP	Horleys Bread Mix
	(16.44)		Horleys Flour

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>GLUTEN FREE PASTA – Special Authority see SA0722 on the preceding page – Hospital pharmacy [HP3]</b>				
Buckwheat Spirals .....	2.00 (3.11)	250 g	OP	Orgran
Corn and Parsley Fettucine .....	2.00 (2.63)	250 g	OP	Orgran
Corn and Spinach Rigatini .....	2.00 (2.92)	250 g	OP	Orgran
Corn and Vegetable Shells .....	2.00 (2.92)	250 g	OP	Orgran
Corn and Vegetable Spirals .....	2.00 (2.92)	250 g	OP	Orgran
Garlic and Parsley Shells .....	2.00 (2.92)	250 g	OP	Orgran
Rice and Corn Garden Herb Pasta .....	2.00 (2.92)	250 g	OP	Orgran
Rice and Corn Lasagne Sheets .....	1.60 (3.82)	200 g	OP	Orgran
Rice and Corn Macaroni .....	2.00 (2.92)	250 g	OP	Orgran
Rice and Corn Penne .....	2.00 (2.92)	250 g	OP	Orgran
Rice and Maize Pasta Spirals .....	2.00 (2.92)	250 g	OP	Orgran
Rice and Millet Spirals .....	2.00 (3.11)	250 g	OP	Orgran
Rice and corn spaghetti noodles .....	2.00 (2.92)	375 g	OP	Orgran
Vegetable and Rice Spirals .....	2.00 (2.92)	250 g	OP	Orgran
Italian long style spaghetti .....	2.00 (3.11)	220 g	OP	Orgran

*(Orgran Corn and Parsley Fettucine to be delisted 1 July 2009)*

### **Foods And Supplements For Inborn Errors Of Metabolism - Other**

#### **SA0732 Special Authority for Subsidy**

**Initial application** only from a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Either:

- 1 dietary management of homocystinuria; or
- 2 dietary management of maple syrup urine disease.

**Renewal** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

#### **Prescribing Guideline**

It can cost up to \$70,000 a year to keep an adult on protein supplements. Because protein substitutes are so expensive and because they are only effective in controlling PKU if a restricted diet is followed, adults with PKU will be required to demonstrate they are following the prescribed diet by regular blood testing. The requirement for testing applies to those aged over 16 years. Failure to follow an appropriate diet results in high blood phenylalanine levels.

The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.

Subsidy (Manufacturer's Price) \$ Fully Subsidised Per Brand or Generic Manufacturer

**Supplements For Homocystinuria**

AMINOACID FORMULA WITHOUT METHIONINE – Special Authority see SA0732 on the preceding page – Hospital pharmacy [HP3]

See prescribing guideline on the preceding page

Powder .....461.94 500 g OP ✓ XMET Maxamum

**Supplements For MSUD**

AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE – Special Authority see SA0732 on the preceding page – Hospital pharmacy [HP3]

See prescribing guideline on the preceding page

Powder .....300.54 500 g OP ✓ MSUD Maxamaid  
 .....437.22 ✓ MSUD Maxamum

**Foods And Supplements For Inborn Errors Of Metabolism - PKU**

▶▶SA0733 Special Authority for Subsidy

**Initial application — (Patient aged over 16)** only from a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 dietary management of PKU; and
- 2 The patient's blood phenylalanine level is < 900 mmol/litre (average of tests over last 12 months).

**Initial application — (Patient aged 16 or under)** only from a relevant specialist. Approvals valid for 3 years where the patient requires dietary management of PKU.

**Renewal — (Patient aged over 16)** only from a relevant specialist. Approvals valid for 1 year where blood phenylalanine level < 900 mmol/litre (average of tests over last 12 months).

**Renewal — (Patient aged 16 or under)** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

**Prescribing Guideline**

It can cost up to \$70,000 a year to keep an adult on protein supplements. Because protein substitutes are so expensive and because they are only effective in controlling PKU if a restricted diet is followed, adults with PKU will be required to demonstrate they are following the prescribed diet by regular blood testing. The requirement for testing applies to those aged over 16 years. Failure to follow an appropriate diet results in high blood phenylalanine levels.

The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.

**Foods For PKU**

PHENYL FREE BAKING MIX – Special Authority see SA0733 above – Hospital pharmacy [HP3]

See prescribing guideline above

Powder .....6.70 500 g OP  
 .....(8.22) Loprofin Mix

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
<b>PHENYL FREE PASTA – Special Authority see SA0733 on the preceding page – Hospital pharmacy [HP3]</b>				
See prescribing guideline on the preceding page				
Animal shapes .....	10.65 (11.91)	500 g OP		Loprofin
Lasagne .....	5.32 (5.95)	250 g OP		Loprofin
Low protein rice pasta .....	10.65 (11.91)	500 g OP		Loprofin
Macaroni .....	5.32 (5.95)	250 g OP		Loprofin
Penne .....	10.65 (11.91)	500 g OP		Loprofin
Spaghetti .....	10.65 (11.91)	500 g OP		Loprofin
Spirals .....	10.65 (11.91)	500 g OP		Loprofin

### Supplements For PKU

**AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA0733 on the preceding page – Hospital pharmacy [HP3]**

See prescribing guideline on the preceding page

Tabs .....	99.00	75 OP	✓ Phlexy 10
Sachets (pineapple/vanilla) 29 g .....	330.10	30 OP	✓ Minaphlex
Sachets (tropical) .....	324.00	30	✓ Phlexy 10
Infant formula .....	174.72	400 g OP	✓ XP Analog LCP
Powder (orange) .....	221.00	500 g OP	✓ XP Maxamaid
	320.00		✓ XP Maxamum
Powder (unflavoured) .....	221.00	500 g OP	✓ XP Maxamaid
	320.00		✓ XP Maxamum
Liquid (berry) .....	15.65	62.5 ml OP	✓ Lophlex LQ
	31.20	125 ml OP	✓ Lophlex LQ
Liquid (citrus) .....	15.65	62.5 ml OP	✓ Lophlex LQ
	31.20	125 ml OP	✓ Lophlex LQ
Liquid (forest berries) .....	30.00	250 ml OP	✓ Easiphen Liquid
Liquid (orange) .....	15.65	62.5 ml OP	✓ Lophlex LQ
	31.20	125 ml OP	✓ Lophlex LQ
Liquid (tropical) .....	30.00	250 ml OP	✓ Easiphen

### Multivitamin And Mineral Supplements

**AMINOACID FORMULA WITH MINERALS WITHOUT PHENYLALANINE – Special Authority see SA0733 on the preceding page – Hospital pharmacy [HP3]**

See prescribing guideline on the preceding page

Powder .....	58.44	250 g OP	✓ Metabolic Mineral Mixture
--------------	-------	----------	-----------------------------

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
	✓	

**Multivitamin Supplements For Inborn Errors Of Metabolism**

►SA0600 **Special Authority for Subsidy**

**Initial application** only from a relevant specialist. Approvals valid for 3 years where the patient has inborn errors of metabolism.

**Renewal** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

MULTIVITAMINS – Special Authority see SA0600 above – Hospital pharmacy [HP3]

Tab .....	19.65	100	✓ Ketovite
Powder .....	36.00	100 g OP	✓ Paediatric Seravit
Oral liq .....	8.98	150 ml OP	
	(13.50)		Ketovite Syrup

**Infant Formulae**

**For Premature Infants**

►SA0602 **Special Authority for Subsidy**

**Initial application** only from a relevant specialist. Approvals valid for 6 months where the patient is infant weighing less than 1.5 kg at birth.

PREMATURE BIRTH FORMULA – Special Authority see SA0602 above – Hospital pharmacy [HP3]

Liquid .....	0.75	100 ml OP	✓ S26LBW Gold RTF
--------------	------	-----------	-------------------

**For Williams Syndrome**

►SA0601 **Special Authority for Subsidy**

**Initial application** only from a relevant specialist. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

**Renewal** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

LOW CALCIUM INFANT FORMULA – Special Authority see SA0601 above – Hospital pharmacy [HP3]

Powder .....	44.40	400 g OP	✓ Locasol
--------------	-------	----------	-----------

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic Manufacturer
\$	Per	✓

**For Gastrointestinal And Other Malabsorptive Problems**

**SA0603 Special Authority for Subsidy**

**Initial application** only from a relevant specialist. Approvals valid for 1 year where the patient is infant suffering from malabsorption and other gastrointestinal problems.

**Renewal** only from a relevant specialist or general practitioner on the recommendation of a relevant specialist. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the specialist and date contacted.

Neocate should be used only as a last resort when the infant is unable to absorb any of the below formulae. The objective with each of the formulae prescribed is to get the infant off them as soon as possible. This may take six months, it may take three years. Because of this, variation on age limit is not regarded as appropriate. These formulae will be available only from a hospital pharmacy. Vivonex Pediatric may be a suitable and less expensive alternative for many children that would otherwise be eligible for a subsidy for Neocate and should, therefore, be tried first in these cases. The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.

ELEMENTAL FORMULA – Special Authority see SA0603 above – Hospital pharmacy [HP3]

Powder .....	15.52	450 g OP	
	(19.01)		Pepti Junior
	63.97	400 g OP	
	(67.08)		Neocate
	(67.08)		Neocate LCP
	5.62	48.5 g OP	
	(6.00)		Vivonex Pediatric
Powder (tropical) .....	52.90	400 g OP	
	(56.00)		Neocate Advance
Powder (unflavoured) .....	52.90	400 g OP	
	(56.00)		Neocate Advance

**For Milk Intolerance**

**SA0604 Special Authority for Subsidy**

**Initial application — (Lactase deficiency or disaccharide intolerance)** only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Patient is less than 3 years of age; and
- 2 Either:
  - 2.1 diagnosed as suffering from congenital lactase deficiency; or
  - 2.2 suffering from disaccharide intolerance.

Notes: Secondary lactose intolerance in children is usually short lasting, and can be controlled by dietary measures and by giving sufficient calories to regenerate digestive enzymes.

The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.

**Initial application — (Infant with intolerance to cows' milk)** only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 intolerant to cows' milk; and
- 2 patient is less than 3 years of age.

Note: The subsidy for these products reflects the philosophy that the patient incurs no additional financial burden for purchasing specialised more expensive products.

continued...

## SPECIAL FOODS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised ✓	Brand or Generic Manufacturer
--	---	-----	--------------------------	-------------------------------------

continued...

**Renewal — (Infant with intolerance to cows' milk)** only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 patient is less than 3 years of age.

GOATS MILK INFANT FORMULA – Special Authority see SA0604 on the preceding page – Retail pharmacy

Powder .....	9.42	900 g OP		
	(22.75)			Karicare Goats Milk Infant Formula

LACTOSE FREE INFANT FORMULA – Special Authority see SA0604 on the preceding page – Retail pharmacy

Powder .....	5.66	900 g OP		
	(17.95)			Delact

SOYA INFANT FORMULA – Special Authority see SA0604 on the preceding page – Retail pharmacy

Powder .....	6.34	900 g OP		
	(19.57)			S26 Soy

### Infant Formulae - Lactose Intolerance and Cows' Milk Protein Intolerance

#### ►SA0757 Special Authority for Subsidy

**Initial application** only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient is less than 2 years of age; and
- 2 Intolerant to cows' milk; and
- 3 Diagnosed as suffering from congenital lactase deficiency.

**Renewal** only from a relevant specialist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

INFANT SOY FORMULA – Special Authority see SA0757 above – Retail pharmacy

Powder .....	7.27	900 g		
	(16.35)			Karicare Soy All Ages

**Pharmaceuticals and quantities that may be obtained on a Practitioner's Supply Order**

ADRENALINE	
✓ Inj 1 in 1,000, 1 ml .....	5
✓ Inj 1 in 10,000, 10 ml .....	5
AMINOPHYLLINE	
✓ Inj 25 mg per ml, 10 ml .....	5
AMIODARONE HYDROCHLORIDE	
✓ Inj 50 mg per ml, 3 ml .....	5
AMOXYCILLIN	
✓ Cap 250 mg .....	30
✓ Grans for oral liq 125 mg per 5 ml .....	200 ml
✓ Grans for oral liq 250 mg per 5 ml .....	200 ml
✓ Inj 1 g .....	5
AMOXYCILLIN CLAVULANATE	
✓ Tab amoxicillin 500 mg with potassium clavulanate 125 mg .....	30
✓ Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml .....	200 ml
✓ Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml .....	200 ml
APPLICATOR	
✓ Applicator – See note on page 73 .....	1
ASPIRIN	
✓ Tab dispersible 300 mg .....	30
ATROPINE SULPHATE	
✓ Inj 600 µg, 1 ml .....	5
✓ Inj 1200 µg, 1 ml .....	5
AZITHROMYCIN	
✓ Tab 500 mg – Subsidy by endorsement – See note on page 89 .....	4
BENDROFLUAZIDE	
✓ Tab 2.5 mg – See note on page 60 .....	150
BENZATHINE BENZYL PENICILLIN	
✓ Inj 1.2 mega u per 2 ml .....	5
BENZTROPINE MESYLATE	
✓ Inj 1 mg per ml, 2 ml .....	5
BENZYL PENICILLIN SODIUM (PENICILLIN G)	
✓ Inj 1 mega u .....	5
CEFTRIAOXONE SODIUM	
✓ Inj 500 mg – Hospital pharmacy [HP3] – Subsidy by endorsement – See note on page 88 .....	5
✓ Inj 1 g – Hospital pharmacy [HP3] – Subsidy by endorsement – See note on page 88 .....	5
CHARCOAL	
✓ Oral liq 50 g per 250 ml .....	250 ml
CHLORPROMAZINE HYDROCHLORIDE	
✓ Tab 10 mg .....	30
✓ Tab 25 mg .....	30
✓ Tab 100 mg .....	30
✓ Inj 25 mg per ml, 2 ml .....	5
CIPROFLOXACIN	
✓ Tab 250 mg .....	5
✓ Tab 500 mg .....	5
CO-TRIMOXAZOLE	
✓ Tab trimethoprim 80 mg and sulphamethoxazole 400 mg .....	30
✓ Oral liq sugar-free trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml .....	200 ml
COMPOUND ELECTROLYTES	
✓ Powder for soln for oral use 5 g .....	10
CONDOMS	
✓ 49 mm .....	144
✓ 52 mm .....	144
✓ 52 mm extra strength .....	144
✓ 53 mm .....	144
✓ 53 mm (chocolate) .....	144
✓ 53 mm (strawberry) .....	144
✓ 53 mm extra strength .....	144
✓ 54 mm, shaped .....	144
✓ 55 mm .....	144
✓ 56 mm, shaped .....	144
✓ 60 mm .....	144
DEXAMETHASONE	
✓ Tab 1 mg – Retail pharmacy-Specialist .....	30
✓ Tab 4 mg – Retail pharmacy-Specialist .....	30
DEXAMETHASONE SODIUM PHOSPHATE	
✓ Inj 4 mg per ml, 1 ml .....	5
✓ Inj 4 mg per ml, 2 ml .....	5
DEXTROSE	
✓ Inj 50%, 10 ml .....	5
✓ Inj 50%, 90 ml .....	5
DIAPHRAGM	
✓ Diaphragm – See note on page 73 .....	1
DIAZEPAM	
✓ Inj 5 mg per ml, 2 ml – Subsidy by endorsement – See note on page 115 .....	5

continued...

✓ fully subsidised brand available

Please refer to Section A for a definition, and conditions of supply, of Practitioner's Supply Orders.

## PRACTITIONER'S AND WHOLESALE SUPPLY ORDERS

(continued)

- ✓ Rectal tubes 5 mg ..... 5
- ✓ Rectal tubes 10 mg ..... 5

### DICLOFENAC SODIUM

- ✓ Inj 25 mg per ml, 3 ml ..... 5
- ✓ Suppos 50 mg ..... 10

### DIGOXIN

- ✓ Tab 62.5 µg ..... 30
- ✓ Tab 250 µg ..... 30

### DOXYCYCLINE HYDROCHLORIDE

- Tab 50 mg ..... 30
- ✓ Tab 100 mg ..... 30

### ERGOMETRINE MALEATE

- ✓ Inj 500 µg per ml, 1 ml ..... 5

### ERYTHROMYCIN ETHYL SUCCINATE

- ✓ Tab 400 mg ..... 30
- ✓ Grans for oral liq 200 mg per 5 ml ..... 200 ml
- ✓ Grans for oral liq 400 mg per 5 ml ..... 200 ml

### ERYTHROMYCIN STEARATE

- Tab 250 mg ..... 30

### ETHINYLOESTRADIOL WITH DESOGESTREL

- Tab 20 µg with desogestrel 150 µg ..... 63
- Tab 20 µg with desogestrel 150 µg and 7 inert tab ..... 84
- Tab 30 µg with desogestrel 150 µg ..... 63
- Tab 30 µg with desogestrel 150 µg and 7 inert tab ..... 84

### ETHINYLOESTRADIOL WITH GESTODENE

- Tab 30 µg with gestodene 75 µg and 7 inert tab ..... 84

### ETHINYLOESTRADIOL WITH LEVONORGESTREL

- ✓ Tab ethinyloestradiol 30 µg with levonorgestrel 50 µg (6) and tab ethinyloestradiol 40 µg with levonorgestrel 75 µg (5), and tab ethinyloestradiol 30 µg with levonorgestrel 125 µg (10) and 7 inert tab ..... 84
- ✓ Tab 50 µg with levonorgestrel 125 µg and 7 inert tab ..... 84
- Tab 30 µg with levonorgestrel 150 µg ..... 63
- ✓ Tab 30 µg with levonorgestrel 150 µg and 7 inert tab ..... 84
- Tab 20 µg with levonorgestrel 100 µg and 7 inert tab ..... 84

### ETHINYLOESTRADIOL WITH NORETHISTERONE

- ✓ Tab 35 µg with norethisterone 1 mg ..... 63

- ✓ Tab 35 µg with norethisterone 1 mg and 7 inert tab ..... 84
- ✓ Tab 35 µg with norethisterone 500 µg ..... 63
- ✓ Tab 35 µg with norethisterone 500 µg and 7 inert tab ..... 84

### FLUCLOXACILLIN SODIUM

- ✓ Cap 250 mg ..... 30
- ✓ Grans for oral liq 125 mg per 5 ml ..... 200 ml
- ✓ Grans for oral liq 250 mg per 5 ml ..... 200 ml
- ✓ Inj 1 g ..... 5

### FLUPENTHIXOL DECANOATE

- ✓ Inj 20 mg per ml, 1 ml ..... 5
- ✓ Inj 20 mg per ml, 2 ml ..... 5
- ✓ Inj 100 mg per ml, 1 ml ..... 5

### FLUPHENAZINE DECANOATE

- ✓ Inj 12.5 mg per 0.5 ml, 0.5 ml ..... 5
- ✓ Inj 25 mg per ml, 1 ml ..... 5
- ✓ Inj 100 mg per ml, 1 ml ..... 5

### FRUSEMIDE

- ✓ Tab 40 mg ..... 30
- ✓ Inj 10 mg per ml, 2 ml ..... 5

### GLUCAGON HYDROCHLORIDE

- ✓ Inj 1 mg syringe kit ..... 5

### GLYCERYL TRINITRATE

- ✓ Tab 600 µg ..... 100
- ✓ Oral pump spray 400 µg per dose ..... 250 dose

### HALOPERIDOL

- ✓ Tab 500 µg ..... 30
- ✓ Tab 1.5 mg ..... 30
- ✓ Tab 5 mg ..... 30
- ✓ Oral liq 2 mg per ml ..... 200 ml
- ✓ Inj 5 mg per ml, 1 ml ..... 5

### HALOPERIDOL DECANOATE

- ✓ Inj 50 mg per ml, 1 ml ..... 5
- ✓ Inj 100 mg per ml, 1 ml ..... 5

### HYDROCORTISONE

- ✓ Inj 50 mg per ml, 2 ml ..... 5

### HYDROXOCOBALAMIN

- ✓ Inj 1 mg per ml, 1 ml ..... 6

### HYOSCINE N-BUTYLBROMIDE

- ✓ Inj 20 mg, 1 ml ..... 5

### IPRATROPIUM BROMIDE

- ✓ Nebuliser soln, 250 µg per ml, 1 ml ..... 40
- ✓ Nebuliser soln, 250 µg per ml, 2 ml ..... 40

continued...

✓ fully subsidised brand available

(continued)

LEVONORGESTREL	
Tab 30 µg.....	84
✓ Tab 1.5 mg.....	5
LIGNOCAINE HYDROCHLORIDE	
✓ Inj 0.5%, 5 ml – See note on page 110.....	5
✓ Inj 1%, 5 ml – See note on page 110.....	5
✓ Inj 1%, 20 ml – See note on page 110.....	5
LOPERAMIDE HYDROCHLORIDE	
✓ Tab 2 mg.....	30
MEDROXYPROGESTERONE ACETATE	
✓ Inj 150 mg per ml, 1 ml.....	5
✓ Inj 150 mg per ml, 1 ml syringe.....	5
METHYLERGOMETRINE	
✓ Inj 200 µg per ml, 1 ml.....	10
METOCLOPRAMIDE HYDROCHLORIDE	
✓ Inj 5 mg per ml, 2 ml.....	5
METRONIDAZOLE	
✓ Tab 200 mg.....	30
MORPHINE SULPHATE	
✓ Inj 5 mg per ml, 1 ml – Only on a controlled drug form.....	5
✓ Inj 10 mg per ml, 1 ml – Only on a controlled drug form.....	5
✓ Inj 15 mg per ml, 1 ml – Only on a controlled drug form.....	5
✓ Inj 30 mg per ml, 1 ml – Only on a controlled drug form.....	5
NALOXONE HYDROCHLORIDE	
✓ Inj 400 µg per ml, 1 ml.....	5
NONOXYNOL-9	
✓ Jelly 2%.....	108 g
NORETHISTERONE	
✓ Tab 350 µg.....	84
✓ Tab 5 mg.....	30
NORETHISTERONE WITH MESTRANOL	
Tab 1 mg with mestranol 50 µg and 7 inert tab.....	84
OXYTOCIN	
✓ Inj 5 iu per ml, 1 ml.....	5
✓ Inj 10 iu per ml, 1 ml.....	5
✓ Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml.....	5
PARACETAMOL	
✓ Tab 500 mg.....	30
✓ Oral liq 120 mg per 5 ml.....	200 ml
✓ Oral liq 250 mg per 5 ml.....	100 ml

PETHIDINE HYDROCHLORIDE	
✓ Inj 50 mg per ml, 1 ml – Only on a controlled drug form.....	5
✓ Inj 50 mg per ml, 1.5 ml – Only on a controlled drug form.....	5
✓ Inj 50 mg per ml, 2 ml – Only on a controlled drug form.....	5
PHENOXYMETHYLPENICILLIN (PENICILLIN V)	
✓ Cap potassium salt 250 mg.....	30
✓ Grans for oral liq 125 mg per 5 ml.....	200 ml
✓ Grans for oral liq 250 mg per 5 ml.....	200 ml
PHENYTOIN SODIUM	
✓ Inj 50 mg per ml, 2 ml.....	5
✓ Inj 50 mg per ml, 5 ml.....	5
PHYTOMENADIONE	
✓ Inj 2 mg per 0.2 ml.....	5
✓ Inj 10 mg per ml, 1 ml.....	5
PIPOTHAZINE PALMITATE	
✓ Inj 50 mg per ml, 1 ml.....	5
✓ Inj 50 mg per ml, 2 ml.....	5
PREDNISOLONE SODIUM PHOSPHATE	
✓ Oral liq 5 mg per ml – See note on page 79.....	30 ml
PREDNISONE	
✓ Tab 5 mg.....	30
PROCAINE PENICILLIN	
✓ Inj 1.5 mega u.....	5
PROCHLORPERAZINE	
✓ Tab 5 mg.....	30
✓ Inj 12.5 mg per ml, 1 ml.....	5
PROMETHAZINE HYDROCHLORIDE	
✓ Inj 25 mg per ml, 2 ml.....	5
SALBUTAMOL	
✓ Inj 500 µg per ml, 1 ml.....	5
✓ Aerosol inhaler, 100 µg per dose CFC free.....	1000 dose
✓ Nebuliser soln, 1 mg per ml, 2.5 ml.....	30
✓ Nebuliser soln, 2 mg per ml, 2.5 ml.....	30
SALBUTAMOL WITH IPRATROPIUM BROMIDE	
✓ Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml.....	20
SILVER SULPHADIAZINE	
✓ Crm 1% with chlorhexidine digluconate 0.2%.....	500 g

continued..

✓ fully subsidised brand available

Please refer to Section A for a definition, and conditions of supply, of Practitioner's Supply Orders.

## PRACTITIONER'S AND WHOLESALE SUPPLY ORDERS

(continued)

### SODIUM BICARBONATE

- ✓ Inj 8.4%, 50ml ..... 5
- ✓ Inj 8.4%, 100 ml ..... 5

### SODIUM CHLORIDE

- ✓ Inf 0.9% – See note on page 48 ..... 2000 ml
- ✓ Inj 0.9%, 5 ml ..... 5
- ✓ Inj 0.9%, 10 ml ..... 5

### TRIMETHOPRIM

- ✓ Tab 300 mg ..... 30

### VERAPAMIL HYDROCHLORIDE

- ✓ Inj 2.5 mg per ml, 2 ml ..... 5

### WATER

- ✓ Purified for inj 2 ml – See note on page 48 ..... 5
- ✓ Purified for inj 5 ml – See note on page 48 ..... 5
- ✓ Purified for inj 10 ml – See note on page 48 ..... 5
- ✓ Purified for inj 20 ml – See note on page 48 ..... 5

### ZUCLOPENTHIXOL DECANOATE

- ✓ Inj 200 mg per ml, 1 ml ..... 5

## Pharmaceuticals that may be obtained on a Wholesale Supply Order

### INTRA-UTERINE DEVICE

- ✓ IUD

### MASK FOR SPACER DEVICE

- ✓ Size 2

### PEAK FLOW METER

- ✓ Low range
- ✓ Normal range

### PREGNANCY TESTS - HCG URINE

- ✓ Cassette

### SPACER DEVICE

- ✓ 230 ml (autoclavable)
- ✓ 230 ml (single patient)

✓ fully subsidised brand available

## Rural Areas for Practitioner's Supply Orders

<b>NORTH ISLAND</b>	Tairua	Marlon	Leeston
<b>Northland DHB</b>	Taumarunui	Ohakune	Lincoln
Dargaville	Te Aroha	Raetihi	Methven
Hikurangi	Te Kauwhata	Taihape	Oxford
Kaeo	Te Kuiti	Waiouru	Rakaia
Kaikohe	Tokoroa	<b>MidCentral DHB</b>	Rolleston
Kaitiaki	Waihi	Dannevirke	Rotherham
Kawakawa	Whangamata	Shannon	Templeton
Kerikeri	Whitianga	Foxton	Waikari
Mangonui	<b>Bay of Plenty DHB</b>	Levin	
Maungaturoto	Edgecumbe	Otaki	
Moerewa	Katikati	Pahiatua	<b>South Canterbury DHB</b>
Ngunguru	Kawerau	Shannon	Fairlie
Paihia	Murupara	Woodville	Geraldine
Rawene	Opotiki	<b>Wairarapa DHB</b>	Pleasant Point
Ruakaka	Taneatua	Carteron	Temuka
Russell	Te Kaha	Featherston	Twizel
Tutukaka	Waihi Beach	Greytown	Waimate
Waipu	Whakatane	Martinborough	
Whangaroa	<b>Lakes DHB</b>	<b>SOUTH ISLAND</b>	
<b>Waitemata DHB</b>	Mangakino	<b>Nelson/Marlborough DHB</b>	<b>Otago DHB</b>
Helensville	Turangi	Havelock	Alexandra
Huapai	<b>Tairāwhiti DHB</b>	Mapua	Balclutha
Kumeu	Ruatoria	Motueka	Cromwell
Snells Beach	Te Araroa	Murchison	Kurow
Waimauku	Te Karaka	Picton	Lawrence
Warkworth	Te Puia Springs	Takaka	Milton
Wellsford	Tikitiki	Wakefield	Oamaru
<b>Auckland DHB</b>	Tokomaru Bay	<b>West Coast DHB</b>	Outram
Great Barrier Island	Tolaga Bay	Dobson	Owaka
Oneroa	<b>Taranaki DHB</b>	Greymouth	Palmerston
Ostend	Eltham	Hokitika	Ranfurly
<b>Counties Manukau DHB</b>	Inglewood	Karamea	Roxburgh
Tuakau	Manaia	Reefton	Tapanui
Waiuku	Oakura	South Westland	Wanaka
<b>Waikato DHB</b>	Okato	Westport	
Coromandel	Opunake	Whataroa	<b>Southland DHB</b>
Huntly	Patea	<b>Canterbury DHB</b>	Gore
Kawhia	Stratford	Akaroa	Lumsden
Matamata	Waverley	Amberley	Mataura
Morrinsville	<b>Hawkes Bay DHB</b>	Amuri	Otautau
Ngatea	Chatham Islands	Cheviot	Queenstown
Otorohanga	Waipawa	Darfield	Riverton
Paeroa	Waipukurau	Diamond Harbour	Te Anau
Pauanui Beach	Wairoa	Hanmer Springs	Tokonui
Putaruru	<b>Whanganui DHB</b>	Kaikoura	Tuatapere
Raglan	Bulls		Winton

✓ fully subsidised brand available

Please refer to Section A for a definition, and conditions of supply, of Practitioner's Supply Orders.

## **SECTION F: COMMUNITY PHARMACEUTICALS DISPENSING PERIOD EXEMPTIONS**

---

### **SECTION F: PART I**

A Community Pharmaceutical identified with a \* within the other sections of the Pharmaceutical Schedule:

- a) is exempt from any requirement to dispense in Monthly Lots;
- b) will only be subsidised if it is dispensed in a 90 Day Lot unless it is Close Control.

A Community Pharmaceutical that is an oral contraceptive and that is identified with a \* within the other sections of the Pharmaceutical Schedule:

- a) is exempt from any requirement to dispense in Monthly Lots;
- b) will only be subsidised if it is dispensed in a 180 Day Lot unless it is Close Control.

### **SECTION F: PART II: CERTIFIED EXEMPTIONS AND ACCESS EXEMPTIONS TO MONTHLY DISPENSING**

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a \* within the other sections of the Pharmaceutical Schedule, may be dispensed in a 90 Day Lot if:

- a) the Community Pharmaceutical is identified with a ▲ within the other sections of the Pharmaceutical Schedule and the prescriber has endorsed the Prescription item(s) on the Prescription to which the exemption applies "certified exemption". In endorsing the Prescription items for a certified exemption, the prescriber is certifying that:
  - i) the patient wished to have the medicine dispensed in a quantity greater than a Monthly Lot; and
  - ii) the patient has been stabilised on the same medicine for a reasonable period of time; and
  - iii) the prescriber has reason to believe the patient will continue on the medicine and is compliant.
- b) a patient, who has difficulty getting to and from a pharmacy, signs the back of the Prescription to qualify for an Access Exemption. In signing the Prescription, the patient or his or her nominated representative must also certify which of the following criteria they meet:
  - i) have limited physical mobility;
  - ii) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
  - iii) are relocating to another area;
  - iv) are travelling extensively and will be out of town when the repeat prescriptions are due.

The following Community Pharmaceuticals are identified with a ▲ within the other sections of the Pharmaceutical Schedule and may be dispensed in a 90 Day Lot if endorsed as a certified exemption in accordance with paragraph (a) in Section F Part II above.

**ALIMENTARY TRACT AND METABOLISM**

INSULIN ASPART  
 INSULIN GLARGINE  
 INSULIN ISOPHANE  
 INSULIN ISOPHANE WITH INSULIN NEUTRAL  
 INSULIN LISPRO  
 INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE  
 INSULIN NEUTRAL

**CARDIOVASCULAR SYSTEM**

AMIODARONE HYDROCHLORIDE  
 Tab 100 mg                      Cordarone-X  
 Tab 200 mg                      Cordarone-X

DISOPYRAMIDE PHOSPHATE

FLECAINIDE ACETATE  
 Tab 50 mg                      Tambocor  
 Tab 100 mg                      Tambocor  
 Cap long-acting 100 mg      Tambocor CR  
 Cap long-acting 200 mg      Tambocor CR

MEXILETINE HYDROCHLORIDE

PROPAFENONE HYDROCHLORIDE

**HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES**

DESMOPRESSIN  
 Nasal drops 100 µg per      Minirin  
 ml  
 Nasal spray 10 µg per      Desmopressin-PH&T  
 dose

**MUSCULO-SKELETAL SYSTEM**

PYRIDOSTIGMINE BROMIDE

**NERVOUS SYSTEM**

AMANTADINE HYDROCHLORIDE  
 APOMORPHINE HYDROCHLORIDE  
 ENTACAPONE  
 GABAPENTIN  
 LAMOTRIGINE  
 LISURIDE HYDROGEN MALEATE  
 PERGOLIDE  
 ROPINIROLE HYDROCHLORIDE  
 TOLCAPONE  
 TOPIRAMATE  
 VIGABATRIN

**SENSORY ORGANS**

BIMATOPROST  
 BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE  
 BRINZOLAMIDE  
 LATANOPROST  
 TRAVOPROST

## SECTION G: SAFETY CAP MEDICINES

Pharmacists are required, under the Code of Ethics of the Pharmacy Council of New Zealand, to endeavour to use safety caps when dispensing any of the medicines listed in Section G in an oral liquid formulation pursuant to a prescription or Practitioner's Supply Order. This includes all proprietary and extemporaneously compounded oral liquid preparations of those pharmaceuticals listed in Section G of the Pharmaceutical Schedule. These medicines will be identified throughout Section B of the Pharmaceutical Schedule with the symbol '‡'.

### Exemptions

Oral liquid preparations of the pharmaceuticals listed in Section G of the Pharmaceutical Schedule will be dispensed in a container with a safety cap unless:

- the practitioner has endorsed the Prescription or Practitioner's Supply Order, stating that, the Pharmaceutical is not to be dispensed in a container with a safety cap; or
- the Contractor has annotated the Prescription or Practitioner's Supply Order stating that, because of infirmity of the particular person, the Pharmaceutical to be used by that person should not be dispensed in a container with a safety cap; or
- the Pharmaceutical is packaged in an Original Pack so designed that on the professional judgement of the Contractor, transfer to a container with a safety cap would be inadvisable or a retrograde procedure.

### Reimbursement

Pharmacists will be reimbursed according to their agreement. Where an additional fee is paid on safety caps it will be paid on all dispensings of oral liquid preparations for those pharmaceuticals listed in Section G of the Pharmaceutical Schedule unless the practitioner has endorsed or the contractor has annotated the Prescription or Practitioner's Supply Order that a safety cap has not been supplied.

### Safety Caps (NZS 5825:1991)

20 mm.....	.Clic-Loc, United Closures & Plastics PLC, England Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
24 mm.....	.Clic-Loc, United Closures & Plastics PLC, England Clic-Loc, ACI Closures under license to Owens-Illinois Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
28 mm.....	.Clic-Loc, United Closures & Plastics PLC, England Clic-Loc, ACI Closures under license to Owens-Illinois Kerr, Cormack Packaging, Sydney, under licence to Kerr USA PDL Squeezlok PDL FG

**ALIMENTARY TRACT AND METABOLISM****FERROUS SULPHATE**

Oral liq 150 mg per 5 ml Ferodan

**CARDIOVASCULAR SYSTEM****AMILORIDE**

Oral liq 1 mg per ml Biomed

**CAPTOPRIL**

Oral liq 5 mg per ml Capoten

**CHLOROTHIAZIDE**

Oral liq 50 mg per ml Biomed

**DIGOXIN**

Oral liq 50 µg per ml Lanoxin

**FRUSEMIDE**

Oral liq 10 mg per ml Lasix

**SPIRONOLACTONE**

Oral liq 5 mg per ml Biomed

**HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES****LEVOTHYROXINE**Tab 50 µg Eltroxin  
GoldshieldTab 100 µg Eltroxin  
Goldshield*(Extemporaneously compounded oral liquid preparations)***MUSCULO-SKELETAL SYSTEM****IBUPROFEN**

Oral liq 100 mg per 5 ml Fenpaed

**QUININE SULPHATE**

Tab 200 mg Q 200

Tab 300 mg Q 300

*(Extemporaneously compounded oral liquid preparations)***NERVOUS SYSTEM****ALPRAZOLAM**

Tab 250 µg Arrow-Alprazolam

Tab 500 µg Arrow-Alprazolam

Tab 1 mg Arrow-Alprazolam

*(Extemporaneously compounded oral liquid preparations)***CARBAMAZEPINE**

Oral liq 100 mg per 5 ml Tegretol

**GLOBAZAM**

Tab 10 mg Frisium

*(Extemporaneously compounded oral liquid preparations)***CLONAZEPAM**

Oral drops 2.5 mg per ml Rivotril

**DIAZEPAM**

Tab 2 mg Pro-Pam

Tab 5 mg Pro-Pam

Tab 10 mg Pro-Pam

*(Extemporaneously compounded oral liquid preparations)***ETHOSUXIMIDE**

Oral liq 250 mg per 5 ml Zaronin

**LORAZEPAM**

Tab 1 mg Ativan

Tab 2.5 mg Ativan

*(Extemporaneously compounded oral liquid preparations)***LORMETAZEPAM**

Tab 1 mg Noctamid

*(Extemporaneously compounded oral liquid preparations)***METHADONE HYDROCHLORIDE**

Oral liq 2 mg per ml Biodone

Oral liq 5 mg per ml Biodone Forte

Oral liq 10 mg per ml Biodone Extra Forte

**MIDAZOLAM**

Tab 7.5 mg Hypnovel

*(Extemporaneously compounded oral liquid preparations)***MORPHINE HYDROCHLORIDE**

Oral liq 1 mg per ml RA-Morph

Oral liq 2 mg per ml RA-Morph

Oral liq 5 mg per ml RA-Morph

Oral liq 10 mg per ml RA-Morph

**NITRAZEPAM**Tab 5 mg Insoma  
Nitrados*(Extemporaneously compounded oral liquid preparations)***OXAZEPAM**

Tab 10 mg Ox-Pam

Tab 15 mg Ox-Pam

*(Extemporaneously compounded oral liquid preparations)***OXYCODONE HYDROCHLORIDE**

Oral liq 5 mg per 5 ml OxyNorm

**PARACETAMOL**

Oral liq 120 mg per 5 ml Paracare Junior

Oral liq 250 mg per 5 ml Paracare Double Strength

## SAFETY CAP MEDICINES

---

### PHENYTOIN SODIUM

Oral liq 30 mg per 5 ml Dilantin

### SODIUM VALPROATE

Oral liq 200 mg per 5 ml Epilim S/F Liquid  
Epilim Syrup

### TEMAZEPAM

Tab 10 mg Normison

*(Extemporaneously compounded oral liquid preparations)*

### TRIAZOLAM

Tab 125 µg Hypam

Tab 250 µg Hypam

*(Extemporaneously compounded oral liquid preparations)*

## RESPIRATORY SYSTEM AND ALLERGIES

### CETIRIZINE HYDROCHLORIDE

Oral liq 1 mg per ml Allerid C  
Cetirizine - AFT

### CHLORPHENIRAMINE MALEATE

Oral liq 2 mg per 5 ml Histafen

### DEXTROCHLORPHENIRAMINE MALEATE

Oral liq 2 mg per 5 ml Polaramine

### PROMETHAZINE HYDROCHLORIDE

Oral liq 5 mg per 5 ml Phenergan

### SALBUTAMOL

Oral liq 2 mg per 5 ml Salapin

### THEOPHYLLINE

Oral liq 80 mg per 15 ml Nuelin

### TRIMEPRAZINE TARTRATE

Oral liq 30 mg per 5 ml Vallergan Forte

## EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

### CODEINE PHOSPHATE

Powder Douglas

*(Extemporaneously compounded oral liquid preparations)*

### METHADONE HYDROCHLORIDE

Powder AFT

*(Extemporaneously compounded oral liquid preparations)*

### PHENOBARBITONE SODIUM

Powder MidWest

*(Extemporaneously compounded oral liquid preparations)*

<b>- Symbols -</b>			
3TC .....	97	Alendronate sodium with cholecalciferol .....	108
<b>- A -</b>		Alfacalcidol .....	38
A-Lices .....	69	Alginate acid .....	26
Abacavir sulphate .....	97	Alitraq .....	178
Abacavir sulphate with lamivudine .....	97	Alkeran .....	134
Abilify .....	122	Allerid C .....	150
Acarbose .....	31	Allersoothe .....	151
ACB .....	56	Allopurinol .....	109
Accu-Chek Performa .....	33	Alpha Adrenoceptor Blockers .....	53
Accupril .....	54	Alpha tocopheryl acetate .....	38
Accuretic 10 .....	54	Alpha-Bromocriptine .....	121
Accuretic 20 .....	54	Alpha-Keri Lotion .....	68
Acebutolol .....	56	Alprazolam .....	126
Acetazolamide .....	159	Alu-Tab .....	26
Acetic acid with 1, 2- propanediol diacetate and benzethonium .....	157	Aluminium hydroxide .....	26
Acetic acid with hydroxyquinoline and ricinoleic acid .....	77	Amantadine hydrochloride .....	121
Acetylcysteine .....	167	Amiloride .....	60
Aci-Jel .....	77	Amiloride with frusemide .....	60
Aciclovir		Amiloride with hydrochlorothiazide .....	60
Infection .....	94	Aminophylline .....	155
Sensory .....	157	Amiodarone hydrochloride .....	55
Acidex .....	26	Amirol .....	113
Acipimox .....	49	Amisulpride .....	122
Acitretin .....	69	Amitrip .....	113
Actigall .....	34	Amitriptyline .....	113
Actos .....	31	Amizide .....	60
Actrapid .....	29	Amlodipine .....	58
Actrapid Penfill .....	29	Amorolfine .....	63
Acupan .....	110	Amoxil Paediatric Drops .....	90
Adalat 10 .....	58	Amoxicillin .....	90
Adalat Oros .....	58	Amoxicillin clavulanate .....	90
Adalimumab .....	106	Amphotericin B .....	37
Adefin XL .....	58	Amyl nitrite .....	61
Adefovir dipivoxil .....	94	Anabolic Agents .....	79
Adrenaline .....	61	Anaesthetics .....	110
Advantan .....	66	Anagrelide hydrochloride .....	138
AFT-Pyrazinamide .....	93	Analgesics .....	110
Agents Affecting the Renin-Angiotensin System .....	53	Anastrozole .....	143
Agents Used in the Treatment of Poisonings .....	162	Anastrozole-DP .....	144
Agrylin .....	138	Androderm .....	80
Alanase .....	155	Antabuse .....	131
Albay .....	150	Antacids and Antiflatulants .....	26
Albustix .....	162	Anten .....	113
Aldara .....	71	Anthelmintics .....	88
Alendronate sodium .....	108	Anti-inflammatory Non Steroidal Drugs (NSAIDs) .....	104
		Antiacne Preparations .....	63
		Antiallergy Preparations .....	150
		Antianaemics .....	44
		Antiandrogen Oral Contraceptives .....	76
		Antiarrhythmics .....	55
		Antibacterials .....	88
		Antibacterials Topical .....	63
		Anticholinesterases .....	104
		Antidepressants .....	113
		Antidiarrhoeals .....	26
		Antiepilepsy Drugs .....	115
		Antifibrinolytics, Haemostatics and Local Sclerosants .....	45
		Antifungals .....	92
		Antifungals Topical .....	63
		Antihæmorrhoidals .....	27
		Antihistamines .....	150
		Antihypotensives .....	56
		Antimalarials .....	93
		Antimigraine Preparations .....	119
		Antinaus .....	121
		Antinausea and Vertigo Agents .....	120
		Antiparkinson Agents .....	121
		Antipruritic Preparations .....	64
		Antipsychotics .....	122
		Antiretrovirals .....	96
		Antiretrovirals - Additional Therapies .....	98
		Antirheumatoid Agents .....	105
		Antispasmodics and Other Agents Altering Gut Motility .....	28
		Antithrombotic Agents .....	45
		Antithymocyte globulin (equine) .....	146
		Antitrichomonal Agents .....	93
		Antituberculous and Antileptotics .....	93
		Antulcerants .....	28
		Antivirals .....	94
		Anusol .....	27
		Anxiolytics .....	126
		Apo-Allopurinol .....	109
		Apo-Amlodipine .....	58
		Apo-Amoxi .....	90
		Apo-Ascorbic Acid .....	38
		Apo-B-Complex .....	38
		Apo-Captopril .....	53
		Apo-Cimetidine .....	28
		Apo-Clopidogrel .....	45
		Apo-Diclo .....	104
		Apo-Diclo SR .....	104
		Apo-Doxazosin .....	53
		Apo-Folic Acid .....	44



Respiratory .....	151, 155	Carboplatin .....	134	Cilicaine .....	91
Budesonide with		Carboplatin Ebewe .....	134	Cilicaine VK .....	91
efortmeterol .....	153	Carbosorb-X .....	162	Ciloxan .....	157
Bumetanide .....	60	Cardinol .....	57	Cimetidine .....	28
Bupivacaine hydrochloride .....	110	Cardinol LA .....	57	Cipflox .....	91
Buprenorphine		Cardizem CD .....	59	Ciprofloxacin	
hydrochloride .....	111	Carmustine .....	134	Infection .....	91
Burinex .....	60	Carvedilol .....	56	Sensory .....	157
Buscopan .....	28	Catapres .....	59	Cisplatin .....	134
Buserelin acetate .....	84	Catapres-TTS-1 .....	59	Cisplatin Ebewe .....	134
Buspirone hydrochloride .....	127	Catapres-TTS-2 .....	59	Citalopram - Rex .....	114
Busulphan .....	134	Catapres-TTS-3 .....	59	Citalopram hydrobromide .....	114
Butacort Aqueous .....	155	CeeNU .....	134	Cladribine .....	136
		Cefaclor monohydrate .....	88	Clarithromycin .....	89
<b>- C -</b>		Cefazolin sodium .....	88	Climara 100 .....	81
Cabergoline .....	87	Cefoxitin sodium .....	88	Climara 50 .....	81
Cafergot .....	119	Ceftriaxone sodium .....	88	Clindamycin .....	92
Cal-d-Forte .....	38	Cefuroxime axetil .....	88	Clinistix .....	32
Calamine .....	64	Cefuroxime sodium .....	89	Clinitest .....	32
Calci-Tab 500 .....	38	Celapram .....	114	Clinoril .....	105
Calci-Tab 600 .....	38	Celestone Chronodose .....	79	Clobazam .....	116
Calcipotriol .....	69	Celiprolol .....	56	Clobetasol propionate .....	65, 70
Calcitonin .....	108	Cellcept .....	146	Clobetasone butyrate .....	65
Calcitriol .....	38	Celol .....	56	Clomazol	
Calcitriol-AFT .....	38	Cerezyme .....	36	Dermatological .....	64
Calcium .....	38	Cetirizine - AFT .....	150	Genito-Urinary .....	77
Calcium carbonate .....	38	Cetirizine hydrochloride .....	150	Clomiphene citrate .....	87
Calcium carbonate with		Cetomacrogol .....	67	Clomipramine hydrochloride .....	113
aminoacetic acid .....	26	Charcoal .....	162	Clonazepam .....	115-116
Calcium Channel Blockers .....	58	Chemotherapeutic Agents .....	134	Clonidine .....	59
Calcium Disodium		Chlorambucil .....	134	Clonidine hydrochloride	
Versenate .....	162	Chloramphenicol .....	157	Cardiovascular .....	59
Calcium folinate .....	135	Chlorhexidine gluconate		Nervous .....	119
Calcium Folate Ebewe .....	135	Alimentary .....	36	Clopidogrel .....	45
Calcium gluconate .....	39	Dermatological .....	67	Clopine .....	123
Calcium Homeostasis .....	107	Chloroform .....	167	Clopixol .....	125
Calcium polystyrene		Chloromycetin .....	157	Clopress .....	113
sulphonate .....	48	Chlorothiazide .....	60	Clotrimaderm 2% .....	77
Calcium Resonium .....	48	Chlorpheniramine maleate .....	150	Clotrimazole	
Calogen .....	172	Chlorpromazine		Dermatological .....	64
Calsource .....	38	hydrochloride .....	123	Genito-Urinary .....	77
Calvasc .....	58	Chlorsig .....	157	Clozapine .....	123
Camptosar .....	137	Chlorthalidone .....	60	Clozaril .....	123
Candesartan .....	54	Chlorvescent .....	49	Co-Renitec .....	54
Canesten .....	64	Cholecalciferol .....	38	Co-trimoxazole .....	92
Capadex .....	111	Cholestyramine with		Coal tar .....	69
Capecitabine .....	135	aspartame .....	49	Coal tar with allantoin, menthol,	
Capoten .....	53	Choline salicylate with		phenol and sulphur .....	69
Capsaicin .....	71	cetalkonium chloride .....	36	Coal tar with salicylic acid and	
Captopril .....	53	Ciclopirox olamine .....	63	sulphur .....	69
Carafate .....	29	Cilazapril .....	53	Coco-Scalp .....	69
Carbamazepine .....	116	Cilazapril with		Codalgin .....	113
Carbimazole .....	83	hydrochlorothiazide .....	54	Codeine phosphate	

Extemporaneous .....	167	Cyclophosphamide .....	134	and polymyxin b sulphate .....	158
Nervous .....	111	Cyclosporin A .....	147	Dexamphetamine sulphate .....	129
Cogentin .....	122	Cyklokapron .....	45	Dextrochlorpheniramine	
Colaspase (L-asparaginase) .....	138	Cyproheptadine		maleate .....	151
Colchicine .....	109	hydrochloride .....	150	Dextropropoxyphene with	
Colestid .....	49	Cyproterone acetate .....	80	paracetamol .....	111
Colestipol hydrochloride .....	49	Cyproterone acetate with		Dextrose .....	48
Colgout .....	109	ethinyloestradiol .....	76	Dextrose with electrolytes .....	49
Colifoam .....	27	Cystic Fibrosis .....	155	DHC Continus .....	111
Colistin sulphomethate .....	92	Cytarabine .....	136	Diabetes .....	29
Colistin-Link .....	92	Cytotec .....	28	Diabetes Management .....	32
Collodion flexible .....	167	Cytoxan .....	134	Diabur 5000 .....	32
Colofac .....	28			Diamox .....	159
Coloxyl .....	35	<b>- D -</b>		Diaphragm .....	73
Combantrin .....	88	D-Penamine .....	105	Diasip .....	174
Combigan .....	159	D-Zol .....	87	Diason RTH .....	174
Combivent .....	154	d4T .....	97	Diastix .....	32
Combivir .....	97	Dacarbazine .....	139	Diastop .....	26
Compound electrolytes .....	48	Daclin .....	105	Diazepam .....	115, 127
Compound		Dactinomycin (actinomycin		Dibenylene .....	53
hydroxybenzoate .....	167	D) .....	139	Dibromopropamide	
Comtan .....	121	Daivonex .....	69	isethionate .....	157
Concerta .....	132	Daktarin		Diclofil .....	90
Condoms .....	73	Alimentary .....	37	Diclofenac sodium	
Condyline .....	71	Dermatological .....	64	Musculo-skeletal .....	104
Contraceptives - Hormonal .....	74	Dalacin C .....	92	Sensory .....	158
Contraceptives -		Danazol .....	87	Dicloxacillin .....	90
Non-hormonal .....	73	Dantrium .....	109	Didanosine [DDI] .....	97
Copaxone .....	129	Dantrolene sodium .....	109	Didronel .....	108
Copper .....	32	Dapsone .....	93	Diffiam .....	36
Corangin .....	61	Daunorubicin .....	139	Diflucortolone valerate .....	65
Cordarone-X .....	55	DDI .....	97	Digestives Including	
Corticosteroids and Related		Deca-Durabolin Orgaject .....	79	Enzymes .....	34
Agents for Systemic Use .....	79	Delact .....	188	Digoxin .....	55
Corticosteroids Topical .....	65	Depo-Medrol .....	79	Dihydrocodeine tartrate .....	111
Cosmegen .....	139	Depo-Medrol with lidocaine .....	79	Dilantin .....	118
Cosopt .....	159	Depo-Provera .....	76	Dilantin Infatab .....	118
Cotazym ECS .....	34	Depo-Testosterone .....	80	Dilatrend .....	56
Coumadin .....	47	Derbac-M .....	69	Diltiazem hydrochloride .....	59
Coversyl .....	54	Dermol .....	65, 70	Dilzem .....	59
Cozaar .....	55	Desferrioxamine mesylate .....	162	Dilzem LA .....	59
Creon 10000 .....	34	Desmopressin .....	87	Dilzem SR .....	59
Creon Forte .....	34	Desmopressin-PH&T .....	87	Dimetiose .....	87
Crixivan .....	98	Detection of Substances in		Dipentum .....	27
Cromolux .....	158	Urine .....	162	Diphemanil methylsulphate .....	67
Crotamiton .....	65	Dexamethasone		Diphenoxylate hydrochloride with	
Crystacide .....	63	Hormone .....	79	atropine sulphate .....	26
Cyclizine hydrochloride .....	120	Sensory .....	158	Diprosone .....	65
Cyclizine lactate .....	120	Dexamethasone sodium		Diprosone OV .....	65
Cycloblastin .....	134	phosphate .....	79	Dipyridamole .....	46
Cyclogyl .....	160	Dexamethasone with framycetin		Disinfecting and Cleansing	
Cyclopentolate		and gramicidin .....	157	Agents .....	67
hydrochloride .....	160	Dexamethasone with neomycin		Disipal .....	122

Disopyramide phosphate .....	55	Eformoterol fumarate .....	152	Ethics Aspirin EC .....	45
Disulfiram .....	131	Efudix .....	71	Ethinylloestradiol .....	82
Dithranol .....	69	Egopsoryl TA .....	69	Ethinylloestradiol with	
Diuretics .....	60	Elemental 028 Extra .....	178	desogestrel .....	74
Diurin 40 .....	60	Eligard .....	86	Ethinylloestradiol with	
Diurin 500 .....	60	Elocon .....	66	gestodene .....	74
Dixarit .....	119	Eloxatin .....	135	Ethinylloestradiol with	
Docetaxel .....	139	Eltroxin .....	83	levonorgestrel .....	75
Docosate sodium .....	35	EMLA .....	110	Ethinylloestradiol with	
Docosate sodium with		Emtricitabine .....	97	norethisterone .....	75
sennosides .....	35	Emtriva .....	97	Ethosuximide .....	116
Domperidone .....	120	Emulsifying ointment .....	67	Etidrate .....	108
Dopergin .....	121	Enalapril .....	54	Etidronate disodium .....	108
Dopress .....	113	Enalapril with		Etopophos .....	140
Dornase alfa .....	155	hydrochlorothiazide .....	54	Etoposide .....	140
Dorzolamide hydrochloride .....	159	Enbrel .....	106	Etoposide phosphate .....	140
Dorzolamide hydrochloride with		Endocrine Therapy .....	143	Eumovate .....	65
timolol maleate .....	159	Endoxan .....	134	Eurax .....	65
Dostinex .....	87	Enerlyte .....	48	Exemestane .....	144
Dothiepin hydrochloride .....	113	Enfuvirtide .....	98	Extemporaneously Compounded	
Doxazosin mesylate .....	53	Ensure .....	173	Preparations and	
Doxepin hydrochloride .....	113	Ensure Plus .....	180	Galenicals .....	167
Doxine .....	91	Ensure Plus RTH .....	180	Eye Preparations .....	157
Doxorubicin .....	140	Entacapone .....	121	Ezetimibe .....	51
Doxorubicin Ebewe .....	140	Entocort CIR .....	26	Ezetimibe with simvastatin .....	51
Doxy-50 .....	91	Enucleus .....	160	Ezetrol .....	51
Doxycycline hydrochloride .....	91	Enzymes .....	109		
DP Lotion .....	68	Epilim .....	118	<b>- F -</b>	
DP Lotn HC .....	66	Epilim Crushable .....	118	Famotidine .....	28
DP-Anastrozole .....	144	Epilim IV .....	118	Famox .....	28
Dr Reddy's Omeprazole .....	29	Epilim S/F Liquid .....	118	Felo 10 ER .....	58
Dr Reddy's Pantoprazole .....	29	Epilim Syrup .....	118	Felo 5 ER .....	58
Dulcolax .....	36	Epirubicin .....	140	Felodipine .....	58
Duocal Super Soluble		Epirubicin Ebewe .....	140	Femara .....	144
Powder .....	171	Eprex .....	44	Femodene 28 .....	74
Duolin .....	154	ERA .....	90	Femtran 100 .....	81
Duphalac .....	35	Ergometrine maleate .....	77	Femtran 50 .....	81
Duphaston .....	82	Ergotamine tartrate with		Fenpaed .....	104
Durex Confidence .....	73	caffeine .....	119	Fentanyl .....	111
Duride .....	61	Erythrocin IV .....	89	Ferdan .....	39
Durogesic .....	111	Erythromycin ethyl succinate .....	89	Ferro-F-Tabs .....	39
Dusting Powders .....	67	Erythromycin lactobionate .....	89	Ferro-Gradumet .....	39
Dydrogesterone .....	82	Erythromycin stearate .....	90	Ferro-tab .....	39
Dynacirc-SRO .....	58	Erythropoietin alpha .....	44	Ferrograd-Folic .....	39
		Erythropoietin beta .....	44	Ferrous fumarate .....	39
<b>- E -</b>		Estelle 35-ED .....	76	Ferrous fumarate with folic	
E-Mycin .....	89	Estraderm TTS 100 .....	81	acid .....	39
Ear Preparations .....	157	Estraderm TTS 25 .....	81	Ferrous gluconate with ascorbic	
Ear/Eye Preparations .....	157	Estraderm TTS 50 .....	81	acid .....	39
Easiphen .....	185	Estroferm .....	81	Ferrous sulphate .....	39
Easiphen Liquid .....	185	Etanercept .....	106	Ferrous sulphate with folic	
Econazole nitrate .....	64	Ethambutol hydrochloride .....	93	acid .....	39
Efavirenz .....	97	Ethics Aspirin .....	110	Ferrum H .....	39
Efexor XR .....	115			Fexofenadine hydrochloride .....	151



Humulin 30/70 .....	30	Immunosuppressants .....	146	Isosource Standard .....	180
Humulin NPH .....	29	Imuran .....	146	Isosource Standard RTH .....	180
Humulin R .....	29	Indapamide .....	60	Isotane 10 .....	63
Hyalase .....	109	Indinavir .....	98	Isotane 20 .....	63
Hyaluronidase .....	109	Indomethacin .....	105	Isotretinoin .....	63
Hybloc .....	57	Infant Formulae .....	186	Isradipine .....	58
Hydralazine .....	61	Influenza vaccine .....	103	Isuprel .....	61
Hydrea .....	140	Inhaled Anticholinergic agents .....	154	Itraconazole .....	93
Hydrocortisone Dermatological .....	66	Inhaled Corticosteroids .....	151	<b>- J -</b>	
Hormone .....	79	Inhaled Long-acting Beta-adrenoceptor Agonists .....	152	Janola .....	67
Hydrocortisone acetate .....	27	Inhibace .....	53	Jevity RTH .....	180
Hydrocortisone butyrate .....	66, 70	Inhibace Plus .....	54	<b>- K -</b>	
Hydrocortisone butyrate with chlorquinaldol .....	66	Insoma .....	129	K-Thrombin .....	45
Hydrocortisone with miconazole .....	66	Insulin aspart .....	30	Kaletra .....	98
Hydrocortisone with natamycin and neomycin .....	67	Insulin glargine .....	30	Karicare Food Thickener .....	182
Hydrocortisone with wool fat and mineral oil .....	66	Insulin isophane .....	29	Karicare Goats Milk Infant Formula .....	188
Hydroderm Lotion .....	68	Insulin isophane with insulin neutral .....	30	Karicare Soy All Ages .....	188
Hydrogen peroxide Alimentary .....	37	Insulin lispro .....	30	Kemadrin .....	122
Dermatological .....	63, 71	Insulin lispro with insulin lispro protamine .....	30	Kenacomb Dermatological .....	67
Hydroxocobalamin .....	37	Insulin neutral .....	29	Sensory .....	157
Hydroxychloroquine sulphate .....	93	Insulin pen needles .....	33	Kenacort-A .....	80
Hydroxyurea .....	140	Insulin syringes, disposable with attached needle .....	34	Kenacort-A40 .....	80
Hygroton .....	60	Intal Spincaps .....	154	Keppra .....	117
Hyoscine (scopolamine) .....	120	Interferon alpha-2a .....	99	Keto-Diabur 5000 .....	33
Hyoscine hydrobromide .....	120	Interferon alpha-2a with ribavirin .....	99	Keto-Diastix .....	33
Hyoscine N-butylbromide .....	28	Interferon alpha-2b .....	100	Ketoconazole Dermatological .....	64, 70
Hypam .....	129	Interferon beta-1-alpha .....	129	Infection .....	93
Hyperuricaemia and Antigout .....	109	Interferon beta-1-beta .....	129	Ketoprofen .....	104
Hypnovel .....	129	Intra-uterine device .....	73	Ketostix .....	33
Hypromellose .....	160	Intron-A .....	100	Ketotifen .....	151
Hyprosin .....	53	Invirase .....	98	Ketovite .....	186
Hytrin .....	53	Ipecacuanha .....	162	Ketovite Syrup .....	186
Hytrin Starter Pack .....	53	Ipratropium bromide .....	154-155	Ketur-Test .....	33
Hyzaar .....	55	Ipratropium Steri-Neb .....	154	Kindergen .....	175
<b>- I -</b>		Irinotecan .....	137	Kivexa .....	97
I-Profen .....	104	Iron polymaltose .....	39	Klacid .....	89
Ibiamox .....	90	Ismo 20 .....	61	Klamycin .....	89
Ibuprofen .....	104	Isogel .....	35	Kliogest .....	82
Idarubicin hydrochloride .....	140	Isoniazid .....	93	Kliovance .....	82
Ifosfamide .....	134	Isoprenaline hydrochloride .....	61	Konakion .....	45
Imatinib mesylate .....	142	Isoptin .....	59	Konakion MM .....	45
Imiglucerase .....	36	Isopto Homatropine .....	160	Konsyl-D .....	35
Imigran .....	119	Isosorbide mononitrate .....	61	<b>- L -</b>	
Imipramine hydrochloride .....	114	Isosource 1.5 .....	180	LA-Morph .....	112
Imiquimod .....	71	Isosource HN .....	180	Labeltalol .....	57
Immune Modulators .....	99	Isosource HN RTH .....	180	Lacri-Lube .....	161







PenMix 40 .....	30	Podophyllotoxin .....	71	Protifar 90 .....	172
PenMix 50 .....	30	Polaramine .....	151	Provera .....	81, 83
Pentasa .....	27	Polaramine Repetab .....	151	PSO .....	189-192
Pentostatin (deoxycytosine) .....	141	Poloxamer .....	35	Psoriasis and Eczema Preparations .....	69
Pepti Junior .....	187	Poly-Tears .....	160	Pulmicort Turbuhaler .....	151
Peptisoothe .....	28	Poly-Visc .....	161	Pulmocare .....	173
Peptisorb .....	178	Polycal .....	170	Pulmozyme .....	155
Pergolide .....	121	Polycose .....	170	Purinethol .....	137
Perhexiline maleate .....	59	Polytar Emollient .....	70	Pyrantel embonate .....	88
Periactin .....	150	Polyvinyl alcohol .....	160	Pyrazinamide .....	93
Pericyazine .....	124	Ponstan .....	104	Pyridostigmine bromide .....	104
Perindopril .....	54	Postinor-1 .....	76	Pyridoxine hydrochloride .....	37
Permax .....	121	Potassium bicarbonate .....	49	Pytazen SR .....	46
Permethrin .....	69	Potassium chloride .....	48-49		
Persantin .....	46	Povidone iodine .....	68	<b>- Q -</b>	
Pethidine hydrochloride .....	113	Prantal .....	67	Q 200 .....	109
Pevaryl .....	64	Pravachol .....	50	Q 300 .....	109
Pexsig .....	59	Pravastatin .....	50	Questran-Lite .....	49
Pharmacare .....	111	Prazosin hydrochloride .....	53	Quetapel .....	124
Phenate .....	87	Pred Forte .....	158	Quetiapine .....	124
Phenelzine sulphate .....	114	Pred Mild .....	158	Quinapril .....	54
Phenergan .....	151	Prednisolone acetate .....	158	Quinapril with hydrochlorothiazide .....	54
Phenobarbitone .....	117	Prednisolone sodium phosphate .....	79	Quinine sulphate .....	109
Phenobarbitone sodium .....	167	Prednisone .....	80	QV .....	67
Phenoxybenzamine hydrochloride .....	53	Prefrin .....	161	<b>- R -</b>	
Phenoxyethylpenicillin (Penicillin V) .....	91	Pregnancy tests - HCG urine .....	77	RA-Morph .....	112
Phentolamine mesylate .....	53	Premarin .....	81	Ranbaxy Amoxicillin .....	90
Phenylephrine hydrochloride .....	161	Premia 2.5 Continuous .....	82	Ranbaxy-Cefaclor .....	88
Phenylephrine hydrochloride with zinc sulphate .....	161	Premia 5 Continuous .....	82	Ranitidine hydrochloride .....	28
Phenytoin sodium .....	115, 118	Priadel .....	123	Rapamune .....	149
Phlexy 10 .....	185	Primidone .....	118	Razene .....	150
Phosphate-Sandoz .....	49	Primolut N .....	83	Recombinant human growth hormone .....	84
Phytomenadione .....	45	Pro-Pam .....	127	Recormon .....	44
Pilocarpine .....	160	Probenecid .....	109	Redipred .....	79
Pilopt .....	160	Procaine penicillin .....	91	Regitine .....	53
Pimafucort .....	67	Procarbazine hydrochloride .....	141	Renilon 7.5 .....	177
Pindol .....	57	Prochlorperazine .....	121	Requip .....	122
Pindolol .....	57	Procyclidine hydrochloride .....	122	Requip Follow-on Pack .....	122
Pinetarsol .....	70	Prodopa .....	59	Requip Starter Pack .....	122
Pioglitazone .....	31	Progout .....	109	Resonium-A .....	49
Piportil .....	125	Prograf .....	149	Resource Diabetic .....	174
Pipothiazine palmitate .....	125	Progy Nova .....	81	Resource Diabetic TF RTH .....	174
Piram-D .....	105	Promethazine hydrochloride .....	151	Resource Just for Kids .....	176
Piroxicam .....	105	Promethazine theoclate .....	121	Resource Plus .....	180
Pizotifen .....	120	Promod .....	172	Resource Thicken Up .....	182
Plaquenil .....	93	Propafenone hydrochloride .....	56	Respigen .....	153
Plavix .....	45	Propamide isethionate .....	157	Respiratory Devices .....	156
Plendil ER .....	58	Propranolol .....	57	Retrovir .....	97
		Propylene glycol .....	168	ReVia .....	133
		Protamine sulphate .....	47	Reyataz .....	98
		Protaphane .....	29		
		Protaphane Penfill .....	29		





**INDEX****Generic Chemicals and Brands**

---

Blood .....	48	Zantac .....	28	Zinc sulphate .....	39
Extemporaneous .....	168	Zarontin .....	116	Zincaps .....	39
Wholesale Supply Order .....	192	Zavedos .....	140	Zincfrin .....	161
Wool fat with mineral oil .....	68	Zeffix .....	95	Zinnat .....	88
<b>- X -</b>		Zeldox .....	125	Ziprasidone .....	125
Xalatan .....	159	Zerit .....	97	Zofran .....	120
Xeloda .....	135	Zetop .....	150	Zofran Zydys .....	120
Xenazine 25 .....	133	Ziagen .....	97	Zoladex .....	85
XMET Maxamum .....	184	Zidovudine [AZT] .....	97	Zopiclone .....	129
XP Analog LCP .....	185	Zidovudine [AZT] with lamivudine .....	97	Zostrix HP .....	71
XP Maxamaid .....	185	Zinacef .....	89	Zovirax .....	157
XP Maxamum .....	185	Zinc .....	67	Zuclopenthixol decanoate .....	125
Xylocaine .....	110	Zinc and castor oil .....	67	Zyprexa .....	123
<b>- Z -</b>		Zinc oxide .....	27	Zyprexa Zydys .....	126
Zadine .....	150				

## AUTHORITY TO SUBSTITUTE

Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

### **Sole Supply Products**

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

### **Other subsidised products**

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

### **Exceptions**

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name: \_\_\_\_\_ NZMC: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

*Authority for the dispensing pharmacist to change a prescribed medicine in this way is contained in regulation 42 (4) of the Medicines Regulations 1984.*

## NOTES

---

## AUTHORITY TO SUBSTITUTE

Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

### **Sole Supply Products**

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

### **Other subsidised products**

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

### **Exceptions**

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name: \_\_\_\_\_ NZMC: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

*Authority for the dispensing pharmacist to change a prescribed medicine in this way is contained in regulation 42 (4) of the Medicines Regulations 1984.*

## NOTES

---

## AUTHORITY TO SUBSTITUTE

Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

### **Sole Supply Products**

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

### **Other subsidised products**

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

### **Exceptions**

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name: \_\_\_\_\_ NZMC: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

*Authority for the dispensing pharmacist to change a prescribed medicine in this way is contained in regulation 42 (4) of the Medicines Regulations 1984.*

## NOTES

---

## AUTHORITY TO SUBSTITUTE

Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

### **Sole Supply Products**

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

### **Other subsidised products**

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

### **Exceptions**

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name: \_\_\_\_\_ NZMC: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

*Authority for the dispensing pharmacist to change a prescribed medicine in this way is contained in regulation 42 (4) of the Medicines Regulations 1984.*

## NOTES

---

## AUTHORITY TO SUBSTITUTE

Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

### **Sole Supply Products**

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

### **Other subsidised products**

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

### **Exceptions**

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name: \_\_\_\_\_ NZMC: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

*Authority for the dispensing pharmacist to change a prescribed medicine in this way is contained in regulation 42 (4) of the Medicines Regulations 1984.*

## NOTES

---

## AUTHORITY TO SUBSTITUTE

Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

### **Sole Supply Products**

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

### **Other subsidised products**

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

### **Exceptions**

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name: \_\_\_\_\_ NZMC: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

*Authority for the dispensing pharmacist to change a prescribed medicine in this way is contained in regulation 42 (4) of the Medicines Regulations 1984.*

## NOTES

---